Current Bibliographies in Medicine 94-2
Ovarian Cancer
CBM 94-2
Ovarian Cancer
January 1990 through January 1994, plus selected earlier references
1908 Citations
Prepared by
Mary E. Conway, M.L.S., National Library of Medicine
Edward L. Trimble, M.D., M.P.H., National Cancer Institute
U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health
National Library of Medicine
Reference Section
8600 Rockville Pike
Bethesda, Maryland 20894
1994
SERIES NOTE
Current Bibliographies in Medicine (CBM) is a continuation in part of
the National Library of Medicine's Literature Search Series, which
ceased in 1987 with No. 87-15. In 1989 it also subsumed the
Specialized Bibliography Series. Each bibliography in the new series
covers a distinct subject area of biomedicine and is intended to fulfill a
current awareness function. Citations are usually derived from
searching a variety of online databases. NLM databases utilized include
MEDLINE, AVLINE, BIOETHICSLINE, CANCERLIT, CATLINE,
HEALTH, POPLINE and TOXLINE. The only criterion for the
inclusion of a particular published work is its relevance to the topic
being presented; the format, ownership, or location of the material is
not considered.
Comments and suggestions on this series may be addressed to:
Karen Patrias, Editor
Current Bibliographies in Medicine
Reference Section
National Library of Medicine
Bethesda, MD 20894
Phone: 301-496-6097
Fax: 301-402-1384
Internet: patrias@nlm.nih.gov
Ordering Information:
Current Bibliographies in Medicine is sold by the Superintendent of
Documents, U.S. Government Printing Office, P.O. 371954,
Pittsburgh, PA 15250-7954. To order the entire CBM series for
calendar year 1994 (approximately 10 bibliographies), send $60.00
($75.00 foreign) to the Superintendent of Documents citing GPO List
ID: CBM94. For your convenience an order blank is given inside the
back cover. Orders for individual bibliographies in the series ($8.50,
$10.63 foreign) should be sent to the Superintendent of Documents
citing the title, CBM number, and the GPO List ID given above.
Internet Access:
The Current Bibliographies in Medicine series is also available at no
cost to anyone with Internet access through FTP (File Transfer
Protocol). FTP to nlmpubs.nlm.nih.gov and login: as nlmpubs. The
index file in the "bibs" directory provides information on the
bibliographies available.
Use of funds for printing this periodical has been approved by the
Director of the Office of Management and Budget through September 30, 1994.
OVARIAN CANCER
Ovarian cancer is the leading cause of death from gynecologic
malignancies in the United States. In 1994, approximately 24,000 new
cases of ovarian cancer will be diagnosed, and 13,600 women will die
of ovarian cancer. Over the past several years much attention has been
paid to the epidemiology, biology, screening, treatment, and follow-up
of ovarian cancer.
This bibliography was prepared in support of the National Institutes of
Health Consensus Development Conference titled "Ovarian Cancer:
Screening, Treatment and Follow-up" convened in Bethesda, Maryland
on April 5-7, 1994. The purpose of the conference was to examine the
relevant data concerning the following questions:
1. What is the current status of screening for ovarian cancer?
2. What is the appropriate management of early ovarian cancer?
3. What is the appropriate management of advanced
epithelialovarian cancer?
4. What is appropriate follow-up after primary therapy forovarian
cancer?
5. What are directions for future research?
The organization of the bibliography reflects the focus of these five
questions. The main subject categories are General Articles; Screening
and Prevention; Management of Early Stage Ovarian Cancer;
Management of Advanced Epithelial Ovarian Cancer; Follow-Up after
Primary Therapy; and New Directions for Research. Separate sections
for monographs and audiovisuals appear at the end. The 1908 citations
include English language journal articles, monographs, book chapters,
dissertations, conference proceedings, and audiovisuals covering the
period January 1990 through January 1994 with some selected earlier
references. Citations under the subject "New Directions for Research"
cover the period January 1992 through January 1994. In general,
letters, case reports, and editorials have been omitted. Audiovisuals are
arranged alphabetically by title; all other sections are arranged
alphabetically by author. A citation may appear in more than one
category.
SEARCH STRATEGY
A variety of online databases are usually searched in preparing
bibliographies in the CBM series. To assist you in updating or
otherwise manipulating the material in this search, the strategy used for
the NLM's MEDLINE database is given below. Please note that the
search strategies presented here differ from individual demand searches
in that they are generally broadly formulated and irrelevant citations
edited out prior to printing.
SS 1 = EXP OVARIAN NEOPLASMS
SS 2 = EXP OVARIAN DISEASES AND NEOPLASMS (PX)
SS 3 = EXP ENDOCRINE GLAND NEOPLASMS OR
EXP GENITAL NEOPLASMS, FEMALE
SS 4 = (TW) OVARY OR OVARIES OR OVARIAN OR
ALL OOPHORECTOM: OR ADNEXAL
SS 5 = EXP ADNEXAL DISEASES OR ADNEXA UTERI OR
OVARIECTOMY
SS 6 = 3 AND 4 OR 3 AND 5
SS 7 = EXP CYSTADENOMA OR
EXP NEOPLASMS, GERM CELL A#D EMBRYONAL
SS 8 = 7 AND 4 OR 7 AND 5
SS 9 = 2 OR 6 OR 8
SS 10 = ALL TAXOL OR ALL TAXANE# (TW)
OR ALL TAXOID# (TW)
SS 11 = 1 AND 10 OR 9 AND 10
SS 12 = 9 AND TH& (PX) OR 9 AND DI& (PX) OR 9 AND SN&(PX)
SS 13 = 9 AND EXP ULTRASONOGRAPHY OR 9 AND
EXP ULTRASONICS
SS 14 = ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE OR
EXP TUMOR MARKERS, BIOLOGICAL OR
GENETIC MARKERS
SS 15 = QUALITY OF LIFE OR
EXP ADAPTATION, PSYCHOLOGICAL
SS 16 = 9 AND 14 OR 9 AND 15 OR 9 AND PX (SH)
SS 17 = EXP SURGERY, LAPAROSCOPIC OR
EXP LAPAROSCOPY OR EXP LAPAROTOMY
SS 18 = 9 AND 17
SS 19 = 1 OR 11 OR 12 OR 13 OR 16 OR 18
GRATEFUL MED
To make online searching easier and more efficient, the Library offers
GRATEFUL MED, microcomputer-based software that provides a
user-friendly interface to most NLM databases. This software was
specifically developed for health professionals and features multiple
choice menus and "fill in the blank" screens for easy search preparation.
GRATEFUL MED runs on an IBM PC (or IBM-compatible) with
DOS 2.0 or a Macintosh, and requires a Hayes (or Hayes-compatible)
modem. It may be purchased from the National Technical Information
Service in Springfield, Virginia, for $29.95 (plus $3.00 per order for
shipping). For your convenience, an order blank has been enclosed at
the back of this bibliography.
SAMPLE CITATIONS
Citations in this bibliographic series are formatted according to the
rules established for Index Medicus*. Sample journal, monograph, and
audiovisual citations appear below. Note also that a colon (:) may
appear within an author's name or article title. The NLM computer
system automatically inserts this symbol in the place of a diacritical
mark.
Journal Article:
Authors Article Title
Deppe G, Malviya VK. Ovarian cancer. Advances in
management.
Surg Clin North Am 1991 Oct;71(5):1023-39.
Abbreviated Journal Date Volume Issue Pages
Title
Monograph:
Authors/Editors Title
Markman, Maurie; Hoskins, William J., eds. Cancer of the
ovary. New York: Raven Press; 1993. 442 p.
Place of Publisher Date Total No.
Publication of Pages
Audiovisual:
Title Media Type Place of
Publication
Cancers that threaten women [videorecording]. Princeton (NJ):
Films for the Humanities; c1992. 1 videocassette: 19 min., sound,
color, 1/2 in. Credits: Herbert Hyman.
Publisher Date Physical
Description
Note
_________________________________
*For details of the formats used for references, see the following
publication:
Patrias, Karen. National Library of Medicine recommended formats for
bibliographic citation. Bethesda (MD): The Library; 1991 Apr.
Available from: NTIS, Springfield, VA; PB91-182030.
TABLE OF CONTENTS
GENERAL ARTICLES
SCREENING AND PREVENTION
Epidemiology
Screening
Prevention
MANAGEMENT OF EARLY STAGE OVARIAN CANCER
Management of the Adnexal Mass
Early Stage Epithelial Ovarian Cancer
Ovarian Tumors of Low Malignant Potential
(BorderlineTumors)
Management of Germ Cell and Sex-Cord Stromal Tumors
Radiotherapy
MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN
CANCER
Preoperative Evaluation and Preparation
Principles of Primary Surgery
Primary Adjuvant Chemotherapy
Taxanes
Second-Look Surgery
FOLLOW-UP AFTER PRIMARY THERAPY
Follow-Up of the Asymptomatic Patient
Surgery for the Symptomatic Patient
Salvage Chemotherapy
Quality of Life Considerations
NEW DIRECTIONS FOR RESEARCH
MONOGRAPHS
AUDIOVISUALS
GENERAL ARTICLES
Alberts DS. Best papers on ovarian cancer. Cancer Invest
1992;10(6):603-4.
Andersen BL, Anderson B. Psychosomatic aspects of gynecologic
oncology: Present status and future directions. Special Issue:
Gynecologic oncology. J Psychosom Obstet Gynaecol 1986
Dec;5(4):233-244.
Averette HE, Donato DM. Ovarian carcinoma. Advances in diagnosis,
staging, and treatment. Cancer 1990 Feb 1;65(3 Suppl):703-8.
Balvert-Locht HR, Coebergh JW, Hop WC, Brolmann HA, Crommelin
M, van Wijck DJ, Verhagen-Teulings MT. Improved prognosis of
ovarian cancer in The Netherlands during the period 1975-1985: a
registry-based study. Gynecol Oncol 1991 Jul;42(1):3-8.
Barakat RR, Benjamin I. Surgery for malignant gynecologic disease.
Curr Opin Obstet Gynecol 1993 Jun;5(3):311-7.
Barber HR. New frontiers in ovarian cancer diagnosis and management.
Yale J Biol Med 1991 Mar-Apr;64(2):127-41.
Barker GH. Recent advances in the treatment of carcinoma of the
ovary. Br J Obstet Gynaecol 1993 Sep;100(9):803-5.
Brown MF, Hebra A, McGeehin K, Ross AJ 3d. Ovarian masses in
children: a review of 91 cases of malignant and benign masses. J Pediatr
Surg 1993 Jul;28(7):930-3.
Cancer of the ovary. ACOG technical bulletin number 141--May 1990
(replaces #73, October 1983). Int J Gynaecol Obstet 1991
Aug;35(4):359-66.
Cannistra SA. Cancer of the ovary. N Engl J Med 1993 Nov
18;329(21):1550-9.
de Souza PL, Friedlander ML. Prognostic factors in ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):761-82.
Deppe G, Malviya VK. Ovarian cancer. Advances in management. Surg
Clin North Am 1991 Oct;71(5):1023-39.
Eriksson JH, Walczak JR. Ovarian cancer. Semin Oncol Nurs 1990
Aug;6(3):214-27.
Ferrier A. Ovarian carcinoma: a continuing challenge. Med J Aust 1993
May 3;158(9):584-6.
Friedlander ML, Dembo AJ. Prognostic factors in ovarian cancer.
Semin Oncol 1991 Jun;18(3):205-12.
Gargano G, Catino A, Correale M, Lorusso V, Abbate I, Izzi G,
Cramarossa A, Picciariello M, Paradiso A, De Leonardis A, et al.
Prognostic factors in epithelial ovarian cancer. Eur J Gynaecol Oncol
1992;13(1 Suppl):45-55.
Gitsch E, Salzer H. The management in ovarian cancer at the First
Dept. of Obstetrics and Gynecology, University of Vienna. Eur J
Gynaecol Oncol 1992;13(1):61-4.
Gitsch E, Salzer H, Sevelda P. Ovarian cancer: introduction and
development in the treatment. Eur J Obstet Gynecol Reprod Biol 1991
Aug 20;41(1):43-6.
Hamilton TC. Ovarian cancer, Part I: Biology. Curr Probl Cancer 1992
Jan-Feb;16(1):1-57.
Hanai A. Trends and differentials in ovarian cancer: incidence, mortality
and survival experience. APMIS Suppl 1990;12:1-20.
Hole DJ, Gillis CR. Use of cancer registry data to evaluate the
treatment of ovarian cancer on a hospital basis. Health Rep
1993;5(1):117-9.
Kennedy AW, Biscotti CV, Hart WR, Tuason LJ. Histologic correlates
of progression-free interval and survival in ovarian clear cell
adenocarcinoma. Gynecol Oncol 1993 Sep;50(3):334-8.
Khoo SK, Battistutta D, Hurst T, Sanderson B, Ward BG, Free K. The
prognostic value of clinical, pathologic, and biologic parameters in
ovarian cancer. Cancer 1993 Jul 15;72(2):531-7.
Kjaer SK, Storm HH. Survival of Danish cancer patients 1943-1987.
Female genital organs. APMIS Suppl 1993;33:107-21.
Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM,
Edwards CL. Endometrioid carcinoma of the ovary: retrospective
review of 145 cases. Gynecol Oncol 1990 Dec;39(3):337-46.
Knobf MT, Morra ME. Women and cancer. NAACOGS Clin Issu
Perinat Womens Health Nurs 1993;4(2):287-301.
Lack EE, Young RH, Scully RE. Pathology of ovarian neoplasms in
childhood and adolescence. Pathol Annu 1992;27(Pt 2):281-356.
Leung Y, DePetrillo AD. Etiology, epidemiology, risk and prognostic
factors, screening, and imaging of gynecologic cancers. Curr Opin
Oncol 1993 Sep;5(5):869-76.
Lowry S. Molecular basis for hormone-related cancer. Lancet 1993 Jun
26;341(8861):1630.
Lowry WS, Atkinson RJ. Tumour suppressor genes and risk of
metastasis in ovarian cancer. BMJ 1993 Aug 28;307(6903):542.
Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological
evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS
1991 Apr;99(4):353-8.
Lund B, Williamson P, van Houwelingen HC, Neijt JP. Comparison of
the predictive power of different prognostic indices for overall survival
in patients with advanced ovarian carcinoma. Cancer Res 1990 Aug
1;50(15):4626-9.
Markman M, Lewis JL Jr, Saigo P, Hakes T, Rubin S, Jones W,
Reichman B, Curtin J, Barakat R, Almadrones L, et al. Impact of age
on survival of patients with ovarian cancer. Gynecol Oncol 1993
May;49(2):236-9.
Marsoni S, Torri W, Taiana A, Gambino A, Grilli R, Liati P, Franzosi
MG, Pistotti V, Parazzini F, Focarile F, et al. Critical review of the
quality and development of randomized clinical trials (RCTs) and their
influence on the treatment of advanced epithelial ovarian cancer. Ann
Oncol 1990 Sep;1(5):343-50.
Marsoni S, Torri V, Valsecchi MG, Belloni C, Bianchi U, Bolis G,
Bonazzi C, Colombo N, Epis A, Favalli G, et al. Prognostic factors in
advanced epithelial ovarian cancer. (Gruppo Interregionale
Cooperativo di Oncologia Ginecologica (GICOG)). Br J Cancer 1990
Sep;62(3):444-50.
McGowan L. Pathology of the ovary. Curr Opin Obstet Gynecol 1991
Aug;3(4):580-6.
Merino MJ, Jaffe G. Age contrast in ovarian pathology. Cancer 1993
Jan 15;71(2 Suppl):537-44.
Montella M, De Marco MR, Romeo F, Ventura R. Survival in ovarian
cancers treated at National Cancer Institute in Naples Italy 1985-1990.
Eur J Gynaecol Oncol 1993;14(3):249-54.
Nakashima N, Nagasaka T, Fukata S, Oiwa N, Nara Y, Fukatsu T,
Takeuchi J. Study of ovarian tumors treated at Nagoya University
Hospital, 1965-1988. Gynecol Oncol 1990 Apr;37(1):103-11.
Nash JD, Young RC. Gynecological malignancies. Cancer Chemother
Biol Response Modif 1990;11:484-509.
Niloff JM. Ovarian malignancy. Curr Opin Obstet Gynecol 1991
Feb;3(1):66-72.
Onwude JL, Holohan MB, Codd MB, Coughlan BM. Prognosis of
ovarian cancer. Ir Med J 1990 Mar;83(1):14-6.
Ozols RF, Hamilton TC, Hoskins WJ, Bast RC Jr, Young RC.
Summary of symposium: Biology and therapy of ovarian cancer. Semin
Oncol 1991 Jun;18(3):297-306.
Perez RP, Godwin AK, Hamilton TC, Ozols RF. Ovarian cancer
biology. Semin Oncol 1991 Jun;18(3):186-204.
Perspectives on Ovarian Cancer in Older-Aged Women. Current
Knowledge and Recommendations for Research. Working conference.
Bethesda, Maryland, November 20-21, 1991. Cancer 1993 Jan 15;71(2
Suppl):513-659.
Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB.
Profiles of women age 30-39 and age less than 30 with epithelial
ovarian cancer. Obstet Gynecol 1993 May;81(5 Pt 1):651-4.
Protopapa E, Miaoulis G, Ferreiro M, Panayiotides J, Katsikas SK,
Delides G. A new expert system for histopathological diagnosis of
human ovarian epithelial cancer. In Vivo 1993 Jul-Aug;7(4):369-72.
Saeed M, Khawaja K, Rizwana I, Malik I, Rizvi J, Khan A. A
clinicopathological analysis of ovarian tumours. JPMA J Pak Med
Assoc 1991 Jul;41(7):161-4.
Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod
Pathol 1990 Mar;3(2):120-8.
Silva EG, Tornos C, Bailey MA, Morris M. Undifferentiated carcinoma
of the ovary. Arch Pathol Lab Med 1991 Apr;115(4):377-81.
Singh P, Arunachalam I, Singh P, Tan BY, Tock EP, Ratnam SS.
Ovarian cancer in Oriental women from Singapore: disease pattern and
survival. Int Surg 1990 Apr-Jun;75(2):115-22.
Swenerton KD. Prognostic indices in ovarian cancer. Their significance
in treatment planning. Acta Obstet Gynecol Scand Suppl
1992;155:67-74.
Talerman A. Ovarian pathology. Curr Opin Obstet Gynecol 1992
Aug;4(4):608-15.
Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP,
Hoskins WJ, Williams S. Age as a prognostic factor in ovarian
carcinoma. The Gynecologic Oncology Group experience. Cancer 1993
Jan 15;71(2 Suppl):606-14.
Tintara H, Mitarnun W. Ovarian neoplasms in childhood and
adolescents in Songklanagarind Hospital, February 1983-March 1989. J
Med Assoc Thai 1990 Jul;73(7):375-80.
Trope C, Makar A. Unsettled questions regarding ovarian cancer. Acta
Obstet Gynecol Scand Suppl 1992;155:7-18.
Tyler CW Jr, Lee NC, Robboy SJ, Kurman RJ, Paris AL, Wingo PA,
Williamson GD. The diagnosis of ovarian cancer by pathologists: how
often do diagnoses by contributing pathologists agree with a panel of
gynecologic pathologists? Am J Obstet Gynecol 1991 Jan;164(1 Pt
1):65-70.
Vani R, Kuntal R, Rao PL. Ovarian tumors in the second decade of life.
Asia Oceania J Obstet Gynaecol 1991 Sep;17(3):231-5.
Watkin W, Silva EG, Gershenson DM. Mucinous carcinoma of the
ovary. Pathologic prognostic factors. Cancer 1992 Jan 1;69(1):208-12.
Williams C. Ovarian and cervical cancer. BMJ 1992 Jun
6;304(6840):1501-4.
Yancik R. Ovarian cancer. Age contrasts in incidence, histology,
disease stage at diagnosis, and mortality. Cancer 1993 Jan 15;71(2
Suppl):517-23.
Yancik R, Moore TD, Martin G, Obrams GI, Reed E. Older women as
the focus for research and treatment of ovarian cancer. An overview for
the National Institute on Aging, National Cancer Institute, and
American Cancer Society Multidisciplinary Working Conference.
Cancer 1993 Jan 15;71(2 Suppl):514-6.
SCREENING AND PREVENTION
Epidemiology
Adami HO, Bergstrom R, Persson I, Sparen P. The incidence of
ovarian cancer in Sweden, 1960-1984. Am J Epidemiol 1990
Sep;132(3):446-52.
Amos CI, Shaw GL, Tucker MA, Hartge P. Age at onset for familial
epithelial ovarian cancer. JAMA 1992 Oct 14;268(14):1896-9.
Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian
cancer. Cancer 1993 Jan 15;71(2 Suppl):566-72.
Anderson DE, Badzioch MD. Familial breast cancer risks. Effects of
prostate and other cancers. Cancer 1993 Jul 1;72(1):114-9.
Augustin J, Wotke R. Ovarian malignancies in the Czech Cancer
Registry. Neoplasma 1990;37(2):213-7.
Ayhan A, Yalcin OT, Tuncer ZS, Gurgan T, Kucukali T. Synchronous
primary malignancies of the female genital tract. Eur J Obstet Gynecol
Reprod Biol 1992 Jun 16;45(1):63-6.
Badawy YA, Bayoumi DM. An epidemiologic study of ovarian cancer.
Part 1: Reproductive and social factors. J Egypt Public Health Assoc
1992;67(3-4):465-77.
Badawy YA, Bayoumi DM. An epidemiologic study of ovarian cancer.
Part 2: Oral contraceptive use and menstrual events. J Egypt Public
Health Assoc 1992;67(5-6):579-91.
Balasch J, Barri PN. Follicular stimulation and ovarian cancer? Hum
Reprod 1993 Jul;8(7):990-6.
Barrett-Connor E. Hormone replacement and cancer.
Br Med Bull 1992 Apr;48(2):345-55.
Bernstein JL, Thompson WD, Risch N, Holford TR. The genetic
epidemiology of second primary breast cancer. Am J Epidemiol 1992
Oct 15;136(8):937-48.
Bernstein L, Ross RK, Henderson BE. Relationship of hormone use to
cancer risk. Monogr Natl Cancer Inst 1992;(12):137-47.
Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT.
Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol
Pathol 1992 Jul;11(3):180-7.
Black DM, Solomon E. The search for the familial breast/ovarian
cancer gene. Trends Genet 1993 Jan;9(1):22-6.
Bokhman JB, Maximov SJ. Relative risk of development and active
detection of primary multiple endometrial, breast and ovarian cancer.
Eur J Gynaecol Oncol 1993;14(2):114-8.
Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics,
1994. CA Cancer J Clin 1994 Jan-Feb;44(1):7-26.
Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary
malignancies following gynecological tumours in Saarland, Germany,
1968-1987. J Cancer Res Clin Oncol 1993;119(3):179-83.
Brenner H, Siegle S, Stegmaier C, Ziegler H. Second primary
neoplasms following breast cancer in Saarland, Germany, 1968-1987.
Eur J Cancer 1993;29A(10):1410-4.
Chen Y, Wu PC, Lang JH, Ge WJ, Hartge P, Brinton LA. Risk factors
for epithelial ovarian cancer in Beijing, China. Int J Epidemiol 1992
Feb;21(1):23-9.
Chi I. The safety and efficacy issues of progestin-only oral
contraceptives--an epidemiologic perspective. Contraception 1993
Jan;47(1):1-21.
Cohen J, Forman R, Harlap S, Johannisson E, Lunenfeld B, de Mouzon
J, Pepperell R, Tarlatzis B, Templeton A. IFFS expert group report on
the Whittemore study related to the risk of ovarian cancer associated
with the use of infertility agents. Hum Reprod 1993 Jul;8(7):996-9.
Cramer DW. Epidemiologic aspects of early menopause and ovarian
cancer. Ann N Y Acad Sci 1990;592: 363-75; discussion 390-4.
Daly MB. The epidemiology of ovarian cancer. Hematol Oncol Clin
North Am 1992 Aug;6(4):729-38.
Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial
ovarian cancer. The WHO Collaborative Study of Neoplasia and
Steroid Contraceptives. Int J Cancer 1991 Sep 9;49(2):191-5.
DePriest PD, Banks ER, Powell DE, van Nagell JR Jr, Gallion HH,
Puls LE, Hunter JE, Kryscio RJ, Royalty MB. Endometrioid carcinoma
of the ovary and endometriosis: the association in postmenopausal
women. Gynecol Oncol 1992 Oct;47(1):71-5.
Dietl J, Marzusch K. Ovarian surface epithelium and human ovarian
cancer. Gynecol Obstet Invest 1993;35(3):129-35.
Edgren RA. Oral contraceptives and cancer. Int J Fertil 1991;36 Suppl
3:37-50.
Engle A, Muscat JE, Harris RE. Nutritional risk factors and ovarian
cancer. Nutr Cancer 1991;15(3-4):239-47.
Fertility drugs and ovarian cancer. International Federation of Fertility
Societies (IFFS). Fertil Steril 1993 Sep;60(3):406-8.
Franceschi S. Female hormones: for which cancers do they matter? Dev
Oncol 1991;63:89-106.
Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini
F, Trichopoulos D, Beral V. Pooled analysis of 3 European
case-control studies of ovarian cancer: II. Age at menarche and at
menopause. Int J Cancer 1991 Aug 19;49(1):57-60. Comment in: Int J
Cancer 1992 May 8;51(2):333-4.
Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V,
Tzonou A, Trichopoulos D. Pooled analysis of 3 European
case-control studies of epithelial ovarian cancer: III. Oral contraceptive
use. Int J Cancer 1991 Aug 19;49(1):61-5.
Freddo JL. Genetic predisposition to ovarian cancer. West J Med 1992
Jun;156(6):652.
Gast K, Snyder T. Combination oral contraceptives and cancer risk.
Kans Med 1990 Jul;91(7):201-8.
Gatphoh ED, Darnal HK. Pattern of ovarian neoplasm in Manipur. J
Indian Med Assoc 1990 Dec;88(12):338-9.
Greggi S, Genuardi M, Benedetti-Panici P, Cento R, Scambia G, Neri
G, Mancuso S. Analysis of 138 consecutive ovarian cancer patients:
incidence and characteristics of familial cases. Gynecol Oncol 1990
Dec;39(3):300-4.
Grimes DA. Neoplastic effects of oral contraceptives. Int J Fertil
1991;36 Suppl 1:19-24.
Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC. The risk of
epithelial ovarian cancer in short-term users of oral contraceptives. Am
J Epidemiol 1992 Jul 1;136(1):46-53.
Grover S, Quinn MA, Weideman P. Patterns of inheritance of ovarian
cancer. An analysis from an ovarian cancer screening program. Cancer
1993 Jul 15;72(2):526-30.
Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL. Pregnancy,
breast feeding, and oral contraceptives and the risk of epithelial ovarian
cancer. J Clin Epidemiol 1990;43(6):559-68.
Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B,
Stampfer MJ. A quantitative assessment of oral contraceptive use and
risk of ovarian cancer. Obstet Gynecol 1992 Oct;80(4):708-14.
Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to
talc and ovarian cancer risk. Obstet Gynecol 1992 Jul;80(1):19-26.
Harlow BL, Cramer DW, Geller J, Willett WC, Bell DA, Welch WR.
The influence of lactose consumption on the association of oral
contraceptive use and ovarian cancer risk. Am J Epidemiol 1991 Sep
1;134(5):445-53. Comment in: Am J Epidemiol 1991 Sep
1;134(5):454-6 and Am J Epidemiol 1991 Sep 1;134(5):457-9;
discussion 460-1.
Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian
cancer risk: collaborative analysis of 12 US case-control studies. III.
Epithelial tumors of low malignant potential in white women.
Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 Nov
15;136(10):1204-11.
Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of
cancer in women. Science 1993 Jan 29;259(5095):633-8.
Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO
blood groups. J Epidemiol Community Health 1993 Aug;47(4):287-9.
Horn-Ross PL, Whittemore AS, Harris R, Itnyre J. Characteristics
relating to ovarian cancer risk: collaborative analysis of 12 U.S.
case-control studies. VI. Nonepithelial cancers among adults.
Collaborative Ovarian Cancer Group. Epidemiology 1992
Nov;3(6):490-5.
Houlston RS, Bourne TH, Collins WP, Whitehead MI, Campbell S,
Slack J. Risk of ovarian cancer and genetic relationship to other
cancers in families. Hum Hered 1993 Mar-Apr;43(2):111-5.
Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization,
hysterectomy, and the subsequent occurrence of epithelial ovarian
cancer. Am J Epidemiol 1991 Aug 15;134(4):362-9.
Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns
BA, Humphrey P, Berchuck A, Ponder BA, Bast RC Jr. Clonal origin
of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53
mutation, and X-chromosome inactivation. J Natl Cancer Inst 1992
Dec 2;84(23):1793-8.
Jacobsen BK, Vollset SE, Kvale G. Reproductive factors and survival
from ovarian cancer. Int J Cancer 1993 Jul 30;54(6):904-6.
Jin F, Shu XO, Devesa SS, Zheng W, Blot WJ, Gao YT. Incidence
trends for cancers of the breast, ovary, and corpus uteri in urban
Shanghai, 1972-89. Cancer Causes Control 1993 Jul;4(4):355-60.
John EM, Whittemore AS, Harris R, Itnyre J. Characteristics relating to
ovarian cancer risk: collaborative analysis of seven U.S. case-control
studies. Epithelial ovarian cancer in black women. Collaborative
Ovarian Cancer Group. J Natl Cancer Inst 1993 Jan 20;85(2):142-7.
Katchy KC, Briggs ND. Clinical and pathological features of ovarian
tumours in Rivers state of Nigeria. East Afr Med J 1992
Aug;69(8):456-9.
Kaunitz AM. Oral contraceptives and gynecologic cancer: an update
for the 1990s. Am J Obstet Gynecol 1992 Oct;167(4 Pt 2):1171-6.
Koch M, Hanson J, Raphael M. Follow-up of controls participating in
case-control studies for cancer risk factors. Int J Epidemiol 1990
Dec;19(4):877-80. Comment in: Int J Epidemiol 1991 Sep;20(3):820.
Kodama M, Kodama T, Totani R, Suzuoki Y, Kodama M. Relation
between the hormonal and epidemiological aspects of ovarian cancer
patients in Japan. Anticancer Res 1992 Sep-Oct;12(5):1593-602.
Koonings PP, Grimes DA, Campbell K, Sommerville M. Bilateral
ovarian neoplasms and the risk of malignancy. Am J Obstet Gynecol
1990 Jan;162(1):167-9.
Kuznesov VV. Selective screening on hormonedependent tumours of
women's reproductive system organs. Eur J Gynaecol Oncol 1992;13(1
Suppl):65-8.
Kvale G, Heuch I, Nilssen S. Reproductive factors and cancers of the
breast and genital organs--are the different cancer sites similarly
affected? Cancer Detect Prev 1991;15(5):369-77.
La Vecchia C, Levi F, Lucchini F, Negri E, Franceschi S. Descriptive
epidemiology of ovarian cancer in Europe. Gynecol Oncol 1992
Aug;46(2):208-15.
La Vecchia C, Negri E, Franceschi S, Parazzini F, Gentile A, Fasoli M.
Alcohol and epithelial ovarian cancer. J Clin Epidemiol 1992
Sep;45(9):1025-30.
Land JA. Ovulation, ovulation induction and ovarian carcinoma.
Baillieres Clin Obstet Gynaecol 1993 Jun;7(2):455-72.
Lanza E, Shankar S, Trock B. Dietary fiber. In: Micozzi MS, Moon
TE, eds. Macronutrients: investigating their role in cancer. New York:
Marcel Dekker; 1992. p. 293-319.
Lauchlan SC. Non-invasive ovarian carcinoma. Int J Gynecol Pathol
1990;9(2):158-69.
Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison
L. Epidemiologic pathology of ovarian cancer from the Vaud Cancer
Registry, Switzerland. Ann Oncol 1993 Apr;4(4):289-94.
Leviton A. Methylxanthine consumption and the risk of ovarian
malignancy. Cancer Lett 1990 May 30;51(2):91-101.
Lund E. Mortality from ovarian cancer among women with many
children. Int J Epidemiol 1992 Oct;21(5):872-6.
Lund E. Number of children and death from hormone-dependent
cancers. Int J Cancer 1990 Dec 15;46(6):998-1000.
Lynch HT, Conway T, Lynch J. Hereditary ovarian cancer. Pedigree
studies, Part II. Cancer Genet Cytogenet 1991 Jun;53(2):161-83.
Lynch HT, Fitzsimmons ML, Conway TA, Bewtra C, Lynch J.
Hereditary carcinoma of the ovary and associated cancers: a study of
two families. Gynecol Oncol 1990 Jan;36(1):48-55.
Lynch HT, Lynch JF. Hereditary ovarian carcinoma. Hematol Oncol
Clin North Am 1992 Aug;6(4):783-811.
Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P,
Lynch JF, Ponder BA. Hereditary ovarian cancer. Heterogeneity in age
at diagnosis. Cancer 1991 Mar 1;67(5):1460-6.
Lynch HT, Watson P, Conway TA, Lynch JF, Slominski-Caster SM,
Narod SA, Feunteun J, Lenoir G. DNA screening for breast/ovarian
cancer susceptibility based on linked markers. A family study. Arch
Intern Med 1993 Sep 13;153(17):1979-87.
Lynch HT, Watson P, Lynch JF, Conway TA, Fili M. Hereditary
ovarian cancer. Heterogeneity in age at onset. Cancer 1993 Jan 15;71(2
Suppl):573-81.
Mahoney MC, Youngblood LG, Weinstein AL, Burnett WS. Evidence
for a spatiotemporal cluster of ovarian cancer cases. Gynecol Oncol
1991 Jun;41(3):234-8.
Makar AP, Trope CG. Endometrial and ovarian malignancies:
epidemiology, etiology and prognostic factors. Acta Obstet Gynecol
Scand 1992 Jul;71(5):331-6.
Maximov SJ, Bokhman JB. Syndrome of primary multiple endometrial,
breast, ovarian and colon adenocarcinoma. Eur J Gynaecol Oncol
1993;14(2):109-13.
Menczer J, Ben-Baruch G. Familial ovarian cancer in Israeli Jewish
women. Obstet Gynecol 1991 Feb;77(2):276-7.
Mettlin CJ. Invited commentary: progress in the nutritional
epidemiology of ovary cancer. Am J Epidemiol 1991 Sep
1;134(5):457-9; discussion 460-1. Comment on: Am J Epidemiol 1991
Sep 1;134(5):445-53; Comment on: Am J Epidemiol 1991 Sep
1;134(5):454-6.
Mettlin CJ, Piver MS. A case-control study of milk-drinking and
ovarian cancer risk. Am J Epidemiol 1990 Nov;132(5):871-6.
Comment in: Am J Epidemiol 1991 Sep 1;134(5):454-6.
Miller WR, Fraser HM. Is cancer in women preventable by hormone
manipulation? J Endocrinol 1991 Aug;130(2):165-8.
Mukherjee AK, Leck I, Langley FA, Ashcroft C. The completeness and
accuracy of health authority and cancer registry records according to a
study of ovarian neoplasms. Public Health 1991 Jan;105(1):69-78.
Negri E, Franceschi S, La Vecchia C, Parazzini F. Incomplete
pregnancies and ovarian cancer risk. Gynecol Oncol 1992
Nov;47(2):234-8.
Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini
F, Beral V, Boyle P, Trichopoulos D. Pooled analysis of 3 European
case-control studies: I. Reproductive factors and risk of epithelial
ovarian cancer. Int J Cancer 1991 Aug 19;49(1):50-6.
Olsson H, Andersson H, Johansson O, Moller TR, Kristoffersson U,
Wenngren E. Population-based cohort investigations of the risk for
malignant tumors in first-degree relatives and wives of men with breast
cancer. Cancer 1993 Feb 15;71(4):1273-8.
Parazzini F, Franceschi S, La Vecchia C, Fasoli M. The epidemiology
of ovarian cancer. Gynecol Oncol 1991 Oct;43(1):9-23.
Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L,
Franceschi S. Oral contraceptive use and the risk of ovarian cancer: an
Italian case-control study. Eur J Cancer 1991;27(5):594-8.
Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L. Family
history of breast, ovarian and endometrial cancer and risk of breast
cancer. Int J Epidemiol 1993 Aug;22(4):614-8.
Parazzini F, Negri E, La Vecchia C, Restelli C, Franceschi S. Family
history of reproductive cancers and ovarian cancer risk: an Italian
case-control study. Am J Epidemiol 1992 Jan 1;135(1):35-40.
Patel AR, Obrams GI. Epidemiology of ovarian cancer. Cancer
Epidemiol Biomarkers Prev 1993 Jan-Feb;2(1):79-83.
Pearl ML, Johnston CM, Frank TS, Roberts JA. Synchronous dual
primary ovarian and endometrial carcinomas. Int J Gynecol Obstet
1993;43(3):305-12.
Pejovic T, Heim S, Mandahl N, Elmfors B, Furgyik S, Floderus UM,
Helm G, Willen H, Mitelman F. Bilateral ovarian carcinoma:
cytogenetic evidence of unicentric origin. Int J Cancer 1991 Feb
1;47(3):358-61.
Petitti DB, Porterfield D. Worldwide variations in the lifetime
probability of reproductive cancer in women: implications of best-case,
worst-case, and likely-case assumptions about the effect of oral
contraceptive use. Contraception 1992 Feb;45(2):93-104.
Pike M. We are on the threshold of an era when breast cancer ... can be
prevented [interview]. Oncology (Huntingt) 1991 May;5(5):14, 16,
21-2.
Pike MC. Reducing cancer risk in women through lifestyle-mediated
changes in hormone levels. Cancer Detect Prev 1990;14(6):595-607.
Piver MS, Baker TR, Jishi MF, Sandecki AM, Tsukada Y, Natarajan
N, Mettlin CJ, Blake CA. Familial ovarian cancer. A report of 658
families from the Gilda Radner Familial Ovarian Cancer Registry
1981-1991. Cancer 1993 Jan 15;71(2 Suppl):582-8.
Piver MS, Baker TR, Piedmonte M, Sandecki AM. Epidemiology and
etiology of ovarian cancer. Semin Oncol 1991 Jun;18(3):177-85.
Polychronopoulou A, Tzonou A, Hsieh CC, Kaprinis G, Rebelakos A,
Toupadaki N, Trichopoulos D. Reproductive variables, tobacco,
ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J
Cancer 1993 Sep 30;55(3):402-7.
Ponder MA. Can cancers be inherited? Prof Nurse 1991
Jul;6(10):593-7.
Prat J, Matias-Guiu X, Barreto J. Simultaneous carcinoma involving
the endometrium and the ovary. A clinicopathologic,
immunohistochemical, and DNA flow cytometric study of 18 cases.
Cancer 1991 Dec 1;68(11):2455-9.
Prentice RL, Sheppard L. Dietary fat and cancer: consistency of the
epidemiologic data, and disease prevention that may follow from a
practical reduction in fat consumption. Cancer Causes Control 1990
Jul;1(1):81-97; discussion 99-109. Published erratum appears in Cancer
Causes Control 1990 Nov;1(3):253.
Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic
evidence for the increased cell proliferation model of carcinogenesis.
Prog Clin Biol Res 1991;369:21-34.
Pukkala E, Poskiparta M, Apter D, Vihko V. Life-long physical activity
and cancer risk among Finnish female teachers. Eur J Cancer Prev 1993
Sep;2(5):369-76.
Puls LE, Powell DE, DePriest PD, Gallion HH, Hunter JE, Kryscio RJ,
van Nagell JR Jr. Transition from benign to malignant epithelium in
mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol
1992 Oct;47(1):53-7.
Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian
cancer. Endocr Rev 1991 Feb;12(1):14-26.
Resta L, Russo S, Colucci GA, Prat J. Morphologic precursors of
ovarian epithelial tumors. Obstet Gynecol 1993 Aug;82(2):181-6.
Ries LA. Ovarian cancer. Survival and treatment differences by age.
Cancer 1993 Jan 15;71(2 Suppl):524-9.
Rosenblatt KA, Szklo M, Rosenshein NB. Mineral fiber exposure and
the development of ovarian cancer. Gynecol Oncol 1992
Apr;45(1):20-5.
Rosenblatt KA, Thomas DB. Lactation and the risk of epithelial ovarian
cancer. The WHO Collaborative Study of Neoplasia and Steroid
Contraceptives. Int J Epidemiol 1993 Apr;22(2):192-7.
Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose
combined oral contraceptives: protection against epithelial ovarian
cancer and the length of the protective effect. The WHO Collaborative
Study of Neoplasia and Steroid Contraceptives. Eur J Cancer
1992;28A(11):1872-6.
Sellers TA, Gapstur SM, Potter JD, Kushi LH, Bostick RM, Folsom
AR. Association of body fat distribution and family histories of breast
and ovarian cancer with risk of postmenopausal breast cancer. Am J
Epidemiol 1993 Nov 15;138(10):799-803.
Shah S, Evans DG, Blair V, Burnell LD, Birch JM. Assessment of
relative risk of second primary tumors after ovarian cancer and of the
usefulness of double primary cases as a source of material for genetic
studies with a cancer registry. Cancer 1993 Aug 1;72(3):819-27.
Smith PE. Familial breast and ovarian cancers. Semin Oncol Nurs 1992
Nov;8(4):258-64.
Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C. Risk
factors for epithelial ovarian cancer in women under age 45. Eur J
Cancer 1993;29A(9):1297-301.
Thanikasalam K, Ho CM, Adeed N, Shahidan MN, Azizah WK.
Pattern of ovarian tumours among Malaysian women at General
Hospital, Kuala Lumpur. Med J Malaysia 1992 Jun;47(2):139-46.
Thomas DB. The WHO Collaborative Study of Neoplasia and Steroid
Contraceptives: the influence of combined oral contraceptives on risk
of neoplasms in developing and developed countries. Contraception
1991 Jun;43(6):695-710.
Tomao S, Taggi F, Sberna RC, Villani C. Ovarian cancer and dietary
habits. Eur J Gynaecol Oncol 1992;13(1):91-5.
Trichopoulou A, Mossialos E, Skalkides J. Mediterranean diet and
cancer. Dev Oncol 1991;63:17-25.
Trope CG, Makar AP. Epidemiology, etiology, screening, prevention,
and diagnosis in female genital cancer. Curr Opin Oncol 1991
Oct;3(5):908-19.
Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of
prostate, ovarian, and endometrial cancer among relatives of women
with breast cancer. BMJ 1992 Oct 10;305(6858):855-7.
Tzonou A, Hsieh CC, Polychronopoulou A, Kaprinis G, Toupadaki N,
Trichopoulou A, Karakatsani A, Trichopoulos D. Diet and ovarian
cancer: a case-control study in Greece. Int J Cancer 1993 Sep
30;55(3):411-4.
Tzonou A, Polychronopoulou A, Hsieh CC, Rebelakos A, Karakatsani
A, Trichopoulos D. Hair dyes, analgesics, tranquilizers and perineal talc
application as risk factors for ovarian cancer. Int J Cancer 1993 Sep
30;55(3):408-10.
Westhoff C, Murphy P, Heller D, Halim A. Is ovarian cancer associated
with an increased frequency of germinal inclusion cysts? Am J
Epidemiol 1993 Jul 15;138(2):90-3.
Whelan SL. Cancer Incidence in Five Continents. Coding practices.
IARC Sci Publ 1992;(120):31-8.
Whittemore AS. Fertility drugs and risk of ovarian cancer. Hum
Reprod 1993 Jul;8(7):999-1000.
Whittemore AS. Personal characteristics relating to risk of invasive
epithelial ovarian cancer in older women in the United States. Cancer
1993 Jan 15;71(2 Suppl):558-65.
Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian
cancer risk: collaborative analysis of 12 US case-control studies. IV.
The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian
Cancer Group. Am J Epidemiol 1992 Nov 15;136(10):1212-20.
Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian
cancer risk: collaborative analysis of 12 US case-control studies. II.
Invasive epithelial ovarian cancers in white women. Collaborative
Ovarian Cancer Group. Am J Epidemiol 1992 Nov
15;136(10):1184-203. Comment in: Am J Epidemiol 1993 Apr
15;137(8):928-9.
Whittemore AS, Harris R, Itnyre J, Halpern J. Characteristics relating
to ovarian cancer risk: collaborative analysis of 12 US case-control
studies. I. Methods. Collaborative Ovarian Cancer Group. Am J
Epidemiol 1992 Nov 15;136(10):1175-83.
Williams JK. Oral contraceptives and reproductive system cancer.
Benefits and risks. J Reprod Med 1991 Mar;36(3 Suppl):247-52.
Yoder LH. The epidemiology of ovarian cancer: a review. Oncol Nurs
Forum 1990 May-Jun;17(3):411-5. Comment in: Oncol Nurs Forum
1990 Jul-Aug;17(4):483-4.
Zheng W, Shu XO, McLaughlin JK, Chow WH, Gao YT, Blot WJ.
Occupational physical activity and the incidence of cancer of the breast,
corpus uteri, and ovary in Shanghai. Cancer 1993 Jun 1;71(11):3620-4.
Screening
Acar B, Posaci C, Dicle O, Topuz A, Erten O. Diagnostic value of
magnetic resonance imaging in gynaecology. Aust N Z J Obstet
Gynaecol 1992 Aug;32(3):252-5.
Adams CH, Smith NJ, Wilbur DC, Grady KE. The relationship of
obesity to the frequency of pelvic examinations: do physician and
patient attitudes make a difference? Women Health 1993;20(2):45-57.
Andolf E. Ultrasound screening in women at risk for ovarian cancer.
Clin Obstet Gynecol 1993 Jun;36(2):423-32.
Andolf E, Jorgensen C. A prospective comparison of transabdominal
and transvaginal ultrasound with surgical findings in gynecologic
disease. J Ultrasound Med 1990 Feb;9(2):71-5.
Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection
of ovarian carcinoma in risk groups. Obstet Gynecol 1990
Jan;75(1):106-9.
Aubel S, Wozney P, Edwards RP. MRI of female uterine and
juxta-uterine masses: clinical application in 25 patients. Magn Reson
Imaging 1991;9(4):485-91.
Averette HE, Steren A, Nguyen HN. Screening in gynecologic cancers.
Cancer 1993 Aug 1;72(3 Suppl):1043-9.
Barzen G, Hierholzer J, Cordes M, Friedmann W, Felix R. Primary
diagnosis and follow-up of ovarian cancer: radioimmunoscintigraphy
with iodine-131 labeled OC 125 monoclonal antibodies versus
computed tomography and second look. Int J Rad Appl Instrum [B]
1991;18(1):69-76.
Benacerraf BR, Finkler NJ, Wojciechowski C, Knapp RC. Sonographic
accuracy in the diagnosis of ovarian masses. J Reprod Med 1990
May;35(5):491-5.
Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM,
Clarke-Pearson DL, Leslie DS, Bast RC Jr. Heterogeneity of antigen
expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol
1990 Apr;162(4):883-8.
Berkowitz RS. CA125 measurement in epithelial ovarian cancer: A
10-year anniversary of clinical investigation. Gynecol Oncol
1993;49(1):1-2.
Biesecker BB, Boehnke M, Calzone K, Markel DS, Garber JE, Collins
FS, Weber BL. Genetic counseling for families with inherited
susceptibility to breast and ovarian cancer. JAMA 1993 Apr
21;269(15):1970-4. Published erratum appears in JAMA 1993 Aug
18;270(7):832.
Bischof P. What do we know about the origin of CA 125? Eur J Obstet
Gynecol Reprod Biol 1993 Apr;49(1-2):93-8.
Bonilla-Musoles F, Ballester MJ, Simon C, Serra V, Raga F. Is
avoidance of surgery possible in patients with perimenopausal ovarian
tumors using transvaginal ultrasound and duplex color Doppler
sonography? J Ultrasound Med 1993 Jan;12(1):33-9.
Bourne T, Reynolds K, Campbell S. Ovarian cancer screening. Eur J
Cancer 1991;27(5):655-9.
Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J,
Royston P, Crayford TJ, Collins WP. Screening for early familial
ovarian cancer with transvaginal ultrasonography and colour blood
flow imaging. BMJ 1993 Apr 17;306(6884):1025-9. Comment in: BMJ
1993 Apr 17;306(6884):1015-6 and BMJ 1993 Jun
19;306(6893):1685-6.
Bourne TH, Hampson J, Reynolds K, Collins WP, Campbell S.
Screening for early ovarian cancer. Br J Hosp Med 1992 Oct 21-Nov
3;48(8):454-9.
Bourne TH, Reynolds K, Campbell S. Ovarian cancer screening. Curr
Opin Radiol 1991 Apr;3(2):216-24.
Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan V, Collins
WP. Ultrasound screening for familial ovarian cancer. Gynecol Oncol
1991 Nov;43(2):92-7. Comment in: Gynecol Oncol 1991
Nov;43(2):89-91 and Gynecol Oncol 1992 Dec;47(3):404.
Bronshtein M, Yoffe N, Brandes JM, Blumenfeld Z. Hair as a
sonographic marker of ovarian teratomas: improved identification using
transvaginal sonography and simulation model. J Clin Ultrasound 1991
Jul-Aug;19(6):351-5.
Brucks JA. Ovarian cancer. The most lethal gynecologic malignancy.
Nurs Clin North Am 1992 Dec;27(4):835-45.
Buamah PK, Rake MO, Drake SR, Skillen AW. Serum CA 12-5
concentrations and CA 12-5/CEA ratios in patients with epithelial
ovarian cancer. J Surg Oncol 1990 Jun;44(2):97-9.
Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C, Prevot S, Hugol
D, Laromiguiere M, Truc JB, Poitout P, et al. Epithelial tumors of the
ovary: CT findings and correlation with US. Radiology 1991
Mar;178(3):811-8.
Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP.
Transabdominal ultrasound screening for early ovarian cancer. BMJ
1989 Dec 2;299(6712):1363-7. Comment in: BMJ 1990 Jan
20;300(6718):193-5 and BMJ 1990 Feb 3;300(6720):330.
Campbell S, Bourne T, Bradley E. Screening for ovarian cancer by
transvaginal sonography and colour Doppler. Eur J Obstet Gynecol
Reprod Biol 1993 Apr;49(1-2):33-4.
Campbell S, Royston P, Bhan V, Whitehead MI, Collins WP. Novel
screening strategies for early ovarian cancer by transabdominal
ultrasonography. Br J Obstet Gynaecol 1990 Apr;97(4):304-11.
Campion MJ, Reid R. Screening for gynecologic cancer. Obstet
Gynecol Clin North Am 1990 Dec;17(4):695-727.
Capstick V, Maclean GD, Suresh MR, Bodnar D, Lloyd S, Shepert L,
Longenecker BM, Krantz M. Clinical evaluation of a new two-site
assay for CA125 antigen. Int J Biol Markers 1991
Apr-Jun;6(2):129-35.
Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for
detecting malignant ovarian tumors. Obstet Gynecol 1990
Apr;75(4):701-4.
Chenevix-Trench G, Leary J, Kerr J, Michel J, Kefford R, Hurst T,
Parsons PG, Friedlander M, Khoo SK. Frequent loss of heterozygosity
on chromosome 18 in ovarian adenocarcinoma which does not always
include the DCC locus. Oncogene 1992 Jun;7(6):1059-65.
Ciotti MC. Screening for gynecologic and colorectal cancer: is it
adequate? Womens Health Issues 1992 Summer;2(2):83-92; discussion
92-3.
Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G,
Podratz KC, Jenkins RB. Human epithelial ovarian cancer allelotype.
Cancer Res 1993 May 15;53(10 Suppl):2393-8.
Cliby W, Sarkar G, Ritland SR, Hartmann L, Podratz KC, Jenkins RB.
Absence of prohibitin gene mutations in human epithelial ovarian
tumors. Gynecol Oncol 1993 Jul;50(1):34-7.
Cole LA, Nam JH, Chambers JT, Schwartz PE. Urinary gonadotropin
fragment, a new tumor marker. II. Differentiating a benign from a
malignant pelvic mass. Gynecol Oncol 1990 Mar;36(3):391-4.
Conte M, Guariglia L, Benedetti Panici PL, Scambia G, Cento R,
Laurelli G, Mancuso S. Ovarian carcinoma: an ultrasound study. Eur J
Gynaecol Oncol 1990;11(1):33-6.
Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet
Gynecol 1991 Jul;165(1):7-10. Comment in: Am J Obstet Gynecol
1992 May;166(5):1591-3.
de Bruijn HW, ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders
JG. Cancer-associated antigen CA 195 in patients with mucinous
ovarian tumours: a comparative analysis with CEA, TATI and CA 125
in serum specimens and cyst fluids. Tumour Biol 1993;14(2):105-15.
de los Frailes MT, Stark S, Jaeger W, Hoerauf A, Wildt L. Purification
and characterization of the CA 125 tumor-associated antigen from
human ascites. Tumour Biol 1993;14(1):18-29.
Demaerel P, Baert AL, Ide P, Obletter N, Marchal G, Van Hecke P,
Bonte J. Magnetic resonance imaging of the pathological female pelvis:
assessment of 24 patients with high-field magnetic resonance imaging.
In: Breit A, ed. Magnetic resonance in oncology. New York:
Springer-Verlag; 1990. p. 117-24.
DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion
HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr. A morphology index
based on sonographic findings in ovarian cancer. Gynecol Oncol 1993
Oct;51(1):7-11. Comment in: Gynecol Oncol 1993 Oct;51(1):4-6.
DePriest PD, van Nagell JR Jr. Transvaginal ultrasound screening for
ovarian cancer. Clin Obstet Gynecol 1992 Mar;35(1):40-4.
DePriest PD, van Nagell JR Jr, Gallion HH, Shenson D, Hunter JE,
Andrews SJ, Powell DE, Pavlik EJ. Ovarian cancer screening in
asymptomatic postmenopausal women. Gynecol Oncol 1993
Nov;51(2):205-9.
Dgani R, Shani A, Elchalal U, Harpaz N, Bentwich Z, Fink A. The
leukocyte adherence inhibition test (LAI) in preoperative diagnosis of
epithelial ovarian cancer. Gynecol Oncol 1993 Jun;49(3):349-53.
DiCioccio RA, Piver MS. The genetics of ovarian cancer. Cancer
Invest 1992;10(2):135-41.
DiSantis DJ, Scatarige JC, Kemp G, Given FT, Hsiu JG, Cramer MS.
A prospective evaluation of transvaginal sonography for detection of
ovarian disease. AJR Am J Roentgenol 1993 Jul;161(1):91-4.
Comment in: AJR Am J Roentgenol 1993 Jul;161(1):95-6.
Dodson MK, Hartmann LC, Cliby WA, DeLacey KA, Keeney GL,
Ritland SR, Su JQ, Podratz KC, Jenkins RB. Comparison of loss of
heterozygosity patterns in invasive low-grade and high-grade epithelial
ovarian carcinomas. Cancer Res 1993 Oct 1;53(19):4456-60.
Dudzinski MR. Tumor markers in ovarian carcinoma. Curr Opin Obstet
Gynecol 1990 Feb;2(1):52-6.
Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage
analysis in familial breast and ovarian cancer: results from 214 families.
The Breast Cancer Linkage Consortium. Am J Hum Genet 1993
Apr;52(4):678-701.
Eccles DM, Cranston G, Steel CM, Nakamura Y, Leonard RC. Allele
losses on chromosome 17 in human epithelial ovarian carcinoma.
Oncogene 1990 Oct;5(10):1599-601.
Eccles DM, Gruber L, Stewart M, Steel CM, Leonard RC. Allele loss
on chromosome 11p is associated with poor survival in ovarian cancer.
Dis Markers 1992 Mar-Apr;10(2):95-9.
Eccles DM, Russell SE, Haites NE, Atkinson R, Bell DW, Gruber L,
Hickey I, Kelly K, Kitchener H, Leonard R, et al. Early loss of
heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer
Genetics Group. Oncogene 1992 Oct;7(10):2069-72.
Ehlen T, Dubeau L. Loss of heterozygosity on chromosomal segments
3p, 6q and 11p in human ovarian carcinomas. Oncogene 1990
Feb;5(2):219-23.
Einhorn N. Ovarian cancer. Early diagnosis and screening. Hematol
Oncol Clin North Am 1992 Aug;6(4):843-50.
Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr,
Zurawski VR Jr. Prospective evaluation of serum CA 125 levels for
early detection of ovarian cancer. Obstet Gynecol 1992 Jul;80(1):14-8.
Ferdeghini M, Gadducci A, dell'Hoste M, Prontera C, Ceccarini T,
Rispoli G, Bianchi R, Fioretti P. CAM26, CAM29 and mucin-like
carcinoma associated antigen in epithelial ovarian cancer. Eur J
Gynaecol Oncol 1990;11(5):395-401.
Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Annicchiarico C,
Prato B, Bianchi R, Fioretti P. Combined evaluation of serum CA 125
and CAM 29 in patients with epithelial ovarian cancer. Tumour Biol
1992;13(5-6):287-93.
Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Fanucchi A,
Annicchiarico C, Facchini V, Bianchi R. Serum soluble interleukin-2
receptor assay in epithelial ovarian cancer. Tumour Biol
1993;14(5):303-9.
Feunteun J, Narod SA, Lynch HT, Watson P, Conway T, Lynch J,
Parboosingh J, O'Connell P, White R, Lenoir GM. A breast-ovarian
cancer susceptibility gene maps to chromosome 17q21. Am J Hum
Genet 1993 Apr;52(4):736-42.
Finkler NJ. Clinical utility of CA 125 in preoperative diagnosis of
patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 1993
Apr;49(1-2):105-7.
Fleischer AC. New applications of pelvic sonography. Urol Radiol
1991;13(1):9-15.
Fleischer AC. Transabdominal and transvaginal sonography of ovarian
masses. Clin Obstet Gynecol 1991 Jun;34(2):433-42.
Fleischer AC, McKee MS, Gordon AN, Page DL, Kepple DM, Worrell
JA, Jones HW 3d, Burnett LS, James AE Jr. Transvaginal sonography
of postmenopausal ovaries with pathologic correlation. J Ultrasound
Med 1990 Nov;9(11):637-44.
Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3d.
Color Doppler sonography of ovarian masses: a multiparameter
analysis. J Ultrasound Med 1993 Jan;12(1):41-8.
Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW 3d,
Gross PR. Color Doppler sonography of benign and malignant ovarian
masses. Radiographics 1992 Sep;12(5):879-85.
Fleischer AC, Rodgers WH, Rao BK, Kepple DM, Worrell JA,
Williams L, Jones HW 3d. Assessment of ovarian tumor vascularity
with transvaginal color Doppler sonography. J Ultrasound Med 1991
Oct;10(10):563-8. Comment in: J Ultrasound Med 1993 Jan;12(1):10,
16.
Foglia M, Verri PG, Calabrese A, Corongiu F, Tarani A, Margiaria
ML, De Pascale A, Tagliati D. Echography and CA 125 in ovarian
pathology. Preliminary data of a new score. J Nucl Med Allied Sci
1990 Oct-Dec;34(4 Suppl):67-70.
Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very
frequent loss of heterozygosity throughout chromosome 17 in sporadic
ovarian carcinoma. Int J Cancer 1993 May 8;54(2):220-5.
Foulkes WD, Campbell IG, Stamp GW, Trowsdale J. Loss of
heterozygosity and amplification on chromosome 11q in human ovarian
cancer. Br J Cancer 1993 Feb;67(2):268-73.
Foulkes WD, Ragoussis J, Stamp GW, Allan GJ, Trowsdale J.
Frequent loss of heterozygosity on chromosome 6 in human ovarian
carcinoma. Br J Cancer 1993 Mar;67(3):551-9.
Freimanis MG, Jones AF. Transvaginal ultrasonography. Radiol Clin
North Am 1992 Sep;30(5):955-76.
Fuith LC, Marth C, Muller-Holzner E, Zechmann W, Daxenbichler G.
Enhancement of CA 125 expression by interferon-gamma in ovarian
carcinoma xenographs. J Tumor Marker Oncol 1991;6(2):85-9.
Gadducci A, Ciancia EM, Malagnino G, De Luca F, Campani D,
Ferdeghini M, Facchini V, Pingitore R, Fioretti P. Comparison between
serum CA 125 and CA 19-9 assays and tissular OC 125 and 1116NS
19-9 reactivity in malignant and benign ovarian tumors. Eur J Gynaecol
Oncol 1992;13(4):346-54.
Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi
R, Fioretti P. The concomitant determination of different tumor
markers in patients with epithelial ovarian cancer and benign ovarian
masses: relevance for differential diagnosis. Gynecol Oncol 1992
Feb;44(2):147-54.
Gadducci A, Ferdeghini M, Prontera C, Moretti L, Pellagatta L,
Bianchi R, Fioretti P. CA 195: a new monoclonal antibody-defined Lea
blood group-related tumor marker in patients with epithelial ovarian
cancer. J Nucl Biol Med 1991 Jan-Mar;35(1):33-7.
Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti
P. Comparison of tumor-associated trypsin inhibitor (TATI) with
CA125 as a marker for diagnosis and monitoring of epithelial ovarian
cancer. Scand J Clin Lab Invest Suppl 1991;207:19-24.
Gallion HH, Bast RC Jr. National Cancer Institute Conference on
Investigational Strategies for Detection and Intervention in Early
Ovarian Cancer. Cancer Res 1993 Aug 15;53(16):3839-42.
Gallion HH, Powell DE, Morrow JK, Pieretti M, Case E, Turker MS,
DePriest PD, Hunter JE, van Nagell JR Jr. Molecular genetic changes
in human epithelial ovarian malignancies. Gynecol Oncol 1992
Nov;47(2):137-42. Comment in: Gynecol Oncol 1992
Nov;47(2):135-6.
Gallion HH, Powell DE, Smith LW, Morrow JK, Martin AW, van
Nagell JR, Donaldson ES. Chromosome abnormalities in human
epithelial ovarian malignancies. Gynecol Oncol 1990 Sep;38(3):473-7.
Gargano G, Correale M, Abbate I, Falco G, De Frenza N, Lorusso V,
De Lena M, De Leonardis A. The role of tumour markers in ovarian
cancer. Clin Exp Obstet Gynecol 1990;17(1):23-9.
Genetic risk and screening techniques for epithelial ovarian cancer.
ACOG Committee Opinion: Committee on Gynecologic Practice.
Number 117--December 1992. Int J Gynaecol Obstet 1993
Jun;41(3):321-3.
Ghazizadeh M, Sasaki Y, Oguro T, Aihara K, Tenjin H, Araki T.
Combined immunohistochemical study of tissue polypeptide antigen
and cancer antigen 125 in human ovarian tumours. Histopathology
1990 Aug;17(2):123-8.
Ghossain MA, Buy JN, Ligneres C, Bazot M, Hassen K, Malbec L,
Hugol D, Truc JB, Decroix Y, Poitout P, et al. Epithelial tumors of the
ovary: comparison of MR and CT findings. Radiology 1991
Dec;181(3):863-70.
Granberg S. Ultrasound in the diagnosis and treatment of ovarian
tumors. Acta Obstet Gynecol Scand 1991;70(4-5):385-6.
Granberg S, Norstrom A, Wikland M. Comparison of endovaginal
ultrasound and cytological evaluation of cystic ovarian tumors. J
Ultrasound Med 1991 Jan;10(1):9-14.
Granberg S, Wikland M. Ultrasound in the diagnosis and treatment of
ovarian cystic tumours. Hum Reprod 1991 Feb;6(2):177-85.
Granberg S, Wikland M, Friberg LG. Tumor marker CA 125 level and
ovarian volume at different cycle day periods and in postmenopause.
Int J Gynaecol Obstet 1990 Oct;33(2):149-52.
Granberg S, Wikland M, Jansson I. Macroscopic characterization of
ovarian tumors and the relation to the histological diagnosis: criteria to
be used for ultrasound evaluation. Gynecol Oncol 1989
Nov;35(2):139-44.
Green J, Murton F, Statham H. Psychosocial issues raised by a familial
ovarian cancer register. J Med Genet 1993 Jul;30(7):575-9.
Grover S, Quinn MA, Weideman P, Koh H. Factors influencing serum
CA 125 levels in normal women. Obstet Gynecol 1992
Apr;79(4):511-4.
Guinet C, Buy JN, Ghossain MA, Malbec L, Hugol D, Truc JB,
Poitout P, Vadrot D. Fat suppression techniques in MR imaging of
mature ovarian teratomas: comparison with CT. Eur J Radiol 1993
Sep;17(2):117-21.
Gynecologic sonography. Report of the ultrasonography task force.
Council on Scientific Affairs, American Medical Association. JAMA
1991 Jun 5;265(21):2851-5.
Hall JM, Friedman L, Guenther C, Lee MK, Weber JL, Black DM,
King MC. Closing in on a breast cancer gene on chromosome 17q. Am
J Hum Genet 1992 Jun;50(6):1235-42.
Hall KL, Dewar MA, Perchalski J. Screening for gynecologic cancer.
Vulvar, vaginal, endometrial, and ovarian neoplasms. Prim Care 1992
Sep;19(3):607-20.
Hamper UM, Sheth S, Abbas FM, Rosenshein NB, Aronson D,
Kurman RJ. Transvaginal color Doppler sonography of adnexal masses:
differences in blood flow impedance in benign and malignant lesions.
AJR Am J Roentgenol 1993 Jun;160(6):1225-8.
Harlozinska A, Bar JK, Gawlikowski W, Richter R, Cislo M. CA 125
and carcinoembryonic antigen levels in cyst fluid, ascites and serum of
patients with ovarian neoplasms. Ann Chir Gynaecol
1991;80(4):368-75.
Hata K, Hata T, Manabe A, Sugimura K, Kitao M. A critical evaluation
of transvaginal Doppler studies, transvaginal sonography, magnetic
resonance imaging, and CA 125 in detecting ovarian cancer. Obstet
Gynecol 1992 Dec;80(6):922-6.
Hata K, Makihara K, Hata T, Takahashi K, Kitao M. Transvaginal
color Doppler imaging for hemodynamic assessment of reproductive
tract tumors. Int J Gynaecol Obstet 1991 Dec;36(4):301-8.
Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock
GW. Prospective study of serum CA-125 levels as markers of ovarian
cancer. JAMA 1993 Mar 3;269(9):1123-6. Comment in: JAMA 1993
Mar 3;269(9):1163 and JAMA 1993 Jun 23-30;269(24):3106-7.
Herrmann UJ. Sonographic patterns of ovarian tumors. Clin Obstet
Gynecol 1993 Jun;36(2):375-83.
Higgins RV, van Nagell JR Jr, Woods CH, Thompson EA, Kryscio RJ.
Interobserver variation in ovarian measurements using transvaginal
sonography. Gynecol Oncol 1990 Oct;39(1):69-71.
Hirai T, Akamatsu N, Sekiba K, Tsubota N, Tsuru S. Qualificated
discrimination of ovarian malignancy by diagnostic ultrasound. Asia
Oceania J Obstet Gynaecol 1993 Jun;19(2):181-9.
Hosono MN, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T,
Hosono M, Nakajima T, Onoyama Y, Konishi J. Different antigenic
nature in apparently healthy women with high serum CA 125 levels
compared with typical patients with ovarian cancer. Cancer 1992 Dec
15;70(12):2851-6.
Houlston R, Bourne TH, Davies A, Whitehead MI, Campbell S, Collins
WP, Slack J. Use of family history in a screening clinic for familial
ovarian cancer. Gynecol Oncol 1992 Nov;47(2):247-52.
Houlston RS, Collins A, Slack J, Campbell S, Collins WP, Whitehead
MI, Morton NE. Genetic epidemiology of ovarian cancer: segregation
analysis. Ann Hum Genet 1991 Oct;55(Pt 4):291-9.
Houvenaeghel G, Delpero JR, Rosello R, Resbeut M, Viens P,
Jacquemier J, Noirclerc M, Guerinel G. Results of a prospective study
with comparison of clinical, endosonographic, computed tomography,
magnetic resonance imaging and pathologic staging of advanced
gynecologic carcinoma and recurrence. Surg Gynecol Obstet 1993
Sep;177(3):231-6.
Hricak H. Carcinoma of the female reproductive organs. Value of
cross-sectional imaging. Cancer 1991 Feb 15;67(4 Suppl):1209-18.
Huengsberg M, MacDonald LM, Bradbeer CS. The use of pelvic
ultrasound in female patients attending a GUM clinic. Int J STD AIDS
1993 Jul-Aug;4(4):190-3.
Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L,
Knapp RC, Bast RC Jr. CA 125 in peritoneal fluid and serum from
patients with benign gynecologic conditions and ovarian cancer.
Gynecol Oncol 1990 Feb;36(2):161-5.
Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl-Tn,
sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and
tissue polypeptide antigen in differentiating ovarian cancer from benign
tumors. Obstet Gynecol 1992 Mar;79(3):434-40.
Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M,
Karino K, Endoh J, Kitao M. Clinical evaluations of the tumor marker
sialyl SSEA-1 antigen for clinical gynecological disease. Gynecol
Obstet Invest 1990;29(3):214-8.
Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M,
Takahashi K, Yoshino N, Karino K, Endoh J, et al. Differential
diagnosis of ovarian cancer, benign ovarian tumor and endometriosis by
a combination assay of serum sialyl SSEA-1 antigen and CA125 levels.
Gynecol Obstet Invest 1990;29(1):71-4.
Jacobs I, Bast RC Jr. Immunodiagnosis of ovarian tumors. Immunol
Ser 1990;53:323-38.
Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas
JG, Oram D. Prevalence screening for ovarian cancer in
postmenopausal women by CA 125 measurement and ultrasonography.
BMJ 1993 Apr 17;306(6884):1030-4. Comment in: BMJ 1993 Apr
17;306(6884):1015-6 ; BMJ 1993 Jun 19;306(6893):1684; discussion
1685-6 ; BMJ 1993 Jun 19;306(6893):1685 ; BMJ 1993 Jun
19;306(6893):1685-6.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A
risk of malignancy index incorporating CA 125, ultrasound and
menopausal status for the accurate preoperative diagnosis of ovarian
cancer. Br J Obstet Gynaecol 1990 Oct;97(10):922-9.
Jacobs IJ, Oram DH, Bast RC Jr. Strategies for improving the
specificity of screening for ovarian cancer with tumor-associated
antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 1992
Sep;80(3 Pt 1):396-9.
Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne
RJ, Leech V, Molyneux A, Berchuck A, Ponder BA, et al. A deletion
unit on chromosome 17q in epithelial ovarian tumors distal to the
familial breast/ovarian cancer locus. Cancer Res 1993 Mar
15;53(6):1218-21.
Jain KA, Friedman DL, Pettinger TW, Alagappan R, Jeffrey RB Jr,
Sommer FG. Adnexal masses: comparison of specificity of endovaginal
US and pelvic MR imaging. Radiology 1993 Mar;186(3):697-704.
Jain KA, Jeffrey RB Jr. Pictorial essay: transabdominal and endovaginal
sonography of adnexal masses. Clin Imaging 1991
Oct-Dec;15(4):245-52.
Jones MH, Nakamura Y. Deletion mapping of chromosome 3p in
female genital tract malignancies using microsatellite polymorphisms.
Oncogene 1992 Aug;7(8):1631-4.
Juhasz B, Kurjak A, Lampe L, Zalud I, Crvenkovic G, Hernadi Z.
Tissue characterization by transvaginal colour Doppler for the
evaluation of gynaecological tumours. 2. Clinical experiences. Acta
Med Hung 1990;47(3-4):149-56.
Karlan BY, Raffel LJ, Crvenkovic G, Smrt C, Chen MD, Lopez E,
Walla CA, Garber C, Cane P, Sarti DA, et al. A multidisciplinary
approach to the early detection of ovarian carcinoma: rationale,
protocol design, and early results. Am J Obstet Gynecol 1993
Sep;169(3):494-501.
Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H, Tomoda Y.
Transvaginal Doppler ultrasound with color flow imaging in the
diagnosis of ovarian cancer. Obstet Gynecol 1992 Feb;79(2):163-7.
Kenemans P, Bon GG, Kessler AC, Verstraeten AA, van Kamp GJ.
Multicenter technical and clinical evaluation of a fully automated
enzyme immunoassay for CA 125. Clin Chem 1992 Aug;38(8 Pt
1):1466-71.
Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous
double-determinant immunoradiometric assay CA 125 II: reliable
second-generation immunoassay for determining CA 125 in serum. Clin
Chem 1993 Dec;39(12):2509-13.
Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125
in gynecological pathology--a review. Eur J Obstet Gynecol Reprod
Biol 1993 Apr;49(1-2):115-24.
Kiechle-Schwarz M, Bauknecht T, Wienker T, Walz L, Pfleiderer A.
Loss of constitutional heterozygosity on chromosome 11p in human
ovarian cancer. Positive correlation with grade of differentiation.
Cancer 1993 Oct 15;72(8):2423-32.
Kier R, Smith RC, McCarthy SM. Value of lipid- and
water-suppression MR images in distinguishing between blood and lipid
within ovarian masses. AJR Am J Roentgenol 1992 Feb;158(2):321-5.
King MC, Rowell S, Love SM. Inherited breast and ovarian cancer.
What are the risks? What are the choices? JAMA 1993 Apr
21;269(15):1975-80.
Kobayashi H, Tamura M, Satoh T, Terao T. Clinical evaluation of new
cancer-associated antigen CA125 II in epithelial ovarian cancers:
comparison with CA125. Clin Biochem 1993 Jun;26(3):213-9.
Kopf I, Strid KG, Islam MQ, Granberg S, Friberg LG, Levan G,
Carstensen J. Heterochromatin variants in 109 ovarian cancer patients
and 192 healthy subjects. Hereditas 1990;113(1):7-16.
Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer
Institute sponsored screening trial for prostatic, lung, colorectal, and
ovarian cancers. Cancer 1993 Jan 15;71(2 Suppl):589-93.
Kuesel AC, Kroft T, Prefontaine M, Smith IC. Lipoprotein(a) and
CA125 levels in the plasma of patients with benign and malignant
ovarian disease. Int J Cancer 1992 Sep 30;52(3):341-6.
Kupfer MC, Schwimer SR, Lebovic J. Transvaginal sonographic
appearance of endometriomata: spectrum of findings. J Ultrasound
Med 1992 Apr;11(4):129-33.
Kurjak A, Predanic M. New scoring system for prediction of ovarian
malignancy based on transvaginal color Doppler sonography. J
Ultrasound Med 1992 Dec;11(12):631-8.
Kurjak A, Predanic M, Kupesic-Urek S, Jukic S. Transvaginal color
and pulsed Doppler assessment of adnexal tumor vascularity. Gynecol
Oncol 1993 Jul;50(1):3-9.
Kurjak A, Salihagic A, Kupesic-Urek S, Predanic A. Clinical value of
the assessment of gynaecological tumour angiogenesis by transvaginal
colour Doppler. Ann Med 1992 Apr;24(2):97-103.
Kurjak A, Schulman H, Sosic A, Zalud I, Shalan H. Transvaginal
ultrasound, color flow, and Doppler waveform of the postmenopausal
adnexal mass. Obstet Gynecol 1992 Dec;80(6):917-21.
Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with
transvaginal color ultrasound. J Ultrasound Med 1991 Jun;10(6):295-7.
Comment in: J Ultrasound Med 1992 Mar;11(3):80.
Laing FC. Ultrasound of gynecologic pathologies. Curr Opin Radiol
1992 Apr;4(2):78-84.
Lee JH, Kavanagh JJ, Wildrick DM, Wharton JT, Blick M. Frequent
loss of heterozygosity on chromosomes 6q, 11, and 17 in human
ovarian carcinomas. Cancer Res 1990 May 1;50(9):2724-8.
Li FP, Garber JE. Gene for familial breast and ovarian cancer. Lancet
1993 Apr 24;341(8852):1060-1. Comment on: Lancet 1993 Apr
24;341(8852):1101-2 ; Comment in: Lancet 1993 May
29;341(8857):1422.
Lotzniker M, Pavesi F, Scarabelli M, Vadacca G, Franchi M, Moratti
R. Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer.
Int J Biol Markers 1991 Apr-Jun;6(2):115-21.
Luxman D, Bergman A, Sagi J, David MP. The postmenopausal
adnexal mass: correlation between ultrasonic and pathologic findings.
Obstet Gynecol 1991 May;77(5):726-8. Comment in: Obstet Gynecol
1991 Oct;78(4):726.
Macri CI, DiSaia PJ. Ovarian cancer screening. West J Med 1992
Jun;156(6):652-3.
Mahon SM, Casperson DS. Focus on oncology: ovarian cancer
screening and early detection. J Urol Nurs 1992 Apr-Jun;11(2):112-9.
Mazoyer S, Lalle P, Narod SA, Bignon YJ, Courjal F, Jamot B,
Dutrillaux B, Stoppa-Lyonnett D, Sobol H. Linkage analysis of 19
French breast cancer families, with five chromosome 17q markers. Am
J Hum Genet 1993 Apr;52(4):754-60.
Menczer J, Ben-Baruch G, Moran O, Lipitz S. Cyst fluid CA 125 levels
in ovarian epithelial neoplasms. Obstet Gynecol 1993 Jan;81(1):25-8.
Mendelson EB, Bohm-Velez M. Transvaginal ultrasonography of
pelvic neoplasms. Radiol Clin North Am 1992 Jul;30(4):703-34.
Milner BJ, Allan LA, Kelly KF, Cruickshank D, Hall M, Johnston A,
Kitchener H, Parkin D, Haites N. Linkage studies with 17q and 18q
markers in a breast/ovarian cancer family. Am J Hum Genet 1993
Apr;52(4):761-6.
Miyao M, Takahashi M, Sumi M, Miyazaki K, Okamura H. Correlation
of CT patterns with histologic findings in parauterine masses. Radiat
Med 1992 Nov-Dec;10(6):223-31.
Mogensen O, Mogensen B, Jakobsen A. Tumor-associated trypsin
inhibitor and cancer antigen 125 in pelvic masses. Gynecol Oncol 1990
Aug;38(2):170-4.
Mogensen O, Mogensen B, Jakobsen A. Tumour-associated trypsin
inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian
tumours. Br J Cancer 1990 Feb;61(2):327-9.
Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, Lopez JJ, Ballesta
A. A prospective study of tumor markers CA 125 and CA 19.9 in
patients with epithelial ovarian carcinomas. Tumour Biol
1992;13(5-6):278-86.
Monoclonal antibodies in breast and ovarian cancer. Proceedings of the
British Association for Cancer Research Workshop, Oxford, 17-19
March, 1991. Dis Markers 1991 May-Aug;9(3-4):125-238.
Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S,
Okazaki E. Cancer antigen 125, carcinoembryonic antigen, and
carbohydrate determinant 19-9 in ovarian tumors. Cancer 1990 Dec
15;66(12):2628-35.
Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H,
Brucks JP, Tsao SW, Berkowitz RS. Screening for ovarian cancer: the
preliminary experience of a familial ovarian cancer center. Gynecol
Oncol 1993 Oct;51(1):12-20.
Nadji M. Tumor markers in gynecologic neoplasms. Clin Lab Med
1990 Mar;10(1):105-17.
Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J,
Lenoir GM. Familial breast-ovarian cancer locus on chromosome
17q12-q23. Lancet 1991 Jul 13;338(8759):82-3. Comment in: Lancet
1991 Aug 17;338(8764):444-5.
Neal CE, Baker MR, Hilgers RD, Fanning J, Burke RC, Snodgrass J,
Cull RD. In-111 CYT-103 immunoscintigraphy in the imaging of
ovarian carcinoma. Clin Nucl Med 1993 Jun;18(6):472-6.
Neal CE, Swenson LC, Fanning J, Texter JH. Monoclonal antibodies in
ovarian and prostate cancer. Semin Nucl Med 1993 Apr;23(2):114-26.
Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H,
Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer
patients. Gynecol Oncol 1993 Feb;48(2):148-54.
Nelson CL, Sellers TA, Rich SS, Potter JD, McGovern PG, Kushi LH.
Familial clustering of colon, breast, uterine, and ovarian cancers as
assessed by family history. Genet Epidemiol 1993;10(4):235-44.
Normand T, Narod S, Labrie F, Simard J. Detection of polymorphisms
in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the
EDH17B2 locus on 17q11-q21. Hum Mol Genet 1993
Apr;2(4):479-83.
Nozawa S, Aoki D, Yajima M, Tsukazaki K, Kobayashi T, Kimura E,
Terashima Y, Inaba N, Takamizawa H, Negishi Y, et al. CA54/61 as a
marker for epithelial ovarian cancer. Cancer Res 1992 Mar
1;52(5):1205-9.
Nozawa S, Yajima M, Sakuma T, Udagawa Y, Kiguchi K, Sakayori M,
Narisawa S, Iizuka R, Uemura M. Cancer-associated
galactosyltransferase as a new tumor marker for ovarian clear cell
carcinoma. Cancer Res 1990 Feb 1;50(3):754-9.
Nozawa S, Yajima M, Sasaki H, Tsukazaki K, Aoki D, Sakayori M,
Udagawa Y, Kobayashi T, Sato I, Furusako S, et al. A new CA125-like
antigen (CA602) recognized by two monoclonal antibodies against a
newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J
Cancer Res 1991 Jul;82(7):854-61.
Occhipinti KA, Frankel SD, Hricak H. The ovary. Computed
tomography and magnetic resonance imaging. Radiol Clin North Am
1993 Sep;31(5):1115-32.
Ohkawa K, Takada K, Hatano T, Takizawa N, Tsukada Y, Yamada K,
Terashima Y, Matsuda M, Machida K. An evaluation of ovarian
carcinoma-associated antigen defined by murine monoclonal antibody
CF511 in sera from patients with ovarian carcinoma. Br J Cancer 1991
Aug;64(2):259-62.
Ohuchi N, Gero E, Mori S, Akimoto M, Matoba N, Nishihira T,
Hirayama K, Colcher D, Schlom J. Clinical evaluation of CA72-4
immunoradiometric assay for serum TAG-72 antigen in patients with
carcinoma. J Tumor Marker Oncol 1990;5(1):1-10.
Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T,
Terada M, Yokota J. Frequent allelic losses and mutations of the p53
gene in human ovarian cancer. Cancer Res 1991 Oct 1;51(19):5171-6.
Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S.
Clinical experience in gynecological cancer management. d). Ovarian
tumors--1) Epithelial: report from the Gynaecological Institutes of
Padua University (1963-1990). Eur J Gynaecol Oncol
1992;13(1):17-33.
Oram DH, Jacobs IJ, Brady JL, Prys-Davies A. Early diagnosis of
ovarian cancer. Br J Hosp Med 1990 Nov;44(5):320, 322, 324.
Patsner B. Preoperative serum CA-125 levels in early stage ovarian
cancer. Eur J Gynaecol Oncol 1990;11(5):319-21.
Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, Floderus UM,
Furgyik S, Helm G, Himmelmann A, Willen H, et al. Chromosome
aberrations in 35 primary ovarian carcinomas. Genes Chromosom
Cancer 1992 Jan;4(1):58-68.
Perkins AC, Powell MC, Wastie ML, Scott IV, Hitchcock A,
Worthington BS, Symonds EM. A prospective evaluation of OC125
and magnetic resonance imaging in patients with ovarian carcinoma.
Eur J Nucl Med 1990;16(4-6):311-6.
Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney
GL, Jenkins RB. Interphase molecular cytogenetic analysis of epithelial
ovarian carcinomas. Am J Pathol 1993 Mar;142(3):733-41.
Phillips N, Ziegler M, Saha B, Xynos F. Allelic loss on chromosome 17
in human ovarian cancer. Int J Cancer 1993 Apr 22;54(1):85-91.
Piver MS, Hempling RE. Screening for gynecologic malignancies in
primary care: ovarian cancer. Emerg Med 1993 Mar;25(4):141-2,
145-6, 148.
Plebani M, Faggian D, Masiero M, Giacomini A, Burlina A. CA 19-9
and CA 125 determination by immunoluminometric assay. J Clin Chem
Clin Biochem 1990 Dec;28(12):919-21.
Popp LW, Gaetje R, Stoyanov M. Accuracy of bimanual palpation
versus vaginosonography in determination of the measurements of
pelvic tumors. Arch Gynecol Obstet 1993;252(4):197-202.
Porter DE, Cohen BB, Wallace MR, Carothers A, Steel CM. Linkage
mapping in familial breast cancer: improved localisation of a
susceptibility locus on chromosome 17q12-21. Int J Cancer 1993 Jan
21;53(2):188-98.
Powell MA. Screening for ovarian cancer. J Am Acad Nurse Pract
1992 Jan-Mar;4(1):36-7.
Pyrgiotis E, Salamalekis E, Loghis C, Dima C, Zourlas PA. CA 125 in
preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol
1993;14(4):279-82.
Quillin SP, Siegel MJ. CT features of benign and malignant teratomas
in children. J Comput Assist Tomogr 1992 Sep-Oct;16(5):722-6.
Reinsberg J, Nocke W. Falsely low results in CA 125 determination
due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2
fragments of the OC125 antibody. Eur J Clin Chem Clin Biochem 1993
May;31(5):323-7.
Reinsberg J, Schultes B, Wagner U, Krebs D. Monitoring cancer
antigen 125 in serum of ovarian cancer patients after administration of
131I-labeled F(ab')2 fragments of OC125 antibody. Clin Chem 1993
May;39(5):891-6.
Riccio TJ, Adams HG, Munzing DE, Mattrey RF. Magnetic resonance
imaging as an adjunct to sonography in the evaluation of the female
pelvis. Magn Reson Imaging 1990;8(6):699-704.
Roberts CG, Tattersall MH. Cytogenetic study of solid ovarian tumors.
Cancer Genet Cytogenet 1990 Sep;48(2):243-53.
Ronay G, Jager W, Weiss K, Feistel H, Wolf F, Tulusan AH, Lang N.
Immunohistochemical identification of CA125 and the F(ab')2
fragments of the murine monoclonal antibody OC125 in ovarian cancer
tissue. Br J Cancer Suppl 1990 Jul;10:67-9.
Runowicz CD. Advances in the screening and treatment of ovarian
cancer. CA Cancer J Clin 1992 Nov-Dec;42(6):327-49. Published
erratum appears in CA Cancer J Clin 1993 May-Jun;43(3):191-2.
Runowicz CD, Goldberg GL, Smith HO. Cancer screening for women
older than 40 years of age. Obstet Gynecol Clin North Am 1993
Jun;20(2):391-408.
Russell SE, Hickey GI, Lowry WS, White P, Atkinson RJ. Allele loss
from chromosome 17 in ovarian cancer. Oncogene 1990
Oct;5(10):1581-3.
Rustin GJ. Impact of tumour marker measurements upon management
of patients with carcinoma of the ovary. Dis Markers 1991
May-Aug;9(3-4):153-8.
Saga T, Endo K, Nakashima T, Awaji T, Koizumi M, Kawamura Y,
Watanabe Y, Konishi J, Nonogaki H, Nanbu Y, et al. Construction of
an immunoradiometric assay for ovarian cancer associated antigen
CA125 recognizing different antigenic determinant. Acta Obstet
Gynecol Scand 1990;69(2):175-81.
Saito H, Inazawa J, Saito S, Kasumi F, Koi S, Sagae S, Kudo R, Saito
J, Noda K, Nakamura Y. Detailed deletion mapping of chromosome
17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and
commonly deleted in tumors. Cancer Res 1993 Jul 15;53(14):3382-5.
Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J, Noda K, Nakamura
Y. Fine-scale deletion mapping of the distal long arm of chromosome 6
in 70 human ovarian cancers. Cancer Res 1992 Oct 15;52(20):5815-7.
Sarti DA. Transvaginal sonography: a call for tempered enthusiasm.
AJR Am J Roentgenol 1993 Jul;161(1):95-6. Comment on: AJR Am J
Roentgenol 1993 Jul;161(1):91-4.
Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB.
Transvaginal sonographic characterization of ovarian disease:
evaluation of a new scoring system to predict ovarian malignancy.
Obstet Gynecol 1991 Jul;78(1):70-6. Comment in: Obstet Gynecol
1991 Dec;78(6):1151-2.
Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of
human ovarian cancer. Cancer Res 1991 Oct 1;51(19):5118-22.
Satoskar P, Deshpande A. The value of ultrasonography in the
diagnosis of adnexal masses. J Postgrad Med 1991 Jan;37(1):35-9.
Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian
cancer screening. A decision analysis model. Ann Intern Med 1993 Jun
1;118(11):838-43. Comment in: Ann Intern Med 1993 Jun
1;118(11):901-2.
Schoenfeld A, Levavi H, Hirsch M, Pardo J, Ovadia J. Transvaginal
sonography in postmenopausal women. J Clin Ultrasound
1990;18(4):350-8.
Schoenfeld A, Levavi H, Ovadia J. Surgery in postmenopausal
women--the value of transvaginal sonography. Surg Endosc
1990;4(2):108-13.
Schwartz MK. Screening for cancer: is it cost effective? Clin Chem
1993 Nov;39(11 Pt 2):2397-403.
Schwartz PE. Ovarian masses: serologic markers. Clin Obstet Gynecol
1991 Jun;34(2):423-32.
Schwartz PE. The role of tumor markers in the preoperative diagnosis
of ovarian cysts. Clin Obstet Gynecol 1993 Jun;36(2):384-94.
Schwartz PE, Chambers JT, Taylor KJ, Pellerito J, Hammers L, Cole
LA, Yang-Feng TL, Smith P, Mayne ST, Makuch R. Early detection of
ovarian cancer: background, rationale, and structure of the Yale Early
Detection Program. Yale J Biol Med 1991 Nov-Dec;64(6):557-71.
Scott IV. The identification of high risk and practical strategies for a
population based randomized trial of ovarian cancer screening. Dis
Markers 1991 May-Aug;9(3-4):133-52.
Scoutt LM, McCarthy SM. Applications of magnetic resonance
imaging to gynecology. Top Magn Reson Imaging 1990
Jun;2(3):37-49.
Scoutt LM, McCarthy SM. Imaging of ovarian masses: magnetic
resonance imaging. Clin Obstet Gynecol 1991 Jun;34(2):443-51.
Semelka RC, Lawrence PH, Shoenut JP, Heywood M, Kroeker MA,
Lotocki R. Primary ovarian cancer: prospective comparison of
contrast-enhanced CT and pre-and postcontrast, fat-suppressed MR
imaging, with histologic correlation. J Magn Reson Imaging 1993
Jan-Feb;3(1):99-106.
Serreyn R, DeBoever J, Martens G, Vandekerckhove D. Quantitive
assessment of CA-125 in the normal ovary and in benign and malignant
ovarian tumors. J Tumor Marker Oncol 1990;5(4):341-9.
Siegel MJ, Surratt JT. Pediatric gynecologic imaging. Obstet Gynecol
Clin North Am 1992 Mar;19(1):103-27.
Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu The V,
Vivier A, Lasko D, Morgan K, Rouleau GA, et al. Genetic mapping of
the breast-ovarian cancer syndrome to a small interval on chromosome
17q12-21: exclusion of candidate genes EDH17B2 and RARA. Hum
Mol Genet 1993 Aug;2(8):1193-9.
Skates SJ, Singer DE. Quantifying the potential benefit of CA 125
screening for ovarian cancer. J Clin Epidemiol 1991;44(4-5):365-80.
Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the
region 17q12-21 in familial breast and ovarian cancer involve the
wild-type chromosome. Nat Genet 1992 Oct;2(2):128-31.
Smith SA, Easton DF, Ford D, Peto J, Anderson K, Averill D, Stratton
M, Ponder M, Pye C, Ponder BA. Genetic heterogeneity and
localization of a familial breast-ovarian cancer gene on chromosome
17q12-q21. Am J Hum Genet 1993 Apr;52(4):767-76.
Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC Jr.
Preoperative serum tumor-associated antigen levels in women with
pelvic masses. Obstet Gynecol 1990 Feb;75(2):249-54.
Sparks JM, Varner RE. Ovarian cancer screening. Obstet Gynecol
1991 May;77(5):787-92.
Spreafico C, Frigerio L, Lanocita R, Spatti GB, Marchiano A, Milella
M, Garbagnati F, Bohm S, Damascelli B. Color-Doppler ultrasound in
ovarian masses: anatomo-pathologic correlation. Tumori 1993 Aug
31;79(4):262-7.
Spurr NK, Kelsell DP, Black DM, Murday VA, Turner G, Crockford
GP, Solomon E, Cartwright RA, Bishop DT. Linkage analysis of
early-onset breast and ovarian cancer families, with markers on the long
arm of chromosome 17. Am J Hum Genet 1993 Apr;52(4):777-85.
Stevens SK, Hricak H, Stern JL. Ovarian lesions: detection and
characterization with gadolinium-enhanced MR imaging at 1.5 T.
Radiology 1991 Nov;181(2):481-8.
Stigbrand T, Riklund K, Tholander B, Hirano K, Lalos O, Stendahl U.
Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase
as tumour marker in relation to CA 125 and TPA for ovarian epithelial
tumours. Eur J Gynaecol Oncol 1990;11(5):351-60.
Surratt JT, Siegel MJ. Imaging of pediatric ovarian masses.
Radiographics 1991 Jul;11(4):533-48.
Sutton CL, McKinney CD, Jones JE, Gay SB. Ovarian masses
revisited: radiologic and pathologic correlation. Radiographics 1992
Sep;12(5):853-77.
Suzuki M, Ohwada M, Aida I, Tamada T, Hanamura T, Nagatomo M.
Macrophage colony-stimulating factor as a tumor marker for epithelial
ovarian cancer. Obstet Gynecol 1993 Dec;82(6):946-50.
Suzuki M, Sekiguchi I, Tamada T. Clinical evaluation of
tumor-associated mucin-type glycoprotein CA 54/61 in ovarian
cancers: comparison with CA 125. Obstet Gynecol 1990 Sep;76(3 Pt
1):422-7.
Taccone W, Mazzon W, Belli M. Evaluation of TATI and other
markers in solid tumors. Scand J Clin Lab Invest Suppl
1991;207:25-32.
Tay SK, Tan YY. Risk factors and a risk scoring system for the
prediction of malignancy in ovarian cysts. Aust N Z J Obstet Gynaecol
1992 Nov;32(4):341-5.
Theillet C, Adelaide J, Louason G, Bonnet-Dorion F, Jacquemier J,
Adnane J, Longy M, Katsaros D, Sismondi P, Gaudray P, et al. FGFRI
and PLAT genes and DNA amplification at 8p12 in breast and ovarian
cancers. Genes Chromosom Cancer 1993 Aug;7(4):219-26.
Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Kiviranta
A, Hallman K, Holm L, Weiner E, Tamsen L. Pretreatment serum
levels of CA-125, carcinoembryonic antigen, tissue polypeptide
antigen, and placental alkaline phosphatase, in patients with ovarian
carcinoma, borderline tumors, or benign adnexal masses: relevance for
differential diagnosis. Gynecol Oncol 1990 Oct;39(1):16-25.
Tholander B, Taube A, Lindgren A, Sjoberg O, Stendahl U, Tamsen L.
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue
polypeptide antigen, and placental alkaline phosphatase in patients with
ovarian carcinoma: influence of histological type, grade of
differentiation, and clinical stage of disease. Gynecol Oncol 1990
Oct;39(1):26-33.
Thorvinger B. Diagnostic and interventional radiology in gynecologic
neoplasms. Acta Radiol Suppl 1992;378(Pt 3):93-108.
Thurnher S, Hodler J, Baer S, Marincek B, von Schulthess GK.
Gadolinium-DOTA enhanced MR imaging of adnexal tumors. J
Comput Assist Tomogr 1990 Nov-Dec;14(6):939-49.
Timor-Tritsch LE, Lerner JP, Monteagudo A, Santos R. Transvaginal
ultrasonographic characterization of ovarian masses by means of color
flow-directed Doppler measurements and a morphologic scoring
system. Am J Obstet Gynecol 1993 Mar;168 (3 Pt 1):909-13.
Toftager-Larsen K, Hording U, Dreisler A, Daugaard S, Lund B, Bock
J, Lundvall F, Frederiksen K, Norgaard-Pedersen B. CA-125, placental
alkaline phosphatase and tissue polypeptide antigen as preoperative
serum markers in ovarian carcinoma. Gynecol Obstet Invest
1992;33(3):177-82.
Tomas C, Penttinen J, Risteli J, Risteli L, Kauppila A. Simultaneous
evaluation of epithelial cell function by CA 125 and stromal cell activity
by aminoterminal propeptide of type III procollagen (PIIINP) in
ovarian carcinoma. Ann Med 1990 Apr;22(2):115-21.
Tsao SW, Mok CH, Knapp RC, Oike K, Muto MG, Welch WR,
Goodman HM, Sheets EE, Berkowitz RS, Lau CC. Molecular genetic
evidence of a unifocal origin for human serous ovarian carcinomas.
Gynecol Oncol 1993 Jan;48(1):5-10. Comment in: Gynecol Oncol 1993
Jan;48(1):1-3.
Tsao SW, Mok CH, Oike K, Muto M, Goodman HM, Sheets EE,
Berkowitz RS, Knapp RC, Lau CC. Involvement of p53 gene in the
allelic deletion of chromosome 17p in human ovarian tumors.
Anticancer Res 1991 Nov-Dec;11(6):1975-82.
van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer.
Neth J Med 1992 Feb;40(1-2):36-51.
van der Zee AG, Duk JM, Aalders JG, Boontje AH, ten Hoor KA, de
Bruijn HW. The effect of abdominal surgery on the serum
concentration of the tumour-associated antigen CA 125. Br J Obstet
Gynaecol 1990 Oct;97(10):934-8.
van Kamp GJ, Verstraeten AA, Kenemans P. Discordant serum CA
125 values in commercial immunoassays. Eur J Obstet Gynecol Reprod
Biol 1993 Apr;49(1-2):99-103.
van Nagell JR Jr, DePriest PD, Gallion HH, Pavlik EJ. Ovarian cancer
screening. Cancer 1993 Feb 15;71(4 Suppl):1523-8.
van Nagell JR Jr, Higgins RV, Donaldson ES, Gallion HH, Powell DE,
Pavlik EJ, Woods CH, Thompson EA. Transvaginal sonography as a
screening method for ovarian cancer. A report of the first 1000 cases
screened. Cancer 1990 Feb 1;65(3):573-7.
Vandamme B, Lissens W, Amfo K, De Sutter P, Bourgain C, Vamos
E, De Greve J. Deletion of chromosome 11p13-11p15.5 sequences in
invasive human ovarian cancer is a subclonal progression factor. Cancer
Res 1992 Dec 1;52(23):6646-52.
Varpula M. Magnetic resonance imaging of female pelvic masses and
local recurrent tumors at an ultra low (0.02 T) magnetic field:
correlation with computed tomography. Magn Reson Imaging
1993;11(1):35-46.
Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K.
CA125 and placental alkaline phosphatase as serum tumor markers in
epithelial ovarian carcinoma. Tumour Biol 1992;13(3):168-74.
Viel A, Giannini F, Tumiotto L, Sopracordevole F, Visentin MC,
Boiocchi M. Chromosomal localisation of two putative 11p
oncosuppressor genes involved in human ovarian tumours. Br J Cancer
1992 Dec;66(6):1030-6.
Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel
EJ. Tumor marker CA 125 in diagnosis, monitoring management and
follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205-8.
Wade RV. Gynecologic applications of real time ultrasound. Appl
Radiol 1993 Feb;22(2):15-9.
Wahl RL. Radiolabeled monoclonal antibodies for the diagnosis and
treatment of ovarian carcinoma. Front Radiat Ther Oncol
1990;24:228-39.
Walsh JM. Cancer screening in older adults. West J Med 1992
May;156(5):495-500. Comment in: West J Med 1992
Oct;157(4):469-70.
Wardle FJ, Collins W, Pernet AL, Whitehead MI, Bourne TH,
Campbell S. Psychological impact of screening for familial ovarian
cancer. J Natl Cancer Inst 1993 Apr 21;85(8):653-7.
Warner BW, Kuhn JC, Barr LL. Conservative management of large
ovarian cysts in children: the value of serial pelvic ultrasonography.
Surgery 1992 Oct;112(4):749-55.
Weiner Z, Beck D, Shteiner M, Borovik R, Ben-Shachar M, Robinzon
E, Brandes JM. Screening for ovarian cancer in women with breast
cancer with transvaginal sonography and color flow imaging. J
Ultrasound Med 1993 Jul;12(7):387-93.
Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes JM.
Differentiating malignant from benign ovarian tumors with transvaginal
color flow imaging. Obstet Gynecol 1992 Feb;79(2):159-62. Comment
in: Obstet Gynecol 1992 Jul;80(1):156-7.
Weinreb JC, Barkoff ND, Megibow A, Demopoulos R. The value of
MR imaging in distinguishing leiomyomas from other solid pelvic
masses when sonography is indeterminate. AJR Am J Roentgenol 1990
Feb;154(2):295-9.
Welander CE. What do CA 125 and other antigens tell us about
ovarian cancer biology? Acta Obstet Gynecol Scand Suppl
1992;155:85-93.
Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and
in the United States. Br J Obstet Gynaecol 1992 Apr;99(4):329-32.
Westhoff C, Levin B, Ladd G, O'Connor J. Sources of variability in
normal CA 125 levels. Cancer Epidemiol Biomarkers Prev 1992
Jul-Aug;1(5):357-9.
Westhoff C, Randall MC. Ovarian cancer screening: potential effect on
mortality. Am J Obstet Gynecol 1991 Sep;165(3):502-5.
Wikborn C, Pettersson F, Silfversward C, Moberg PJ. Symptoms and
diagnostic difficulties in ovarian epithelial cancer. Int J Gynaecol Obstet
1993 Sep;42(3):261-4.
Williams L. Ovarian cancer screening. The search for cost-effective
methods. Postgrad Med 1992 Dec;92(8):63-6, 72.
Willson JR. Ultrasonography in the diagnosis of gynecologic disorders.
Am J Obstet Gynecol 1991 Apr;164(4):1064-7; discussion 1067-71.
Comment in: Am J Obstet Gynecol 1992 Apr;166(4):1310-1.
Wolf SI, Gosink BB, Feldesman MR, Lin MC, Stuenkel CA, Braly PS,
Pretorius DH. Prevalence of simple adnexal cysts in postmenopausal
women. Radiology 1991 Jul;180(1):65-71.
Wong JG, Feussner JR. Screening for ovarian cancer: not worthwhile
for most patients. N C Med J 1993 Sep;54(9):438-40.
Wu JT, Carlisle P. Low frequency and low level of elevation of serum
CA 72-4 in human carcinomas in comparison with established tumor
markers. J Clin Lab Anal 1992;6(1):59-64.
Yang-Feng TL, Han H, Chen KC, Li SB, Claus EB, Carcangiu ML,
Chambers SK, Chambers JT, Schwartz PE. Allelic loss in ovarian
cancer. Int J Cancer 1993 Jun 19;54(4):546-51.
Yang-Feng TL, Li S, Han H, Schwartz PE. Frequent loss of
heterozygosity on chromosomes Xp and 13q in human ovarian cancer.
Int J Cancer 1992 Oct 21;52(4):575-80.
Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE.
Trisomy 12 and K-ras-2 amplification in human ovarian tumors. Int J
Cancer 1991 Jul 9;48(5):678-81.
Yedema CA, Kenemans P, Wobbes T, Thomas CM, Bon GG, Mulder
C, Voorhorst FJ, Verstraeten AA, van Kamp GJ, Hilgers J. Use of
serum tumor markers in the differential diagnosis between ovarian and
colorectal adenocarcinomas. Tumour Biol 1992;13(1-2):18-26.
Yedema KA, Kenemans P, Wobbes T, van Kamp GJ, de Bruijn HW,
Thomas CM, Massuger LF, Schijf CP, Bon GG, Vermorken JB, et al.
Carcinoma-associated mucin serum markers CA M26 and CA M29:
efficacy in detecting and monitoring patients with cancer of the breast,
colon, ovary, endometrium and cervix. Int J Cancer 1991 Jan
21;47(2):170-9.
Yedema KA, Thomas CM, Segers MF, Doesburg WH, Kenemans P.
Comparison of five immunoassay procedures for the ovarian
carcinoma-associated antigenic determinant CA 125 in serum. Eur J
Obstet Gynecol Reprod Biol 1992 Dec 28;47(3):245-52.
Yoder LH. The epidemiology of ovarian cancer: a review. Oncol Nurs
Forum 1990 May-Jun;17(3):411-5. Comment in: Oncol Nurs Forum
1990 Jul-Aug;17(4):483-4.
Yoffe N, Bronshtein M, Brandes J, Blumenfeld Z. Hemorrhagic ovarian
cyst detection by transvaginal sonography: the great imitator. Gynecol
Endocrinol 1991 Jun;5(2):123-9.
Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT,
Klug TL, Zurawski VR Jr, Bast RC Jr. Coexpression of different
antigenic markers on moieties that bear CA 125 determinants. Cancer
Res 1991 Jan 15;51(2):468-75.
Zangwill BC, Balsara G, Dunton C, Varello M, Rebane BA, Hernandez
E, Atkinson BF. Ovarian carcinoma heterogeneity as demonstrated by
DNA ploidy. Cancer 1993 Apr 1;71(7):2261-7.
Zawin M, McCarthy S, Scoutt LM, Comite F. High-field MRI and US
evaluation of the pelvis in women with leiomyomas. Magn Reson
Imaging 1990;8(4):371-6.
Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O.
Tumor marker CA-125 in tissues of the female reproductive tract and
in serum during the normal menstrual cycle. Fertil Steril 1993
May;59(5):1028-35.
Zimmermann W, Bender E, Rohde K, Reis A, Wiseman R, Futreal A,
Krause H, Prokoph H, Werner S, Scherneck S. Linkage analysis in
German breast cancer families with early onset of the disease, using
highly polymorphic markers from the chromosome 17q11-q24 region.
Am J Hum Genet 1993 Apr;52(4):789-91.
Zimny ME. Ovarian cancer: a nursing overview. Oncology (Huntingt)
1991 Aug;5(8):147-53; discussion 154.
Zurawski VR Jr, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast
RC Jr, Eklund G, Mattsson B, Connor RJ, Prorok PC, et al.
Prospective evaluation of serum CA 125 levels in a normal population,
phase I: the specificities of single and serial determinations in testing for
ovarian cancer. Gynecol Oncol 1990 Mar;36(3):299-305.
Prevention
Barber HR. Prophylaxis in ovarian cancer. Cancer 1993 Feb 15;71(4
Suppl):1529-33.
Boike G, Averette H, Hoskins W, Chmiel J, Zuber K, Karnell L,
Winchester D. National survey of ovarian carcinoma. IV. Women with
prior hysterectomy: a failure of prevention? [abstract]. Gynecol Oncol
1993 Apr;49(1):112-3.
Cruickshank DJ, Haites N, Anderson S, Matheson H, Hall MH, Milner
B, Ah-See A, Gunn I, Eremin O, Gilbert F, et al. The multidisciplinary
management of a family with epithelial ovarian cancer. Br J Obstet
Gynaecol 1992 Mar;99(3):226-31.
Dicker RC, Scally MJ, Greenspan JR, Layde PM, Ory HW, Maze JM,
Smith JC. Hysterectomy among women of reproductive age. Trends in
the United States, 1970-1978. JAMA 1982 Jul 16;248(3):323-7.
Estrogen use and postmenopausal women: a National Institutes of
Health Consensus Development Conference. Ann Intern Med 1979
Dec;91(6):921-2.
Fine BA, Yazigi R, Risser R. Prognosis of ovarian cancer developing in
the residual ovary. Gynecol Oncol 1991 Nov;43(2):164-6.
Fogarty P. Prophylactic oophorectomy in Northern Ireland. Ulster Med
J 1991 Oct;60(2):172-5.
Houlston RS, Hampson J, Collins WP, Whitehead MI, Campbell S,
Slack J. Correlation in ages at death from familial ovarian cancer
among sisters. Gynecol Oncol 1992 Nov;47(2):253-4.
Kerlikowske K, Brown JS, Grady DG. Should women with familial
ovarian cancer undergo prophylactic oophorectomy? Obstet Gynecol
1992 Oct;80(4):700-7. Comment in: Obstet Gynecol 1993
Feb;81(2):315-6.
Klein B, Lurie H, Stein M, Kuten A, Steinherz R. Hereditary ovarian
cancer: a dilemma in prognosis. Isr J Med Sci 1992 Jan;28(1):16-9.
Madsen EM, Lidegaard O, Tabor A. Oophorectomy in the prevention
of ovarian cancer. Acta Obstet Gynecol Scand 1993
Nov;72(8):599-600.
Meijer WJ, van Lindert AC. Prophylactic oophorectomy. Eur J Obstet
Gynecol Reprod Biol 1992 Oct 23;47(1):59-65.
Parazzini F, Negri E, La Vecchia C, Luchini L, Mezzopane R.
Hysterectomy, oophorectomy, and subsequent ovarian cancer risk.
Obstet Gynecol 1993 Mar;81(3):363-6.
Pokras R, Hufnagel VG. Hysterectomy in the United States, 1965-84.
Am J Public Health 1988 Jul;78(7):852-3.
Ponder BA, Easton DF, Peto J. Risk of ovarian cancer associated with
a family history: preliminary report of the OPCS study. In: Sharp F,
Mason WP, Leake RE, eds. Ovarian cancer: biological and therapeutic
challenges. London: Chapman and Hall Medical; 1990. p. 3-6.
Schildkraut JM, Thompson WD. Familial ovarian cancer: a
population-based case-control study. Am J Epidemiol 1988
Sep;128(3):456-66.
Schumaker D. Preventing gynecologic cancer: every woman's guide... a
risk factor checklist. Can Nurs 1991 Oct;87(9):23-4.
Schwartz PE. The role of prophylactic oophorectomy in the avoidance
of ovarian cancer. Int J Gynaecol Obstet 1992 Nov;39(3):175-84.
Sheth S, Malpani A. Routine prophylactic oophorectomy at the time of
vaginal hysterectomy in postmenopausal women. Arch Gynecol Obstet
1992;251(2):87-91.
Sightler SE, Boike GM, Estape RE, Averette HE. Ovarian cancer in
women with prior hysterectomy: a 14-year experience at the University
of Miami. Obstet Gynecol 1991 Oct;78(4):681-4. Comment in: Obstet
Gynecol 1992 Feb;79(2):317-9.
Speroff T, Dawson NV, Speroff L, Haber RJ. A risk-benefit analysis of
elective bilateral oophorectomy: effect of changes in compliance with
estrogen therapy on outcome. Am J Obstet Gynecol 1991 Jan;164(1 Pt
1):165-74.
MANAGEMENT OF EARLY STAGE OVARIAN CANCER
Management of the Adnexal Mass
Alvarez RD, Kilgore LC, Partridge EE, Austin JM, Shingleton HM.
Staging ovarian cancer diagnosed during laparoscopy: accuracy rather
than immediacy. South Med J 1993 Nov;86(11):1256-8.
Archie JT, Witt TR. Peritoneoscopy for biopsy, staging, and therapy of
intra-abdominal tumors. In: Economou SG, Witt TR, Deziel DJ, et al.,
eds. Adjuncts to cancer surgery. Philadelphia: Lea and Febiger; 1991.
p. 195-203.
Barber HRK, Creasman WT, Knapp RC. A rational approach to
ovarian masses. Patient Care 1993 Jan 15;27(1):50-4, 61-2, 65-8
passim.
Bouwman DL. The management of unexpected findings at surgery.
Surg Clin North Am 1993 Apr;73(2):203-12.
Bret PM, Atri M, Guibaud L, Gillett P, Seymour RJ, Senterman MK.
Ovarian cysts in postmenopausal women: preliminary results with
transvaginal alcohol sclerosis. Work in progress. Radiology 1992
Sep;184(3):661-3. Comment in: Radiology 1992 Sep;184(3):605-6.
Bret PM, Guibaud L, Atri M, Gillett P, Seymour RJ, Senterman MK.
Transvaginal US-guided aspiration of ovarian cysts and solid pelvic
masses. Radiology 1992 Nov;185(2):377-80. Comment in: Radiology
1993 Jun;187(3):878.
Bruhat MA, Mage G, Pouly JL, Canis M, Wattiez A, Chapron C.
Advances in pelviscopic surgery. Ann N Y Acad Sci 1991;626:367-71.
Caspi B, Zalel Y, Lurie S, Elchlal U, Katz Z. Ultrasound-guided
aspiration for relief of pain generated by simple ovarian cysts. Gynecol
Obstet Invest 1993;35(2):121-2.
Conklin JT, Maguire RT. Monoclonal antibodies as an aid in the
imaging of cancer. In: Economou SG, Witt TR, Deziel DJ, et al., eds.
Adjuncts to cancer surgery. Philadelphia: Lea and Febiger; 1991. p.
219-28.
Cristalli B, Cayol A, Izard V, Levardon M. Benefit of operative
laparoscopy for ovarian tumors suspected of benignity. J Laparoendosc
Surg 1992 Apr;2(2):69-73.
Curtin JP. Diagnosis and staging of epithelial ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 153-62.
Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass:
benign or malignant? Evaluation of a risk of malignancy index. Br J
Obstet Gynaecol 1993 Oct;100(10):927-31.
Dordoni D, Zaglio S, Zucca S, Favalli G. The role of sonographically
guided aspiration in the clinical management of ovarian cysts. J
Ultrasound Med 1993 Jan;12(1):27-31.
el-Yahia AR, Rahman J, Rahman MS, al-Suleiman SA. Ovarian
tumours in pregnancy. Aust N Z J Obstet Gynaecol 1991
Nov;31(4):327-30.
Fleischer AC, Shah DM, Entman SS. Sonographic evaluation of
maternal disorders during pregnancy. Radiol Clin North Am 1990
Jan;28(1):51-8.
Grimes DA. Frontiers of operative laparoscopy: a review and critique
of the evidence. Am J Obstet Gynecol 1992 Apr;166(4):1062-71.
Comment in: Am J Obstet Gynecol 1993 Apr;168(4):1333-4.
Hasson HM. Laparoscopic management of ovarian cysts. J Reprod
Med 1990 Sep;35(9):863-7.
Heloury Y, Guiberteau V, Sagot P, Plattner V, Baron M, Rogez JM.
Laparoscopy in adnexal pathology in the child: a study of 28 cases. Eur
J Pediatr Surg 1993 Apr;3(2):75-8.
Hulka JF, Parker WH, Surrey MW, Phillips JM. Management of
ovarian masses. AAGL 1990 survey. J Reprod Med 1992
Jul;37(7):599-602.
Johns A. Laparoscopic oophorectomy/ oophorocystectomy. Clin
Obstet Gynecol 1991 Jun;34(2):460-6.
Khanna AK, Misra MK, Khanna A, Misra VK, Khanna S. Fine-needle
aspiration cytology of abdominal masses. J Surg Oncol 1990
May;44(1):15-9.
Khaw KT, Walker WJ. Ultrasound guided fine needle aspiration of
ovarian cysts: diagnosis and treatment in pregnant and non-pregnant
women. Clin Radiol 1990 Feb;41(2):105-8.
Kier R, McCarthy SM, Scoutt LM, Viscarello RR, Schwartz PE. Pelvic
masses in pregnancy: MR imaging. Radiology 1990 Sep;176(3):709-13.
Kullendorff CM. Diagnosis and treatment of ovarian cysts in children.
Ann Chir Gynaecol 1991;80(1):65-7.
Langebrekke A, Urnes A. Laparoscopic adnexectomy. Acta Obstet
Gynecol Scand 1991;70(7-8):605-9.
Larkin KR. Cancer and pregnancy. NAACOGS Clin Issu Perinat
Womens Health Nurs 1990;1(2):255-61.
Lee CL, Soong YK. Laparoscopic management of benign ovarian
tumors. J Formos Med Assoc 1993 Mar;92(3):245-8.
Lee CL, Soong YK, Lai YM, Chang SY, Chang MY. Simplified
instrumentation for laparoscopic ovarian cystectomy. Chang Keng I
Hsueh 1992 Mar;15(1):28-32.
Lipitz S, Seidman DS, Menczer J, Bider D, Oelsner G, Moran O,
Shalev J. Recurrence rate after fluid aspiration from sonographically
benign-appearing ovarian cysts. J Reprod Med 1992 Oct;37(10):845-8.
Maiman M, Seltzer V, Boyce J. Laparoscopic excision of ovarian
neoplasms subsequently found to be malignant. Obstet Gynecol 1991
Apr;77(4):563-5. Comment in: Obstet Gynecol 1991
Aug;78(2):319-21.
Martin DC. Laparoscopic treatment of ovarian endometriomas. Clin
Obstet Gynecol 1991 Jun;34(2):452-9.
Mettler L, Irani S, Semm K. Ovarian surgery via pelviscopy. J Reprod
Med 1993 Feb;38(2):130-2.
Miller RC, Nash JD, Weiser EB, Hoskins WJ. The postmenopausal
palpable ovary syndrome. A retrospective review with histopathologic
correlates. J Reprod Med 1991 Aug;36(8):568-71.
Moore JL Jr, Martin JN Jr. Cancer and pregnancy. Obstet Gynecol Clin
North Am 1992;19(4):815-27.
Moran O, Menczer J, Ben-Baruch G, Lipitz S, Goor E. Cytologic
examination of ovarian cyst fluid for the distinction between benign and
malignant tumors. Obstet Gynecol 1993 Sep;82(3):444-6.
Nezhat F, Nezhat C, Silfen SL. Videolaseroscopy for oophorectomy.
Am J Obstet Gynecol 1991 Nov;165(5 Pt 1):1323-30. Comment in:
Am J Obstet Gynecol 1992 Oct;167(4 Pt 1):1150.
Obwegeser R, Deutinger J, Bernascheck G. The risk of malignancy
with an apparently simple adnexal cyst on ultrasound. Arch Gynecol
Obstet 1993;253(3):117-20.
Ovadia J, Goldman GA. Ovarian masses in postmenopausal women. Int
J Gynaecol Obstet 1992 Sep;39(1):35-9.
Parker WH, Berek JS. Management of the adnexal mass by operative
laparoscopy. Clin Obstet Gynecol 1993 Jun;36(2):413-22.
Phipps JH, Monaghan JM. Laparoscopic hysterectomy and cancer.
Surg Oncol 1993;2 Suppl 1:67-72.
Pinto MM, Bernstein LH, Brogan DA, Parikh F, Lavy G. Measurement
of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian
cyst fluid: diagnostic adjunct to cytology. Diagn Cytopathol
1990;6(3):160-3.
Reich H, McGlynn F, Sekel L, Taylor P. Laparoscopic management of
ovarian dermoid cysts. J Reprod Med 1992 Jul;37(7):640-4.
Ron-El R, Herman A, Weinraub Z, Golan A, Langer R, Caspi E,
Bukovsky I. Clear ovarian cyst aspiration guided by vaginal
ultrasonography. Eur J Obstet Gynecol Reprod Biol 1991 Nov
3;42(1):43-7.
Rubin SC, Curtin JP. Surgery for gynecologic malignancies. Curr Opin
Oncol 1992 Oct;4(5):923-9.
Seltzer V. Laparoscopic surgery for ovarian lesions: potential pitfalls.
Clin Obstet Gynecol 1993 Jun;36(2):402-12.
Semm K, O'Neill-Freys I. Pelviscopy. Curr Opin Obstet Gynecol 1991
Jun;3(3):413-21.
Sommerville M, Grimes DA, Koonings PP, Campbell K. Ovarian
neoplasms and the risk of adnexal torsion. Am J Obstet Gynecol 1991
Feb;164(2):577-8.
Sutton C. Operative laparoscopy. Curr Opin Obstet Gynecol 1992
Jun;4(3):430-8.
Thornton KL, DeCherney AH. Laparoscopic management of ovarian
cysts: an endocrinologist view. Yale J Biol Med 1991
Nov-Dec;64(6):599-606.
Warner BW, Kuhn JC, Barr LL. Conservative management of large
ovarian cysts in children: the value of serial pelvic ultrasonography.
Surgery 1992 Oct;112(4):749-55.
Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and
in the United States. Br J Obstet Gynaecol 1992 Apr;99(4):329-32.
Early Stage Epithelial Ovarian Cancer
Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K.
Prognostic factors in patients with stage I epithelial ovarian cancer.
Obstet Gynecol 1990 Feb;75(2):263-73.
DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer.
Compr Ther 1990 Nov;16(11):35-42.
Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of adjuvant cisplatin
and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol
1991 Dec;43(3):203-5.
Finn CB, Luesley DM, Buxton EJ, Blackledge GR, Kelly K, Dunn JA,
Wilson S. Is stage I epithelial ovarian cancer overtreated both surgically
and systemically? Results of a five-year cancer registry review. Br J
Obstet Gynaecol 1992 Jan;99(1):54-8. Comment in: Br J Obstet
Gynaecol 1992 Jun;99(6):530-1.
Finn CB, Luesley DM, Buxton EJ, Blackledge GR, Kelly K, Dunn JA,
Wilson S. Is stage I epithelial ovarian cancer over-treated both
surgically and systematically? Results of a five-year cancer registry
review. Obstet Gynecol Surv 1992;47(7):491-3.
Fox H. Pathology of early malignant change in the ovary. Int J Gynecol
Pathol 1993 Apr;12(2):153-5.
Gadducci A, Del Bravo B, Cardosi Carrara A, D'Amico M, Fioretti P.
Adjuvant treatment of early stage ovarian carcinoma. Clin Exp Obstet
Gynecol 1990;17(3-4):131-9.
Hudson CN, Potsides P, Curling OM. An audit of surgical treatment of
ovarian cancer in a metropolitan health region. Association of
Obstetricians and Gynaecologists of the North East Thames Region. J
R Soc Med 1991 Apr;84(4):206-9.
Lentz SS, Cha SS, Wieand HS, Podratz KC. Stage I ovarian epithelial
carcinoma: survival analysis following definitive treatment. Gynecol
Oncol 1991 Dec;43(3):198-202. Comment in: Gynecol Oncol 1991
Dec;43(3):193-4.
Linasmita V, Sakonratanakul P, Bhamarapravati Y. Survival of patients
with stage I epithelial ovarian carcinoma, 1981-1985 at Ramathibodi
Hospital. J Med Assoc Thai 1990 Feb;73 Suppl 1:7-10.
Malmstrom H, Larsson D, Simonsen E. Phase I study of intraperitoneal
carboplatin as adjuvant therapy in early ovarian cancer. Gynecol Oncol
1990 Dec;39(3):289-94.
Marchetti M, Romagnolo C. Fertility after ovarian cancer treatment.
Clin Exp Obstet Gynecol 1992;19(3):199-202.
Marchetti M, Romagnolo C. Fertility after ovarian cancer treatment.
Eur J Gynaecol Oncol 1992;13(6):498-501.
Monga M, Carmichael JA, Shelley WE, Kirk ME, Krepart GV, Jeffrey
JF, Pater JL. Surgery without adjuvant chemotherapy for early
epithelial ovarian carcinoma after comprehensive surgical staging.
Gynecol Oncol 1991 Dec;43(3):195-7. Comment in: Gynecol Oncol
1991 Dec;43(3):193-4.
Moore DH. Primary surgical management of early epithelial ovarian
carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York:
McGraw-Hill; 1993. p. 219-39.
O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear
cell epithelial ovarian cancer (mesonephroid): bad prognosis only in
early stages. Gynecol Oncol 1993 May;49(2):250-4.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Piver MS, Malfetano J, Baker TR, Hempling RE. Five-year survival for
stage IC or stage I grade 3 epithelial ovarian cancer treated with
cisplatin-based chemotherapy. Gynecol Oncol 1992 Sep;46(3):357-60.
Plaxe SC, Deligdisch L, Dottino PR, Cohen CJ. Ovarian intraepithelial
neoplasia demonstrated in patients with stage I ovarian carcinoma.
Gynecol Oncol 1990 Sep;38(3):367-72.
Raju KS, Wolfe CD. Is Stage I epithelial ovarian cancer overtreated
both surgically and systemically? Results of a five-year cancer registry
review (5). Br J Obstet Gynaecol 1992;99(6):530-1.
Rubin SC, Jones WB, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ.
Second-look laparotomy in stage I ovarian cancer following
comprehensive surgical staging. Obstet Gynecol 1993
Jul;82(1):139-42.
Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ.
Platinum-based chemotherapy of high-risk stage I epithelial ovarian
cancer following comprehensive surgical staging. Obstet Gynecol 1993
Jul;82(1):143-7.
Schilder RJ, Young RC. Management of early-stage ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):867-77.
Schneider J, Centeno MM, Montoya F, Rodriguez-Escudero FJ.
Negative second-look laparotomy does not preclude recurrence in
stage I ovarian carcinoma of any histological variety. Eur J Gynaecol
Oncol 1993;14(1):36-9.
Schueler JA, Cornelisse CJ, Hermans J, Trimbos JB, van der Burg ME,
Fleuren GJ. Prognostic factors in well-differentiated early-stage
epithelial ovarian cancer. Cancer 1993 Feb 1;71(3):787-95.
Sevelda P, Vavra N, Schemper M, Salzer H. Prognostic factors for
survival in stage I epithelial ovarian carcinoma. Cancer 1990 May
15;65(10):2349-52.
Soper JT, Berchuck A, Clarke-Pearson DL. Adjuvant intraperitoneal
chromic phosphate therapy for women with apparent early ovarian
carcinoma who have not undergone comprehensive surgical staging.
Cancer 1991 Aug 15;68(4):725-9.
Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL. Adjuvant
therapy with intraperitoneal chromic phosphate (32P) in women with
early ovarian carcinoma after comprehensive surgical staging. Obstet
Gynecol 1992 Jun;79(6):993-7.
Thigpen JT, Lambuth BW, Vance RB. Management of stage I and II
ovarian carcinoma. Semin Oncol 1991 Dec;18(6):596-602.
Trimbos JB, Schueler JA, van der Burg M, Hermans J, van Lent M,
Heintz AP, Fleuren GJ. Watch and wait after careful surgical treatment
and staging in well-differentiated early ovarian cancer. Cancer 1991
Feb 1;67(3):597-602.
Trimbos JB, Schueler JA, van Lent M, Hermans J, Fleuren GJ. Reasons
for incomplete surgical staging in early ovarian carcinoma. Gynecol
Oncol 1990 Jun;37(3):374-7.
van Nagell JR Jr, DePriest PD. Early diagnosis of epithelial ovarian
cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New
York: Raven Press; 1993. p. 127-31.
Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Trope
CG. Analysis of prognostic factors in stage I epithelial ovarian
carcinoma: importance of degree of differentiation and
deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet
Gynecol 1993 Jul;169(1):40-52.
Walton LA, Yadusky A, Rubinstein L, Roth LM, Young RC. Stage II
carcinoma of the ovary: an analysis of survival after comprehensive
surgical staging and adjuvant therapy. Gynecol Oncol 1992
Jan;44(1):55-60.
Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT,
Clarke-Pearson DL, Oram DH, Bast RC Jr. Elevation of multiple serum
markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993
Nov 3;85(21):1748-51.
Young RC. Management of early stage ovarian cancer. In: Markman
M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press;
1993. p. 359-73.
Young RC, Brady MF, Walton LA, Homesley HD, Averette HE, Long
HJ. Localized ovarian cancer in the elderly. The Gynecologic Oncology
Group experience. Cancer 1993 Jan 15;71(2 Suppl):601-5.
Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD,
Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I
and stage II epithelial ovarian cancer. Results of two prospective
randomized trials. N Engl J Med 1990 Apr 12;322(15):1021-7.
Comment in: N Engl J Med 1990 Apr 12;322(15):1076-8 and N Engl J
Med 1991 Mar 14;324(11):775.
Ovarian Tumors of Low Malignant Potential
(BorderlineTumors)
Ayhan A, Akarin R, Develioglu O, Yarali H, Kucukali T, Bilgin F.
Borderline epithelial ovarian tumours. Aust N Z J Obstet Gynaecol
1991 May;31(2):174-6.
Ball NJ, Robertson DI, Duggan MA, Snider DD. Intestinal
differentiation in ovarian mucinous tumours. Virchows Arch A Pathol
Anat Histopathol 1990;417(3):197-201.
Barnhill DR, O'Connor DM. Management of ovarian neoplasms of low
malignant potential. Oncology (Huntingt) 1991 Apr;5(4):21-6;
discussion 26, 28, 31-2.
Bell DA, Scully RE. Clinical perspective on borderline tumors of the
ovary. In: Greer BE, Berek JS, eds. Gynecologic oncology: treatment
rationale and techniques. New York: Elsevier; 1991. p. 119-34.
Bell DA, Scully RE. Ovarian serous borderline tumors with stromal
microinvasion: a report of 21 cases. Hum Pathol 1990
Apr;21(4):397-403.
Biscotti CV, Hart WR. Peritoneal serous micropapillomatosis of low
malignant potential (serous borderline tumors of the peritoneum). A
clinicopathologic study of 17 cases. Am J Surg Pathol 1992
May;16(5):467-75.
Cajigas HE, Fariza E, Scully RE, Thor AD. Enhancement of
tumor-associated glycoprotein-72 antigen expression in
hormone-related ovarian serous borderline tumors. Cancer 1991 Jul
15;68(2):348-54.
Carter J, Fowler J, Carlson J, Carson L, Twiggs LB. Borderline and
invasive epithelial ovarian tumors in young women. Obstet Gynecol
1993 Nov;82(5):752-6.
Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW. Epithelial
ovarian tumors of borderline malignancy: long-term follow-up. Gynecol
Oncol 1993 Sep;50(3):316-22.
Criscuolo M, Martinelli AM, Migaldi M, Zunarelli E, Bergamaschi M,
Falchi AM, De Gaetani C. Prognostic significance of nucleolar
organizer regions in ovarian epithelial tumors. Int J Gynecol Pathol
1993 Jul;12(3):259-63.
de Nictolis M, Montironi R, Tommasoni S, Carinelli S, Ojeda B,
Matias-Guiu X, Prat J. Serous borderline tumors of the ovary. A
clinicopathologic, immunohistochemical, and quantitative study of 44
cases. Cancer 1992 Jul 1;70(1):152-60.
Drescher CW, Flint A, Hopkins MP, Roberts JA. Prognostic
significance of DNA content and nuclear morphology in borderline
ovarian tumors. Gynecol Oncol 1993 Feb;48(2):242-6.
Eriksen B, Miller DS, Murad TM, Lurain JR, Bauer KD.
Dual-parameter flow cytometric analysis coupling the measurements of
forward-angle light scatter and DNA content of archival ovarian
carcinomas of low malignant potential. Anal Quant Cytol Histol 1991
Feb;13(1):45-53.
Gershenson DM, Silva EG. Serous ovarian tumors of low malignant
potential with peritoneal implants. Cancer 1990 Feb 1;65(3):578-85.
Goldman TL, Chalas E, Chumas J, Loesch M, Mann WJ. Management
of borderline tumors of the ovary. South Med J 1993 Apr;86(4):423-5.
Griffiths AP, Cross D, Kingston RE, Harkin P, Wells M, Quirke P.
Flow cytometry and AgNORs in benign, borderline, and malignant
mucinous and serous tumours of the ovary. Int J Gynecol Pathol 1993
Oct;12(4):307-14.
Hanselaar AG, Vooijs GP, Mayall B, Ras-Zeijlmans GJ,
Chadha-Ajwani S. Epithelial markers to detect occult microinvasion in
serous ovarian tumors. Int J Gynecol Pathol 1993 Jan;12(1):20-7.
Harlow BL, Fuhr JE, McDonald TW, Schwartz SM, Beuerlein FJ,
Weiss NS. Flow cytometry as a prognostic indicator in women with
borderline epithelial ovarian tumors. Gynecol Oncol 1993
Sep;50(3):305-9.
Harlow BL, Weiss NS, Holmes EH. Plasma alpha-L-fucosidase activity
and the risk of borderline epithelial ovarian tumors. Cancer Res 1990
Aug 1;50(15):4702-3.
Hata K, Hata T, Manabe A, Kitao M. Ovarian tumors of low malignant
potential: transvaginal Doppler ultrasound features. Gynecol Oncol
1992 Jun;45(3):259-64.
Heinonen PK. Androgen production by epithelial ovarian tumours in
post-menopausal women. Maturitas 1991 Jun;13(2):117-22.
Hytiroglou P, Harpaz N, Heller DS, Liu ZY, Deligdisch L, Gil J.
Differential diagnosis of borderline and invasive serous
cystadenocarcinomas of the ovary by computerized interactive
morphometric analysis of nuclear features. Cancer 1992 Feb
15;69(4):988-92.
Kaern J, Trope C, Kjorstad KE, Abeler V, Pettersen EO. Cellular DNA
content as a new prognostic tool in patients with borderline tumors of
the ovary. Gynecol Oncol 1990 Sep;38(3):452-7.
Kaern J, Trope CG, Abeler VM. A retrospective study of 370
borderline tumors of the ovary treated at the Norwegian Radium
Hospital from 1970 to 1982. A review of clinicopathologic features and
treatment modalities. Cancer 1993 Mar 1;71(5):1810-20.
Khattech A, Spatz A, Prade M, Duvillard P, Charpentier P, Bognel C,
Michel G, Lhomme C. Nucleolar organizer regions in ovarian tumors:
discrimination between carcinoma and borderline tumor. Int J Gynecol
Pathol 1992;11(1):11-4.
Kurman RJ, Trimble CL. The behavior of serous tumors of low
malignant potential: are they ever malignant? Int J Gynecol Pathol 1993
Apr;12(2):120-7.
Leake JF. Tumors of low malignant potential. Curr Opin Obstet
Gynecol 1992 Feb;4(1):81-5.
Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term
follow-up of serous ovarian tumors of low malignant potential. Gynecol
Oncol 1992 Nov;47(2):150-8.
Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal
lymphatic involvement with epithelial ovarian tumors of low malignant
potential. Gynecol Oncol 1991 Aug;42(2):124-30.
Long L, Jiang P, Liu FZ, Wang XP, Zhao TJ. Treatment of ovarian
malignant germ cell tumors with preservation of fertility. Chin Med J
(Engl) 1993 Apr;106(4):303-6.
Manchul LA, Simm J, Levin W, Fyles AW, Dembo AJ, Pringle JF,
Rawlings GA, Sturgeon JF, Thomas GM. Borderline epithelial ovarian
tumors: a review of 81 cases with an assessment of the impact of
treatment. Int J Radiat Oncol Biol Phys 1992;22(5):867-74.
Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman
WT. Epithelial ovarian tumors of low malignant potential. Obstet
Gynecol 1991 Dec;78(6):1027-32.
McLellan R, Buscema J, Guerrero E, Shah KV, Woodruff JD, Currie
JL. Investigation of ovarian neoplasia of low malignant potential for
human papillomavirus. Gynecol Oncol 1990 Sep;38(3):383-5.
Michael H, Roth LM, Kotylo PK. Recent developments in the
pathology of ovarian epithelial tumors of low malignant potential and
related neoplasms. Pathol Annu 1993;28(Pt 2):1-22.
Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG,
Berkowitz RS, Tsao SW. Mutation of K-ras protooncogene in human
ovarian epithelial tumors of borderline malignancy. Cancer Res 1993
Apr 1;53(7):1489-92.
Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T,
Takeuchi J. Ovarian epithelial tumors of borderline malignancy in
Japan. Gynecol Oncol 1990 Jul;38(1):90-8.
Norris HJ. Proliferative endometrioid tumors and endometrioid tumors
of low malignant potential of the ovary. Int J Gynecol Pathol 1993
Apr;12(2):134-40.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Padberg BC, Arps H, Franke U, Thiedemann C, Rehpenning W,
Stegner HE, Lietz H, Schroder S, Dietel M. DNA cytophotometry and
prognosis in ovarian tumors of borderline malignancy. A
clinicomorphologic study of 80 cases. Cancer 1992 May
15;69(10):2510-4.
Padberg BC, Stegner HE, von Sengbusch S, Arps H, Schroder S.
DNA-cytophotometry and immunocytochemistry in ovarian tumours of
borderline malignancy and related peritoneal lesions. Virchows Arch A
Pathol Anat Histopathol 1992;421(6):497-503.
Parazzini F, Restelli C, La Vecchia C, Negri E, Chiari S, Maggi R,
Mangioni C. Risk factors for epithelial ovarian tumours of borderline
malignancy. Int J Epidemiol 1991 Dec;20(4):871-7.
Rice LW, Berkowitz RS, Mark SD, Yavner DL, Lage JM. Epithelial
ovarian tumors of borderline malignancy. Gynecol Oncol 1990
Nov;39(2):195-8.
Rice LW, Lage JM, Berkowitz RS, Goodman A, Muto MG, Knapp
RC, Bell DA. Preoperative serum CA-125 levels in borderline tumors
of the ovary. Gynecol Oncol 1992 Aug;46(2):226-9.
Rutgers JL, Bell DA. Immunohistochemical characterization of ovarian
borderline tumors of intestinal and mullerian types. Mod Pathol 1992
Jul;5(4):367-71.
Segal GH, Hart WR. Ovarian serous tumors of low malignant potential
(serous borderline tumors). The relationship of exophytic surface tumor
to peritoneal implants. Am J Surg Pathol 1992 Jun;16(6):577-83.
Seidman JD, Norris HJ, Griffin JL, Hitchcock CL. DNA flow
cytometric analysis of serous ovarian tumors of low malignant
potential. Cancer 1993 Jun 15;71(12):3947-51.
Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno M.
Clinicostatistical study of low potential malignancy ovarian
cystadenoma (borderline cases). Asia Oceania J Obstet Gynaecol 1991
Jun;17(2):107-12.
Snider DD, Stuart GC, Nation JG, Robertson DI. Evaluation of
surgical staging in stage I low malignant potential ovarian tumors.
Gynecol Oncol 1991 Feb;40(2):129-32.
Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC,
Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p.
425-49.
Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB,
Bonfiglio T. Stage III ovarian tumors of low malignant potential
treated with cisplatin combination therapy (a Gynecologic Oncology
Group study). Gynecol Oncol 1991 Jun;41(3):230-3.
Trimble EL, Trimble CL. Epithelial ovarian tumors of low malignant
potential. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New
York: Raven Press; 1993. p. 415-29.
Vaccarello L, Kanbour A, Kanbour-Shakir A, Whiteside TL.
Tumor-infiltrating lymphocytes from ovarian tumors of low malignant
potential. Int J Gynecol Pathol 1993 Jan;12(1):41-50.
Yazigi R, Munoz AK, Sandstad J, Lifshitz S, Choi DJ. Cisplatin based
combination chemotherapy in the treatment of stage III ovarian
epithelial tumors of low malignant potential. Eur J Gynaecol Oncol
1991;12(6):451-5.
Germ Cell and Sex-Cord Stromal Tumors
Barrenetxea G, Schneider J, Centeno MM, Martinez AJ, Fernandez de
Larrino A, Gonzales del Tanago J, Rodriguez-Escudero FJ. Pure theca
cell tumors. A clinicopathologic study of 29 cases. Eur J Gynaecol
Oncol 1990;11(6):429-32.
Bazot M, Ghossain MA, Buy JN, Deligne L, Hugol D, Truc JB,
Poitout P, Vadrot D. Fibrothecomas of the ovary: CT and US findings.
J Comput Assist Tomogr 1993 Sep-Oct;17(5):754-9.
Beamer WG, Shultz KL, Tennent BJ, Shultz LD. Granulosa cell
tumorigenesis in genetically hypogonadal-immunodeficient mice grafted
with ovaries from tumor-susceptible donors. Cancer Res 1993 Aug
15;53(16):3741-6.
Berkowitz RS. Recent advances in the biology and treatment of
gestational trophoblastic diseases and germ cell tumors. Curr Opin
Oncol 1990 Oct;2(5):901-5.
Bjorkholm E, Lundell M, Gyftodimos A, Silfversward C.
Dysgerminoma. The Radiumhemmet series 1927-1984. Cancer 1990
Jan 1;65(1):38-44.
Brammer HM 3d, Buck JL, Hayes WS, Sheth S, Tavassoli FA. From
the archives of the AFIP. Malignant germ cell tumors of the ovary:
radiologic-pathologic correlation. Radiographics 1990
Jul;10(4):715-24.
Chadha S, Cornelisse CJ, Schaberg A. Flow cytometric DNA ploidy
analysis of ovarian granulosa cell tumors. Gynecol Oncol 1990
Feb;36(2):240-5.
Chang CY, Yeh WR, Chao KC, Ng HT. Granulosa cell tumor of the
ovary. Chung Hua I Hsueh Tsa Chih (Taipei) 1990 Sep;46(3):172-6.
Chiara S, Merlini L, Campora E, Bruzzone M, Giudici S, Rosso R,
Ragni N. Cisplatin-based chemotherapy in recurrent or high risk
ovarian granulosa-cell tumor patients. Eur J Gynaecol Oncol
1993;14(4):314-7.
Conte M, Guariglia L, Benedetti Panici P, Scambia G, Rabitti C,
Capelli A, Mancuso S. Ovarian fibrothecoma: sonographic and
histologic findings. Gynecol Obstet Invest 1991;32(1):51-4.
Coppes MJ, Ye Y, Rackley R, Zhao XL, Liefers GJ, Casey G, Williams
BR. Analysis of WT1 in granulosa cell and other sex cord-stromal
tumors. Cancer Res 1993 Jun 15;53(12):2712-4.
Danhier S, Van Houtte P. Ovarian dysgerminoma: a therapeutic
challenge. J Belge Radiol 1993 Mar;76(2):102-4.
Daugaard G, Hansen HH, Rorth M. Treatment of malignant germ cell
tumors. Ann Oncol 1990;1(3):195-202.
De Jong FH, Grootenhuis AJ, Steenbergen J, van Sluijs FJ, Foekens
JA, ten Kate FJ, Oosterhuis JW, Lamberts SW, Klijn JG. Inhibin
immunoreactivity in gonadal and non-gonadal tumors. J Steroid
Biochem Mol Biol 1990 Dec 20;37(6):863-6.
De Palo G, Zambetti M, Pilotti S, Rottoli L, Spatti G, Fontanelli R,
Musumeci R, Kenda R, Bombardieri E, Stefanon B, et al.
Nondysgerminomatous tumors of the ovary treated with cisplatin,
vinblastine, and bleomycin: long-term results. Gynecol Oncol 1992
Nov;47(2):239-46.
Dietl J, Horny HP, Ruck P, Kaiserling E. Dysgerminoma of the ovary.
An immunohistochemical study of tumor-infiltrating lymphoreticular
cells and tumor cells. Cancer 1993 Apr 15;71(8):2562-8.
dos Santos Silva I, Swerdlow AJ. Ovarian germ cell malignancies in
England: epidemiological parallels with testicular cancer. Br J Cancer
1991 May;63(5):814-8.
Fletcher JA, Gibas Z, Donovan K, Perez-Atayde A, Genest D, Morton
CC, Lage JM. Ovarian granulosa-stromal cell tumors are characterized
by trisomy 12. Am J Pathol 1991 Mar;138(3):515-20.
Germa JR, Izquierdo MA, Segui MA, Climent MA, Ojeda B, Alonso
C. Malignant ovarian germ cell tumors: the experience at the Hospital
de la Santa Creu i Sant Pau. Gynecol Oncol 1992 May;45(2):153-9.
Gershenson DM. Ovarian germ cell and stromal tumors. In: Greer BE,
Berek JS, eds. Gynecologic oncology: treatment rationale and
techniques. New York: Elsevier; 1991. p. 167-84.
Gershenson DM. Update on malignant ovarian germ cell tumors.
Cancer 1993 Feb 15;71(4 Suppl):1581-90.
Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA,
Edwards CL, Silva EG, Wharton JT. Treatment of malignant germ cell
tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin
Oncol 1990 Apr;8(4):715-20.
Gitsch G, Kohlberger P, Hanzal E, Kolbl H, Breitenecker G.
Immunohistochemical differentiation between ovarian granulosa cell
tumors and ovarian carcinomas. Arch Gynecol Obstet
1991;249(4):173-7.
Gitsch G, Kohlberger P, Steiner A, Neumeister B, Breitenecker G.
Expression of cytokeratins in granulosa cell tumors and ovarian
carcinomas. Arch Gynecol Obstet 1992;251(4):193-7.
Gorski GK, McMorrow LE, Blumstein L, Faasse D, Donaldson MH.
Trisomy 14 in two cases of granulosa cell tumor of the ovary. Cancer
Genet Cytogenet 1992 Jun;60(2):202-5.
Gribbon M, Ein SH, Mancer K. Pediatric malignant ovarian tumors: a
43-year review. J Pediatr Surg 1992 Apr;27(4):480-4.
Haba R, Miki H, Kobayashi S, Ohmori M. Combined analysis of flow
cytometry and morphometry of ovarian granulosa cell tumor. Cancer
1993 Dec 1;72(11):3258-62.
Hawkins EP. Pathology of germ cell tumors in children. Crit Rev Oncol
Hematol 1990;10(2):165-79.
Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M,
Grant P, Day AJ, Rome R, Campbell JJ. Elevated serum inhibin
concentrations in postmenopausal women with ovarian tumors. N Engl
J Med 1993 Nov 18;329(21):1539-42.
Hicks ML, Piver MS. Conservative surgery plus adjuvant therapy for
vulvovaginal rhabdomyosarcoma, diethylstilbestrol clear cell
adenocarcinoma of the vagina, and unilateral germ cell tumors of the
ovary. Obstet Gynecol Clin North Am 1992 Mar;19(1):219-33.
Inoue M, Fujita M, Azuma C, Saji F, Tanizawa O. Histogenetic
analysis of ovarian germ cell tumors by DNA fingerprinting. Cancer
Res 1992 Dec 15;52(24):6823-6.
Jacoby AF, Young RH, Colvin RB, Flotte TJ, Preffer F, Scully RE,
Swymer CM, Bell DA. DNA content in juvenile granulosa cell tumors
of the ovary: a study of early- and advanced-stage disease. Gynecol
Oncol 1992 Jul;46(1):97-103.
Jones WB. Sex cord-stromal tumors of the ovary. In: Markman M,
Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993.
p. 385-405.
Kawai M, Furuhashi Y, Kano T, Misawa T, Nakashima N, Hattori S,
Okamoto Y, Kobayashi I, Ohta M, Arii Y, et al. Alpha-fetoprotein in
malignant germ cell tumors of the ovary. Gynecol Oncol 1990
Nov;39(2):160-6.
Kawai M, Kano T, Furuhashi Y, Iwata M, Nakashima N, Imai N,
Kuzuya K, Hayashi H, Ohta M, Arii Y, et al. Immature teratoma of the
ovary. Gynecol Oncol 1991 Feb;40(2):133-7.
Kawai M, Kano T, Furuhashi Y, Mizuno K, Nakashima N, Hattori SE,
Kazeto S, Iida S, Ohta M, Arii Y, et al. Prognostic factors in yolk sac
tumors of the ovary. A clinicopathologic analysis of 29 cases. Cancer
1991 Jan 1;67(1):184-92.
Kawai M, Kano T, Kikkawa F, Morikawa Y, Oguchi H, Nakashima N,
Ishizuka T, Kuzuya K, Ohta M, Arii Y, et al. Seven tumor markers in
benign and malignant germ cell tumors of the ovary. Gynecol Oncol
1992 Jun;45(3):248-53.
Kelley JL 3d, Naus GJ, Christopherson WA. Endodermal sinus tumor
of the ovary: a case series with flow cytometric DNA content analysis.
Gynecol Oncol 1991 Jul;42(1):34-8.
Klemi PJ, Joensuu H, Salmi T. Prognostic value of flow cytometric
DNA content analysis in granulosa cell tumor of the ovary. Cancer
1990 Mar 1;65(5):1189-93.
Kumar L, Bhargawa VL, Kumar S. Cisplatin, vinblastine and bleomycin
in advanced and relapsed germ cell tumours of ovary. Asia Oceania J
Obstet Gynaecol 1993 Jun;19(2):133-40.
Lappohn RE, Burger HG, Bouma J, Bangah M, Krans M. Inhibin as a
marker for granulosa cell tumor. Acta Obstet Gynecol Scand Suppl
1992;155:61-5.
Malik ST, Slevin ML. Medroxyprogesterone acetate (MPA) in
advanced granulosa cell tumours of the ovary--a new therapeutic
approach? Br J Cancer 1991 Mar;63(3):410-1. Comment in: Br J
Cancer 1992 Jan;65(1):140.
Motawy MS, Szymendera JJ, al-Jazzaf H, Behbehani AE, Foudeh MO,
Ebraheem AK, Nasralla MY, Ali MA. Serum AFP, hCG and CEA in
the management of patients with testicular, ovarian and extragonadal
germ cell tumors. Int J Biol Markers 1992 Apr-Jun;7(2):80-6.
Muram D, Gale CL, Thompson E, Marina N. Ovarian cancer in
children and adolescents. Adolesc Pediatr Gynecol 1992;5(1):21-6.
Murty VV, Dmitrovsky E, Bosl GJ, Chaganti RS. Nonrandom
chromosome abnormalities in testicular and ovarian germ cell tumor
cell lines. Cancer Genet Cytogenet 1990 Nov 1;50(1):67-73.
Onnis A, Marchetti M, Piazza M. Clinical experience in gynaecological
cancer management. D) Ovarian tumors--non-epithelial: report from
the Gynaecological Institute of Padua University. Eur J Gynaecol
Oncol 1993;14(1):5-17.
Otis CN, Powell JL, Barbuto D, Carcangiu ML. Intermediate
filamentous proteins in adult granulosa cell tumors. An
immunohistochemical study of 25 cases. Am J Surg Pathol 1992
Oct;16(10):962-8.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Palmquist MB, Webb MJ, Lieber MM, Gaffey TA, Nativ O. DNA
ploidy of ovarian dysgerminomas: correlation with clinical outcome.
Gynecol Oncol 1992 Jan;44(1):13-6.
Pectasides D, Alevizakos N, Athanassiou AE. Cisplatin-containing
regimen in advanced or recurrent granulosa cell tumours of the ovary.
Ann Oncol 1992 Apr;3(4):316-8.
Pfleiderer A. Therapy of ovarian malignant germ cell tumors and
granulosa tumors. Int J Gynecol Pathol 1993 Apr;12(2):162-5.
Pliskow S. Endodermal sinus tumor of the ovary: review of 10 cases.
South Med J 1993 Feb;86(2):187-9.
Porter S, Gilks CB. Genomic imprinting: a proposed explanation for
the different behaviours of testicular and ovarian germ cell tumors. Med
Hypotheses 1993 Jul;41(1):37-41.
Price FV, Schwartz PE. Management of ovarian stromal tumors. In:
Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill;
1993. p. 405-23.
Rajkumar T, Sagar TG, Maitreyan V, Vasanthan A, Devika A, Sastry
DV, Shanta V. Germ-cell tumours of the ovary--treatment and results
at Cancer Institute, Madras. Indian J Cancer 1992 Mar;29(1):18-23.
Rogo KO, Persson H, Stendahl U. Dysgerminoma of the ovary:
treatment results in northern Sweden. Eur J Gynaecol Oncol
1990;11(1):43-9.
Schwartz PE, Chambers SK, Chambers JT, Kohorn E, McIntosh S.
Ovarian germ cell malignancies: the Yale University experience.
Gynecol Oncol 1992 Apr;45(1):26-31.
Shiromizu K, Kawana T, Sugase M, Izumi R, Mizuno M.
Clinicostatistical study of ovarian tumors of germ cell origin. Asia
Oceania J Obstet Gynaecol 1991 Sep;17(3):207-15.
Sivanesaratnam V, Dutta R, Jayalakshmi P. Ovarian fibroma--clinical
and histopathological characteristics. Int J Gynaecol Obstet 1990
Nov;33(3):243-7.
Skinner MA, Schlatter MG, Heifetz SA, Grosfeld JL. Ovarian
neoplasms in children. Arch Surg 1993 Aug;128(8):849-53; discussion
853-4.
Stewart CJ, Farquharson MA, Foulis AK. Characterization of the
inflammatory infiltrate in ovarian dysgerminoma: an
immunocytochemical study. Histopathology 1992 Jun;20(6):491-7.
Suh KS, Silverberg SG, Rhame JG, Wilkinson DS. Granulosa cell
tumor of the ovary. Histopathologic and flow cytometric analysis with
clinical correlation. Arch Pathol Lab Med 1990 May;114(5):496-501.
Susnerwala SS, Pande SC, Shrivastava SK, Dinshaw KA.
Dysgerminoma of the ovary: review of 27 casesa. J Surg Oncol 1991
Jan;46(1):43-7.
Swanson SA, Norris HJ, Kelsten ML, Wheeler JE. DNA content of
juvenile granulosa tumors determined by flow cytometry. Int J Gynecol
Pathol 1990;9(2):101-9.
Tandon R, Kumar L, Vaid A, Kochupillai V, Kumar S, Kriplani A,
Bhargava VL. Management of malignant germ cell tumours of ovary.
Indian J Cancer 1992 Sep;29(3):122-5.
Tennent BJ, Shultz KL, Beamer WG. Genetic susceptibility for C19
androgen induction of ovarian granulosa cell tumorigenesis in SWXJ
strains of mice. Cancer Res 1993 Mar 1;53(5):1059-63.
Tennent BJ, Shultz KL, Sundberg JP, Beamer WG. Ovarian granulosa
cell tumorigenesis in SWR-derived F1 hybrid mice: preneoplastic
follicular abnormality and malignant disease progression. Am J Obstet
Gynecol 1990 Aug;163(2):625-34.
Ulbright TM, Roth LM. A pathologic analysis of lesions following
modern chemotherapy for metastatic germ-cell tumors. Pathol Annu
1990;25 (Pt 1):313-40.
van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit
VT, Kuppen PJ, van Ravenswaay Claasen HH, Cornelisse CJ, Schrier
PI. Establishment and characterization of 7 ovarian carcinoma cell lines
and one granulosa tumor cell line: growth features and cytogenetics. Int
J Cancer 1993 Feb 20;53(4):613-20.
Vergote IB, Abeler VM, Kjorstad KE, Trope C. Management of
malignant ovarian immature teratoma. Role of adriamycin. Cancer 1990
Sep 1;66(5):882-6.
Williams SD. Chemotherapy of ovarian germ cell tumors. Hematol
Oncol Clin North Am 1991 Dec;5(6):1261-9.
Williams SD. Germ cell tumors. Hematol Oncol Clin North Am 1992
Aug;6(4):967-74.
Williams SD. Ovarian germ cell tumors. In: Rubin SC, Sutton GP, eds.
Ovarian cancer. New York: McGraw-Hill; 1993. p. 391-404.
Williams SD. Treatment of germ cell tumors of the ovary. Semin Oncol
1991 Jun;18(3):292-6.
Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of
advanced dysgerminoma: trials of the Gynecologic Oncology Group. J
Clin Oncol 1991 Nov;9(11):1950-5.
Williams SD, Gershenson DM. Management of germ cell tumors of the
ovary. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New
York: Raven Press; 1993. p. 375-84.
Williams SD, Gershenson DM, Horowitz CJ, Scully RE. Ovarian germ
cell and stromal tumors. In: Hoskins WJ, Perez CA, Young RC, eds.
Principles and practice of gynecologic oncology. Philadelphia:
Lippincott; 1992. p. 715-30.
Williams SD, Loehrer PJ, Nichols CR, Einhorn LN. Chemotherapy of
male and female germ cell tumors. Semin Oncol 1992 Apr;19(2 Suppl
5):19-23; discussion 23-4.
Wollner N, Ghavimi F, Wachtel A, Luks E, Exelby P, Woodruff J.
Germ cell tumors in children: gonadal and extragonadal. Med Pediatr
Oncol 1991;19(4):228-39.
Wong LC, Collins RJ, Ngan HY, Ma HK. Etoposide combination
chemotherapy in refractory ovarian malignant germ cell tumor. Gynecol
Oncol 1990 Nov;39(2):123-6.
Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman
SJ, Stephens RL, Natale RB, Bouroncle BA, Blumenstein BA, et al. A
randomized trial of cisplatin, vinblastine, and bleomycin versus
vinblastine, cisplatin, and etoposide in the treatment of advanced germ
cell tumors of the testis: a Southwest Oncology Group study. J Clin
Oncol 1991 Jan;9(1):70-6. Comment in: J Clin Oncol 1991
Jun;9(6):1092-4.
Wu PC, Huang RL, Lang JH, Huang HF, Lian LJ, Tang MY.
Treatment of malignant ovarian germ cell tumors with preservation of
fertility: a report of 28 cases. Gynecol Oncol 1991 Jan;40(1):2-6.
Young RH. New and unusual aspects of ovarian germ cell tumors. Am
J Surg Pathol 1993 Dec;17(12): 1210-24.
Young RH. Ovarian tumors other than those of surface
epithelial-stromal type. Hum Pathol 1991 Aug;22(8):763-75.
Zaghloul MS, Khattab TY. Dysgerminoma of the ovary: good
prognosis even in advanced stages. Int J Radiat Oncol Biol Phys
1992;24(1):161-5.
Zambetti M, Escobedo A, Pilotti S, De Palo G.
cis-platinum/vinblastine/bleomycin combination chemotherapy in
advanced or recurrent granulosa cell tumors of the ovary. Gynecol
Oncol 1990 Mar;36(3):317-20.
Radiotherapy
Arian-Schad KS, Kapp DS, Hackl A, Juettner FM, Leitner H, Porsch
G, Lahousen M, Pickel H. Radiation therapy in stage III ovarian cancer
following surgery and chemotherapy: prognostic factors, patterns of
relapse, and toxicity: a preliminary report. Gynecol Oncol 1990
Oct;39(1):47-55.
Belch RZ, Coughlin CT, Cooney LC, Forcier RJ, Maurer LH. Lack of
acute toxicity associated with a multimodality treatment of stage III
ovarian epithelial carcinoma. Gynecol Oncol 1990 Apr;37(1):17-20.
Bertelsen K, Jakobsen A. Radiotherapy for gynecologic cancer. Curr
Opin Oncol 1993 Sep;5(5):885-90.
Bolis G, Zanaboni F, Vanoli P, Russo A, Franchi M, Scarfone G,
Pecorelli S. The impact of whole-abdomen radiotherapy on survival in
advanced ovarian cancer patients with minimal residual disease after
chemotherapy. Gynecol Oncol 1990 Nov;39(2):150-4.
Bruzzone M, Repetto L, Chiara S, Campora E, Conte PF, Orsatti M,
Vitale V, Rubagotti A, Rosso R. Chemotherapy versus radiotherapy in
the management of ovarian cancer patients with pathological complete
response or minimal residual disease at second look. Gynecol Oncol
1990 Sep;38(3):392-5.
Buckman R, De Angelis C, Shaw P, Covens A, Osborne R, Kerr I,
Reed R, Michaels H, Woo M, Reilly R, et al. Intraperitoneal therapy of
malignant ascites associated with carcinoma of ovary and breast using
radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992
Oct;47(1):102-9.
Calkins AR, Rosenshein NB, Fox MG, Order SE. Delayed split whole
abdominal irradiation in the combined modality treatment of ovarian
cancer. Int J Radiat Oncol Biol Phys 1991 Apr;20(4):661-5.
Carey MS, Dembo AJ, Simm JE, Fyles AW, Treger T, Bush RS.
Testing the validity of a prognostic classification in patients with
surgically optimal ovarian carcinoma: a 15-year review. Int J Gynecol
Cancer 1993;3(1):24-35.
Chiara S, Orsatti M, Franzone P, Scarpati D, Bruzzone M, Repetto L,
Vitale V, Conte PF, Rosso R. Abdominopelvic radiotherapy following
surgery and chemotherapy in advanced ovarian cancer. Clin Oncol (R
Coll Radiol) 1991 Nov;3(6):340-4.
De Pooter CM, Scalliet PG, Elst HJ, Huybrechts JJ, Gheuens EE, Van
Oosterom AT, Fichtinger-Schepman AM, De Bruijn EA. Resistance
patterns between cis-diamminedichloroplatinum(II) and ionizing
radiation. Cancer Res 1991 Sep 1;51(17):4523-7.
Dembo AJ. Epithelial ovarian cancer: the role of radiotherapy. Int J
Radiat Oncol Biol Phys 1992;22(5):835-45.
Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, Reid
JG. Ovarian carcinoma: improved survival following abdominopelvic
irradiation in patients with a completed pelvic operation. Am J Obstet
Gynecol 1979 Aug 1;134(7):793-800.
Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon JF.
The Princess Margaret Hospital study of ovarian cancer: stages I, II,
and asymptomatic III presentations. Cancer Treat Rep 1979
Feb;63(2):249-54.
Dufour P, Bergerat JP, Liu KL, Bohbot A, Maloisel F, Duclos B,
Herbrecht R, Faradji A, Jung JM, Oberling F. High dose melphalan and
ABMT with or without abdominal radiotherapy as consolidation
treatment for ovarian carcinoma in complete remission or with
microscopic residual disease. Eur J Gynaecol Oncol
1991;12(6):457-61.
Eifel PJ, Gershenson DM, Delclos L, Wharton JT, Peters LJ.
Twice-daily, split-course abdominopelvic radiation therapy after
chemotherapy and positive second-look laparotomy for epithelial
ovarian carcinoma. Int J Radiat Oncol Biol Phys 1991
Sep;21(4):1013-8.
Franchin G, Tumolo S, Scarabelli C, De Paoli A, Boz G, Crivellari D,
Arcicasa M, Bortolus R, Gobitti C, Minatel E, et al. Whole abdomen
radiation therapy after a short chemotherapy course and second-look
laparotomy in advanced ovarian cancer. Gynecol Oncol 1991
Jun;41(3):206-11.
Fuller DB, Sause WT, Plenk HP, Menlove RL. Analysis of
postoperative radiation therapy in stage I through III epithelial ovarian
carcinoma. J Clin Oncol 1987 Jun;5(6):897-905.
Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul LA, Pringle JF,
Rawlings GA, Sturgeon JF, Thomas GM, Simm J. Analysis of
complications in patients treated with abdomino-pelvic radiation
therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys
1992;22(5):847-51.
Garton GR, Gunderson LL, Webb MJ, Wilson TO, Martenson JA Jr,
Cha SS, Podratz KC. Intraoperative radiation therapy in gynecologic
cancer: the Mayo Clinic experience. Gynecol Oncol 1993
Mar;48(3):328-32.
Goldberg N, Peschel RE. Postoperative abdominopelvic radiation
therapy for ovarian cancer. Int J Radiat Oncol Biol Phys 1988
Mar;14(3):425-9.
Hammond R, Bull C, Houghton CR. Primary adjunctive whole
abdominal radiotherapy in epithelial ovarian cancer: results of 10-years'
experience. Aust N Z J Obstet Gynaecol 1992 Aug;32(3):267-9.
Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C,
Stewart JS, Mason P, Lambert HE, Epenetos AA. Adjuvant therapy of
ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993
Aug;68(2):403-6.
Holt JA, Scharl A, Kullander S, Beckmann MW. Intracellular actions
of steroid hormones and their therapeutic value, including the potential
of radiohalosteroids against ovarian cancer. Acta Obstet Gynecol Scand
Suppl 1992;155:39-54.
Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse
LD, Creasman WT. The role of adjuvant therapy in Stage I ovarian
cancer. Am J Obstet Gynecol 1980 Sep 15;138(2):139-45.
Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J,
Heaps J, Weiden P. A phase I trial of a rhenium 186-labeled
monoclonal antibody administered intraperitoneally in ovarian
carcinoma: toxicity and clinical response. Obstet Gynecol 1993
Oct;82(4 Pt 1):586-93.
Jusko WJ, Kung LP, Schmelter RF. Immunopharmacokinetics of
111In-CYT-103 in ovarian cancer patients. Targeted Diagn Ther
1992;6:177-90.
King LA, Downey GO, Potish RA, Adcock LL, Carson LF, Twiggs
LB. Concomitant whole-abdominal radiation and intraperitoneal
chemotherapy in advanced ovarian carcinoma. A pilot study. Cancer
1991 Jun 1;67(11):2867-71.
Kohler MF, Soper JT, Tucker JA Jr, Clarke-Pearson DL. Isolated
incisional metastases after intraperitoneal radioactive chromic
phosphate therapy for ovarian carcinoma. Cancer 1991;68(6):1380-3.
Konski AA, Neisler J, Phibbs G, Bronn DG, Dobelbower RR Jr. A
pilot study investigating intraoperative electron beam irradiation in the
treatment of ovarian malignancies. Gynecol Oncol 1990
Jul;38(1):121-4.
Kosmas C, Man S, Epenetos AA, Courtenay-Luck NS. The role of
humoral and cellular immunity in patients developing human
anti-murine immunoglobulin antibody responses after
radioimmunotherapy. Br J Cancer Suppl 1990 Jul;10:85-8.
Kosmas C, Snook D, Gooden CS, Courtenay-Luck NS, McCall MJ,
Meares CF, Epenetos AA. Development of humoral immune responses
against a macrocyclic chelating agent (DOTA) in cancer patients
receiving radioimmunoconjugates for imaging and therapy. Cancer Res
1992 Feb 15;52(4):904-11.
Kucera PR, Berman ML, Treadwell P, Sheets EE, Micha JP,
Rettenmaier MA, Colman M, DiSaia PJ. Whole-abdominal
radiotherapy for patients with minimal residual epithelial ovarian
cancer. Gynecol Oncol 1990 Mar;36(3):338-42.
Lanciano RM, Randall M. Update on the role of radiotherapy in
ovarian cancer. Semin Oncol 1991 Jun;18(3):233-47.
Lawton F, Luesley D, Blackledge G, Hilton C, Kelly K, Latief T,
Mould J, Spooner D, Rollason T, Wade-Evans T, et al. A randomized
trial comparing whole abdominal radiotherapy with chemotherapy
following cisplatinum cytoreduction in epithelial ovarian cancer. West
Midlands Ovarian Cancer Group Trial II. Clin Oncol (R Coll Radiol)
1990 Jan;2(1):4-9.
Ledermann JA, Dembo AJ, Sturgeon JF, Fine S, Bush RS, Fyles AW,
Pringle JF, Rawlings GA, Thomas GM, Simm J. Outcome of patients
with unfavorable optimally cytoreduced ovarian cancer treated with
chemotherapy and whole abdominal radiation. Gynecol Oncol 1991
Apr;41(1):30-5.
Lentz SS, Schray MF, Wilson TO. Chylous ascites after
whole-abdomen irradiation for gynecologic malignancy. Int J Radiat
Oncol Biol Phys 1990 Aug;19(2):435-8.
Lindner H, Willich H, Atzinger A. Primary adjuvant whole abdominal
irradiation in ovarian carcinoma. Int J Radiat Oncol Biol Phys 1990
Nov;19(5):1203-6.
Linstadt DE, Stern JL, Quivey JM, Leibel SA, Lacey CG. Salvage
whole-abdominal irradiation following chemotherapy failure in
epithelial ovarian carcinoma. Gynecol Oncol 1990 Mar;36(3):327-30.
Manetta A, Lucci J, Soopikian J, Granger G, Berman ML, DiSaia PJ.
In vitro cytotoxicity of human recombinant tumor necrosis factor alpha
in association with radiotherapy in a human ovarian carcinoma cell line.
Gynecol Oncol 1990 Aug;38(2):200-2.
Martinez A, Schray MF, Howes AE, Bagshaw MA. Postoperative
radiation therapy for epithelial ovarian cancer: the curative role based
on a 24-year experience. J Clin Oncol 1985 Jul;3(7):901-11.
Martinez Monge R, Jurado M, Azinovic I, Aristu JJ, Tangco E, Viera
JC, Berian JM, Calvo FA. Intraoperative radiotherapy in recurrent
gynecological cancer. Radiother Oncol 1993 Aug;28(2):127-33.
May LF, Belinson JL, Roland TA. Palliative benefit of radiation therapy
in advanced ovarian cancer. Gynecol Oncol 1990 Jun;37(3):408-11.
Moore DH. Role of radiation therapy in ovarian cancer. Curr Opin
Obstet Gynecol 1990 Feb;2(1):64-8.
Mothersill C, Seymour CB, Bonnar J. Effect of radiation and other
cytotoxic agents on the growth of cells cultured from normal and tumor
tissues from the female genital tract. Gynecol Oncol 1990
May;37(2):210-8.
Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC,
Zurawski VR Jr, Weadock K, Tumeh SS, Lavin P, et al. Intraperitoneal
radioimmunotherapy of refractory ovarian carcinoma utilizing
iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 1992
Jun;45(3):265-72.
Mychalczak BR, Fuks Z. The current role of radiotherapy in the
management of ovarian cancer. Hematol Oncol Clin North Am 1992
Aug;6(4):895-913.
Mychalczak BR, Fuks Z. The role of radiotherapy in the management
of epithelial ovarian cancer. In: Markman M, Hoskins WJ, eds. Cancer
of the ovary. New York: Raven Press; 1993. p. 229-41.
Peters WA 3d, Smith MR, Cain JM, Lee RB, Yon JL Jr. Intraperitoneal
P-32 is not an effective consolidation therapy after a negative
second-look laparotomy for epithelial carcinoma of the ovary. Gynecol
Oncol 1992 Nov;47(2):146-9.
Pickel H, Petru E, Lahousen M, Stettner H, Heydarfadai M,
Arian-Schad K, Hackl A. Consolidation radiotherapy following
carboplatin-based chemotherapy in radically operated advanced ovarian
cancer. A pilot study. Am J Clin Oncol 1991 Jun;14(3):184-7.
Pirkowski M, Holloway R, Delgado G, Barnes W, Thomas D, Torrisi
J, Popescu G, Rodgers J, Dritschilo A. Radiotherapy of malignant
subdiaphragmatic implants in advanced ovarian carcinoma: a new
technique. Int J Radiat Oncol Biol Phys 1992;22(5):1105-8.
Piver MS, Malfetano J, Hempling RE, Baker TR, Driscoll DL.
Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a
preliminary report. Gynecol Oncol 1990 Dec;39(3):249-52.
Potish RA, King LA, Downey GO, Adcock LL, Carson LF, Twiggs
LB. The integration of whole abdominal radiotherapy and
intraperitoneal cisplatin into the primary management of advanced
ovarian carcinoma. Am J Clin Oncol 1991 Aug;14(4):312-6.
Randall ME. Curative potential of primary whole-abdomen irradiation
in ovarian carcinoma. South Med J 1991 Sep;84(9):1119-22.
Randall ME, Evans L. Issues in gynecologic radiation oncology. Curr
Opin Oncol 1991 Oct;3(5):920-9.
Reddy S, Lee MS, Yordan E, Graham J, Sarin P, Hendrickson FR.
Salvage whole abdomen radiation therapy: its role in ovarian cancer.
Int J Radiat Oncol Biol Phys 1993 Nov 15;27(4):879-84.
Redman CW, Mould J, Warwick J, Rollason T, Luesley DM, Budden J,
Lawton FG, Blackledge GR, Chan KK. The West Midlands epithelial
ovarian cancer adjuvant therapy trial. Clin Oncol (R Coll Radiol)
1993;5(1):1-5.
Reid GC, Roberts JA, Hopkins MP, Schoeppel SL, Perez-Tamayo C,
Drescher C, Chamberlain D, Morley GW. Primary treatment of stage
III ovarian carcinoma with sequential chemotherapy and whole
abdominal radiation therapy. Gynecol Oncol 1993 Jun;49(3):333-8.
Reinfuss M, Kojs Z, Skolyszewski J. External beam radiotherapy in the
management of ovarian carcinoma. Radiother Oncol 1993
Jan;26(1):26-32.
Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana
G, Clarke-Pearson DL. Improved palliation of cerebral metastases in
epithelial ovarian cancer using a combined modality approach including
radiation therapy, chemotherapy, and surgery. J Clin Oncol 1992
Oct;10(10):1553-60.
Rogers L, Varia M, Halle J, Freddo J, Qaqish B, O'Keefe T, Fowler W.
32P following negative second-look laparotomy for epithelial ovarian
cancer. Gynecol Oncol 1993 Aug;50(2):141-6. Comment in: Gynecol
Oncol 1993 Aug;50(2):139-40.
Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young
RC. Dose-intensive induction therapy with cyclophosphamide,
cisplatin, and consolidative abdominal radiation in advanced-stage
epithelial ovarian cancer. J Clin Oncol 1992 May;10(5):727-34.
Comment in: J Clin Oncol 1992 May;10(5):683-5 and J Clin Oncol
1992 Nov;10(11):1820-1.
Rotmensch J, Roeske J, Chen G, Pelizzari C, Montag A, Weichselbaum
R, Herbst AL. Estimates of dose to intraperitoneal micrometastases
from alpha and beta emitters in radioimmunotherapy. Gynecol Oncol
1990 Sep;38(3):478-85.
Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J. Randomized
study of whole-abdomen irradiation versus pelvic irradiation plus
cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol
1990 Jun;37(3):367-73.
Slotman BJ, Karim AB, Rao BR. Ovarian cancer: radiation sensitivity
in vitro. Radiother Oncol 1990 Dec;19(4):323-7.
Sorbe B, Berglind AM, De Bruijn K. Tropisetron, a new 5-HT3
receptor antagonist, in the prevention of irradiation-induced nausea,
vomiting and diarrhoea. Eur J Gynaecol Oncol 1992;13(5):382-9.
Spanos WJ Jr, Day T, Abner A, Jose B, Paris K, Pursell S.
Complications in the use of intra-abdominal 32P for ovarian carcinoma.
Gynecol Oncol 1992 Jun;45(3):243-7.
Stewart JS, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G,
Papadimitriou JT, Rowlinson G, Sullivan M, Lambert HE, et al.
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian
cancer. J Clin Oncol 1990 Dec;8(12):1941-50. Comment in: J Clin
Oncol 1990 Dec;8(12):1938-40.
Thomas GM. Is there a role for consolidation or salvage radiotherapy
after chemotherapy in advanced epithelial ovarian cancer? Gynecol
Oncol 1993 Oct;51(1):97-103.
Thomas GM, Dembo AJ. Integrating radiation therapy into the
management of ovarian cancer. Cancer 1993 Feb 15;71(4
Suppl):1710-8.
Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet
Gynecol Scand 1993;72(8):682-4.
Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard
MW, Kjorstad KE, Trope CG. Randomized trial comparing cisplatin
with radioactive phosphorus or whole-abdomen irradiation as adjuvant
treatment of ovarian cancer. Cancer 1992 Feb 1;69(3):741-9.
Vergote IB, Winderen M, De Vos LN, Trope CG. Intraperitoneal
radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313
patients treated primarily or at second-look laparotomy. Cancer 1993
Apr 1;71(7):2250-60.
Wahl RL. Radiolabeled monoclonal antibodies for the diagnosis and
treatment of ovarian carcinoma. Front Radiat Ther Oncol
1990;24:228-39.
Walton LA, Yadusky A, Rubinstein L. Intraperitoneal radioactive
phosphate in early ovarian carcinoma: an analysis of complications. Int
J Radiat Oncol Biol Phys 1991 May;20(5):939-44.
Weiser EB, Burke TW, Heller PB, Woodward J, Hoskins WJ, Park
RC. Determinants of survival of patients with epithelial ovarian
carcinoma following whole abdomen irradiation (WAR). Gynecol
Oncol 1988 Jun;30(2):201-8.
Whelan TJ, Dembo AJ, Bush RS, Sturgeon JF, Fine S, Pringle JF,
Rawlings GA, Thomas GM, Simm J. Complications of whole
abdominal and pelvic radiotherapy following chemotherapy for
advanced ovarian cancer. Int J Radiat Oncol Biol Phys
1992;22(5):853-8.
MANAGEMENT OF ADVANCED EPITHELIAL OVARIAN
CANCER
Preoperative Evaluation and Preparation
Adelson MD. Cytoreduction of diaphragmatic metastases using the
Cavitron Ultrasonic Surgical Aspirator. Gynecol Oncol 1991
Jun;41(3):220-2.
Adelson MD. Ultrasonic surgical aspirator in cytoreduction of splenic
metastases to avoid splenectomy. J Reprod Med 1992
Nov;37(11):917-20.
Barbieri RL, Niloff JM, Bast RC Jr, Scaetzl E, Kistner RW, Knapp RC.
Elevated serum concentrations of CA-125 in patients with advanced
endometriosis. Fertil Steril 1986 May;45(5):630-4.
Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H,
Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr,
Knapp RC. A radioimmunoassay using a monoclonal antibody to
monitor the course of epithelial ovarian cancer. N Engl J Med 1983 Oct
13;309(15):883-7.
Beck DE, Fazio VW. Current preoperative bowel cleansing methods.
Results of a survey. Dis Colon Rectum 1990 Jan;33(1):12-5.
Bertelsen K. Tumor reduction surgery and long-term survival in
advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990
Aug;38(2):203-9.
Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen
JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G, et al. A
prospective randomized comparison of 6 and 12 cycles of
cyclophosphamide, adriamycin, and cisplatin in advanced epithelial
ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
Gynecol Oncol 1993 Apr;49(1):30-6.
Bostofte E, Larsen T, Torp-Pedersen S, Ottesen M. Preoperative
investigations for suspected pelvic masses. Eur J Obstet Gynecol
Reprod Biol 1992 Dec 28;47(3):239-43.
Bourne TH, Campbell S, Whitehead MI, Royston P, Steer CV, Collins
WP. Detection of endometrial cancer in postmenopausal women by
transvaginal ultrasonography and colour flow imaging. BMJ 1990 Aug
18-25;301(6748):369. Comment in: BMJ 1990 Oct
13;301(6756)873-4.
Buchsbaum HJ, Lifshitz S. Staging and surgical evaluation of ovarian
cancer. Semin Oncol 1984 Sep;11(3):227-37.
Buy JN, Ghossain MA, Sciot C, Bazot M, Guinet C, Prevot S, Hugol
D, Laromiguiere M, Truc JB, Poitout P, et al. Epithelial tumors of the
ovary: CT findings and correlation with US. Radiology 1991
Mar;178(3):811-8.
Corfitsen MT, Pedersen IR, Lebech AM, Kaae HH. Appendectomy and
carcinoma ovarii. Cytoreduction, palliation, or simple tradition? Acta
Obstet Gynecol Scand 1991;70(7-8):601-4.
Creasman WT. New gynecologic cancer staging. Obstet Gynecol 1990
Feb;75(2):287-8.
Crippa F, Presti M, Marini A, D'Onofrio B, Bolis G, Buraggi GL.
Clinical value of radioimmunoscintigraphy in the follow-up of ovarian
carcinoma: a prospective study. Int J Biol Markers 1990
Jul-Sep;5(3):103-8.
Deppe G, Malviya VK, Malone JM Jr, Christensen CW. Debulking of
pelvic and para-aortic lymph node metastases in ovarian cancer with the
cavitron ultrasonic surgical aspirator. Obstet Gynecol 1990
Dec;76(6):1140-2.
Dershaw DD, Panicek DM. Radiologic evaluation of ovarian cancer.
In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York:
Raven Press; 1993. p. 133-52.
Einhorn N, Bast RC Jr, Knapp RC, Tjernberg B, Zurawski VR Jr.
Preoperative evaluation of serum CA 125 levels in patients with
primary epithelial ovarian cancer. Obstet Gynecol 1986
Mar;67(3):414-6.
Eisenkop SM, Nalick RH, Teng NN. Modified posterior exenteration
for ovarian cancer. Obstet Gynecol 1991 Nov;78(5 Pt 1):879-85.
Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The
impact of subspecialty training on the management of advanced ovarian
cancer. Gynecol Oncol 1992 Nov;47(2):203-9.
Eisner RF, Montz FJ, Berek JS. Cytoreductive surgery for advanced
ovarian cancer: cardiovascular evaluation with pulmonary artery
catheters. Gynecol Oncol 1990 Jun;37(3):311-4.
Gore ME, Cooke JC, Wiltshaw E, Crow JM, Cosgrove DO, Parsons
CA. The impact of computed tomography and ultrasonography on the
management of patients with carcinoma of the ovary. Br J Cancer 1989
Nov;60(5):751-4.
Granberg S, Wikland M, Jansson I. Macroscopic characterization of
ovarian tumors and the relation to the histological diagnosis: criteria to
be used for ultrasound evaluation. Gynecol Oncol 1989
Nov;35(2):139-44.
Grilli R, Alexanian A, Apolone G, Fossati R, Marsoni S, Nicolucci A,
Torri V, Zola P, Compagnucci M, Di Mambro E, et al. The impact of
cancer treatment guidelines on actual practice in Italian general
hospitals: the case of ovarian cancer. Ann Oncol 1990;1(2):112-8.
Comment in: Ann Oncol 1991 Mar;2(3):216.
Grilli R, Apolone G, Marsoni S, Nicolucci A, Zola P, Liberati A. The
impact of patient management guidelines on the care of breast,
colorectal, and ovarian cancer patients in Italy. Med Care 1991
Jan;29(1):50-63.
Guidozzi F, Sonnendecker EW. Evaluation of preoperative
investigations in patients admitted for ovarian primary cytoreductive
surgery. Gynecol Oncol 1991 Mar;40(3):244-7.
Hallenbeck P, Sanniez CK, Ryan AB, Neiley B, Sugarbaker PH.
Cytoreductive surgery and intraperitoneal chemotherapy. Treatment for
peritoneal carcinomatosis. AORN J 1992 Jul;56(1):50-7, 60-72.
Hammond RH, Houghton CR. The role of bowel surgery in the primary
treatment of epithelial ovarian cancer. Aust N Z J Obstet Gynaecol
1990 May;30(2):166-9.
Hricak H. Role of imaging in the evaluation of pelvic cancer. Important
Adv Oncol 1991:103-33.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A
risk of malignancy index incorporating CA 125, ultrasound and
menopausal status for the accurate preoperative diagnosis of ovarian
cancer. Br J Obstet Gynaecol 1990 Oct;97(10):922-9.
Johnson RJ, Blackledge G, Eddleston B, Crowther D.
Abdomino-pelvic computed tomography in the management of ovarian
carcinoma. Radiology 1983 Feb;146(2):447-52.
Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with
transvaginal color ultrasound. J Ultrasound Med 1991 Jun;10(6):295-7.
Comment in: J Ultrasound Med 1992 Mar;11(3):80.
La Fianza A, Campani R, Dore R, Babilonti L, Tateo S. The clinical
value of computed tomography and lymphography in detecting lymph
node metastases from epithelial ovarian cancer. Rofo Fortschr Geb
Rontgenstr Neuen Bildgeb Verfahr 1992 Aug;157(2):162-6.
Malkasian GD Jr, Knapp RC, Lavin PT, Zurawski VR Jr, Podratz KC,
Stanhope CR, Mortel R, Berek JS, Bast RC Jr, Ritts RE. Preoperative
evaluation of serum CA 125 levels in premenopausal and
postmenopausal patients with pelvic masses: discrimination of benign
from malignant disease. Am J Obstet Gynecol 1988 Aug;159(2):341-6.
Penalver M, Averette H, Sevin BU, Lichtinger M, Girtanner R.
Gastrointestinal surgery in gynecologic oncology: evaluation of surgical
techniques. Gynecol Oncol 1987 Sep;28(1):74-82.
Perioperative total parenteral nutrition in surgical patients. The
Veterans Affairs Total Parenteral Nutrition Cooperative Study Group.
N Engl J Med 1991 Aug 22;325(8):525-32. Comment in: N Engl J
Med 1991 Aug 22;325(8):573-5; N Engl J Med 1992 Jan
23;326(4):273; discussion 274; N Engl J Med 1992 Jan
23;326(4):273-4.
Russell AH, Anderson M, Walter J, Kinney W, Smith L, Scudder S.
The integration of computed tomography and magnetic resonance
imaging in treatment planning for gynecologic cancer. Clin Obstet
Gynecol 1992 Mar;35(1):55-72.
Schwartz PE. An oncologic view of when to do endoscopic surgery.
Clin Obstet Gynecol 1991 Jun;34(2):467-72.
Solla JA, Rothenberger DA. Preoperative bowel preparation. A survey
of colon and rectal surgeons. Dis Colon Rectum 1990 Feb;33(2):154-9.
Taylor PT, consultant. Advanced ovarian cancer: principles of
management. In: Wanabo HJ, ed. Common problems in cancer surgery.
Chicago: Year Book; 1990. p.280-4.
Whitley N, Brenner D, Francis A, Kwon T, Villasanta U, Aisner J,
Wiernik P, Whitley J. Use of the computed tomographic whole body
scanner to stage and follow patients with advanced ovarian carcinoma.
Invest Radiol 1981 Nov-Dec;16(6):479-86.
Principles of Primary Surgery
Aalders JG, Neijt JP. Aspects of surgery in ovarian and endometrial
carcinoma. Eur J Cancer 1993;29A(4): 624-8.
Archer JC, Soeters RP, Bloch B, Dehaeck CM, Levin W. Repeat
laparotomy in ovarian carcinoma after primary surgery. S Afr Med J
1991 Sep 21;80(6):276-7.
Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS,
Zuber K, Karnell LH, Winchester DP. National survey of ovarian
carcinoma. I. A patient care evaluation study of the American College
of Surgeons. Cancer 1993 Feb 15;71(4 Suppl):1629-38.
Brand E, Lidor Y. The decline of CA 125 level after surgery reflects
the size of residual ovarian cancer. Obstet Gynecol 1993
Jan;81(1):29-32.
Brand E, Pearlman N. Electrosurgical debulking of ovarian cancer: a
new technique using the argon beam coagulator. Gynecol Oncol 1990
Nov;39(2):115-8.
Bridges JE, Leung Y, Hammond IG, McCartney AJ. En bloc resection
of epithelial ovarian tumors with concomitant rectosigmoid colectomy:
The KEMH experience. Int J Gynecol Cancer 1993;3(4):199-202.
Buchsbaum HJ, Lifshitz S. Staging and surgical evaluation of ovarian
cancer. Semin Oncol 1984 Sep;11(3):227-37.
Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H.
Patterns of pelvic and paraaortic lymph node involvement in ovarian
cancer. Gynecol Oncol 1991 Feb;40(2):103-6.
Fioretti P, Gadducci A, Del Bravo B, Prato B. The potential of primary
cytoreductive surgery in patients with FIGO stages III and IV ovarian
carcinoma. Eur J Gynaecol Oncol 1990;11(3):175-9.
Fontanelli R, Paladini D, Raspagliesi F, di Re E. The role of
appendectomy in surgical procedures for ovarian cancer. Gynecol
Oncol 1992 Jul;46(1):42-4.
Hacker NF. Surgery for gynaecological cancer: results since the
introduction of radical operations. Aust N Z J Obstet Gynaecol 1990
Feb;30(1):24-8.
Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC,
Chapman D, Almadrones L, Lewis JL Jr. Randomized prospective trial
of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin
in advanced ovarian carcinoma. Gynecol Oncol 1992 Jun;45(3):284-9.
Hand R, Fremgen A, Chmiel JS, Recant W, Berk R, Sylvester J, Sener
S. Staging procedures, clinical management, and survival outcome for
ovarian carcinoma. JAMA 1993 Mar 3;269(9):1119-22. Comment in:
JAMA 1993 Mar 3;269(9):1163 and JAMA 1993 Sep
8;270(10):1196-7.
Heintz AP. Cytoreductive surgery for ovarian cancer. In: Greer BE,
Berek JS, eds. Gynecologic oncology: treatment rationale and
techniques. New York: Elsevier;1991. p. 135-48.
Hoskins WJ. Primary cytoreduction. In: Markman M, Hoskins WJ, eds.
Cancer of the ovary. New York: Raven Press; 1993. p. 163-73.
Hoskins WJ. Primary surgical management of advanced epithelial
ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New
York: McGraw-Hill; 1993. p. 241-53.
Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial
ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1534-40.
Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of
cytoreductive surgery on recurrence-free interval and survival in
small-volume stage III epithelial ovarian cancer: a Gynecologic
Oncology Group study. Gynecol Oncol 1992 Nov;47(2):159-66.
Hoskins WJ, Rubin SC. Surgery in the treatment of patients with
advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.
Hudson CN, Potsides P, Curling OM. An audit of surgical treatment of
ovarian cancer in a metropolitan health region. Association of
Obstetricians and Gynaecologists of the North East Thames Region. J
R Soc Med 1991 Apr;84(4):206-9.
Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in
advanced ovarian carcinoma: is maximum cytoreductive surgery an
independent determinant of prognosis? Am J Obstet Gynecol 1992
Feb;166(2):504-11. Comment in: Am J Obstet Gynecol 1993
Jul;169(1):236-7.
Jadhon ME, Morgan MA, Kelsten ML, Carlson JA Jr, Mikuta JJ.
Cytologic smears of peritoneal surfaces as a sampling technique in
epithelial ovarian carcinoma. Obstet Gynecol 1990 Jan;75(1):102-5.
Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural involvement in
stage III ovarian carcinoma: role of diaphragm resection. Gynecol
Oncol 1990 Nov;39(2):135-8.
Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Itamochi H,
Terakawa N. Evaluation of cytoreductive surgery with
lymphadenectomy including para-aortic nodes for advanced ovarian
cancer. Eur J Surg Oncol 1993 Jun;19(3):273-8.
Kirschner CV, DeSerto TM, Isaacs JH. Surgical treatment of the
elderly patient with gynecologic cancer. Surg Gynecol Obstet 1990
May;170(5):379-84.
Lawton F, Luesley D, Redman C, Chan KK, Varma R, Blackledge G.
Feasibility and outcome of complete secondary tumor resection for
patients with advanced ovarian cancer. J Surg Oncol 1990
Sep;45(1):14-9.
Luesley DM, Williams DR, Ward K, Redman CR, Lawton FG.
Prospective comparative cytologic study of direct peritoneal smears
and lavage fluids in patients with epithelial ovarian cancer and benign
gynecologic disease. Acta Cytol 1990 Jul-Aug;34(4):539-44.
Magli G, De Marco I, Biello A, Turtoro L, Esposito A. Regional
surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol
1992;13(1 Suppl):97-8.
Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM.
Treatment of advanced ovarian carcinoma in the elderly. Gynecol
Oncol 1993 Apr;49(1):86-91.
Markman M. Surgeon's skill key to ovarian cancer management. Cleve
Clin J Med 1993 May-Jun;60(3):183-4.
Mayer AR, Chambers SK, Graves E, Holm C, Tseng PC, Nelson BE,
Schwartz PE. Ovarian cancer staging: does it require a gynecologic
oncologist? Gynecol Oncol 1992 Nov;47(2):223-7.
McGowan L. Patterns of care in carcinoma of the ovary. Cancer 1993
Jan 15;71(2 Suppl):628-33.
Menczer J. Cytoreductive surgery in the treatment of advanced ovarian
carcinoma. Some controversial aspects. Eur J Gynaecol Oncol
1992;13(3):246-55.
Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic
computed tomographic prediction of optimal cytoreduction in epithelial
ovarian carcinoma. J Clin Oncol 1993 Jan;11(1):166-72.
Nishimura H, Hamaguchi K, Miyahara K, Tazaki T, Tateno N,
Yakushiji M. The current therapeutic approaches to advanced ovarian
cancer. Nippon Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12):1691-6.
Obiakor I, Maiman M, Mittal K, Awobuluyi M, DiMaio T,
Demopoulos R. The accuracy of frozen section in the diagnosis of
ovarian neoplasms. Gynecol Oncol 1991 Oct;43(1):61-3.
Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S.
Clinical experience in gynecological cancer management. d). Ovarian
tumors--1) Epithelial: report from the Gynaecological Institutes of
Padua University (1963-1990). Eur J Gynaecol Oncol
1992;13(1):17-33.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Partridge EE, Gunter BC, Gelder MS, Alvarez RD, Soong SJ, Austin
JM, Kilgore LC. The validity and significance of substages of advanced
ovarian cancer. Gynecol Oncol 1993 Feb;48(2):236-41.
Penalver M, Averette H, Sevin BU, Lichtinger M, Girtanner R.
Gastrointestinal surgery in gynecologic oncology: evaluation of surgical
techniques. Gynecol Oncol 1987 Sep;28(1):74-82.
Petru E, Pickel H, Tamussino K, Lahousen M, Heydarfadai M,
Posawetz W, Jakse R. Pretherapeutic scalene lymph node biopsy in
ovarian cancer. Gynecol Oncol 1991 Dec;43(3):262-4.
Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck S.
Long-term survival in stage III and IV ovarian cancer. Arch Gynecol
Obstet 1991;249(2):87-93.
Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton
HM. Primary surgical therapy of ovarian cancer: how much and when.
Gynecol Oncol 1991 Mar;40(3):195-200.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Rakar S, Kovacic J, Cavic M, Lukanovic A, Mozina A. Prognostic
factors in ovarian cancer. Eur J Gynaecol Oncol 1990;11(3):171-3.
Rose PG. The cavitational ultrasonic surgical aspirator for
cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992
Mar;166(3):843-6. Comment in: Am J Obstet Gynecol 1993
Feb;168(2):736.
Rose PG, Reale FR, Fisher A, Hunter RE. Appendectomy in primary
and secondary staging operations for ovarian malignancy. Obstet
Gynecol 1991 Jan;77(1):116-8.
Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):851-65.
Scott NA, Schofield PF. Cytoreductive surgery for ovarian carcinoma.
Br J Surg 1990 May;77(5):481-2.
Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of
partial sigmoid colectomy for debulking epithelial ovarian carcinoma.
Gynecol Oncol 1991 Jun;41(3):239-44. Comment in: Gynecol Oncol
1992 Jul;46(1):138.
Soper JT, Johnson P, Johnson V, Berchuck A, Clarke-Pearson DL.
Comprehensive restaging laparotomy in women with apparent early
ovarian carcinoma. Obstet Gynecol 1992 Dec;80(6):949-53.
Tsuruchi N, Kamura T, Tsukamoto N, Akazawa K, Saito T, Kaku T,
To N, Nakano H. Relationship between paraaortic lymph node
involvement and intraperitoneal spread in patients with ovarian
cancer--a multivariate analysis. Gynecol Oncol 1993 Apr;49(1):51-5.
Tummarello D, Menichetti ET, Miseria S, Torresi U, Guidi F,
Gramazio A, Vissani L, Cellerino R. Advanced epithelial ovarian
cancer: no difference in survival rate between exploratory laparotomy
and inadequate debulking surgery as treatment approach before
chemotherapy. J Chemother 1990 Aug;2(4):260-3.
Unzelman RF. Advanced epithelial ovarian carcinoma: long-term
survival experience at the community hospital. Am J Obstet Gynecol
1992 Jun;166(6 Pt 1):1663-71; discussion 1671-2.
Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor debulking
followed by immediate combination chemotherapy in advanced ovarian
carcinoma. Phase II. Acta Obstet Gynecol Scand 1992 Jul;71(5):361-7.
Venesmaa P, Ylikorkala O. Morbidity and mortality associated with
primary and repeat operations for ovarian cancer. Obstet Gynecol 1992
Feb;79(2): 168-72. Comment in: Obstet Gynecol 1992 Jul;80(1):155-6.
Vergote IB. Surgery for gynecologic malignancies. Curr Opin Oncol
1993 Sep;5(5):877-84.
Wils JA. Long-term follow-up of patients with advanced ovarian
carcinoma treated with debulking surgery and chemotherapy consisting
of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic
Oncology Group of the Comprehensive Cancer Center. Oncology
1990;47(2):115-20.
Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet
1990 Mar;170(3):276-81.
Yedema CA, Kenemans P, Thomas CM, Massuger LF, Wobbes T,
Verstraeten R, van Kamp GJ, Hilgers J. CA 125 serum levels in the
early post-operative period do not reflect tumour reduction obtained by
cytoreductive surgery. Eur J Cancer 1993;29A(7):966-71.
Primary Adjuvant Chemotherapy
Abel U. Chemotherapy of advanced epithelial cancer - A critical
review. Biomed Pharmacother 1992;46(10):439-52.
Alberts DS, Canetta R, Mason-Liddil N. Carboplatin in the first-line
chemotherapy of ovarian cancer. Semin Oncol 1990 Feb;17(1 Suppl
2):54-60.
Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R,
Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ. Analysis of
patient age as an independent prognostic factor for survival in a phase
III study of cisplatin-cyclophosphamide versus
carboplatin-cyclophosphamide in stages III (suboptimal) and IV
ovarian cancer. A Southwest Oncology Group study. Cancer 1993 Jan
15;71(2 Suppl):618-27.
Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D,
Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ.
Improved therapeutic index of carboplatin plus cyclophosphamide
versus cisplatin plus cyclophosphamide: final report by the Southwest
Oncology Group of a phase III randomized trial in stages III and IV
ovarian cancer. J Clin Oncol 1992 May;10(5):706-17. Published
erratum appears in J Clin Oncol 1992 Sep;10(9):1505. Comment in: J
Clin Oncol 1992 May;10(5):683-5.
Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM. Survival
determinants in patients with advanced ovarian cancer. Gynecol Oncol
1993 Aug;50(2):215-20.
Araujo CE, Cervellino JC, Pirisi C, Pannunzio O, Callegari J.
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the
treatment of ovarian cancer: a study of the Grupo de Estudio y
Tratamiento Latino-Americano del Cancer. J Surg Oncol 1991
Mar;46(3):198-202.
Barrett RJ, Muss HB. Gynecologic malignancies. In: Lokich JJ, ed.
Cancer chemotherapy by infusion. 2nd ed. Chicago; Precept Press;
1990. p.463-83.
Belinson JL, Lee KR, Jarrell MA, McClure M. Management of
epithelial ovarian neoplasms using a platinum-based regimen: a 10-year
experience. Gynecol Oncol 1990 Apr;37(1):66-73.
Beller U, Speyer J, Colombo N, Sorich J, Wernz J, Hochster H,
Zeleniuch-Jacquotte A, Porges R, Beckman EM. Consolidation with
intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
J Clin Oncol 1991 May;9(5):809-17.
Bertelsen K, Bastholt L. High-dose platinum chemotherapy in
advanced ovarian cancer: a phase II study. Gynecol Oncol 1992
Jan;44(1):79-82.
Bicher A, Sarosy G, Kohn E, Adamo DO, Davis P, Jacob J, Chabner
BA, Reed E. Age does not influence taxol dose intensity in recurrent
carcinoma of the ovary. Cancer 1993 Jan 15;71(2 Suppl):594-600.
Bruckner HW, Cohen C, Mandeli J, Chesser MR, Kabakow B, Wallach
R, Holland J. Hexamethylmelamine for the treatment of ovarian
cancer--the Mount Sinai experience. Cancer Treat Rev 1991 Mar;18
Suppl A:57-65.
Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant
chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 1990
Jun;37(3):327-31.
Chemotherapy in advanced ovarian cancer: an overview of randomised
clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 1991
Oct 12;303(6807):884-93. Comment in: BMJ 1991 Nov
16;303(6812):1269 and BMJ 1992 Jan 11;304(6819):119.
Cherchi PL, Bagella MP, Campiglio A, Rubattu A, Farina M,
Ambrosini A. Fist line chemotherapy in advanced ovarian cancer: a
comparison of three therapeutic regimes. Eur J Gynaecol Oncol
1990;11(6):453-6.
Cheson BD. Clinical trials referral resource. Ovarian cancer. Oncology
(Huntingt) 1990 Aug;4(8):69-75.
Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone M, Sertoli MR,
Parodi GC, Ragni N, Foglia G, Odicino F, et al. Adjuvant
cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year
experience. Eur J Cancer 1991;27(10):1211-5. Comment in: Eur J
Cancer 1991;27(10):1196.
Conte PF. Role of anthracyclines in first line combination
chemotherapy of ovarian carcinoma. Bull Cancer 1993;80(2):152-5.
Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V,
Fioretti P, Foglia G, Gadducci A, Gallo L, et al. Carboplatin,
doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and
cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian
carcinoma. J Clin Oncol 1991 Apr;9(4):658-63.
Cornelison TL, Reed E. Dose intensity analysis of high-dose
carboplatin in refractory ovarian carcinoma relative to age. Cancer
1993 Jan 15;71(2 Suppl):650-5.
Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RCJr,
Fujii S, Long HJ 3d, Halberg F, Tamura K. Toward a chronotherapy of
ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by
efficacy. Chronobiologia 1992;19(3-4):131-49.
Creasman WT, Omura GA, Brady MF, Yordan E, DiSaia PJ, Beecham
J. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin
with or without bacillus Calmette-Guerin in patients with suboptimal
stage III and IV ovarian cancer: a Gynecologic Oncology Group study.
Gynecol Oncol 1990 Dec;39(3):239-43.
Cruickshank DJ, Paul J, Lewis CR, McAllister EJ, Kaye SB. An
independent evaluation of the potential clinical usefulness of proposed
CA-125 indices previously shown to be of prognostic significance in
epithelial ovarian cancer. Br J Cancer 1992 Apr;65(4):597-600.
Cruickshank DJ, Terry PB, Fullerton WT. CA125-response assessment
in epithelial ovarian cancer. Int J Cancer 1992 Apr 22;51(1):58-61.
Cruickshank DJ, Terry PB, Fullerton WT. The potential value of
CA125 as a tumour marker in small volume, non-evaluable epithelial
ovarian cancer. Int J Biol Markers 1991 Oct-Dec;6(4):247-52.
Cyclophosphamide plus cisplatin versus cyclophosphamide,
doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a
meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol
1991 Sep;9(9):1668-74.
Davidson NG, Khanna S, Kirwan PH, Bircumshaw D.
Prechemotherapy serum CA125 level as a predictor of survival
outcome in epithelial carcinoma of the ovary. Clin Oncol (R Coll
Radiol) 1991 Jan;3(1):32-6.
Davidson NG, Khanna S, Kirwan PH, Naftalin NJ, Roy UK, Chui D,
Mitchell S. Long-term survival after chemotherapy with cisplatinum,
adriamycin and cyclophosphamide for carcinoma of the ovary. Clin
Oncol (R Coll Radiol) 1990 Jul;2(4):206-9.
de Oliveira CF, Lacave AJ, Villani C, Wolff JP, di Re F, Namer M,
Maskens A, George M, Dalesio O, Rotmensz N, et al. Randomized
comparison of cyclophosphamide, doxorubicin and cisplatin (CAP)
versus cyclophosphamide and doxorubicin (CA) for the treatment of
advanced ovarian cancer (ADOVCA). A EORTC Gynecological
Cancer Cooperative Group Study. Eur J Gynaecol Oncol
1990;11(5):323-30.
de Vries EG, Biesma B, Willemse PH, Mulder NH, Stern AC, Aalders
JG, Vellenga E. A double-blind placebo-controlled study with
granulocyte-macrophage colony-stimulating factor during
chemotherapy for ovarian carcinoma. Cancer Res 1991 Jan
1;51(1):116-22.
Edmonson JH, Su J, Krook JE. Treatment of ovarian cancer in elderly
women. Mayo Clinic-North Central Cancer Treatment Group studies.
Cancer 1993 Jan 15;71(2 Suppl):615-7.
Eiermann W, Achterrath W, Lenaz L, Hepp H. Carboplatin/etoposide
as first-line chemotherapy in advanced ovarian carcinoma: a pilot study.
Cancer Chemother Pharmacol 1991;27(5):389-93.
Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin,
doxorubicin, and cyclophosphamide versus cisplatin and
cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol
1992 Dec;80(6):954-60. Comment in: Obstet Gynecol 1993
Apr;81(4):641-2.
Fisken J, Leonard RC, Stewart M, Beattie GJ, Sturgeon C, Aspinall L,
Roulston JE. The prognostic value of early CA125 serum assay in
epithelial ovarian carcinoma. Br J Cancer 1993 Jul;68(1):140-5.
Gadducci A, Brunetti I, Bruzzone M, Carnino F, Chiara S, Conte PF,
Fioretti P, Foglia G, Ragni N. Cisplatin-based combination
chemotherapy with or without doxorubicin in advanced epithelial
ovarian cancer: 8-year update of a randomized multicentric clinical
trial. The Gruppo Oncologico Nord Ovest (GONO). Eur J Gynaecol
Oncol 1992;13(1 Suppl): 36-9.
Gadducci A, Ferdeghini M, Ceccarini T, Prontera C, Facchini V,
Bianchi R, Fioretti P. A comparative evaluation of the ability of serum
CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in
reflecting the course of disease in patients with ovarian carcinoma. Eur
J Gynaecol Oncol 1990;11(2):127-33.
Gadducci A, Ferdeghini M, Cristofani R, Fioretti P. Comparison of
common clinico-pathological prognostic variables and serum CA 125
assay as predictors of clinical outcome in patients with advanced
ovarian carcinoma. Ital J Gynaecol Obstet 1993;5(1):16-23.
Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Burke TW,
Morris M, Kavanagh JJ, Warner D, Wharton JT. Age contrasts in
patients with advanced epithelial ovarian cancer. The M.D. Anderson
Cancer Center experience. Cancer 1993 Jan 15;71(2 Suppl):638-43.
Gershenson DM, Mitchell MF, Atkinson N, Silva EG, Kavanagh JJ,
Morris M, Burke TW, Warner D, Wharton JT. The effect of prolonged
cisplatin-based chemotherapy on progression-free survival in patients
with optimal epithelial ovarian cancer: maintenance therapy
reconsidered. Gynecol Oncol 1992 Oct;47(1):7-13. Comment in:
Gynecol Oncol 1992 Oct;47(1):5-6.
Gershenson DM, Silva EG, Mitchell MF, Atkinson EN, Wharton JT.
Transitional cell carcinoma of the ovary: a matched control study of
advanced-stage patients treated with cisplatin-based chemotherapy. Am
J Obstet Gynecol 1993 Apr;168(4):1178-85; discussion 1185-7.
Goodman HM, Harlow BL, Sheets EE, Muto MG, Brooks S, Steller
M, Knapp RC, Berkowitz RS. The role of cytoreductive surgery in the
management of stage IV epithelial ovarian carcinoma. Gynecol Oncol
1992 Sep;46(3):367-71.
Greco FA, Johnson DH, Hainsworth JD. A comparison of
hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin,
and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and
cisplatin (CAP) in advanced ovarian cancer. Cancer Treat Rev 1991
Mar;18 Suppl A:47-55.
Grem J, O'Dwyer P, Elson P, Simon N, Trump D, Frontiera M,
Falkson G, Vogl S. Cisplatin, carboplatin, and cyclophosphamide
combination chemotherapy in advanced-stage ovarian carcinoma: an
Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1991
Oct;9(10):1793-800.
Hainsworth JD, Burnett LS, Jones HW 3d, Grosh WW, Johnson DH,
Greco FA. High-dose cisplatin combination chemotherapy in the
treatment of advanced epithelial ovarian carcinoma. J Clin Oncol 1990
Mar;8(3):502-8. Comment in: J Clin Oncol 1990 Jul;8(7):1287-8.
Hainsworth JD, Jones HW 3d, Burnett LS, Johnson DH, Greco FA.
The role of hexamethylmelamine in the combination chemotherapy of
advanced ovarian cancer: a comparison of hexamethylmelamine,
cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus
cyclophosphamide, doxorubicin, and cisplatin (CAP). Am J Clin Oncol
1990 Oct;13(5):410-5.
Hallmark RJ, Snyder JM, Jusenius K, Tamimi HK. Factors influencing
ototoxicity in ovarian cancer patients treated with Cis-platinum based
chemotherapy. Eur J Gynaecol Oncol 1992;13(1):35-44.
Hannigan EV, Green S, Alberts DS, O'Toole R, Surwit E. Results of a
Southwest Oncology Group phase III trial of carboplatin plus
cyclophosphamide versus cisplatin plus cyclophosphamide in advanced
ovarian cancer. Oncology 1993 Nov;50 Suppl 2:2-9.
Harding M, Milsted R, Hole D, Cordiner J, Barr W, Soukop M,
Kennedy J, Soutter WP, Kaye S. Long term results of
cyclophosphamide, adriamycin and platinum chemotherapy in advanced
epithelial ovarian cancer. Ann Oncol 1991 Mar;2(3):231-3.
Hardy JR, Wiltshaw E, Blake PR, Harper P, Slevin M, Perren TJ, Tan
S. Cisplatin and carboplatin in combination for the treatment of stage
IV ovarian carcinoma. Ann Oncol 1991 Feb;2(2):131-6.
Harvey VJ, Evans BD, Mitchell PL, Mak D, Neave LM, Langley GB,
Dickson DS. Reduction of carboplatin induced emesis by ondansetron.
Br J Cancer 1991 Jun;63(6):942-4.
Heintz AP. Sequential cisplatin--doxorubicin, early debulking in
advanced ovarian cancer. Eur J Cancer 1992;28A(6-7):1009-10.
Hempling RE, Piver MS, Natarajan N, Baker TR, Thompson JM,
Hicks ML, Mettlin CJ. Predictive value of serum CA125 following
optimal cytoreductive surgery during weekly cisplatin induction therapy
for advanced ovarian cancer. J Surg Oncol 1993 Sep;54(1):38-44.
Hogberg T, Carstensen J, Simonsen E. Treatment results and
prognostic factors in a population-based study of epithelial ovarian
cancer. Gynecol Oncol 1993 Jan;48(1):38-49.
Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125
during induction chemotherapy as a prognostic indicator for survival in
ovarian carcinoma. Acta Obstet Gynecol Scand 1990;69(5):423-9.
Homesley HD, Harry DS, O'Toole RV, Hoogstraten B, Franklin EW,
Cavanagh D, Nahhas WA, Smith JJ, Lovelace JV. Randomized
comparison of cisplatin plus epirubicin or doxorubicin for advanced
epithelial ovarian carcinoma. A multicenter trial. Am J Clin Oncol 1992
Apr;15(2):129-34.
Hoskins PJ, O'Reilly SE, Swenerton KD, Spinelli JJ, Fairey RN,
Benedet JL. Ten-year outcome of patients with advanced epithelial
ovarian carcinoma treated with cisplatin-based multimodality therapy. J
Clin Oncol 1992 Oct;10(10):1561-8. Comment in: J Clin Oncol 1993
Mar;11(3):587-8.
Hoskins WJ. Treatment strategies for advanced ovarian cancer. In:
Greer BE, Berek JS, eds. Gynecologic oncology: treatment rationale
and techniques. New York: Elsevier; 1991. p. 149-66.
Hunter RE, Griffin TW, Stevens S, Roman LD, Bokhari F, Reale FR,
Tak WK, Fitzgerald TJ, Dillon MB, Rose PG. High-dose,
short-duration cisplatin/doxorubicin combination chemotherapy for
advanced ovarian epithelial cancer. Cancer 1991 Nov 1;68(9):1890-4.
Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson
DL, Bast RC Jr. The prognostic significance of CA 125 half-life in
patients with ovarian cancer who have received primary chemotherapy
after surgical cytoreduction. Am J Obstet Gynecol 1990 Oct;163(4 Pt
1):1164-7. Comment in: Am J Obstet Gynecol 1991 Sep;165(3):779.
Inoue M, Nakanishi K, Ueda G, Tanizawa O. Intermittent intensive
combination chemotherapy with cisplatin, doxorubicin, and
cyclophosphamide (cyclic PAC chemotherapy) for ovarian cancer. Am
J Clin Oncol 1992 Feb;15(1):1-6.
Inoue M, Tanaka Y, Sugita N, Yamasaki M, Yamanaka T, Minagawa
J, Nakamuro K, Tani T, Okudaira Y, Karita T, et al. Improvement of
long-term prognosis in patients with ovarian cancers by adjuvant
sizofiran immunotherapy: a prospective randomized controlled study.
Biotherapy 1993;6(1):13-8.
Iversen OE. Modern cytostatic therapy and survival in ovarian
carcinoma (1). Acta Obstet Gynecol Scand 1993;72(1):69.
Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW,
Wharton JT. Neoadjuvant chemotherapy and interval debulking for
advanced epithelial ovarian cancer. Gynecol Oncol 1991
Aug;42(2):146-50.
Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP,
Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between
carboplatin exposure and tumor response and toxicity in patients with
ovarian cancer. J Clin Oncol 1992 Apr;10(4):520-8. Comment in: J
Clin Oncol 1992 Apr;10(4):513-4.
Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert
W, Bell J, Host H, Prior P, Karjalainen S, et al. Leukemia following
chemotherapy for ovarian cancer. N Engl J Med 1990 Jan 4;322(1):1-6.
Comment in: N Engl J Med 1990 Jan 4;322(1):52-3.
Karrer K, Salzer H, Sevelda P, Dittrich C. The role of chemotherapy
including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian
Cancer Study Group. Cancer Chemother Pharmacol 1990;26
Suppl:S30-2.
Kaye SB. Chemotherapy for ovarian cancer. Eur J Cancer
1993;29A(4):632-5.
Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC,
Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, et al.
Randomised study of two doses of cisplatin with cyclophosphamide in
epithelial ovarian cancer. Lancet 1992 Aug 8;340(8815):329-33.
Comment in: Lancet 1992 Sep 12;340(8820):678-9.
Kehoe S, Redman C, Varma R, Buxton J, Luesley D, Blackledge G,
Stanley A. Single agent high-dose cisplatin (200 mg m-2) treatment in
ovarian carcinoma. Br J Cancer 1992 Oct;66(4):717-9.
Kjorstad K, Harris A, Bertelsen K, Slevin M, Schultz H, Hellman K,
Janssens N, Martin A, Canetta R. A multicenter phase II study of
carboplatin in advanced ovarian carcinoma: final report. Ann Oncol
1992 Mar;3(3):217-22.
Kolb BA, Buller RE, Connor JP, DiSaia PJ, Berman ML. Effects of
early postoperative chemotherapy on wound healing. Obstet Gynecol
1992 Jun;79(6):988-92. Comment in: Obstet Gynecol 1992
Oct;80(4):730.
Krommer CF, Szalai JP. Cyclophosphamide, adriamycin and cisplatin
(CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in
the treatment of advanced ovarian cancer: a randomized study. Ann
Oncol 1992 Jan;3(1):37-9.
Krommer CF, Szalai JP. A review of 28 years of treating advanced
ovarian cancer. Anticancer Res 1993 May-Jun;13(3):817-25.
Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized
trial comparing single-agent carboplatin with carboplatin followed by
radiotherapy for advanced ovarian cancer: a North Thames Ovary
Group study. J Clin Oncol 1993 Mar;11(3):440-8.
Lawton F, Meanwell C, Mould J, Blackledge G. A five-drug alternating
chemotherapy regimen for patients with advanced epithelial ovarian
cancer. Gynecol Oncol 1990 Jan;36(1):19-22.
Lawton FG, Hilton C, Mould JJ, Chan KK, Blackledge G.
Short-duration (three cycles) cisplatin combination chemotherapy with
alkylating agent consolidation in advanced epithelial ovarian cancer.
Gynecol Oncol 1991 Mar;40(3):225-9.
Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy
regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer
Inst 1993 Nov 3;85(21):1732-42.
Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide
chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma.
Clin Oncol (R Coll Radiol) 1993;5(4):198-202.
Locatelli MC, D'Antona A, Carcione R, Cesana B, Dallavalle G, Vinci
M, Clerici M, Labianca R, Pasquinucci C, Luporini G. A
cisplatinum-cyclophosphamide regimen in advanced ovarian cancer:
reporting 5-year results. Oncology 1993 Mar-Apr;50(2):92-9.
Long-term results of a randomized trial comparing cisplatin with
cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and
adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale
Cooperativo Oncologico Ginecologia), Italy. Gynecol Oncol 1992
May;45(2):115-7.
Lund B. Clinical and prognostic features of advanced ovarian
carcinoma. Dan Med Bull 1993;40(5):537-45.
Lund B, Hansen M, Hansen HH, Thomsen HK, Sorensen BL, Nielsen
NC, Lundvall F. A randomized study of sequential versus alternating
combination chemotherapy in advanced ovarian carcinoma. Ann Oncol
1990;1(2):134-40.
Lund B, Hansen M, Hansen OP, Hansen HH. Combined high-dose
carboplatin and cisplatin, and ifosfamide in previously untreated ovarian
cancer patients with residual disease. J Clin Oncol 1990
Jul;8(7):1226-30.
Lund B, Hansen OP, Hansen HH, Hansen M. Combination therapy
with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Semin
Oncol 1992 Feb;19(1 Suppl 1):26-9.
Lund B, Williamson P. Prognostic factors for overall survival in
patients with advanced ovarian carcinoma. Ann Oncol 1991
Apr;2(4):281-7. Comment in: Ann Oncol 1991 Apr;2(4):245-7.
Makar AP, Kristensen GB, Bormer OP, Trope CG. Serum CA 125
level allows early identification of nonresponders during induction
chemotherapy. Gynecol Oncol 1993 Apr;49(1):73-9.
Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope
CG. Prognostic value of pre- and postoperative serum CA 125 levels in
ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol
1992 Jun;79(6):1002-10.
Malviya VK, Deppe G, Boike G, Young J. Pharmacokinetics of
intraperitoneal doxorubicin in combination with systemic
cyclophosphamide and cis-platinum in the treatment of stage III ovarian
cancer. Gynecol Oncol 1990 Feb;36(2):185-8.
Marchetti DL, Lele SB, Priore RL, McPhee ME, Hreshchyshyn MM.
Treatment of advanced ovarian carcinoma in the elderly. Gynecol
Oncol 1993 Apr;49(1):86-91.
Markman M, Lewis JL Jr, Saigo P, Hakes T, Jones W, Rubin S,
Reichman B, Barakat R, Curtin J, Almadrones L, et al. Epithelial
ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer
Center experience. Cancer 1993 Jan 15;71(2 Suppl):634-7.
Markmann M, Rothman R, Reichman B, Hakes T, Lewis JL Jr, Rubin
S, Jones W, Almadrones L, Hoskins W. Persistent hypomagnesemia
following cisplatin chemotherapy in patients with ovarian cancer. J
Cancer Res Clin Oncol 1991;117(2):89-90.
Markowska J, Kopczynski Z, Manys G, Szewierski Z. CA 125 in
monitoring chemotherapy of patients with ovarian cancer: early
response to the treatment. Neoplasma 1990;37(6):687-92.
Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a
marker of ovarian cancer. Eur J Gynaecol Oncol 1992;13(4):360-5.
Markowska J, Manys G, Szewierski Z. CA 125 in monitoring clinical
course in ovarian cancer patients. A prospective clinical study. Eur J
Gynaecol Oncol 1992;13(2):201-4.
Martoni A, Ercolino L, Bellucco A, Canova N, Lelli G, Pannuti F.
Cisplatinum plus epirubicin alternated with cyclophosphamide plus
5-fluorouracil in ovarian cancer. J Chemother 1990 Feb;2(1):62-6.
Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase II
study of carboplatin and cyclophosphamide in advanced ovarian
carcinoma. J Chemother 1993 Feb;5(1):47-51.
Masding J, Sarkar TK, White WF, Barley VL, Chawla SL, Boesen E,
Rostom AY, Menday AP. Intravenous treosulfan versus intravenous
treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet
Gynaecol 1990 Apr;97(4):342-51.
McGuire WP. Primary chemotherapy of epithelial ovarian cancer. In:
Rubin SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill;
1993. p. 255-68.
McGuire WP. Primary treatment of epithelial ovarian malignancies.
Cancer 1993 Feb 15;71(4 Suppl):1541-50.
McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and
experimental approaches in ovarian cancer therapy. Semin Oncol 1991
Jun;18(3):255-69.
Mirshahi SS, Pujade-Lauraine E, Soria C, Mirshahi M, Fretault J,
Bernadou A, Soria J. D-dimer and CA 125 levels in patients with
ovarian cancer during antineoplastic therapy. Prognostic significance
for the success of anti-cancer treatment. Cancer 1992 May
1;69(9):2289-92.
Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer.
Gynecol Oncol 1992 Mar;44(3):207-12. Comment in: Gynecol Oncol
1992 Mar;44(3):205 and Gynecol Oncol 1992 Oct;47(1):131-2.
Mogensen O, Mogensen B, Jakobsen A. Predictive value of CA 125
during early chemotherapy of advanced ovarian cancer. Gynecol Oncol
1990 Apr;37(1):44-6.
Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi H, Nakashima N,
Ishizuka T, Furuhashi Y, Hattori SE, Kuzuya K, et al. Clinical
remission criteria for epithelial carcinoma of the ovary. Gynecol Oncol
1993 Mar;48(3):342-8.
Murphy D, Crowther D, Renninson J, Prendiville J, Ranson M, Lind M,
Patel U, Dougal M, Buckley CH, Tindall VR. A randomised dose
intensity study in ovarian carcinoma comparing chemotherapy given at
four week intervals for six cycles with half dose chemotherapy given
for twelve cycles. Ann Oncol 1993 May;4(5):377-83.
Nash JD, Young RC. Gynecologic malignancies. Cancer Chemother
Biol Response Modif 1991;12:549-69.
Neijt JP. Treatment of advanced ovarian cancer: 10 years of
experience. Ann Oncol 1992 Jan;3(1):17-27.
Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom
AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen
E, van Lent M, et al. Long-term survival in ovarian cancer. Mature data
from The Netherlands Joint Study Group for Ovarian Cancer. Eur J
Cancer 1991;27(11):1367-72.
Ng LW, Rubin SC, Hoskins WJ, Jones WB, Hakes TB, Markman M,
Reichman B, Almadrones L, Lewis JL Jr. Aggressive chemosurgical
debulking in patients with advanced ovarian cancer. Gynecol Oncol
1990 Sep;38(3):358-63.
Nguyen HN, Averette HE, Hoskins W, Penalver M, Sevin BU, Steren
A. National survey of ovarian carcinoma. Part V. The impact of
physician's specialty on patients' survival. Cancer 1993 Dec
15;72(12):3663-70.
Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren
A. National survey of ovarian carcinoma. VI. Critical assessment of
current International Federation of Gynecology and Obstetrics staging
system. Cancer 1993 Nov 15;72(10):3007-11.
Nishida T, Nagasue N, Yakushiji M. Treatment of gynecological
malignancies with a combination of cisplatin, Adriamycin and
ifosfamide. Cancer Chemother Pharmacol 1990;26 Suppl:S39-42.
Ojeda-Gonzalez MB, Alvarez-Lopez I, Alonso-Munoz MC,
Badia-Serra J, Delgado-Latre E, de Andres-Basauri L, Lopez-Lopez JJ.
Chemotherapy (CAP) for the treatment of advanced ovarian cancer and
second-effort surgery in the second look. Oncology 1991;48(1):7-12.
Omura GA, Brady MF, Fanning J, Hilgers RD. Meta-analysis of
cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and
cyclophosphamide chemotherapy of ovarian carcinoma (1). Obstet
Gynecol 1993;81(4):641-2.
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ,
Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor
analysis in advanced ovarian carcinoma: the Gynecologic Oncology
Group experience. J Clin Oncol 1991 Jul;9(7):1138-50.
Omura GA, Buyse M, Marsoni S, Bertelsen K, Conte PF, Jakobsen A,
Vermorken J. Cyclophosphamide plus cisplatin versus
cyclophosphomide, doxorubicin, and cisplatin chemotherapy of ovarian
carcinoma: A meta-analysis. J Clin Oncol 1991;9(9):1668-74.
Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S.
Clinical experience in gynecological cancer management. d). Ovarian
tumors--1) Epithelial: report from the Gynaecological Institutes of
Padua University (1963-1990). Eur J Gynaecol Oncol
1992;13(1):17-33.
Ozols RF. Advances in the chemotherapy of gynecologic malignancies.
Hematol Oncol 1992 Jan-Feb;10(1):43-51.
Ozols RF. Chemotherapy for advanced epithelial ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.
Ozols RF. New developments with carboplatin in the treatment of
ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.
Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;6(6):328-38.
Ozols RF. Ovarian cancer: new clinical approaches. Cancer Treat Rev
1991 Mar;18 Suppl A:77-83.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Ozols RF. Role of carboplatin in ovarian cancer. Current results and
thoughts for the future. Acta Obstet Gynecol Scand Suppl
1992;155:75-7.
Ozols RF. Role of chemotherapy in the future treatment of ovarian
cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.
Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol
1991 Jun;18(3):222-32.
Panici PB, Greggi S, Scambia G, Baiocchi G, Lomonaco M, Conti G,
Mancuso S. Efficacy and toxicity of very high-dose cisplatin in
advanced ovarian carcinoma: 4-Year survival analysis and neurological
follow-up. Int J Gynecol Cancer 1993;3(1):44-53.
Perren TJ, Wiltshaw E, Harper P, Slevin M, Stein R, Tan S, Gore M,
Fryatt IJ, Blake PR. A randomised study of carboplatin vs sequential
ifosfamide/ carboplatin for patients with FIGO stage III epithelial
ovarian carcinoma. Br J Cancer 1993;68(6):1190-4.
Petru E, Pickel H, Heydarfadai M, Lahousen M. Remission induction
with carboplatin-epirubicin-prednimustine followed by consolidation
radiotherapy in advanced ovarian cancer. Int J Clin Pharmacol Res
1992;12(4):205-7.
Petru E, Pickel H, Lahousen M, Boike G, Heydarfadai M. Combination
chemotherapy in radically operated advanced ovarian cancer. Cancer
Treat Rev 1990 Sep;17(2-3):329-34.
Petru E, Sevin BU, Averette HE, Koechli OR, Hilsenbeck S.
Long-term survival in stage III and IV ovarian cancer. Arch Gynecol
Obstet 1991;249(2):87-93.
Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries F, Kains JP,
Gobert P, Domange AM, Sculier JP, Gompel C. Cisplatin combined
with carboplatin: a new way of intensification of platinum dose in the
treatment of advanced ovarian cancer. Belgian Study Group for
Ovarian Carcinoma. J Natl Cancer Inst 1990 Apr 18;82(8):703-7.
Pinto V, Marinaccio M, Miniello G, Cagnazzo G. Simplified
ondansetron regimens for antiemetic prophylaxis in cisplatin-based
chemotherapy of ovarian cancer. Eur J Gynaecol Oncol
1993;14(4):302-7.
Piura B, Glezerman M, Cohen Y. Experience in the treatment of
epithelial ovarian carcinoma with cisplatinum-containing combination
chemotherapy and dose intensity calculation. Eur J Gynaecol Oncol
1990;11(5):389-93.
Piver MS, Malfetano J, Hempling RE, Baker TR, Driscoll DL.
Cisplatin-based chemotherapy for stage II ovarian adenocarcinoma: a
preliminary report. Gynecol Oncol 1990 Dec;39(3):249-52.
Plaxe SC, Dottino PR, Cohen CJ. Therapeutic and metabolic effects of
high (greater than 1 g/m2) systemic cumulative doses of cis-platinum in
patients with ovarian carcinoma. Gynecol Oncol 1990
May;37(2):250-3.
Poka R, Hernadi Z, Juhasz B, Lampe L. Comparison of four antiemetic
regimens for the treatment of cisplatin-induced vomiting. Int J
Gynaecol Obstet 1993 Jul;42(1):19-24.
Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G,
Lucarelli C. Measurement of the ovarian cancer-associated antigen CA
125 in monitoring tumor burden and response to chemotherapy.
Tumori 1991 Apr 30;77(2):167-9.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J,
Cruickshank D, Davis J, Duncan ID, Fullerton W, et al. A randomised
study comparing standard dose carboplatin with chlorambucil and
carboplatin in advanced ovarian cancer. Br J Cancer 1992
Feb;65(2):275-81.
Redman CW, Blackledge GR, Kelly K, Powell J, Buxton EJ, Luesley
DM. Early serum CA125 response and outcome in epithelial ovarian
cancer. Eur J Cancer 1990;26(5):593-6.
Reed E, Jacob J, Brawley O. Measures of renal function in patients
with cisplatin-related chronic renal disease. J Natl Med Assoc 1991
Jun;83(6):522-6.
Reed E, Janik J, Bookman MA, Rothenberg M, Smith J, Young RC,
Ozols RF, VanderMolen L, Kohn E, Jacob JL, et al. High-dose
carboplatin and recombinant granulocyte-macrophage
colony-stimulating factor in advanced-stage recurrent ovarian cancer. J
Clin Oncol 1993 Nov;11(11):2118-26.
Repetto L, Chiara S, Pace M, Guido T, Bruzzone M, Oliva C, Murolo
C, Conte PF, Rosso R. Prognostic factors in stage IV ovarian
carcinoma treated with platinum-based regimens. Tumori 1990 Jun
30;76(3):274-7.
Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C,
Guido T, Conte PF, Campora E, Rubagotti A, et al. The impact of
received dose intensity on the outcome of advanced ovarian cancer.
Eur J Cancer 1993;29A(2):181-4.
Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater
JL, Burroughs JN, Novak MJ, Sridhara R. Impact of cyclophosphamide
on relationships between carboplatin exposure and response or toxicity
when used in the treatment of advanced ovarian cancer. J Clin Oncol
1993 Jun;11(6):1156-64.
River MS, Fanning J, Sprance HE. Five-year survival for
cisplatin-based chemotherapy versus single-agent melphalan in patients
with advanced ovarian cancer and optimal debulking surgery. J Surg
Oncol 1991 Sep;48(1):39-44.
Rosen A, Sevelda P, Klein M, Spona J, Beck A. A CA125 score as a
prognostic index in patients with ovarian cancer. Arch Gynecol Obstet
1990;247(3):125-9.
Rubin SC, Curtin JP. Surgery for gynecologic malignancies. Curr Opin
Oncol 1992 Oct;4(5):923-9.
Russo A, Gebbia V, Palmeri S, Geraci P, Maneschi F, Guarnieri G,
Carollo F, Leonardi V, Meli M, Gebbia N, et al. Results of the
combination of cisplatin, adriamycin and cyclophosphamide in the
treatment of ovarian carcinoma. Eur J Gynaecol Oncol
1993;14(3):228-33.
Rustin GJ. Impact of tumour marker measurements upon management
of patients with carcinoma of the ovary. Dis Markers 1991
May-Aug;9(3-4):153-8.
Rustin GJ, Nelstrop A, Stilwell J, Lambert HE. Savings obtained by
CA-125 measurements during therapy for ovarian carcinoma. The
North Thames Ovary Group. Eur J Cancer 1992;28(1):79-82.
Saksela E. Prognostic markers in epithelial ovarian cancer. Int J
Gynecol Pathol 1993 Apr;12(2):156-61.
Sawada M, Yamasaki M, Urabe T, Ozaki M, Yanagita T, Takayama K,
Taki I. Comparative study of combination chemotherapy of ovarian
cancer: cyclophosphamide, adriamycin and cisplatin versus
5-fluorouracil, cyclophosphamide and mitomycin C. Asia Oceania J
Obstet Gynaecol 1990 Dec;16(4):315-21.
Schneider J, Martin M, Erasun F, Matia JC, Rodriguez-Escudero FJ.
Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in
ovarian carcinoma. Results after second-look laparotomy. Oncology
1990;47(2):109-11.
Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C. Randomized
comparison of hexamethylmelamine, adriamycin, cyclophosphamide
(HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced
ovarian cancer: long-term results. Cancer Treat Rev 1991 Mar;18
Suppl A:37-46.
Sevelda P, Dittrich C, Kurz C, Schemper M, Haider F, Denison U,
Breitenecker G, Czerwenka K, Salzer H. Prospective randomized trial
of sequential alternating chemotherapy in advanced ovarian carcinoma.
Onkologie 1992;15(4):288-92.
Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of
doxorubicin by a 6-hour infusion regimen. A prospective randomized
evaluation. Cancer 1990 Feb 15;65(4):870-3.
Shimizu Y, Hasumi K. Treatment of ovarian cancer at FIGO stage III
and IV - Prognostic factors for patients receiving neoadjuvant
chemotherapy. Acta Obstet Gynaecol Jpn 1993;45(7):665-72.
Smith DB, Rustin GJ, Howells N, Lambert HE, McQuade B. A phase
II study of ondansetron as antiemetic prophylaxis in patients receiving
carboplatin for advanced ovarian cancer. The North Thames Ovary
Group. Ann Oncol 1991 Sep;2(8):607-8.
Smyth JF, Beattie GJ, Stewart ME, Cowie VJ, Smart GE, Livingstone
JR, Leonard RC. Cisplatinum and prednimustine, an active regimen for
advanced epithelial ovarian cancer. Ann Oncol 1991
Nov-Dec;2(10):755-8.
Sorbe B, Hallen C. Betamethasone-dixyrazine versus
betamethasone-metoclopramide as antiemetic treatment of
cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.
Eur J Gynaecol Oncol 1991;12(1):31-7.
Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A. Dose-toxicity
relationship of carboplatin in combination with cyclophosphamide in
ovarian cancer patients. Cancer Chemother Pharmacol
1991;28(5):397-401.
Stoot J, Wils J, von Geuns H, Smeets J, Schouten L. Chemotherapy
consisting of cisplatin, epirubicin, and cyclophosphamide in advanced
ovarian carcinoma. The Gynecologic Oncology Group of the
Comprehensive Cancer Center, Limburg, The Netherlands. Cancer
Invest 1993;11(1):1-5.
Sweetenham JW, McKendrick JJ, Jones DH, Whitehouse JM, Williams
CJ. High dose intensity combination chemotherapy for advanced
epithelial ovarian carcinoma: results of a pilot study. Br J Cancer 1990
Feb;61(2):319-22.
Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J,
Drouin P, Stanimir R, O'Connell G, MacLean G, et al.
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in
advanced ovarian cancer: a randomized phase III study of the National
Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992
May;10(5):718-26. Comment in: J Clin Oncol 1992 May;10(5):683-5.
Swenerton KD, Pater JL. Carboplatin in the treatment of carcinoma of
the ovary: the National Cancer Institute of Canada experience. Ovarian
Cancer Subcommittee. Semin Oncol 1992 Feb;19(1 Suppl 2):114-9.
Takada M, Usui N, Yoshida K, Hirayama H, Suzuki M, Takeuchi H,
Wada H, Iwasa T, Yamamoto T, Nagasawa I. Cumulative survival rate
of chemotherapy with CDDP for malignant ovarian tumors. Acta
Obstet Gynaecol Jpn 1990;42(4):333-8.
Tattersall MH, Swanson CE, Solomon HJ. Long-term survival with
advanced ovarian cancer: an analysis of 5-year survivors in the
Australian trial comparing combination versus sequential chlorambucil
and cisplatin therapy. Gynecol Oncol 1992 Dec;47(3): 292-7.
Tedeschi M, De Cesare A, Oriana S, Perego P, Silva A, Venturino P,
Zunino F. The role of glutathione in combination with cisplatin in the
treatment of ovarian cancer. Cancer Treat Rev 1991 Dec;18(4):253-9.
Teeling M, Carney DN. Phase II study of carboplatin and
cyclophosphamide combination chemotherapy for the treatment of
advanced ovarian cancer. Eur J Gynaecol Oncol 1990;11(3):219-24.
Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN.
Carboplatin/cyclophosphamide combination chemotherapy for
advanced ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):102-6.
ten Bokkel Huinink WW, Dalesio O, Rodenhuis S, Dubbelman R,
Hilton A, Franklin H, Koier I, van Tinteren H, van der Burg ME, van
Oosterom AT, et al. Replacement of cisplatin with carboplatin in
combination chemotherapy against ovarian cancer: long-term treatment
results of a study of the Gynaecological Cancer Cooperative Group of
the EORTC and experience at The Netherlands Cancer Institute. Semin
Oncol 1992 Feb;19(1 Suppl 2):99-101.
Thigpen JT. Chemotherapy in the management of celomic epithelial
carcinoma of the ovary. In: Markman M, Hoskins WJ, eds. Cancer of
the ovary. New York: Raven Press; 1993. p. 277-86.
Tibben JG, Schijf CP, Beex LV. Results of cyclophosphamide and
cisplatin combination chemotherapy in patients with ovarian carcinoma.
Eur J Gynaecol Oncol 1992;13(4):331-9.
Torri V, Korn EL, Simon R. Dose intensity analysis in advanced
ovarian cancer patients. Br J Cancer 1993 Jan;67(1):190-7.
Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M.
Statistical model to determine the relationship of response and survival
in patients with advanced ovarian cancer treated with chemotherapy. J
Natl Cancer Inst 1992 Mar 18;84(6):407-14. Comment in: J Natl
Cancer Inst 1992 Mar 18;84(6):376-8.
Tothill P, Klys HS, Matheson LM, McKay K, Smyth JF. The long-term
retention of platinum in human tissues following the administration of
cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer
1992;28A(8-9):1358-61.
Trask C, Silverstone A, Ash CM, Earl H, Irwin C, Bakker A, Tobias
JS, Souhami RL. A randomized trial of carboplatin versus iproplatin in
untreated advanced ovarian cancer. J Clin Oncol 1991 Jul;9(7):1131-7.
Unzelman RF. Advanced epithelial ovarian carcinoma: long-term
survival experience at the community hospital. Am J Obstet Gynecol
1992 Jun;166(6 Pt 1):1663-71; discussion 1671-2.
van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, van
Houwelingen C, Neijt JP. Incidence of neuropathy in 395 patients with
ovarian cancer treated with or without cisplatin. Cancer 1990 Oct
15;66(8):1697-702.
van der Hoop RG, Vecht CJ, van der Burg ME, Elderson A, Boogerd
W, Heimans JJ, Vries EP, van Houwelingen JC, Jennekens FG, Gispen
WH, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9)
analogue in patients with ovarian cancer. N Engl J Med 1990 Jan
11;322(2):89-94. Comment in: N Engl J Med 1990 Jan
11;322(2):126-7.
Vardi JR, Tadros GH, Zamurovic D, Rafla SD. Tumor debulking
followed by immediate combination chemotherapy in advanced ovarian
carcinoma. Phase II. Acta Obstet Gynecol Scand 1992 Jul;71(5):361-7.
Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet
Gynecol Scand 1993;72(8):682-4.
Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K.
CA125 and placental alkaline phosphatase as serum tumor markers in
epithelial ovarian carcinoma. Tumour Biol 1992;13(3):168-74.
Vermorken JB. High-dose intensity regimens with epirubicin in ovarian
cancer. Pathol Biol (Paris) 1992 Nov;39(9):833.
Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel
EJ. Tumor marker CA 125 in diagnosis, monitoring management and
follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205-8.
Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B,
Tripcony L, Free KE. The management of ovarian carcinoma is
improved by the use of cancer-associated serum antigen and CA 125
assays. Cancer 1993 Jan 15;71(2):430-8.
Waters GS, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity
due to cis-diamminedichloroplatinum in the treatment of ovarian
cancer: influence of dosage and schedule of administration. Ear Hear
1991 Apr;12(2):91-102.
Welander CE. What do CA 125 and other antigens tell us about
ovarian cancer biology? Acta Obstet Gynecol Scand Suppl
1992;155:85-93.
Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G,
Davis TE, Fazzini E, Cheuvart B, Horton J. Hexamethylmelamine and
low or moderate dose cisplatin with or without pyridoxine for
treatment of advanced ovarian carcinoma: a study of the Eastern
Cooperative Oncology Group. Cancer Invest 1992;10(1):1-9.
Willemse PH, Aalders JG, de Bruyn HW, Mulder NH, Sleijfer DT, de
Vries EG. CA-125 in ovarian cancer: relation between half-life,
doubling time and survival. Eur J Cancer 1991;27(8):993-5.
Willemse PH, van Lith J, Mulder NH, Aalders JG, Bouma J, de Vries
EG, Sleijfer DT. Risks and benefits of cisplatin in ovarian cancer. A
quality-adjusted survival analysis. Eur J Cancer 1990
Mar;26(3):345-52.
Williams CJ. Implications of an overview of chemotherapy in advanced
ovarian carcinoma. Br J Cancer 1992;66(2):225-6.
Williams CJ, Stewart L, Parmar M, Guthrie D. Meta-analysis of the
role of platinum compounds in advanced ovarian carcinoma. The
Advanced Ovarian Cancer Trialists Group. Semin Oncol 1992 Feb;19(1
Suppl 2):120-8.
Wils JA. Long-term follow-up of patients with advanced ovarian
carcinoma treated with debulking surgery and chemotherapy consisting
of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic
Oncology Group of the Comprehensive Cancer Center. Oncology
1990;47(2):115-20.
Wiltshaw E, Perren TJ, Fryatt ID, Blake PR, Harper P, Slevin M.
Carboplatin and ifosfamide in ovarian cancer phase II and III trials.
London Gynaecological Oncology Group. Cancer Chemother
Pharmacol 1990;26 Suppl:S48-50.
Yedema CA, Kenemans P, Voorhorst F, Bon G, Schijf C, Beex L,
Verstraeten A, Hilgers J, Vermorken J. CA 125 half-life in ovarian
cancer: a multivariate survival analysis. Br J Cancer 1993
Jun;67(6):1361-7.
Zambetti M, Gianni L, Di Re F, Spatti G, Fontanelli R, Escobedo A,
De Palo G, Bonadonna G. Cisplatin and cyclophosphamide in advanced
ovarian carcinoma: activity and toxicity of an ambulatory regimen. Am
J Clin Oncol 1990 Jun;13(3):199-203.
Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D,
Dormont D. Chemotherapy by the intravenous and intraperitoneal
routes combined in ovarian cancer. Gynecol Oncol 1990
Feb;36(2):271-6.
Taxanes
Arbuck SG, Canetta R, Onetto N, Christian MC. Current dosage and
schedule issues in the development of paclitaxel (Taxol). Semin Oncol
1993 Aug;20(4 Suppl 3):31-9.
Bissett D, Kaye SB. Taxol and taxotere--current status and future
prospects. Eur J Cancer 1993;29A(9):1228-31.
Boven E, Venema-Gaberscek E, Erkelens CA, Bissery MC, Pinedo
HM. Antitumor activity of taxotere (RP 56976, NSC 628503), a new
taxol analog, in experimental ovarian cancer. Ann Oncol 1993
Apr;4(4):321-4.
Brown J, McDermott B, Runzer N. Taxol: women with ovarian cancer
participate in a new clinical trial. Can Oncol Nurs J 1992
May;2(2):47-50.
Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J,
Craig J, Phillips J, Von Hoff D. A phase I trial of taxol given by a
6-hour intravenous infusion. J Clin Oncol 1991 Jul;9(7):1261-7.
Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss
G, Eckardt J, Rodriguez G, et al. Phase I clinical trial of taxotere
administered as either a 2-hour or 6-hour intravenous infusion. J Clin
Oncol 1993 May;11(5):950-8.
Caldas C, McGuire WP 3d. Paclitaxel (Taxol) therapy in ovarian
carcinoma. Semin Oncol 1993 Aug;20(4 Suppl 3):50-5.
Cheson BD. Clinical trials referral resource. Clinical trials with taxol.
Oncology (Huntingt) 1992 Mar;6(3):67-70.
Cheson BD. Clinical trials referral resource. Update on taxol trials.
Oncology (Huntingt) 1993 Jan;7(1): 63, 66-7.
Cheson BD, Arbuck SG, Phillips PH. Clinical trials referral resource.
Clinical trials with Docetaxel (Taxotere). Oncology (Huntingt) 1993
Sep;7(9):51-2.
Chuang LT, Lotzova E, Cook KR, Cristoforoni P, Morris M, Wharton
JT. Effect of new investigational drug taxol on oncolytic activity and
stimulation of human lymphocytes. Gynecol Oncol 1993
Jun;49(3):291-8.
Cornelissen G, Halberg E, Long HJ 3d, Prem K, Bakken E, Touitou Y,
Elg S, Haus E, Halberg F. Toward a chronotherapy of ovarian cancer
with taxol. Part I: Basic background. Chronobiologia 1991
Oct-Dec;18(4):153-66.
Diergarten K, Dreps A. Taxol: A new antineoplastic agent. Onkologie
1993;16(5):329-37.
Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase
II study and long-term follow-up of patients treated with taxol for
advanced ovarian adenocarcinoma. J Clin Oncol 1992
Nov;10(11):1748-53.
Einzig AI, Wiernik PH, Schwartz EL. Taxol: a new agent active in
melanoma and ovarian cancer. Cancer Treat Res 1991;58:89-100.
Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase
I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503)
given as a short intravenous infusion. Cancer Res 1993 Mar
1;53(5):1037-42.
Granai CO. Ovarian cancer--unrealistic expectations. N Engl J Med
1992 Jul 16;327(3):197-200. Comment in: N Engl J Med 1993 Mar
4;328(9):663-4 and N Engl J Med 1993 Mar 4;328(9):664; discussion
664-5.
Gregory RE, DeLisa AF. Paclitaxel: a new antineoplastic agent for
refractory ovarian cancer. Clin Pharm 1993 Jun;12(6):401-15.
Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D,
Mitchell JB, Kaufman D. Taxol in combination with doxorubicin or
etoposide. Possible antagonism in vitro. Cancer 1993 Nov 1;72(9):
2705-11.
Hamers FP, Pette C, Neijt JP, Gispen WH. The ACTH-(4-9) analog,
ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol
1993 Mar 16;233(1):177-8.
Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC, Von Hoff DD.
Effects of Taxotere and taxol on in vitro colony formation of freshly
explanted human tumor cells. Anticancer Drugs 1992 Apr;3(2):121-4.
Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel
Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH.
Pharmacokinetics of paclitaxel and metabolites in a randomized
comparative study in platinum-pretreated ovarian cancer patients. J Clin
Oncol 1993 Nov;11(11):2127-35.
Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of
multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the
cyclopeptolide SDZ 280-446. J Natl Cancer Inst 1993 Mar
17;85(6):478-83.
Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and
Taxotere against cisplatin-sensitive and -resistant human ovarian
carcinoma cell lines. Cancer Chemother Pharmacol 1992;30(6):444-50.
Knox JD, Mitchel RE, Brown DL. Effects of taxol and
taxol/hyperthermia treatments on the functional polarization of
cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993;24(2):129-38.
Leu JG, Chen BX, Schiff PB, Erlanger BF. Characterization of
polyclonal and monoclonal anti-taxol antibodies and measurement of
taxol in serum. Cancer Res 1993 Mar 15;53(6):1388-91.
Lubejko BG, Sartorius SE. Nursing considerations in paclitaxel (Taxol)
administration. Semin Oncol 1993 Aug;20(4 Suppl 3):26-30.
Markman M. Taxol: an important new drug in the management of
epithelial ovarian cancer. Yale J Biol Med 1991
Nov-Dec;64(6):583-90.
Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL
Jr, Rubin S, Curtin J, Barakat R, Phillips M, et al. Phase I trial of
intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin
Oncol 1992 Sep;10(9):1485-91.
McGuire WP. Taxol: a new drug with significant activity as a salvage
therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 1993
Oct;51(1):78-85.
McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and
experimental approaches in ovarian cancer therapy. Semin Oncol 1991
Jun;18(3):255-69.
Nicolaou KC, Riemer C, Kerr MA, Rideout D, Wrasidlo W. Design,
synthesis and biological activity of protaxols. Nature 1993 Jul
29;364(6436):464-6.
Ozols RF. Advances in the chemotherapy of gynecologic malignancies.
Hematol Oncol 1992 Jan-Feb;10(1):43-51.
Ozols RF. Chemotherapy for advanced epithelial ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.
Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;6(6):328-38.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Ozols RF. Role of chemotherapy in the future treatment of ovarian
cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.
Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The
taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev
1993 Oct;19(4):351-86.
Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J,
Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MM, et al.
Phase I trial of Taxotere: five-day schedule. J Natl Cancer Inst 1992
Dec 2;84(23):1781-8.
Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP,
Onetto N, Hubbard JL, Piccart M, Gianni L, Rowinsky EK. Successful
re-treatment with taxol after major hypersensitivity reactions. J Clin
Oncol 1993 May;11(5):885-90.
Pokalo CL. The promise of taxol. Todays OR Nurse 1992
Dec;14(12):31-2.
Rowinsky EK, Citardi MJ, Noe DA, Donehower RC.
Sequence-dependent cytotoxic effects due to combinations of cisplatin
and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin
Oncol 1993;119(12):727-33.
Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel
(Taxol). Semin Oncol 1993 Aug;20(4 Suppl 3):16-25.
Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower
RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin
Oncol 1993 Aug;20(4 Suppl 3):1-15.
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB,
Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, et al.
Sequences of taxol and cisplatin: a phase I and pharmacologic study. J
Clin Oncol 1991 Sep;9(9):1692-703.
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere
AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG,
Kaufmann SH, et al. Phase I and pharmacologic study of topotecan: a
novel topoisomerase I inhibitor. J Clin Oncol 1992 Apr;10(4):647-56.
Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of
the taxanes, an important new class of antitumor agents. Semin Oncol
1992 Dec;19(6):646-62.
Runowicz CD, Wiernik PH, Einzig AI, Goldberg GL, Horwitz SB.
Taxol in ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1591-6.
Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO,
Ognibene FP, Cunnion RE, Reed E. Phase I study of taxol and
granulocyte colony-stimulating factor in patients with refractory
ovarian cancer. J Clin Oncol 1992 Jul;10(7):1165-70.
Sarosy G, Reed E. Taxol dose intensification and its clinical
implications. J Natl Med Assoc 1993 Jun;85(6):427-31.
Slichenmyer WJ, Von Hoff DD. New natural products in cancer
chemotherapy. J Clin Pharmacol 1990 Sep;30(9):770-88.
Steren A, Sevin BU, Perras J, Angioli R, Nguyen H, Guerra L, Koechli
O, Averette HE. Taxol sensitizes human ovarian cancer cells to
radiation. Gynecol Oncol 1993 Feb;48(2):252-8.
Steren A, Sevin BU, Perras J, Ramos R, Angioli R, Nguyen H, Koechli
O, Averette HE. Taxol as a radiation sensitizer: a flow cytometric
study. Gynecol Oncol 1993 Jul;50(1):89-93.
ten Bokkel Huinink WW, Eisenhauer E, Swenerton K. Preliminary
evaluation of a multicenter, randomized comparative study of TAXOL
(paclitaxel) dose and infusion length in platinum-treated ovarian cancer.
Canadian-European Taxol Cooperative Trial Group. Cancer Treat Rev
1993;19 Suppl C:79-86.
Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation
sensitizer. Int J Radiat Oncol Biol Phys 1992;22(3):613-7.
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA,
Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, et al.
Paclitaxel for platinum-refractory ovarian cancer: results from the first
1,000 patients registered to National Cancer Institute Treatment
Referral Center 9103. J Clin Oncol 1993 Dec;11(12):2405-10.
Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J,
Woodcock D. Measurement of cremophor EL following taxol: plasma
levels sufficient to reverse drug exclusion mediated by the
multidrug-resistant phenotype. J Natl Cancer Inst 1993 Oct
20;85(20):1685-90.
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump
DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B.
Hypersensitivity reactions from taxol. J Clin Oncol 1990
Jul;8(7):1263-8.
Williams S, Mutch DG, Xu L, Collins JL. Divergent effects of taxol on
tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma
cells. Am J Obstet Gynecol 1992 Dec;167(6):1870-6.
Workman P, Kaye SB, Schwartsmann G. Laboratory and phase I
studies of new cancer drugs. Curr Opin Oncol 1992 Dec;4(6):1065-72.
Published erratum appears in Curr Opin Oncol 1993 Mar;5(2):434.
Second-Look Surgery
Aravantinos D, Michalas S, Papazefkos V, Christoforaki M, Stypsaneli
A, Vlachos G, Athanasiadis P. Predictive values of CA 125 antigen
levels and CT scan in second-look procedures for ovarian cancer. Eur J
Obstet Gynecol Reprod Biol 1990 Dec;37(3):265-70.
Ayhan A, Urman B, Yarali H, Yuce K, Ayhan A. Predictors of
recurrent disease after negative second-look laparotomy for epithelial
ovarian cancer. J Surg Oncol 1990 Jun;44(2):119-21.
Ayhan A, Yarali H, Develioglu O, Uren A, Ozyilmaz F.
Prognosticators of second-look laparotomy findings in patients with
epithelial ovarian cancer. J Surg Oncol 1991 Apr;46(4):222-5.
Bar-Am A, Kovner F, Lessing JB, Inbar M, Chaitchik S, Azem F,
Brenner SH, Peyser MR. A second thought on second look
laparotomy. Acta Obstet Gynecol Scand 1993 Jul;72(5):386-90.
Barakat RR, Rubin SC, Saigo PE, Lewis JL Jr, Jones WB, Curtin JP.
Second-look laparotomy in carcinoma of the fallopian tube. Obstet
Gynecol 1993 Nov;82(5):748-51.
Barrenetxea G, Martin-Mateos M, Barzazan MJ, Montoya F, Matia JC,
Rodriguez-Escudero FJ. Serum CA 125, CA 15.3 and CA 19.9 levels
and surgical findings in patients undergoing second look operations for
ovarian carcinomas. Eur J Gynaecol Oncol 1990;11(5):369-74.
Barter JF, Barnes WA. Second-look laparotomy. In: Rubin SC, Sutton
GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993. p. 269-300.
Bell J, Mojzisik C, Hinkle G Jr, Derman H, Schlom J, Martin E.
Intraoperative radioimmunodetection of ovarian cancer using
monoclonal antibody B72.3 and a portable gamma-detecting probe.
Obstet Gynecol 1990 Oct;76(4):607-11.
Bokhman YaV, Vinokurov VL, Gulo EI. The controversial
'second-look' laparotomy. Acta Obstet Gynecol Scand Suppl
1992;155:79-83.
Camera L, Del Vecchio S, Petrillo A, Esposito G, Frasci G, Iaffaioli
RV, Bianco AR, Salvatore M. Evaluation of therapeutic response using
iodine-131-B72.3 monoclonal antibody in patients with ovarian
carcinoma. Eur J Nucl Med 1991;18(4):269-73.
Carson LF, Rubin SC. Secondary cytoreduction--thoughts on the pro
side. Gynecol Oncol 1993 Oct;51(1):127-30.
Cromer DW. Second-look laparotomy in ovarian carcinoma patients
after 8 and after 12 courses of cisplatin-based chemotherapy. Surg
Gynecol Obstet 1990;170(4):69.
Davidson NG, Khanna S, Kirwan P, Bircumshaw D. Advanced ovarian
cancer: long-term results following chemotherapy and second-look
laparotomy. Gynecol Oncol 1990 Dec;39(3):295-9.
Deligdisch L, Kerner H, Cohen CJ, Dargent D, Gil J. Morphometric
differentiation between responsive tumor cells and mesothelial
hyperplasia in second-look operations for ovarian cancer. Hum Pathol
1993 Feb;24(2):143-7.
Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE,
Stanhope CR, Everson LK, Laurie JA, Ebbert LP, Malkasian GD, et al.
Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in
stage III-IV ovarian carcinoma: a comparison of equally
myelosuppressive regimens. J Natl Cancer Inst 1989 Oct
4;81(19):1500-4.
Elg SA, Yu Y, Carson LF, Adcock LL, Twiggs LB, Prem KA,
Ramakrishnan S. Serum levels of macrophage colony-stimulating factor
in patients with ovarian cancer undergoing second-look laparotomy.
Am J Obstet Gynecol 1992 Jan;166(1 Pt 1):134-7.
Friedman JB, Weiss NS. Second thoughts about second-look
laparotomy in advanced ovarian cancer. N Engl J Med 1990 Apr
12;322(15):1079-82.
Gallion HH, Hunter JE, van Nagell JR, Averette HE, Cain JM,
Copeland LJ, Higgins RV, Husseinzadeh N, Nahhas WA, Partridge EE,
et al. The prognostic implications of low serum CA 125 levels prior to
the second-look operation for stage III and IV epithelial ovarian
cancer. Gynecol Oncol 1992 Jul;46(1):29-32.
Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N,
Edwards CL, Rutledge FN. Prognosis of surgically determined
complete responders in advanced ovarian cancer. Cancer 1985 Mar
1;55(5):1129-35.
Ghatage P, Krepart GV, Lotocki R. Factor analysis of false-negative
second-look laparotomy. Gynecol Oncol 1990 Feb;36(2):172-5.
Goldberg GL, Scheiner J, Friedman A, O'Hanlan KA, Davidson SA,
Runowicz CD. Lymph node sampling in patients with epithelial ovarian
carcinoma. Gynecol Oncol 1992 Nov;47(2):143-5.
Granowska M, Mather SJ, Britton KE. Diagnostic evaluation of 111In
and 99mTc radiolabelled monoclonal antibodies in ovarian and
colorectal cancer: correlations with surgery. Int J Rad Appl Instrum [B]
1991;18(4):413-24.
Granowska M, Mather SJ, Jobling T, Naeem M, Burchell J,
Taylor-Papadimitriou J, Shepherd J, Britton KE. Radiolabelled stripped
mucin, SM3, monoclonal antibody for immunoscintigraphy of ovarian
tumours. Int J Biol Markers 1990 Apr-Jun;5(2):89-96.
Hartmann LC, Sebo TJ, Kamel NA, Podratz KC, Cha SS, Wieand HS,
Keeney GL, Roche PC. Proliferating cell nuclear antigen in epithelial
ovarian cancer: relation to results at second-look laparotomy and
survival. Gynecol Oncol 1992 Nov;47(2):191-5.
Hoskins JH, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo
P, Markman M, Hakes T, Reichman B, Jones WB, et al. Influence of
secondary cytoreduction at the time of second-look laparotomy on the
survival of patients with epithelial ovarian carcinoma. Gynecol Oncol
1989 Sep;34(3):365-71.
Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial
ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1534-40.
Hoskins WJ, Rubin SC. Surgery in the treatment of patients with
advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.
Jager W, Feistel H, Paterok EM, Ronay G, Tulusan AH, Wolf F, Lang
N. Resection guided by antibodies (REGAJ): a diagnostic procedure
during second-look operation in ovarian cancer patients. Br J Cancer
Suppl 1990 Jul;10:18-20.
Kamura T, Tsukamoto N, Saito T, Kaku T, Matsuyama T, Nakano H.
Efficacy of second-look laparotomy for patients with epithelial ovarian
carcinoma. Int J Gynaecol Obstet 1990 Oct;33(2):141-7.
Krag DN, Ford P, Smith L, Taylor M, Schneider PD, Bushberg JT,
Goodnight JE. Clinical immunoscintigraphy of recurrent ovarian cancer
with indium 111-labeled B72.3 monoclonal antibody. Arch Surg 1993
Jul;128(7):819-23.
Krag KJ, Canellos GP, Griffiths CT, Knapp RC, Parker LM, Welch
WR, Klatt M, Andersen J. Predictive factors for long-term survival in
patients with advanced ovarian cancer. Gynecol Oncol 1989
Jul;34(1):88-93.
Kudo R, Takashina T, Ito E, Mizuuchi H, Sagae S, Moriwaka O,
Tamagawa A. Peritoneal washing cytology at second-look laparotomy
in cisplatin-treated ovarian cancer patients. Acta Cytol 1990
Jul-Aug;34(4):545-8.
Lastoria S, Panza N, Esposito G, Vergara E, Castelli L, Caraco C,
Battista C, Pacilio G, Salvatore M. Management of patients with
ovarian cancer using monoclonal antibodies. Biomed Pharmacother
1992;46(10):453-63.
Liu L, Hong W, Hou Y, Yao Z, Wu A, Wang X. Evaluation of
second-look laparotomy for ovarian cancer: second-look vs. serum
CA125. Chin Med Sci J 1991 Jun;6(2):96-9.
Lund B, Williamson P. Prognostic factors for outcome of and survival
after second-look laparotomy in patients with advanced ovarian
carcinoma. Obstet Gynecol 1990 Oct;76(4):617-22.
Makar AP, Kristensen GB, Bormer OP, Trope CG. CA 125 measured
before second-look laparotomy is an independent prognostic factor for
survival in patients with epithelial ovarian cancer. Gynecol Oncol 1992
Jun;45(3):323-8.
Miller DS, Spirtos NM, Ballon SC, Cox RS, Soriero OM, Teng NN.
Critical reassessment of second-look exploratory laparotomy for
epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value
in patients with persistent cancer. Cancer 1992 Jan 15;69(2):502-10.
Morgan MA, Noumoff JS, King S, Mikuta JJ. A formula for predicting
the risk of a positive second-look laparotomy in epithelial ovarian
cancer: implications for a randomized trial. Obstet Gynecol 1992
Dec;80(6):944-8.
Mottolese M, Salzano M, Vincenzoni C, Benevolo M, Bigotti A,
Iacovelli A, Lombardi A, Atlante G, Natali PG. The use of a panel of
monoclonal antibodies can lower false-negative diagnoses of peritoneal
washings in ovarian tumors. Cancer 1991 Oct 15;68(8):1803-7.
Nishimura H, Hamaguchi K, Miyahara K, Tazaki T, Tateno N,
Yakushiji M. The current therapeutic approaches to advanced ovarian
cancer. Nippon Sanka Fujinka Gakkai Zasshi 1990 Dec;42(12):1691-6.
Ojeda-Gonzalez MB, Alvarez-Lopez I, Alonso-Munoz MC,
Badia-Serra J, Delgado-Latre E, de Andres-Basauri L, Lopez-Lopez JJ.
Chemotherapy (CAP) for the treatment of advanced ovarian cancer and
second-effort surgery in the second look. Oncology 1991;48(1):7-12.
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ,
Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor
analysis in advanced ovarian carcinoma: the Gynecologic Oncology
Group experience. J Clin Oncol 1991 Jul;9(7):1138-50.
Papazefkos V, Michalas S, Papantoniou V, Datseris J, Athanasiadis P,
Akrivos T, Leonti A, Xygakis A, Aravantinos D. Comparative study of
RIS with the 131I-OC 125 F(ab')2 Mab and CT scan prior to second
look operation for ovarian cancer. Eur J Obstet Gynecol Reprod Biol
1990 Dec;37(3):271-7.
Patsner B, Orr JW Jr, Mann WJ Jr, Taylor PT, Partridge E, Allmen T.
Does serum CA-125 level prior to second-look laparotomy for invasive
ovarian adenocarcinoma predict size of residual disease? Gynecol
Oncol 1990 Jun;37(3):319-22.
Patsner B, Orr JW Jr, Mann WJ Jr, Taylor PT, Partridge E, Allmen T.
Does serum CA-125 level prior to second-look laparotomy for invasive
ovarian adenocarcinoma predict size of residual disease? Gynecol
Oncol 1990 Sep;38(3):373-6.
Pectasides D, Kayianni H, Facou A, Bobotas N, Barbounis V, Zis J,
Athanassiou A. Correlation of abdominal computed tomography
scanning and second-look operation findings in ovarian cancer patients.
Am J Clin Oncol 1991 Dec;14(6):457-62.
Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, DeGeest K,
Mortel R. Survival of patients with ovarian epithelial carcinomas after
second-look laparotomy. Gynecol Oncol 1990 Jan;36(1):43-7.
Podratz KC, Kinney WK. Second-look operation in ovarian cancer.
Cancer 1993 Feb 15;71(4 Suppl):1551-8.
Podratz KC, Malkasian GD Jr, Hilton JF, Harris EA, Gaffey TA.
Second-look laparotomy in ovarian cancer: evaluation of pathologic
variables. Am J Obstet Gynecol 1985 May 15;52(2):230-8.
Podratz KC, Malkasian GD Jr, Wieand HS, Cha SS, Lee RA, Stanhope
CR, Williams TJ. Recurrent disease after negative second-look
laparotomy in stages III and IV ovarian carcinoma. Gynecol Oncol
1988 Mar;29(3):274-82.
Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA,
Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of
treatment and survival after positive second-look laparotomy. Gynecol
Oncol 1988 Sep;31(1):9-24.
Potter ME. Secondary cytoreduction in ovarian cancer: pro or con?
Gynecol Oncol 1993 Oct;51(1):131-5.
Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr,
Shingleton HM. Second-look laparotomy and salvage therapy: a
research modality only? Gynecol Oncol 1992 Jan;44(1):3-9. Comment
in: Gynecol Oncol 1992 Nov;47(2):275.
Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G,
Lucarelli C. Measurement of the ovarian cancer-associated antigen CA
125 in monitoring tumor burden and response to chemotherapy.
Tumori 1991 Apr 30;77(2):167-9.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Redman CW, Blackledge G, Lawton FG, Varma R, Luesley DM, Chan
KK. Early second surgery in ovarian cancer--improving the potential
for cure or another unnecessary operation? Eur J Surg Oncol 1990
Oct;16(5):426-9.
Redman CW, Chapman SE, Chan SY, Buxton EJ, Blackledge G,
Luesley DM. Out-patient peritoneal lavage cytology in the detection of
residual epithelial ovarian cancer. Cytopathology 1991;2(6):291-8.
Rose PG, Reale FR, Fisher A, Hunter RE. Appendectomy in primary
and secondary staging operations for ovarian malignancy. Obstet
Gynecol 1991 Jan;77(1):116-8.
Rubin SC. Second-look laparotomy in ovarian cancer. In: Markman M,
Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993.
p. 175-85.
Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):851-65.
Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman
M, Reichman B, Almadrones L, Lewis JL Jr. Prognostic factors for
recurrence following negative second-look laparotomy in ovarian
cancer patients treated with platinum-based chemotherapy. Gynecol
Oncol 1991 Aug;42(2):137-41.
Scambia G, Panici PB, Baiocchi G, Gallo A, Laurelli G, Iacobelli S,
Mancuso S. Recombinant alpha-2b-interferon dynamic test as a
potential tool in predicting disease status during second look in ovarian
cancer. A preliminary report. Cancer 1991 Dec 15;68(12):2582-5.
Second-look surgery for ovarian carcinoma. ACOG Committee
Opinion: Committee on Gynecologic Practice. Number 100--November
1991. Int J Gynaecol Obstet 1992 Sep;39(1):61-2.
Segna RA, Dottino PR, Mandeli JP, Konsker K, Cohen CJ. Secondary
cytoreduction for ovarian cancer following cisplatin therapy. J Clin
Oncol 1993 Mar;11(3):434-9.
Soeters RP, Bloch B, Dehaeck K, Levin W. The influence of initial
residual disease on the outcome of second-look laparotomy in patients
with carcinoma of the ovary. Eur J Gynaecol Oncol 1992;13(3):223-7.
Soper JT, Couchman G, Berchuck A, Clarke-Pearson D. The role of
partial sigmoid colectomy for debulking epithelial ovarian carcinoma.
Gynecol Oncol 1991 Jun;41(3):239-44. Comment in: Gynecol Oncol
1992 Jul;46(1):138.
Tomas C, Kauppila A. Tumor markers of epithelial and stromal cell
origin at second-look laparotomy in ovarian carcinoma. Gynecol Oncol
1992 Jun;45(3):279-83.
Torretta L, Balestreri D, Fasola M, Schinko E, Scorbati E, Tateo S.
Diagnostic alternatives to second look in ovarian cancer. Eur J
Gynaecol Oncol 1990;11(2):145-8.
Torri V, Simon R, Russek-Cohen E, Midthune D, Friedman M.
Statistical model to determine the relationship of response and survival
in patients with advanced ovarian cancer treated with chemotherapy. J
Natl Cancer Inst 1992 Mar 18;84(6):407-14. Comment in: J Natl
Cancer Inst 1992 Mar 18;84(6):376-8.
Tuxen MK, Lund B, Hansen OP, Hansen M. Second-look laparotomy
in the management of patients after radical surgery for ovarian cancer.
Ann Oncol 1993 Feb;4(2):169-71.
van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer.
Neth J Med 1992 Feb;40(1-2):36-51.
van Kranenburg DL, van Kroonenburgh MJ, Trimbos JB, Fleuren GJ,
Pauwels EK. Imaging of ovarian cancer with radiolabelled monoclonal
antibodies. Arch Gynecol Obstet 1990;247(3):107-16.
Venesmaa P, Ylikorkala O. Morbidity and mortality associated with
primary and repeat operations for ovarian cancer. Obstet Gynecol 1992
Feb;79(2): 168-72. Comment in: Obstet Gynecol 1992 Jul;80(1):155-6.
Vergote IB. Surgery for gynecologic malignancies. Curr Opin Oncol
1993 Sep;5(5):877-84.
Vergote IB, Onsrud M, Bormer OP, Sert BM, Moen M. CA125 in
peritoneal fluid of ovarian cancer patients. Gynecol Oncol 1992
Feb;44(2):161-5.
Wangensteen OH, Lewis FJ, Tongen LA. The "second-look" in cancer
surgery: a patient with colic cancer and involved lymph nodes negative
on the "sixth -look." J Lancet 1951 Aug;51(8):303-7.
Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B,
Tripcony L, Free KE. The management of ovarian carcinoma is
improved by the use of cancer-associated serum antigen and CA 125
assays. Cancer 1993 Jan 15;71(2):430-8.
Williams L. The role of secondary cytoreductive surgery in epithelial
ovarian malignancies. Oncology (Huntingt) 1992 Aug;6(8):25-32;
discussion 37-9. Comment in: Oncology (Huntingt) 1993 Feb;7(2):21.
Wong RJ, DeCosse JJ. Cytoreductive surgery. Surg Gynecol Obstet
1990 Mar;170(3):276-81.
Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM,
Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, et al. OVX1
radioimmunoassay complements CA-125 for predicting the presence of
residual ovarian carcinoma at second-look surgical surveillance
procedures. J Clin Oncol 1993 Aug;11(8):1506-10.
FOLLOW-UP AFTER PRIMARY SURGERY
Follow-Up of the Asymptomatic Patient
Beattie GJ, Sturgeon C, Fisken J, Roulston JE. The effect of surgery on
the serum concentration of CA125 in epithelial ovarian cancer. Ann
Clin Biochem 1993 Jul;30(Pt 4):402-3.
Bruzzone M, Onetto M, Campora E, Chiara S, Oliva C, Guido T,
Merlini L, Parodi S, Bentivoglio G, Ventrella W, et al. CA-125
monitoring in the management of ovarian cancer. Anticancer Res 1990
Sep-Oct;10(5A):1353-9.
Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. CA 125
regression: a model for epithelial ovarian cancer response. Am J Obstet
Gynecol 1991 Aug;165(2):360-7.
Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ. Serum
CA125 regression in epithelial ovarian cancer: correlation with
reassessment findings and survival. Gynecol Oncol 1992
Oct;47(1):87-92.
Buller RE, Manetta A, Bloss JD, DiSaia PJ, Berman ML. Does
intraperitoneal CA-125 reflect disease status? Gynecol Oncol 1991
Jan;40(1):66-9.
Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH,
Harmer CL, Blake PR, Chilvers CE. Hormone replacement therapy and
survival after surgery for ovarian cancer. BMJ 1991 Feb
2;302(6771):259-62. Comment in: BMJ 1991 Mar 30;302(6779):790.
Fioretti P, Gadducci A, Ferdeghini M, Prontera C, Malagnino G,
Facchini V, Mariani G, Bianchi R. The concomitant determination of
different serum tumor markers in epithelial ovarian cancer: relevance
for monitoring the response to chemotherapy and follow-up of patients.
Gynecol Oncol 1992 Feb;44(2):155-60.
Fisken J, Leonard RC, Badley A, Jonrup I, Aspinall L, Sturgeon C,
Roulston JE. Serological monitoring of epithelial ovarian cancer. Dis
Markers 1991 May-Aug;9(3-4):175-90.
Gerli M, Palumbo R, Angelini A, Gerli S, Brunelli E, Pupita P, Bonaca
S, Spagnolo W. Immunoscintigraphy in the follow up of patients with
ovarian cancer. Eur J Gynaecol Oncol 1990;11(3):203-4.
Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993
Aug;50(2):202-7.
Hising C, Anjegard IM, Einhorn N. Clinical relevance of the CA 125
assay in monitoring of ovarian cancer patients. Am J Clin Oncol 1991
Apr;14(2):111-4.
Hogberg T, Kagedal B. Long-term follow-up of ovarian cancer with
monthly determinations of serum CA 125. Gynecol Oncol 1992
Aug;46(2):191-8.
Jimenez-Vicioso A, Torres M, Jimenez-Heffernan A, Grana MD, Latre
JM, Llamas JM, Carreras JL, Mateo A. Immunoscintigraphy with 131I
or 111In labelled OC 125 F(ab')2 fragments in patients with ovarian
carcinoma. Int J Biol Markers 1990 Oct-Dec;5(4):159-65.
Kamiya N, Mizuno K, Kawai M, Kano T, Furuhashi Y, Tomoda Y.
Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide
antigen, and immunosuppressive acidic protein to predict recurrence of
ovarian cancer. Obstet Gynecol 1990 Sep;76(3 Pt 1):417-21.
Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S. CA 125
in gynecological pathology--a review. Eur J Obstet Gynecol Reprod
Biol 1993 Apr;49(1-2):115-24.
Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasmussen K.
Correlation of abdominal ultrasound and computed tomography scans
with second- or third-look laparotomy in patients with ovarian
carcinoma. Gynecol Oncol 1990 May;37(2): 279-83.
Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA 125 at
the time of relapse a prognostic indicator for further survival prognosis
in patients with ovarian cancer? Gynecol Oncol 1993 Apr;49(1):3-7.
Comment in: Gynecol Oncol 1993 Apr;49(1):1-2.
Markowska J, Kojczynski Z, Szewierski Z, Manys G. CA 125 in
monitoring chemotherapy of the patients with ovarian cancer. Eur J
Gynaecol Oncol 1990;11(3):209-14.
Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a
marker of ovarian cancer. Eur J Gynaecol Oncol 1992;13(4):360-5.
Maughan TS, Haylock B, Hayward M, Facey P, Evans WD, Shelley
MD, Fish RG, Adams M. OC125 immunoscintigraphy in ovarian
carcinoma: a comparison with alternative methods of assessment. Clin
Oncol (R Coll Radiol) 1990 Jul;2(4):199-205.
Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal
chemotherapy versus no treatment in patients with ovarian carcinoma
who are in complete clinical remission. Cancer 1992 Oct
1;70(7):1956-9.
Menczer J, Ben-Baruch G, Rizel S, Brenner H. Intraperitoneal cisplatin
chemotherapy in ovarian carcinoma patients who are clinically in
complete remission. Gynecol Oncol 1992 Aug;46(2):222-5.
Ngan HY, Wong LC, Chan SY, Ma HK. Role of CA125 and
abdominal pelvic computerized axial tomogram in the monitoring of
chemotherapy treatment of ovarian cancer. Cancer Invest
1990;8(5):467-70.
Nishimura H, Tashiro M, Hamaguchi K, Kiyozuka Y, Ide H, Tateno N,
Miyoshi T, Yakushiji M. Significance of the serum CA125 level in
recurrent ovarian cancer. Asia Oceania J Obstet Gynaecol 1992
Mar;18(1):37-43.
Oncoscint for detection of disseminated colorectal and ovarian cancer.
Med Lett Drugs Ther 1993 Jun 11;35(898):52-3.
Patsner B. Is there a role for CT scanning to monitor therapy of
optimally debulked patients with advanced ovarian epithelial cancer?
Int J Gynecol Cancer 1994;4(1):19-21.
Peltier P, Dutin JP, Chatal JF, Fumoleau P, Bourguet P, Liehn JC,
Vuillez JP, Herry JY, Loboguerrero A. Usefulness of imaging ovarian
cancer recurrence with In-111-labeled monoclonal antibody (OC 125)
specific for CA 125 antigen. The INSERM Research Network (Nantes,
Rennes, Reims, Vuillejuif, Saclay). Ann Oncol 1993 Apr;4(4):307-11.
Peltier P, Wiharto K, Dutin JP, Chatal JF, Bourguet P, Liehn JC,
Vuillez JP, Herry JY, Loboguerrero A. Correlative imaging study in the
diagnosis of ovarian cancer recurrences. The INSERM Research
Network (Nantes, Rennes, Reims, Villejuif, Saclay, France). Eur J Nucl
Med 1992;19(12):1006-10.
Perkins AC, Powell MC, Wastie ML, Scott IV, Hitchcock A,
Worthington BS, Symonds EM. A prospective evaluation of OC125
and magnetic resonance imaging in patients with ovarian carcinoma.
Eur J Nucl Med 1990;16(4-6):311-6.
Pirtoli L, Risso G, Inaudi P, Landoni F, Pepi F, Bindi M, Tucci E,
D'Antona N, Mangioni C. A role for tumor markers in therapeutic
decisions after chemotherapy induction of objective remission in stage
III epithelial ovarian neoplasms. Int J Biol Markers 1991
Apr-Jun;6(2):107-14.
Prayer L, Kainz C, Kramer J, Stiglbauer R, Schurawitzki H, Baldt M,
Schima W, Poelzleitner D, Reinthaller A, Koelbl H, et al. CT and MR
accuracy in the detection of tumor recurrence in patients treated for
ovarian cancer. J Comput Assist Tomogr 1993 Jul-Aug;17(4):626-32.
Prayer L, Stiglbauer R, Kramer J, Wimberger D, Poelzleitner D,
Schima W, Kainz C, Koelbl H, Haugen I, Imhof H. Superparamagnetic
particles as oral contrast medium in magnetic resonance imaging of
patients with treated ovarian cancer--comparison with plain MRI. Br J
Radiol 1993 May;66(785):415-9.
Prosser ES, Pomeroy M, Barker F, Carroll K, Davis M, Duffy J, Duffy
G, Fennelly JJ, O'Kennedy R. The relationship between 111In-labelled
immunoscintigraphy and serum CA-125 levels in ovarian carcinoma
patients postchemotherapy. Biochem Soc Trans 1992 Feb;20(1):54S.
Quaranta M, Coviello M, Donadeo A, Rella C, Lorusso V, Micelli G,
Lucarelli C. Measurement of the ovarian cancer-associated antigen CA
125 in monitoring tumor burden and response to chemotherapy.
Tumori 1991 Apr 30;77(2):167-9.
Rustin GJ. Impact of tumour marker measurements upon management
of patients with carcinoma of the ovary. Dis Markers 1991
May-Aug;9(3-4):153-8.
Sevelda P, Rosen A, Denison U, Barrada M, Spona J, Salzer H. Is
CA-125 monitoring useful in patients with epithelial ovarian carcinoma
and preoperative negative CA-125 serum levels? Gynecol Oncol 1991
Nov;43(2):154-8.
van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer.
Neth J Med 1992 Feb;40(1-2):36-51.
van der Burg ME, Lammes FB, Verweij J. The role of CA 125 and
conventional examinations in diagnosing progressive carcinoma of the
ovary. Surg Gynecol Obstet 1993 Apr;176(4):310-4.
van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the
early diagnosis of progressive disease in ovarian cancer. Ann Oncol
1990 Jul;1(4):301-2.
van Kranenburg DL, van Kroonenburgh MJ, Trimbos JB, Fleuren GJ,
Pauwels EK. Imaging of ovarian cancer with radiolabelled monoclonal
antibodies. Arch Gynecol Obstet 1990;247(3):107-16.
Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K.
CA125 and placental alkaline phosphatase as serum tumor markers in
epithelial ovarian carcinoma. Tumour Biol 1992;13(3):168-74.
Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel
EJ. Tumor marker CA 125 in diagnosis, monitoring management and
follow-up of patients with ovarian tumors. Eur J Gynaecol Oncol
1992;13(2):205-8.
Ward BG, McGuckin MA, Ramm LE, Coglan M, Sanderson B,
Tripcony L, Free KE. The management of ovarian carcinoma is
improved by the use of cancer-associated serum antigen and CA 125
assays. Cancer 1993 Jan 15;71(2):430-8.
Welander CE. What do CA 125 and other antigens tell us about
ovarian cancer biology? Acta Obstet Gynecol Scand Suppl
1992;155:85-93.
Wojcik EM, Selvaggi SM, Johnson SC, Martier SS, Ager JW. Factors
influencing fine-needle aspiration cytology in the management of
recurrent gynecologic malignancies. Gynecol Oncol 1992
Sep;46(3):281-6.
Surgery for the Symptomatic Patient
Adelson MD, Kasowitz MH. Percutaneous endoscopic drainage
gastrostomy in the treatment of gastrointestinal obstruction from
intraperitoneal malignancy. Obstet Gynecol 1993 Mar;81(3):467-71.
Allum WH, Ambrose NS, Fielding JW, Chan KK. Selective salvage
surgery in gastrointestinal and gynaecological cancer. Ann R Coll Surg
Engl 1990 Jan;72(1):2-5.
Ball HG 3d. Secondary surgery for epithelial ovarian cancer. Curr Opin
Obstet Gynecol 1990 Feb;2(1):57-63.
Barnhill D, Doering D, Remmenga S, Bosscher J, Nash J, Park R.
Intestinal surgery performed on gynecologic cancer patients. Gynecol
Oncol 1991 Jan;40(1):38-41.
Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige JE. A new
approach to the management of malignant ascites; a permanently
implanted abdominal drain. Eur J Surg Oncol 1990 Feb;16(1):47-53.
Brown CL, Lewis JL Jr. Palliative surgery in ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 217-28.
Burke TW, Morris M. Secondary cytoreductive operations. In: Rubin
SC, Sutton GP, eds. Ovarian cancer. New York: McGraw-Hill; 1993.
p. 301-12.
Chevinsky AH, Minton JP. Ablation of recurrent and metastatic
intraabdominal tumor with the CO2 laser. Lasers Surg Med
1990;10(1):5-11.
Clarke-Pearson DL, Rodriguez GC, Boente M. Palliative surgery for
epithelial ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian
cancer. New York: McGraw-Hill; 1993. p. 351-73.
Donato D, Angelides A, Irani H, Penalver M, Averette H. Infectious
complications after gastrointestinal surgery in patients with ovarian
carcinoma and malignant ascites. Gynecol Oncol 1992 Jan;44(1):40-7.
Gilly FN, Carry PY, Brachet A, Sayag AC, Panteix G, Salle B,
Bienvenu J, Banssillon V, Burgard G, Manchon M, Rochette A,
Braillon G. Treatment of malignant peritoneal effusion in digestive and
ovarian cancer. Med Oncol Tumor Pharmacother 1992;9(4):177-81.
Herman LL, Hoskins WJ, Shike M. Percutaneous endoscopic
gastrostomy for decompression of the stomach and small bowel.
Gastrointest Endosc 1992 May-Jun;38(3):314-8.
Hogan WM, Boente MP. The role of surgery in the management of
recurrent gynecologic cancer. Semin Oncol 1993 Oct;20(5):462-72.
Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial
ovarian cancer. Cancer 1993 Feb 15;71(4 Suppl):1534-40.
Hoskins WJ, Rubin SC. Surgery in the treatment of patients with
advanced ovarian cancer. Semin Oncol 1991 Jun;18(3):213-21.
Isaacs JH. Cytoreductive surgery for nonresectable ovarian cancer. In:
Economou SG, Witt TR, Deziel DJ, et al., eds. Adjuncts to cancer
surgery. Philadelphia: Lea and Febiger; 1991. p. 334-8.
Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JR,
Graeff H. Radical surgical procedure improves survival time in patients
with recurrent ovarian cancer. Cancer 1992 Oct 15;70(8):2129-36.
Lee MJ, Saini S, Brink JA, Morrison MC, Hahn PF, Mueller PR.
Malignant small bowel obstruction and ascites: not a contraindication
to percutaneous gastrostomy. Clin Radiol 1991 Nov;44(5):332-4.
LeRoux PD, Berger MS, Elliott JP, Tamimi HK. Cerebral metastases
from ovarian carcinoma. Cancer 1991 Apr 15;67(8):2194-9.
Morris M, Gershenson DM, Wharton JT, Copeland LJ, Edwards CL,
Stringer CA. Secondary cytoreductive surgery for recurrent epithelial
ovarian cancer. Gynecol Oncol 1989 Sep;34(3):334-8.
Paganelli AM, Leone V, Malagutti V, Vescovo M, Sallusto A.
Intestinal surgery in patients with ovarian carcinoma. Eur J Gynaecol
Oncol 1990;11(2):157-60.
Potter ME. Secondary cytoreduction in ovarian cancer: pro or con?
Gynecol Oncol 1993 Oct;51(1):131-5.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Rubin SC. Surgery for ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):851-65.
Rubin SC, Benjamin I, Hoskins WJ, Pierce VK, Lewis JL Jr. Intestinal
surgery in gynecologic oncology. Gynecol Oncol 1989 Jul;34(1):30-3.
Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr. Palliative surgery for
intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989
Jul;34(1):16-9.
Rubin SC, Hoskins WJ, Hakes TB, Markman M: Cain JM, Lewis JL Jr.
Recurrence after negative second-look laparotomy for ovarian cancer:
analysis of risk factors. Am J Obstet Gynecol 1988 Nov;159(5):1094-8.
Rubin SC, Lewis JL Jr. Tumor antigens in ovarian malignancy. Clin
Obstet Gynecol 1986 Sep;29(3):693-704.
Sun A, Lian L, Tang M. Surgical treatment for recurrent ovarian
malignancies. Proc Chin Acad Med Sci Peking Union Med Coll
1990;5(4):219-22.
Taal BG, Steinmetz R, Den Hartog Jager FC. Rectosigmoid
obstruction caused by ovarian cancer. Clin Radiol 1990
Mar;41(3):170-4.
van der Burg ME, van Lent M, Kobierska A, Colombo N, Favalli G,
Lacave AJ, Nardi M, Renard J, Buyse M, Pecorelli S. Intervention
debulking surgery (IDS) does improve survival in advanced epithelial
ovarian cancer (EOC): an EORTC Gynecological Cancer Cooperative
Group (GCCG) Study [abstract]. Program Proc Am Soc Clin Oncol
1993 Mar;12:258.
van Ooijen B, van der Burg ME, Planting AS, Siersema PD, Wiggers
T. Surgical treatment or gastric drainage only for intestinal obstruction
in patients with carcinoma of the ovary or peritoneal carcinomatosis of
other origin. Surg Gynecol Obstet 1993 May;176(5):469-74.
Williams L. The role of secondary cytoreductive surgery in epithelial
ovarian malignancies. Oncology (Huntingt) 1992 Aug;6(8):25-32;
discussion 37-9. Comment in: Oncology (Huntingt) 1993 Feb;7(2):21.
Williams LL. Secondary cytoreduction of ovarian malignancies. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 187-203.
Salvage Chemotherapy
Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR,
Ueno W, Wampler GL, Yeung KY, Alt D, et al. Hormonal palliation of
chemoresistant ovarian cancer: three consecutive phase II trials of the
Mid-Atlantic Oncology Program. J Clin Oncol 1993
Oct;11(10):1957-68.
Alberts DS, Mason-Liddil N, Stock-Novack D, O'Toole RV, Abbott
TM, Salmon SE. A phase II evaluation of esorubicin in ovarian cancer.
A Southwest Oncology Group study. Am J Clin Oncol 1992
Apr;15(2):146-9.
Altretamine for ovarian cancer. Med Lett Drugs Ther 1991 Aug
9;33(850):76-7.
Asbury RF, Blessing JA, Look KY, Clarke-Pearson D, Homesley HD.
A Gynecologic Oncology Group phase II study of amonafide (NSC
308847) in epithelial ovarian cancer. Am J Clin Oncol 1993
Dec;16(6):529-31.
Baker TR, Piver MS, Hempling RE. The addition of etoposide and
ifosfamide to cisplatin as second line therapy in ovarian carcinoma. Eur
J Gynaecol Oncol 1993;14(1):18-22.
Beddoe AM, Dottino PR, Cohen CJ. Phase II trial of etoposide,
carboplatin, and ifosfamide as salvage therapy in advanced ovarian
carcinoma. Mt Sinai J Med 1993 Sep;60(4):311-6.
Benedetti Panici P, Greggi S, Scambia G, Salerno MG, Baiocchi G,
Cento R, Mancuso S. Mitomycin C and 5-fluorouracil salvage
chemotherapy in platinum-resistant ovarian carcinoma. Oncology
1992;49(3):183-7.
Benedetti Panici P, Scambia G, Greggi S, Salerno G, Cento R,
Mancuso S. Doxorubicin and cyclophosphamide, alternated with
bleomycin and mitomycin C as a second-line regimen in advanced
ovarian carcinoma resistant to cisplatin-based chemotherapy. Oncology
1990;47(4):296-8.
Bezwoda WR, Golombick T, Dansey R, Keeping J. Treatment of
malignant ascites due to recurrent/refractory ovarian cancer: the use of
interferon-alpha or interferon-alpha plus chemotherapy in vivo and in
vitro. Eur J Cancer 1991;27(11):1423-9.
Bruzzone M, Campora E, Merlini L, Giudici S, Bottero G, Iskra L,
Donadio M, Ferrari I, Ragni N. Ifosfamide and etoposide salvage
treatment in advanced ovarian cancer. J Chemother 1991
Oct;3(5):332-4.
Chauvergne J, Fumoleau P, Cappelaere P, Metz R, Armand JP,
Chevallier B, Kerbrat P, de Forni M, Lhomme C, Roche H, et al. Phase
II study of pirarubicin (THP) in patients with cervical, endometrial and
ovarian cancer: study of the Clinical Screening Group of the European
Organization for Research and Treatment of Cancer (EORTC). Eur J
Cancer 1993;29A(3):350-4.
Chiara S, Campora E, Merlini L, Simoni C, Iskra L, Odicino F, Ragni
N, Conto PF, Rosso R. Recurrent ovarian carcinoma: Salvage
treatment with platinum in patients responding to first-line
platinum-based regimens (3). Eur J Cancer 1993;29A(4):652.
Covens A, O'Connell G, Rusthoven J, Mazurka J. Phase II study of
mitomycin C and 5 fluorouracil in platinum resistant ovarian cancer.
Eur J Gynaecol Oncol 1992;13(2):125-30.
Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB, Morrow CP.
Ifosfamide-induced neurotoxicity. Gynecol Oncol 1991;42(3):193-6.
de Graeff A, van Hoef ME, Tjia P, Heintz AP, Neijt JP. Continuous
infusion of 5-fluorouracil in ovarian cancer patients refractory to
cisplatin and carboplatin. Ann Oncol 1991 Oct;2(9):691-2.
De Vriese G, Bonte J. Possible role of goserelin, an LH-RH agonist in
the treatment of gynaecological cancers. Eur J Gynaecol Oncol
1993;14(3):187-91.
De Vriese G, Bonte J. Possible role of goserelin, an LH-RH agonist in
the treatment of gynaecological cancers. J Gynaecol Endocrinol
1991-92;7-8(1-4):5-9.
Delaloye JF, Tran L, Leyvraz S, Bauer J, De Grandi P. Intraperitoneal
carboplatin in advanced ovarian carcinoma. Gynakol Geburtshilfliche
Rundsch 1993;33(1):25-30.
Dittrich C, Baur M, Vavra N, Hudec M, Fazeny B, Barrada M, Salzer
H, Sevelda P. Etoposide and carboplatin as salvage and first-line
therapy in ovarian cancer patients. Ann Oncol 1993 Sep;4(8):697-9.
Du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall P, Pfisterer J,
Baukneckt T. Phase II study of pirarubicin combined with cisplatin in
recurrent ovarian cancer. J Cancer Res Clin Oncol 1994;120(3):173-8.
Dufour P, Maloisel F, Bergerat JP, Barats JC, Dellenbach P, Renaud R,
Ritter P, Herbrecht R, Wendling C, Audhuy B, et al. Intraperitoneal
mitoxantrone as consolidation treatment for stage III ovarian
carcinoma: a pilot study. Bull Cancer (Paris) 1991;78(3):273-80.
Eckhardt S, Hernadi Z, Thurzo L, Telekes A, Sopkova B, Mechl Z,
Pawlicki M, Kerpel-Fronius S. Phase II clinical evaluation of etoposide
(VP-16-213, Vepesid) as a second-line treatment in ovarian cancer.
Results of the South-East European Oncology Group (SEEOG) Study.
Oncology 1990;47(4):289-95.
Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review
of its pharmacodynamic and pharmacokinetic properties, and
therapeutic potential in the chemotherapy of cancer. Drugs
1991;41(3):401-49.
Frasci G, Pacelli R, Scala S, Facchini G, Rinaldi L, Tinessa V, Bianco
AR, Iaffaioli RV. Intraperitoneal mitoxantrone via temporary catheter
in patients with ovarian cancer: Toxicity and feasibility evaluation. Adv
Ther 1990;7(3):124-35.
Frasci G, Tortoriello A, Facchini G, Conforti S, Cardone A, Persico G,
Mastrantonio P, Iaffaioli RV. Intraperitoneal (ip)
cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients
with minimal residual disease. Gynecol Oncol 1993 Jul;50(1):60-7.
Fromm GL, Freedman RS, Fritsche HA, Atkinson EN, Scott W.
Sequentially administered ethinyl estradiol and medroxyprogesterone
acetate in the treatment of refractory epithelial ovarian carcinoma in
patients with positive estrogen receptors. Cancer 1991 Nov
1;68(9):1885-9.
Gallion HH, Liu PY, Alberts DE, O'Toole RV, O'Sullivan J, Mills G,
Smith HO, Hynes HE. Phase II trial of amonafide in previously treated
patients with advanced ovarian cancer: a Southwest Oncology Group
study. Gynecol Oncol 1992 Aug;46(2):230-2.
Gore ME, Fryatt I, Wiltshaw I, Dawson T. Treatment of relapsed
carcinoma of the ovary with cisplatin or carboplatin following initial
treatment with these compounds. Obstet Gynecol Surv
1990;45(8):553-4.
Greco FA. Chronic etoposide administration: overview of clinical
experience. Cancer Treat Rev 1993;19 Suppl C:35-45.
Green MD, Speyer JL, Wernz JC, Colombo N, Beller U, Muggia FM,
Beckman EM. Phase II study of esorubicin (4'deoxydoxorubicin) in
anthracycline naive patients with ovarian cancer. Invest New Drugs
1990 Aug;8(3):333-6.
Hamilton TC, Ozols RF, Dabrow MB. Multidrug resistance to
alkylating agents and platinum compounds: state of our knowledge.
Oncology (Huntingt) 1990 Mar;4(3):101-6; discussion 106, 109.
Hamilton TC, Schilder RJ, Onishi Y, Ozols RF. Mechanisms of
resistance to the cytotoxicity of classic alkylating agents and
platinum-containing drugs. In: Nagourney RA and Sheikh KM, eds.
Clinical management of the drug-resistant cancer patient: new options
in clinical oncology. Long Beach (CA): Memorial Medical Center
Foundation Press; 1991. p. 49-59.
Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16-213
(etoposide) administered orally in advanced ovarian cancer. Gynecol
Oncol 1990 Mar;36(3):369-70.
Hansen LA, Hughes TE. Altretamine. DICP 1991 Feb;25(2):146-52.
Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness
of patients with advanced ovarian carcinoma to tamoxifen. A
Gynecologic Oncology Group study of second-line therapy in 105
patients. Cancer 1991 Jul 15;68(2):269-71.
Hauge MD, Long HJ, Hartmann LC, Edmonson JH, Webb MJ, Su J.
Phase II trial of intravenous hexamethylmelamine in patients with
advanced ovarian cancer. Invest New Drugs 1992 Nov;10(4):299-301.
Hendrick AM, Harris AL, Cantwell BM. Verapamil with mitoxantrone
for advanced ovarian cancer: a negative phase II trial. Ann Oncol 1991
Jan;2(1):71-2.
Hirono M, Yoshihara T, Hayashi Y, Suzuki M, Majima H. Multi-drug
chemotherapy for patients with peritonitis carcinomatosa associated
with ascites. J Jpn Soc Cancer Ther 1990;25(3):672-8.
Hoskins PJ, McMurtrie E, Swenerton KD. A phase II trial of
mitomycin in patients with epithelial ovarian carcinoma resistant to
cisplatin or carboplatin. Am J Clin Oncol 1990 Oct;13(5):416-9.
Judson IR, Calvert AH, Gore ME, Balmanno K, Gumbrell LA, Perren
T, Wiltshaw E. Phase II trial of trimelamol in refractory ovarian cancer.
Br J Cancer 1991 Feb;63(2):311-3.
Kaye SB. Chemotherapy for ovarian cancer. Eur J Cancer
1993;29A(4):632-5.
Kaye SB, Wanders J, Clavel M, Verweij J, Piccart MJ, Smyth JF, Ten
Bokkel Huinink WW, Wagener DJ, Judson IR, Cavalli F. Phase II trials
of fosquidone (GR63178A) in carcinoma of the breast, head and neck,
ovary and melanoma. Ann Oncol 1992 May;3(5):406-8.
Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB.
A phase II trial of intraperitoneal cisplatin and etoposide as salvage
treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991
Apr;9(4):649-57.
Kirmani S, McVey L, Loo D, Howell SB. A phase I clinical trial of
intraperitoneal thiotepa for refractory ovarian cancer. Gynecol Oncol
1990 Mar;36(3):331-4.
Langer CJ, Nash S, Catalano R, Rosenblum NG, Hogan WM, Comis
RL, O'Dwyer PJ. Phase II trial of thio-TEPA in relapsed and refractory
ovarian carcinoma. Gynecol Oncol 1991 Dec;43(3):242-6.
Leopold KA, Oleson JR, Clarke-Pearson D, Soper J, Berchuck A,
Samulski TV, Page RL, Blivin J, Tomberlin JK, Dewhirst MW.
Intraperitoneal cisplatin and regional hyperthermia for ovarian
carcinoma. Int J Radiat Oncol Biol Phys 1993;27(5):1245-51.
Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M,
Simmons D, Carmichael J, Harris AL. A phase II trial of goserelin
(Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 1992
Apr;65(4):621-3.
Long HJ 3d, Laurie JA, Wieand HS, Edmonson JH, Levitt R, Krook
JE, Abu-Ghazaleh S. A phase II evaluation of menogaril in
cisplatin-refractory advanced ovarian carcinoma. A collaborative trial
of the North Central Cancer Treatment Group and the Mayo Clinic.
Cancer 1991 Aug 15;68(4):730-2.
Look KY, Blessing JA, Muss HB, DeGeest K. 5-fluorouracil and
low-dose leucovorin in the treatment of recurrent epithelial ovarian
carcinoma. A phase II trial of the Gynecologic Oncology Group. Am J
Clin Oncol 1992 Dec;15(6):494-6.
Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A,
De Lena M. Carboplatin plus ifosfamide as salvage treatment of
epithelial ovarian cancer: a pilot study. J Clin Oncol 1993
Oct;11(10):1952-6.
Louvet C, de Gramont A, Demuynck B, Varette C, Beerblock K,
Bennamoun M, Krulik M. Bi-weekly 2-day schedule of high-dose
folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced
epithelial ovarian cancer: a phase II study. Ann Oncol 1992
Sep;3(8):657-8.
Malfetano J, Beecham JB, Bundy BN, Hatch KD. A phase II trial of
medroxyprogesterone acetate in epithelial ovarian cancers. A
Gynecologic Oncology Group study. Am J Clin Oncol 1993 Apr;16(2):
149-51.
Malfetano JH, Blessing JA, Adelson MD. A phase II trial of gallium
nitrate (NSC #15200) in previously treated ovarian carcinoma. A
Gynecologic Oncology Group Study. Am J Clin Oncol 1991
Aug;14(4):349-51.
Malfetano JH, Blessing JA, Jacobs AJ. A phase II trial of Didemnin B
(NSC #335319) in patients with previously treated epithelial ovarian
cancer. A Gynecologic Oncology Group Study. Am J Clin Oncol 1993
Feb;16(1):47-9.
Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson
JE, Schein P. Analysis of prognostic factors and survival in patients
with ovarian cancer treated with second-line hexamethylmelamine
(altretamine). Cancer Treat Rev 1991 Mar;18 Suppl A:23-9.
Manetta A, MacNeill C, Lyter JA, Scheffler B, Podczaski ES, Larson
JE, Schein P. Hexamethylmelamine as a single second-line agent in
ovarian cancer. Gynecol Oncol 1990 Jan;36(1):93-6.
Markman M. Salvage intraperitoneal chemotherapy for ovarian cancer:
a possible role for mitoxantrone? Eur J Cancer 1993;29A(9):1225-6.
Comment on: Eur J Cancer 1993;29A(9):1242-8.
Markman M. Salvage therapy in ovarian cancer: is there a role for
intraperitoneal drug delivery? Gynecol Oncol 1993 Oct;51(1):86-9.
Markman M, Alberts D, Rubin S, Hakes T, Lewis JL Jr, Reichman B,
Jones W, Curtin J, Barakat R, Brodar F, et al. Evidence for persistence
of mitoxantrone within the peritoneal cavity following intraperitoneal
delivery. Gynecol Oncol 1993 Feb;48(2):185-8.
Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley
HD. Characteristics of patients with small-volume residual ovarian
cancer unresponsive to cisplatin-based ip chemotherapy: lessons
learned from a Gynecologic Oncology Group phase II trial of ip
cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992
Apr;45(1):3-8. Comment in: Gynecol Oncol 1992 Apr;45(1):1-2.
Markman M, Blessing JA, Major F, Manetta A. Salvage intraperitoneal
therapy of ovarian cancer employing cisplatin and etoposide: a
Gynecologic Oncology Group study. Gynecol Oncol 1993
Aug;50(2):191-5.
Markman M, DeMarco LC, Birkhofer M, Budman D, Hakes T,
Reichman B, Rubin S, Jones W, Barakat R, Curtin J, et al. Phase II trial
of zeniplatin (CL 286,558), a new patinum compound, in patients with
advanced ovarian cancer previously treated with organoplatinum-based
therapy. J Cancer Res Clin Oncol 1993;119(4):234-6.
Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S,
Jones W, Almadrones L, Lewis JL Jr. Phase II trial of intraperitoneal
mitoxantrone in the management of refractory ovarian cancer. J Clin
Oncol 1990 Jan;8(1):146-50.
Markman M, Hakes T, Reichman B, Barakat R, Curtin J, Jones W,
Lewis JL Jr, Rubin S, Almadrones L, Hoskins W. Exploring the use of
chronic low-dose oral etoposide in ovarian cancer: is there a role for
this new drug in the management of platinum-refractory disease? Semin
Oncol 1992 Dec;19(6 Suppl 14):25-7.
Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S,
Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Phase 2 trial of
chronic low-dose oral etoposide as salvage therapy of
platinum-refractory ovarian cancer. J Cancer Res Clin Oncol
1992;119(1):55-7.
Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W,
Almadrones L, Yordan EL Jr, Eriksson J, Lewis JL Jr. Intraperitoneal
cisplatin and cytarabine in the treatment of refractory or recurrent
ovarian carcinoma. J Clin Oncol 1991 Feb;9(2):204-10. Comment in: J
Clin Oncol 1991 Feb;9(2):197-9.
Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W,
Almadrones L, Hoskins W. Phase II trial of weekly or biweekly
intraperitoneal mitoxantrone in epithelial ovarian cancer. J Clin Oncol
1991 Jun;9(6):978-82.
Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W,
Almadrones L, Pizzuto F, Hoskins W. Ifosfamide and mesna in
previously treated advanced epithelial ovarian cancer: activity in
platinum-resistant disease. J Clin Oncol 1992 Feb;10(2):243-8.
Markman M, Hakes T, Reichman B, Rubin S, Curtin J, Barakat R,
Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Salvage
intraperitoneal mitoxantrone therapy of ovarian cancer: influence of
increasing the volume of treatment. Gynecol Oncol 1993
May;49(2):185-9.
Markman M, Iannotti N, Hakes T, Reichman B, Rubin S, Jones W,
Hoskins W, Lewis JL Jr. A pilot trial of the daily intraperitoneal
administration of recombinant interleukin-2. Reg Cancer Treat
1990;3(1):44-6.
Markman M, Reichman B, Hakes T, Curtin J, Barakat R, Rubin S,
Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Association between
pretreatment CA-125 levels and surgically documented complete
responses in patients with ovarian cancer treated with second-line
intraperitoneal therapy. J Cancer Res Clin Oncol 1992;118(5):391-4.
Markman M, Reichman B, Hakes T, Lewis JL Jr, Jones W, Rubin S,
Barakat R, Curtin J, Almadrones L, Hoskins W. Impact on survival of
surgically defined favorable responses to salvage intraperitoneal
chemotherapy in small-volume residual ovarian cancer. J Clin Oncol
1992 Sep;10(9):1479-84.
Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr,
Barakat R, Curtin J, Almadrones L, Hoskins W. Phase 2 trial of
intraperitoneal carboplatin and etoposide as salvage treatment of
advanced epithelial ovarian cancer. Gynecol Oncol 1992
Dec;47(3):353-7.
Markman M, Reichman B, Hakes T, Rubin S, Jones W, Lewis JL Jr,
Barakat R, Curtin J, Almadrones L, Hoskins W. The use of
recombinant human erythropoietin to prevent carboplatin-induced
anemia. Gynecol Oncol 1993 May;49(2):172-6.
Markman M, Reichman B, Hakes T, Rubin S, Lewis JL Jr, Jones W,
Barakat R, Curtin J, Almadrones L, Hoskins W. Evidence supporting
the superiority of intraperitoneal cisplatin compared to intraperitoneal
carboplatin for salvage therapy of small-volume residual ovarian
cancer. Gynecol Oncol 1993 Jul;50(1):100-4.
Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S,
Jones W, Almadrones L, Lewis JL Jr. Second-line platinum therapy in
patients with ovarian cancer previously treated with cisplatin. J Clin
Oncol 1991 Mar;9(3):389-93.
Markman M, Rothman R, Hakes T, Reichman B, Lewis JL Jr, Rubin S,
Jones W, Almadrones L, Hoskins W. Late effects of cisplatin-based
chemotherapy on renal function in patients with ovarian carcinoma.
Gynecol Oncol 1991 Jun;41(3):217-9.
Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'Incalci M,
Cavalli F, Mangioni C. Low-dose oral etoposide in epithelial cancer of
the ovary. Ann Oncol 1993 Jun;4(6):517-9.
McGuire WP, Rowinsky EK. Old drugs revisited, new drugs, and
experimental approaches in ovarian cancer therapy. Semin Oncol 1991
Jun;18(3):255-69.
McGuire WP 3d, Blessing JA, Berek JS, Munoz A. Phase II study of
N-methylformamide (N-MF) (NSC 3051) in patients with advanced
epithelial ovarian cancer. A Gynecologic Oncology Group study. Invest
New Drugs 1990 May;8(2):191-4.
Menczer J, Ben-Baruch G, Rizel S, Brenner H. Cisplatin in
combination with continuous VP16 infusion as second line
chemotherapy in ovarian carcinoma. A pilot study. Eur J Gynaecol
Oncol 1992;13(4):316-8.
Menczer J, Ben-Baruch G, Rizel S, Brenner H. Extraperitoneal
metastases after intraperitoneal chemotherapy of ovarian cancer
patients with a negative second-look laparotomy. Int J Gynecol Cancer
1993;3(6):359-62.
Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate
in patients with advanced epithelial ovarian carcinoma. A Gynecologic
Oncology Group study. Am J Clin Oncol 1992 Apr;15(2):125-8.
Moore DH, Fowler WC Jr, Jones CP, Crumpler LS.
Hexamethylmelamine chemotherapy for persistent or recurrent
epithelial ovarian cancer. Am J Obstet Gynecol 1991 Sep;165(3):573-6.
Moore DH, Valea F, Crumpler LS, Fowler WC Jr.
Hexamethylmelamine/altretamine as second-line therapy for epithelial
ovarian carcinoma. Gynecol Oncol 1993 Oct;51(1):109-12.
Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J,
Curtin J, Morrow CP. Intraperitoneal carboplatin and etoposide for
persistent epithelial ovarian cancer: analysis of results by prior
sensitivity to platinum-based regimens. Gynecol Oncol 1993
Aug;50(2):232-8.
Murphy D, Lind MJ, Prendiville J, Renninson J, Smith DR, Thompson
G, Ranson M, Crowther D. Phase I/II study of intraperitoneal
iproplatin in patients with minimal residual disease following
platinum-based systemic therapy for epithelial ovarian carcinoma. Eur J
Cancer 1992;28A(4-5):870-2.
Muss HB, Blessing JA, Baker VV, Barnhill DR, Adelson MD.
Echinomycin (NSC 526417) in advanced ovarian cancer. A phase II
trial of the Gynecologic Oncology Group. Am J Clin Oncol 1990
Aug;13(4):299-301.
Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G,
Calabresi F. Intraperitoneal recombinant alpha-2-interferon alternating
with cisplatin as salvage therapy for minimal residual-disease ovarian
cancer: a phase II study. J Clin Oncol 1990 Jun;8(6):1036-41.
Nash JD, Young RC. Gynecologic malignancies. Cancer Chemother
Biol Response Modif 1991;12:549-69.
Neijt JP. Treatment of advanced ovarian cancer: 10 years of
experience. Ann Oncol 1992 Jan;3(1):17-27.
Nicoletto MO, Fiorentino MV, Vinante O, Prosperi A, Tredese F,
Tumolo S, Cima GP, Monfardini S. Experience with intraperitoneal
alpha-2a interferon. Oncology 1992;49(6):467-73.
Nicoletto MO, Padrini R, Ferrazzi E, Nascimben O, Visona E, Tumolo
S, Palumbo M, Costa L, Vinante O, Monfardini S, et al. Phase I-II
intraperitoneal mitoxantrone in advanced pretreated ovarian cancer.
Eur J Cancer 1993;29A(9):1242-8. Comment in: Eur J Cancer
1993;29A(9):1225-6.
Nieminen U, Kauppila A, Gronroos M, Kuoppala T, Vayrynen M.
Placebo-controlled study on the efficacy of the pyrimido-pyrimidine
derivative RA 233 in ovarian cancer. Gynecol Oncol 1990
Feb;36(2):226-31.
O'Brien ME, Hardy J, Tan S, Walling J, Peters B, Hatty S, Wiltshaw E.
A phase II study of sulofenur, a novel sulfonylurea, in recurrent
epithelial ovarian cancer. Cancer Chemother Pharmacol 1992;30(3):
245-8.
O'Dwyer PJ, LaCreta F, Hogan M, Rosenblum N, O'Dwyer JL, Comis
RL. Pharmacologic study of etoposide and cisplatin by the
intraperitoneal route. J Clin Pharmacol 1991 Mar;31(3):253-8.
Onnis A, Marchetti M, Maggino T, De Toffoli J, Blandamura S.
Clinical experience in gynecological cancer management. d). Ovarian
tumors--1) Epithelial: report from the Gynaecological Institutes of
Padua University (1963-1990). Eur J Gynaecol Oncol
1992;13(1):17-33.
Ozols RF. Advances in the chemotherapy of gynecologic malignancies.
Hematol Oncol 1992 Jan-Feb;10(1):43-51.
Ozols RF. Chemotherapy for advanced epithelial ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.
Ozols RF. New developments with carboplatin in the treatment of
ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.
Ozols RF. Ovarian cancer. Semin Surg Oncol 1990;6(6):328-38.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Ozols RF. Role of carboplatin in ovarian cancer. Current results and
thoughts for the future. Acta Obstet Gynecol Scand Suppl
1992;155:75-7.
Ozols RF. Role of chemotherapy in the future treatment of ovarian
cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.
Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol
1991 Jun;18(3):222-32.
Panici PB, Scambia G, Greggi S, Salerno G, Cento R, Mancuso S.
Doxorubicin and cyclophosphamide, alternated with bleomycin and
mitomycin C as a second-line regimen in advanced ovarian carcinoma
resistant to cisplatin-based chemotherapy. Oncology 1990;47(4):296-8.
Pfeiffer P, Bennedbaek O, Bertelsen K. Intraperitoneal carboplatin in
the treatment of minimal residual ovarian cancer. Gynecol Oncol 1990
Mar;36(3):306-11.
Ploin DY, Tranchand B, Guastalla JP, Rebattu P, Chauvin F, Clavel M,
Ardiet C. Pharmacokinetically guided dosing for intravenous
melphalan: a pilot study in patients with advanced ovarian
adenocarcinoma. Eur J Cancer 1992;28A(8-9):1311-5. Comment in:
Eur J Cancer 1992;28A(8-9):1302-4.
Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr,
Shingleton HM. Second-look laparotomy and salvage therapy: a
research modality only? Gynecol Oncol 1992 Jan;44(1):3-9. Comment
in: Gynecol Oncol 1992 Nov;47(2):275.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE.
Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer
1992;28A(4-5):864-6.
Reed E, Jacob J, Ozols RF, Young RC, Allegra C. 5-Fluorouracil
(5-FU) and leucovorin in platinum-refractory advanced stage ovarian
carcinoma. Gynecol Oncol 1992 Sep;46(3):326-9.
Reichman B. Second-line intravenous chemotherapy for refractory
ovarian cancer. In: Rubin RC, Sutton GP, eds. Ovarian cancer. New
York: McGraw-Hill; 1993. p. 313-24.
Reichman B, Markman M, Hakes T, Rubin S, Jones W, Curtin J,
Barakat R, Almadrones L, Lewis JL Jr, Hoskins W. Mitomycin-C plus
a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive
salvage regimen for platinum-resistant ovarian carcinoma. Gynecol
Oncol 1993 Jul;50(1):30-3.
Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte
PF, Rosso R. Intraperitoneal chemotherapy with carboplatin and
interferon alpha in the treatment of relapsed ovarian cancer: a pilot
study. Anticancer Res 1991 Jul-Aug;11(4):1641-3.
Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V,
Donadio G, Odicino F, Ragni N, Conte PF, et al. Crossover study with
cisplatin or carboplatin in advanced ovarian cancer. Gynecol Oncol
1990 Nov;39(2):146-9.
Rosso R, Alama A, Repetto L, Conte PF. Timed sequential
chemotherapy following ifosfamide-induced kinetic recruitment in
refractory ovarian cancer. Cancer Chemother Pharmacol 1990;26
Suppl:S43-4.
Schein PS, Scheffler B, McCulloch W. The role of
hexamethylmelamine in the management of ovarian cancer. Cancer
Treat Rev 1991 Mar;18 Suppl A:67-75.
Scotto V, Sbiroli C. Weekly cis-platinum as third line chemotherapy in
advanced ovarian carcinoma. Phase II study. Eur J Gynaecol Oncol
1991;12(1):51-3.
Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F. Phase II
study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The
EORTC Early Clinical Trials Group. Eur J Cancer 1990
Feb;26(2):137-8.
Sherman AI, Rosenberg R, Fink D. Use of intraperitoneal
chemotherapy for treatment of ovarian cancer. Eur J Gynaecol Oncol
1992;13(4):295-305.
Smalley RV, Goldstein D, Bulkowski D, Hannon C, Buchler D,
Knudsen C, Tuttle RL. A phase II study of crisnatol mesylate in
patients with ovarian carcinoma. Invest New Drugs 1992
Jul;10(2):107-12.
Speyer JL, Beller U, Colombo N, Sorich J, Wernz JC, Hochster H,
Green M, Porges R, Muggia FM, Canetta R, et al. Intraperitoneal
carboplatin: favorable results in women with minimal residual ovarian
cancer after cisplatin therapy. J Clin Oncol 1990 Aug;8(8):1335-41.
Speyer JL, Sorich J. Intraperitoneal carboplatin: rationale and
experience. Semin Oncol 1992 Feb;19(1 Suppl 2):107-13.
Sutton G. Ifosfamide and mesna in epithelial ovarian carcinoma.
Gynecol Oncol 1993 Oct;51(1):104-8.
Sutton GP, Blessing JA, Adelson MD, Hanjani P. Phase II trial of
vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology
Group study. Invest New Drugs 1990 Nov;8(4):377-9.
Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W.
Gynecologic Oncology Group studies with ifosfamide. Semin Oncol
1992 Dec;19(6 Suppl 12):31-4.
Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
Early phase II Gynecologic Oncology Group experience with
ifosfamide/mesna in gynecologic malignancies. Cancer Chemother
Pharmacol 1990;26 Suppl:S55-8.
Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD.
Gynecologic Oncology Group experience with ifosfamide. Semin Oncol
1990 Apr;17(2 Suppl 4):6-10.
Tarraza HM Jr, Boyce CR, Smith WG, Jones MA. Consolidation
intraperitoneal chemotherapy in epithelial ovarian cancer patients
following negative second-look laparotomy. Gynecol Oncol 1993
Sep;50(3):287-90.
Taylor CW, Alberts DS, Peng YM, McCloskey TM, Matzner M, Roe
DJ, Plezia PM, Grindey GB, Hamilton M, Seitz D. Antitumor activity
and clinical pharmacology of sulofenur in ovarian cancer. J Natl Cancer
Inst 1992 Dec 2;84(23):1798-802.
ten Tije BJ, Wils J. Intraperitoneal cisplatin in the treatment of
refractory or recurrent advanced ovarian carcinoma. Oncology
1992;49(6):442-4.
Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for
recurrent carcinoma of the ovary. Cancer 1993 Feb 15;71(4
Suppl):1559-64.
Thigpen T, Lambuth BW, Vance RB. Ifosfamide in the management of
gynecologic cancers. Semin Oncol 1990 Apr;17(2 Suppl 4):11-8.
Thompson P, Wilson P, Osborne R, Slevin M, Wiltshaw F, Blake P,
Harper P, Coleman R, Williams C, Sweetenham J, et al. The clinical
activity of cyproterone acetate in advanced ovarian carcinoma. A
London Gynaecology Oncology Group Study. Br J Cancer 1991
Nov;64(5):973-4.
Triptorelin pamoate. Phase III Drug Profiles 1993;3(3):1-8.
Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide
combined with ifosfamide as second-line therapy in cisplatin-resistant
ovarian carcinomas. Cancer Chemother Pharmacol 1990;26
Suppl:S45-7.
van der Burg ME, Hoff AM, van Lent M, Rodenburg CJ, van Putten
WL, Stoter G. Carboplatin and cyclophosphamide salvage therapy for
ovarian cancer patients relapsing after cisplatin combination
chemotherapy. Eur J Cancer 1991;27(3):248-50.
van der Gaast A, Splinter TA. Teniposide (VM-26) in ovarian cancer: a
review. Semin Oncol 1992 Apr;19(2 Suppl 6):95-7.
van Oosterom AT, ten Bokkel Huinink WW, van der Burg ME,
Vermorken JB, Willemse PH, Neijt JP. Phase II clinical trial of
doxifluridine in patients with advanced ovarian cancer. Eur J Cancer
1991;27(6):747-9.
Venesmaa P, Ylikorkala O. Subrenal capsule assay in selection of
chemotherapy after operation for recurrent ovarian cancer. Br J Cancer
1991 Jan;63(1):84-6.
Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K,
Trope C. Hexamethylmelamine as second-line therapy in platin-resistant
ovarian cancer. Gynecol Oncol 1992 Dec;47(3):282-6. Comment in:
Gynecol Oncol 1992 Dec;47(3):279-81.
Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet
Gynecol Scand 1993;72(8):682-4.
Weiss G, Green S, Alberts DS, Thigpen JT, Hines HE, Hanson K,
Pierce HI, Baker LH, Goodwin JW. Second-line treatment of advanced
measurable ovarian cancer with iproplatin: a Southwest Oncology
Group study. Eur J Cancer 1991;27(2):135-8.
Wharton JT. Hexamethylmelamine (altretamine) activity as a single
agent in previously untreated advanced ovarian cancer. Cancer Treat
Rev 1991 Mar;18 Suppl A:15-21.
Whelan JS, van Dam PA, Shepherd JH, Slevin ML. The treatment of
microscopic residual ovarian cancer with intraperitoneal interferon: a
clinical and flow cytometric study. Br J Obstet Gynaecol 1992
Jul;99(7):615-7.
Willemse PH, de Vries EG, Mulder NH, Aalders JG, Bouma J, Sleijfer
DT. Intraperitoneal human recombinant interferon alpha-2b in minimal
residual ovarian cancer. Eur J Cancer 1990 Mar;26(3):353-8.
Willemse PH, Gietema JA, Mulder NH, de Vries EG, Meijer S, Bouma
J, Birkhofer M, Rastogi RB, Sleijfer DT. Zeniplatin in patients with
advanced ovarian cancer, a phase II study with a third generation
platinum complex. Eur J Cancer 1993;29A(3):359-62.
Willemse PH, Sleijfer DT, de Vries EG, Boonstra H, Bouma J, Mulder
NH. A phase I-II study with intraperitoneal cisplatin plus systemic
etoposide in patients with minimal residual ovarian cancer. Eur J
Cancer 1992;28(2-3):479-81.
Willemse PH, v.d. Burg ME, v.d. Gaast A, Neijt JP, ten Bokkel
Huinink WW, Aalders JG, de Vries EG. Ifosfamide given as a 24-h
infusion with mesna in patients with recurrent ovarian cancer:
preliminary results. Cancer Chemother Pharmacol 1990;26
Suppl:S51-4.
Williams CJ. Implications of an overview of chemotherapy in advanced
ovarian carcinoma. Br J Cancer 1992;66(2):225-6.
Williams CJ. A phase II study of oral idarubicin in advanced recurrent
or refractory ovarian carcinoma. Cancer Chemother Pharmacol
1990;25(4):304-5.
Williams LL, Fudge M, Burnett LS, Jones HW 3d. Salvage carboplatin
therapy for advanced ovarian cancer after first-line treatment with
cisplatin. Am J Clin Oncol 1992 Aug;15(4):331-6.
Zanaboni F, Scarfone G, Presti M, Maggi R, Borello C, Bolis G.
Salvage chemotherapy for ovarian cancer recurrence: weekly cisplatin
in combination with epirubicin or etoposide. Gynecol Oncol 1991
Oct;43(1):24-8.
Zylberberg B, Ravina JH, Salat-Baroux J, Madelenat P, Zarca D,
Dormont D. Chemotherapy by the intravenous and intraperitoneal
routes combined in ovarian cancer. Gynecol Oncol 1990
Feb;36(2):271-6.
Quality of Life Considerations
August DA, Thorn D, Fisher RL, Welchek CM. Home parenteral
nutrition for patients with inoperable malignant bowel obstruction.
JPEN J Parenter Enteral Nutr 1991 May-Jun;15(3):323-7. Comment in:
JPEN J Parenter Enteral Nutr 1992 Mar-Apr;16(2):190-1.
Cain JM. Quality of life considerations in the therapy of epithelial
ovarian cancer. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New
York: McGraw-Hill; 1993. p. 451-64.
Cassem EH. Appropriate treatment limits in advanced cancer. In:
Billings JA. Outpatient management of advanced cancer: symptom
control, support, and hospice-in-the-home. Philadelphia: Lippincott;
1985. p. 139-51.
Cella DF, Jacobsen PB, Lesko LM. Research methods in
psychooncology. In: Holland JC; Rowland JH, eds. Handbook of
psychooncology: psychological care of the patient with cancer. New
York: Oxford; 1989. p. 737-49.
Donovan K, Sanson-Fisher RW, Redman S. Measuring quality of life in
cancer patients. J Clin Oncol 1989 Jul;7(7):959-68.
Fries JF. Aging, natural death, and the compression of morbidity. N
Engl J Med 1980 Jul 17;303(3):130-5.
Lamb MA. Psychosexual issues: the woman with gynecologic cancer.
Semin Oncol Nurs 1990 Aug;6(3):237-43.
Lew S. A tribute to Gayle. Can Oncol Nurs J 1993 Aug;3(3):156.
MacDonald N. Oncology and palliative care: the case for co-ordination.
Cancer Treat Rev 1993;19 Suppl A:29-41.
Makar AP, Trope CG. Gynecologic malignancy and surgery: from
quantity to quality of life. Curr Opin Obstet Gynecol 1992
Jun;4(3):419-29.
Mann SC, Andrews PA, Howell SB. Modulation of
cis-diamminedichloroplatinum(II) accumulation and sensitivity by
forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant
human ovarian carcinoma cells. Int J Cancer 1991 Jul 30;48(6):866-72.
Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect
of dietary counseling on food intake, body weight, response rate,
survival, and quality of life in cancer patients undergoing
chemotherapy: A prospective, randomized study. J Clin Oncol
1993;11(10):2043-9.
Ovesen L, Hannibal J, Mortensen EL. The interrelationship of weight
loss, dietary intake, and quality of life in ambulatory patients with
cancer of the lung, breast, and ovary. Nutr Cancer 1993;19(2):159-67.
Payne SA. Coping with palliative chemotherapy. J Adv Nurs 1990
Jun;15(6):652-8.
Payne SA. A study of quality of life in cancer patients receiving
palliative chemotherapy. Soc Sci Med 1992 Dec;35(12):1505-9.
Pickard-Holley S. Fatigue in cancer patients. A descriptive study.
Cancer Nurs 1991 Feb;14(1):13-9.
Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival
in patients with terminal cancer. Arch Intern Med 1988
Jul;148(7):1586-91.
Roberts CS, Rossetti K, Cone D, Cavanagh D. Psychosocial impact of
gynecologic cancer: a descriptive study. J Psychosoc Oncol
1992;10(1):99-109.
Schonwetter RS, Teasdale TA, Storey P, Luchi RJ. Estimation of
survival time in terminal cancer patients: an impedance to hospice
admissions? Hosp J 1990;6(4):65-79.
Smith EM, Redman R, Burns TL, Sagert KM. Perceptions of social
support among patients with recently diagnosed breast, endometrial,
and ovarian cancer: An exploratory study. J Psychosoc Oncol 1985
Fall;3(3):65-81.
Sneed NV, Edlund B, Dias JK. Adjustment of gynecological and breast
cancer patients to the cancer diagnosis: comparisons with males and
females having other cancer sites. Health Care Women Int 1992
Jan-Mar;13(1):11-22.
Stjernsward J. WHO cancer pain relief programme. Cancer Surv
1988;7(1):195-208.
NEW DIRECTIONS FOR RESEARCH
Abbate I, Correale M, Gargano G, Tedone T, Izzi G, Catino A, Musci
MD, Dragone D, Cramarossa A. Tumor necrosis factor and soluble
interleukin-2 receptor: two immunological biomarkers in female
neoplasms. Eur J Gynaecol Oncol 1992;13(1 Suppl):92-6.
Adelson MD. Future directions in the surgical management of ovarian
carcinoma. In: Rubin SC, Sutton GP, eds. Ovarian cancer. New York:
McGraw-Hill; 1993. p. 465-83.
Alama A, Merlo F, Chiara S, Muttini MP, Guido T, Nicolo G, Conte
PF, Ragni N. Prediction of survival by thymidine labelling index in
patients with resistant ovarian carcinoma. Eur J Cancer
1992;28A(6-7):1079-80.
Antman KH, Souhami RL. High-dose chemotherapy in solid tumours.
A review of published data in selected tumours with a commentary.
Ann Oncol 1993;4 Suppl 1:29-44.
Ariad S, Bezwoda WR. High-dose chemotherapy: Therapeutic
potential in the age of growth factor support. Isr J Med Sci
1992;28(6):377-85.
Autio-Harmainen H, Karttunen T, Hurskainen T, Hoyhtya M, Kauppila
A, Tryggvason K. Expression of 72 kilodalton type IV collagenase
(gelatinase A) in benign and malignant ovarian tumors. Lab Invest 1993
Sep;69(3):312-21.
Baker V. Oncogenes in gynecologic malignancy. Curr Opin Obstet
Gynecol 1992 Feb;4(1):75-80.
Balkwill FR. Tumour necrosis factor and cancer. Prog Growth Factor
Res 1992;4(2):121-37.
Barletta C, Lazzaro D, Prosperi Porta R, Testa U, Grignani F, Ragusa
RM, Leone R, Patella A, Carenza L, Peschle C. C-MYB activation and
the pathogenesis of ovarian cancer. Eur J Gynaecol Oncol
1992;13(1):53-9.
Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M,
Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer
1993 Feb 15;71(4 Suppl):1597-601.
Beattie GJ, Roulston JE, Eccles DM, Richardson JM, Fisken J,
Leonard RC. Alpha-fucosidase as a marker of genetic deletion in
ovarian carcinoma. Ann Clin Biochem 1993 Mar;30(Pt 2):207-8.
Becker JL, Prewett TL, Spaulding GF, Goodwin TJ.
Three-dimensional growth and differentiation of ovarian tumor cell line
in high aspect rotating-wall vessel: morphologic and embryologic
considerations. J Cell Biochem 1993 Mar;51(3):283-9.
Bell DA. Flow cytometry of ovarian neoplasms. Curr Top Pathol
1992;85:337-56.
Benchekroun MN, Parker R, Reed E, Sinha BK. Inhibition of DNA
repair and sensitization of cisplatin in human ovarian carcinoma cells by
interleukin-1 alpha. Biochem Biophys Res Commun 1993 Aug
31;195(1):294-300.
Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT,
Clarke-Pearson DL, Bast RC Jr, Bacus SS. Ploidy analysis of epithelial
ovarian cancers using image cytometry. Gynecol Oncol 1992
Jan;44(1):61-5.
Berchuck A, Kohler MF, Bast RC Jr. Oncogenes in ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):813-27.
Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS,
Bast RC Jr. Growth regulation and transformation of ovarian
epithelium. Cancer 1993 Jan 15;71(2 Suppl):545-51.
Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA,
Clarke-Pearson DL, Bast RC Jr. Regulation of growth of normal
ovarian epithelial cells and ovarian cancer cell lines by transforming
growth factor-beta. Am J Obstet Gynecol 1992 Feb;166(2):676-84.
Berek JS. Intraperitoneal immunotherapy for ovarian cancer with alpha
interferon. Eur J Cancer 1992;28A(4-5):719-21.
Berns EM, Klijn JG, Henzen-Logmans SC, Rodenburg CJ, van der
Burg ME, Foekens JA. Receptors for hormones and growth factors and
(onco)-gene amplification in human ovarian cancer. Int J Cancer 1992
Sep 9;52(2):218-24.
Bhalla K, Holladay C, Lutzky J, Ibrado AM, Bullock G, Jasiok M,
Singh S. Deoxycytidine protects normal bone marrow progenitors
against Ara-C and gemcitabine cytotoxicity without compromising their
activity against cisplatin-resistant human ovarian cancer cells. Gynecol
Oncol 1992 Apr;45(1):32-9.
Bicher A, Kohn E, Sarosy G, Davis P, Adamo DO, Jacob J, Christian
M, Reed E. The absence of cumulative bone marrow toxicity in patients
with recurrent adenocarcinoma of the ovary receiving dose-intense
taxol and granulocyte colony stimulating factor. Anticancer Drugs 1993
Apr;4(2):141-8.
Biesma B, Willemse PH, Mulder NH, Sleijfer DT, Gietema JA, Mull R,
Limburg PC, Bouma J, Vellenga E, de Vries EG. Effects of
interleukin-3 after chemotherapy for advanced ovarian cancer. Blood
1992 Sep 1;80(5):1141-8.
Bissett D, McLaughlin K, Kelland LR, Brown R. Cisplatin-DNA
damage recognition proteins in human tumour extracts. Br J Cancer
1993 Apr;67(4):742-8.
Blaakaer J, Hogdall CK, Hording U, Bennett P, Toftager-Larsen K,
Daugaard S, Bock J. Hormonal factors and prognosis in epithelial
ovarian cancer: A multivariate analysis. Eur J Obstet Gynecol Reprod
Biol 1993;51(1):21-7.
Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu
FJ, Marks J, Clarke-Pearson DL, Bast RC Jr. The effect of interferon
gamma on epidermal growth factor receptor expression in normal and
malignant ovarian epithelial cells. Am J Obstet Gynecol 1992
Dec;167(6):1877-82.
Boente MP, Hurteau J, Rodriguez GC, Bast RC Jr, Berchuck A. The
biology of ovarian cancer. Curr Opin Oncol 1993 Sep;5(5):900-7.
Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB,
Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, et al.
Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted
lymphocytes: a multicenter study. Int J Cancer Suppl 1992;7:78-81.
Bonetti A, Howell SB, McClay E, Kirmani S, Goel R, Plaxe S, Braly P,
Kim S. High-dose biweekly intraperitoneal cisplatin: An effective way
to increase cisplatin dose intensity. Gynecol Oncol 1993;49(3):318-24.
Bookman MA. Biologic therapy in the management of refractory
ovarian cancer. Gynecol Oncol 1993 Oct;51(1):113-26.
Bookman MA, Berek JS. Biologic and immunologic therapy of ovarian
cancer. Hematol Oncol Clin North Am 1992 Aug;6(4):941-65.
Borresen AL. Oncogenesis in ovarian cancer. Acta Obstet Gynecol
Scand Suppl 1992;155:25-30.
Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53
accumulation in ovarian carcinomas and its prognostic implications.
Hum Pathol 1993 Nov;24(11):1175-9.
Bose CK, Mukherjea M. Alpha-fetoprotein in advanced epithelial
ovarian cancer. Br J Obstet Gynaecol 1993;100(12):1149-50.
Braly PS, Klevecz RR. Flow cytometric evaluation of ovarian cancer.
Cancer 1993 Feb 15;71(4 Suppl):1621-8.
Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye
SB. Increased accumulation of p53 protein in cisplatin-resistant ovarian
cell lines. Int J Cancer 1993 Oct 21;55(4):678-84.
Buijs WC, Massuger LF, Claessens RA, Kenemans P, Corstens FH.
Dosimetric evaluation of immunoscintigraphy using indium-111-labeled
monoclonal antibody fragments in patients with ovarian cancer. J Nucl
Med 1992 Jun;33(6):1113-20.
Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Clinical trials
with the topoisomerase I inhibitors. Semin Oncol 1992;19(6):663-9.
Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson
WG, Liotta LA. Evaluation of basement membrane components and
the 72 kDa type IV collagenase in serous tumors of the ovary. Am J
Surg Pathol 1992 May;16(5):500-7.
Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier
C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is
partly mediated by CD44H. Cancer Res 1993 Aug 15;53(16):3830-8.
Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast
TH. An immunohistochemical evaluation of androgen and progesterone
receptors in ovarian tumors. Hum Pathol 1993 Jan;24(1):90-5.
Chang K, Pai LH, Batra JK, Pastan I, Willingham MC.
Characterization of the antigen (CAK1) recognized by monoclonal
antibody K1 present on ovarian cancers and normal mesothelium.
Cancer Res 1992 Jan 1;52(1):181-6.
Chang K, Pastan I, Willingham MC. Isolation and characterization of a
monoclonal antibody, K1, reactive with ovarian cancers and normal
mesothelium. Int J Cancer 1992 Feb 1;50(3):373-81.
Chen G, Zeller WJ. Multiple effects of 3-aminobenzamide on DNA
damage induced by cisplatin (DDP) in DDP-sensitive and -resistant rat
ovarian tumor cell lines. Cancer Lett 1992 Oct 30;67(1):27-33.
Chen JT, Hasumi K, Masubuchi K. Interferon-alpha, interferon-gamma
and sizofiran in the adjuvant therapy in ovarian cancer--a preliminary
trial. Biotherapy 1992;5(4):275-80.
Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton
TC, Tsichlis PN, Testa JR. AKT2, a putative oncogene encoding a
member of a subfamily of protein-serine/threonine kinases, is amplified
in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992 Oct
1;89(19):9267-71.
Chien CH, Chow SN. Point mutation of the ras oncogene in human
ovarian cancer. DNA Cell Biol 1993 Sep;12(7):623-7.
Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell
SB. In vitro modulation of cisplatin accumulation in human ovarian
carcinoma cells by pharmacologic alteration of microtubules. J Clin
Invest 1993 Jul;92(1):431-40.
Cimoli G, Valenti M, Venturini M, Conte P, Russo P. Augmentation of
antineoplastic effects by the combination of recombinant human tumor
necrosis factor and mitoxantrone on primary culture of human ovarian
cancer cells. Anticancer Res 1992 Sep-Oct;12(5):1411-4.
Colombo N, Peccatori F, Paganin C, Bini S, Brandely M, Mangioni C,
Mantovani A, Allavena P. Anti-tumor and immunomodulatory activity
of intraperitoneal IFN-gamma in ovarian carcinoma patients with
minimal residual tumor after chemotherapy. Int J Cancer 1992 Apr
22;51(1):42-6.
Crown J, Wassherheit C, Hakes T, Fennelly D, Reich L, Moore M,
Schneider J, Curtin J, Rubin SC, Reichman B, Moore M, Yao TJ,
Gilewski T, Gulati S, Markman M, Norton L. Rapid delivery of
multiple high-dose chemotherapy courses with granulocyte
colony-stimulating factor and peripheral blood-derived hematopoietic
progenitor cells. J Natl Cancer Inst 1992;84(24):1935-6.
Cuijpers VM, Boerman OC, Salet van de Pol MR, Vooijs GP, Poels
LG, Ramaekers FC. Immunocytochemical detection of ovarian
carcinoma cells in serous effusions. Acta Cytol 1993
May-Jun;37(3):272-9.
Daoud SS, Sakata MK. In vitro interaction of liposomal valinomycin
and platinum analogs: cytotoxic and cytokinetic effects. Anticancer
Drugs 1993 Aug;4(4):479-86.
de Gramont A, Demuynck B, Louvet C, Gonzalez-Canali G, Varette C,
Pigne A, Marpeau L, Herbulot P, Lagadec B, Cady J, et al. Survival
with intraperitoneal cisplatin in advanced ovarian cancer after
second-look laparotomy. Am J Clin Oncol 1992 Feb;15(1):7-11.
de Gramont A, Demuynck B, Varette C, Louvet C, Pigne A, Marpeau
L, Lagadec B, Cady J, Couturier JY, Delfau S, et al. Sequential
cisplatin-doxorubicin, early debulking surgery and intraperitoneal
chemotherapy in advanced ovarian cancer. Groupe d'Etude et de
Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J
Cancer 1992;28(1):53-8.
Deisseroth AB, Kavanagh JJ, Hanania EG, Fu S, Kornblau SM, Estey
E, Talpaz M, Kantarjian HM, Claxton DF, Reading CL, Dixon DA,
Anderson RW, Lopez-Berestein G, Holmes FA, Logothetis CJ,
Andreeff M, Benedict W. Gene therapy: Chemoprotection,
immunoenhancement, and modification of tumor cells. Cancer Bull
1993;45(2):139-45.
DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas
G, Dachowski L, Cole JW, Steinberg SM, Glatstein E. Phase I study of
debulking surgery and photodynamic therapy for disseminated
intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993 Feb
15;25(3):445-57.
Dempke WC, Shellard SA, Hosking LK, Fichtinger-Schepman AM,
Hill BT. Mechanisms associated with the expression of cisplatin
resistance in a human ovarian tumor cell line following exposure to
fractionated X-irradiation in vitro. Carcinogenesis 1992
Jul;13(7):1209-15.
Dempke WC, Whelan RD, Hill BT. Expression of resistance to
etoposide and vincristine in vitro and in vivo after X-irradiation of
ovarian tumor cells. Anticancer Drugs 1992 Aug;3(4):395-9.
Devine PL, McGuckin MA, Ramm LE, Ward BG, Pee D, Long S.
Serum mucin antigens CASA and MSA in tumors of the breast, ovary,
lung, pancreas, bladder, colon, and prostate. A blind trial with 420
patients. Cancer 1993 Sep 15;72(6):2007-15.
Devine PL, McGuckin MA, Ward BG. Circulating mucins as tumor
markers in ovarian cancer (review). Anticancer Res 1992
May-Jun;12(3):709-17.
Di Re F, Bohm S, Oriana S, Spatti GB, Pirovano C, Tedeschi M,
Zunino F. High-dose cisplatin and cyclophosphamide with glutathione
in the treatment of advanced ovarian cancer. Ann Oncol 1993
Jan;4(1):55-61.
Dittrich C, Sevelda P, Baur M, Marth C, Hudec M, Vavra N, Grunt T,
Fazeny B, Salzer H. In vitro and in vivo evaluation of the combination
of cisplatin and its analogue carboplatin for platinum dose
intensification in ovarian carcinoma. Cancer 1993 May
15;71(10):3082-90.
Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard
RC. Overexpression of the p53 protein and allele loss at 17p13 in
ovarian carcinoma. Br J Cancer 1992 Jan;65(1):40-4.
Elg SA, Carson LF, Fowler JM, Twiggs LB, Moradi MM,
Ramakrishnan S. Ascites levels of haptoglobin in patients with ovarian
cancer. Cancer 1993 Jun 15;71(12):3938-41.
Elsasser-Beile U, von Kleist S, Sauther W, Gallati H, Monting JS.
Impaired cytokine production in whole blood cell cultures of patients
with gynaecological carcinomas in different clinical stages. Br J Cancer
1993 Jul;68(1):32-6.
Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F,
Schulz KD. Intracellular actions of gonadotropic and peptide hormones
and the therapeutic value of GnRH-agonists in ovarian cancer. Acta
Obstet Gynecol Scand Suppl 1992;155:31-8.
Erba E, Sen S, Lorico A, D'Incalci M. Potentiation of etoposide
cytotoxicity against a human ovarian cancer cell line by pretreatment
with non-toxic concentrations of methotrexate or aphidicolin. Eur J
Cancer 1992;28(1):66-71.
Fady C, Gardner AM, Gera JF, Lichtenstein A. Interferon-induced
increase in sensitivity of ovarian cancer targets to lysis by
lymphokine-activated killer cells: selective effects on
HER2/neu-overexpressing cells. Cancer Res 1992 Feb 15;52(4):764-9.
Ferrandina G, Scambia G, Benedetti Panici P, Bonanno G, De
Vincenzo R, Rumi C, Bussa S, Genuardi M, Spica Romano V,
Mancuso S. Effects of dexamethasone on the growth and epidermal
growth factor receptor expression of the OVCA 433 ovarian cancer
cells. Mol Cell Endocrinol 1992 Feb;83(2-3):183-93.
Ferrandina G, Scambia G, Benedetti Panici P, Ranelletti FO, De
Vincenzo R, Piantelli M, Distefano M, Capelli A, Mancuso S. Type II
estrogen-binding sites in human ovarian cancer: correlation with
estrogen, progesterone, and epidermal growth factor receptor. Gynecol
Oncol 1993 Apr;49(1):67-72.
Fisken J, Roulston JE, Sturgeon C, Badley RA, Jonrup I, Aspinall L,
Leonard RC. The value of the human milk fat globule membrane
antigen HMFG2 in epithelial ovarian cancer monitoring: comparison
with CA125. Br J Cancer 1993 May;67(5):1065-70.
Flynn MK, Johnston W, Bigner S. Carcinoma of ovarian and other
origins in effusions. Immunocytochemical study with a panel of
monoclonal antibodies. Acta Cytol 1993 Jul-Aug;37(4):439-47.
Francis P, Markman M, Hakes T, Reichman B, Rubin S, Jones W,
Lewis JL Jr, Curtin J, Barakat R, Phillips M, et al.
Diethyldithiocarbamate chemoprotection of carboplatin--induced
hematological toxicity. J Cancer Res Clin Oncol 1993;119(6):360-2.
Freedman RS, Ioannides CG, Mathioudakis G, Platsoucas CD. Novel
immunologic strategies in ovarian carcinoma. Am J Obstet Gynecol
1992 Nov;167(5):1470-8.
Funato T, Yoshida E, Jiao L, Tone T, Kashani-Sabet M, Scanlon KJ.
The utility of an anti-fos ribozyme in reversing cisplatin resistance in
human carcinomas. Adv Enzyme Regul 1992;32:195-209.
Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol
stimulates cell growth and secretion of procathepsin D and a
120-kilodalton protein in the human ovarian cancer cell line BG-1. J
Clin Endocrinol Metab 1992 Dec;75(6):1497-502.
Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr, Old LJ, Rettig WJ.
Trophoblast and ovarian cancer antigen LK26. Sensitivity and
specificity in immunopathology and molecular identification as a
folate-binding protein. Am J Pathol 1993 Feb;142(2):557-67.
Garzetti GG, Cignitti M, Ciavattini A, Fabris N, Romanini C. Natural
killer cell activity and progression-free survival in ovarian cancer.
Gynecol Obstet Invest 1993;35(2):118-20.
Garzetti GG, Possati L, Ciavattini A, Recanatini E, Cignitti M,
Valensise H, Romanini C. Immuno-biologic integration for therapeutic
approach in ovarian carcinoma. Eur J Gynaecol Oncol
1992;13(6):514-21.
Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH,
Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive
thrombocytosis in patients with epithelial ovarian cancer. Br J
Haematol 1993 Mar;83(3):433-41.
Gatanaga M, Grosen EA, Burger RA, Granger GA, Gatanaga T.
Release of soluble TNF/LT receptors from a human ovarian tumor cell
line (PA-1) by stimulation with cytokines in vitro. Lymphokine
Cytokine Res 1993 Aug;12(4):249-53.
Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC,
Anderson ME. High resistance to cisplatin in human ovarian cancer cell
lines is associated with marked increase of glutathione synthesis. Proc
Natl Acad Sci U S A 1992 Apr 1;89(7):3070-4.
Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC.
Growth regulation of ovarian cancer. Hematol Oncol Clin North Am
1992 Aug;6(4):829-41.
Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer
development. Cancer 1993 Jan 15;71(2 Suppl):530-6.
Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA,
Hamilton TC. Spontaneous transformation of rat ovarian surface
epithelial cells: association with cytogenetic changes and implications of
repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst
1992 Apr 15;84(8):592-601. Comment in: J Natl Cancer Inst 1992 Apr
15;84(8):556-8.
Goldberg BB, Liu JB, Merton DA, Feld RI, Miller LS, Cohn HE,
Barbot D, Gillum DR, Vernick JJ, Winkel CA. Sonographically guided
laparoscopy and mediastinoscopy using miniature catheter-based
transducers. J Ultrasound Med 1993 Jan;12(1):49-54.
Gordon JD, Polan ML. The use of GnRH agonists in breast and
gynecologic cancers. Semin Reprod Endocrinol 1993;11(2):187-94.
Gorn AH, Lin HY, Yamin M, Auron PE, Flannery MR, Tapp DR,
Manning CA, Lodish HF, Krane SM, Goldring SR. Cloning,
characterization, and expression of a human calcitonin receptor from an
ovarian carcinoma cell line. J Clin Invest 1992 Nov;90(5):1726-35.
Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS,
Martinez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of
patients with ovarian and other intra-abdominal cancers. Cytokine 1992
Sep;4(5):385-90.
Green JA, Robertson LJ, Clark AH. Glutathione S-transferase
expression in benign and malignant ovarian tumours. Br J Cancer 1993
Aug;68(2):235-9.
Grosen EA, Granger GA, Gatanaga M, Ininns EK, Hwang C, DiSaia P,
Berman M, Manetta A, Emma D, Gatanaga T. Measurement of the
soluble membrane receptors for tumor necrosis factor and lymphotoxin
in the sera of patients with gynecologic malignancy. Gynecol Oncol
1993 Jul;50(1):68-77.
Grunt TW, Oeller H, Somay C, Dittrich E, Fazeny B, Mannhalter C,
Dittrich C. Modulation of the immunophenotype of ovarian cancer cells
by N,N-dimethylformamide and transforming growth factor-beta 1. J
Cell Physiol 1993 Aug;156(2):358-66.
Grunt TW, Somay C, Ellinger A, Pavelka M, Dittrich E, Dittrich C.
The differential effects of N,N-dimethylformamide and transforming
growth factor-beta 1 on a human ovarian cancer cell line (HOC-7). J
Cell Physiol 1992 Apr;151(1):13-22.
Grunt TW, Somay C, Oeller H, Dittrich E, Dittrich C. Comparative
analysis of the effects of dimethyl sulfoxide and retinoic acid on the
antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci
1992 Oct;103(Pt 2):501-9.
Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH,
Poirier MC. Relationship between patient response in ovarian and
breast cancer and platinum drug-DNA adduct formation. Cancer
Epidemiol Biomarkers Prev 1993 May-Jun;2(3):229-34.
Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ, Ozols RF,
Hamilton TC. Cross-resistance to diverse drugs is associated with
primary cisplatin resistance in ovarian cancer cell lines. Cancer Res
1993 Nov 1;53(21):5225-32.
Harant H, Korschineck I, Krupitza G, Fazeny B, Dittrich C, Grunt TW.
Retinoic acid receptors in retinoid responsive ovarian cancer cell lines
detected by polymerase chain reaction following reverse transcription.
Br J Cancer 1993;68(3):530-6.
Harlozinska A, Bar JK, Cislo M, Richter R, Rabczynski J. Density
distribution and immunological reactivity of tumor cells from peritoneal
effusions of patients with ovarian neoplasms. Anal Cell Pathol 1992
Jan;4(1):1-12.
Harlozinska A, Bar JK, Jothy S, Sedlaczek P, Slesak B, Richter R.
Carcinoembryonic antigen isotypes in tissue sections and loose cyst
fluid cells of ovarian neoplasms. Tumour Biol 1993;14(1):1-8.
Harlozinska A, Bar JK, Richter R, Cislo M. Comparison of cellular
phenotypes in tumor cyst and ascitic fluid from ovarian serous
carcinoma. Acta Cytol 1992 Nov-Dec;36(6):869-74.
Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y.
Titanocendichloride activity in cisplatin and doxorubicin-resistant
human ovarian carcinoma cell lines. Eur J Cancer 1993;29A(7):1000-2.
Hawkins MJ. New anticancer agents: taxol, camptothecin analogs, and
anthrapyrazoles Oncology (Huntingt) 1992 Dec;6(12):17-23;
discussion 27-30. Published erratum appears in Oncology (Huntingt)
1993 Mar;7(3):105.
Hayward IP, Hurst T, Parsons PG, Khoo SK. Combination
chemotherapy tested in a short-term thymidine incorporation assay in
primary cultures of ovarian adenocarcinomas. Int J Cell Cloning 1992
May;10(3):182-9.
Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M,
Grant P, Day AJ, Rome R, Campbell JJ. Elevated serum inhibin
concentrations in postmenopausal women with ovarian tumors. N Engl
J Med 1993 Nov 18;329(21):1539-42.
Helle M, Helin H, Ashorn P, Putkinen EL, Krohn K, Wahlstrom T. The
expression of CEA, CA 19-9 and HMFG antigens in ovarian clear-cell
and endometrioid carcinomas. Pathol Res Pract 1992
Feb;188(1-2):74-7.
Helm CW, Shrestha K, Thomas S, Shingleton HM, Miller DM. A
unique c-myc-targeted triplex-forming oligonucleotide inhibits the
growth of ovarian and cervical carcinomas in vitro. Gynecol Oncol
1993 Jun;49(3):339-43.
Hengstler JG, Fuchs J, Oesch F. DNA strand breaks and DNA
cross-links in peripheral mononuclear blood cells of ovarian cancer
patients during chemotherapy with cyclophosphamide/carboplatin.
Cancer Res 1992 Oct 15;52(20):5622-6.
Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg
K. Expression and prognostic significance of platelet-derived growth
factor and its receptors in epithelial ovarian neoplasms. Cancer Res
1993 Oct 1;53(19):4550-4.
Henzen-Logmans SC, van der Burg ME, Foekens JA, Berns PM,
Brussee R, Fieret JH, Klijn JG, Chadha S, Rodenburg CJ. Occurrence
of epidermal growth factor receptors in benign and malignant ovarian
tumors and normal ovarian tissues: an immunohistochemical study. J
Cancer Res Clin Oncol 1992;118(4):303-7.
Hereiz HA, Bayoumi FA. Evaluation of diagnosis of ovarian
malignancy using immunohistochemical technique. J Egypt Public
Health Assoc 1992;67(5-6):697-707.
Hightower RD, Sevin BU, Perras J, Nguyen H, Angioli R, Untch M,
Averette H. In vitro evaluation of the novel chemotherapeutic agents
U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Cancer Invest 1993;11(3):276-82.
Hightower RD, Sevin BU, Perras JP, Untch M, Angioli R, Ramos R,
Averette H. Comparison of U-73,975 and cisplatin cytotoxicity in fresh
cervical and ovarian carcinoma specimens with the
ATP-chemosensitivity assay. Gynecol Oncol 1992 Nov;47(2):186-90.
Hill BT, Shellard SA, Hosking LK, Dempke WC, Fichtinger-Schepman
AM, Tone T, Scanlon KJ, Whelan RD. Characterization of a
cisplatin-resistant human ovarian carcinoma cell line expressing
cross-resistance to 5-fluorouracil but collateral sensitivity to
methotrexate. Cancer Res 1992 Jun 1;52(11):3110-8.
Hirata J, Kikuchi Y, Kita T, Imaizumi E, Tode T, Ishii K, Kudoh K,
Nagata I. Modulation of sensitivity of human ovarian cancer cells to
cis-diamminedichloroplatinum(II) by
12-O-tetradecanoylphorbol-13-acetate and
D,L-buthionine-S,R-sulphoximine. Int J Cancer 1993 Sep
30;55(3):521-7.
Hirte HW, Clark DA, Mazurka J, O'Connell G, Rusthoven J. A rapid
and simple method for the purification of tumor cells from ascitic fluid
of ovarian carcinoma. Gynecol Oncol 1992 Mar;44(3):223-6.
Hirte HW, Clark DA, O'Connell G, Rusthoven J, Mazurka J. Reversal
of suppression of lymphokine-activated killer cells by transforming
growth factor-beta in ovarian carcinoma ascitic fluid requires
interleukin-2 combined with anti-CD3 antibody. Cell Immunol 1992
Jun;142(1):207-16.
Hoffman AG, Burghardt RC, Tilley R, Auersperg N. An in vitro model
of ovarian epithelial carcinogenesis: changes in cell-cell communication
and adhesion occurring during neoplastic progression. Int J Cancer
1993 Jul 9;54(5):828-38.
Hogdall CK, Christensen L, Clemmensen I. The prognostic value of
tetranectin immunoreactivity and plasma tetranectin in patients with
ovarian cancer. Cancer 1993 Oct 15;72(8):2415-22.
Hornby AE, Pan J, Auersperg N. Intermediate filaments in rat ovarian
surface epithelial cells:changes with neoplastic progression in culture.
Biochem Cell Biol 1992 Jan;70(1):16-25.
Hovestadt A, van der Burg ME, Verbiest HB, van Putten WL, Vecht
CJ. The course of neuropathy after cessation of cisplatin treatment,
combined with Org 2766 or placebo. J Neurol 1992 Mar;239(3):143-6.
Hruza C, Dobianer K, Beck A, Czerwenka K, Hanak H, Klein M,
Leodolter S, Medl M, Mullauer-Ertl S, Preiser J, et al. HER-2 and
INT-2 amplification estimated by quantitative PCR in
paraffin-embedded ovarian cancer tissue samples. Eur J Cancer
1993;29A(11):1593-7.
Hsieh-Ma ST, Eaton AM, Shi T, Ring DB. In vitro cytotoxic targeting
by human mononuclear cells and bispecific antibody 2B1, recognizing
c-erbB-2 protooncogene product and Fc gamma receptor III. Cancer
Res 1992 Dec 15;52(24):6832-9.
Huettner PC, Carney WP, Naber SP, DeLellis RA, Membrino W,
Wolfe HJ. Neu oncogene expression in ovarian tumors: a quantitative
study. Mod Pathol 1992 May;5(3):250-6.
Huettner PC, Weinberg DS, Lage JM. Assessment of proliferative
activity in ovarian neoplasms by flow and static cytometry. Correlation
with prognostic features. Am J Pathol 1992 Sep;141(3):699-706.
Hughes PM, Zammit-Maempel I, Murphy D. Computed tomographic
assessment of intraperitoneal fluid distribution prior to intraperitoneal
chemotherapy for ovarian cancer. Br J Radiol 1992;65(772):295-7.
Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR.
Aberrant expression of the c-erbB-2/neu protooncogene in ovarian
cancer. Cancer Lett 1992 Jan 10;61(2):95-103.
Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R,
Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human
lymphocytes redirected with a chimeric gene composed of an antibody
variable region and the Fc receptor gamma chain. J Exp Med 1993 Jul
1;178(1):361-6.
Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in
vivo reversal of multidrug resistance by GF120918, an
acridonecarboxamide derivative. Cancer Res 1993 Oct
1;53(19):4595-602.
Ikarashi H, Aoki Y, Fujita K, Kodama S, Tanaka K. Solid-phase
anti-CD3 antibody activation and cryopreservation of human
tumor-infiltrating lymphocytes derived from epithelial ovarian cancer.
Jpn J Cancer Res 1992 Dec;83(12):1359-65.
Imaishi K. Intraperitoneal transplantation of ascitic cancer cells from a
7,12-dimethylbenz[a]anthracene (DMBA)-induced ovarian cancer.
Kurume Med J 1992;39(3):195-201.
Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA.
Cytotoxic T cells isolated from ovarian malignant ascites recognize a
peptide derived from the HER-2/neu proto-oncogene. Cell Immunol
1993 Oct 1;151(1):225-34.
Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ.
Cytotoxic T cells from ovarian malignant tumors can recognize
polymorphic epithelial mucin core peptides. J Immunol 1993 Oct
1;151(7):3693-703.
Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor Wharton J,
Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour
infiltrating lymphocytes recognize common determinants on
non-ovarian tumour clones. Scand J Immunol 1993 Apr;37(4):413-24.
Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB,
Freedman RS. Induction of interleukin-2 receptor by tumor necrosis
factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer
Immunol Immunother 1992;35(2):83-91.
Ishii K, Kikuchi Y, Hirata J, Tode T, Kita T, Nagata I, Tsuru S,
Rokutanda M. Antitumor effect of PSK in nude mice with human
ovarian carcinoma cells and its combined effect with
cis-diammine-dichloroplatinum (II). Cancer J 1993;6(2):87-90.
Ishii S, Naito M, Tsuruo T. Expression behavior of 85-kDa membrane
protein in adriamycin-resistant tumor cells and the inhibition of human
tumor growth in athymic mice by MRK-20 monoclonal antibody
against the protein. Jpn J Cancer Res 1993 Jul;84(7):776-82.
Islam MQ, Kopf I, Levan A, Granberg S, Friberg LG, Levan G.
Cytogenetic findings in 111 ovarian cancer patients: therapy-related
chromosome aberrations and heterochromatic variants. Cancer Genet
Cytogenet 1993 Jan;65(1):35-46.
Isonishi S, Jekunen AP, Hom DK, Eastman A, Edelstein PS, Thiebaut
FB, Christen RD, Howell SB. Modulation of cisplatin sensitivity and
growth rate of an ovarian carcinoma cell line by bombesin and tumor
necrosis factor-alpha. J Clin Invest 1992 Oct;90(4):1436-42.
Ito K, Sasano H, Ozawa N, Sato S, Silverberg SG, Yajima A.
Immunolocalization of epidermal growth factor receptor and c-erbB-2
oncogene product in human ovarian carcinoma. Int J Gynecol Pathol
1992 Oct;11(4):253-7.
James RD, Wilkinson PM, Belli F, Welch R, Cowan R. Recombinant
human erythropoietin in patients with ovarian carcinoma and anaemia
secondary to cisplatin and carboplatin chemotherapy: preliminary
results. Acta Haematol 1992;87 Suppl 1:12-5.
Jekunen A, Vick J, Sanga R, Chan TC, Howell SB. Synergism between
dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.
Cancer Res 1992 Jul 1;52(13):3566-71.
Johnson SW, Ozols RF, Hamilton TC. Mechanisms of drug resistance
in ovarian cancer. Cancer 1993 Jan 15;71(2 Suppl):644-9.
Jones M, Siracky J, Kelland LR, Harrap KR. Acquisition of platinum
drug resistance and platinum cross resistance patterns in a panel of
human ovarian carcinoma xenografts. Br J Cancer 1993 Jan;67(1):24-9.
Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC Jr, Kinney RB,
Berchuck A. Determination of proliferation index in advanced ovarian
cancer using quantitative image analysis. Am J Clin Pathol 1993
Jun;99(6):736-40.
Jozan S, Guerrin M, Mazars P, Dutaur M, Monsarrat B, Cheutin F,
Bugat R, Martel P, Valette A. Transforming growth factor beta 1
(TGF-beta 1) inhibits growth of a human ovarian carcinoma cell line
(OVCCR1) and is expressed in human ovarian tumors. Int J Cancer
1992 Nov 11;52(5):766-70.
Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. NEU
protein overexpression in benign, borderline, and malignant ovarian
neoplasms. Gynecol Oncol 1992 Mar;44(3):245-53.
Kamada M, Mori T, Sakamoto Y, Daitoh T, Furumoto H, Irahara M,
Aono T, Mori T. Heterophile antigens in serous cystadenocarcinoma of
the human ovary. Asia Oceania J Obstet Gynaecol 1992
Dec;18(4):387-95.
Karlan BY, Chamorro T, Fowler JM, Muderspach LI, Greenberg S,
Lagasse LD. Concurrent interstitial radiotherapy and infusional
chemotherapy for recurrent gynecologic malignancies. Int J Gynecol
Cancer 1993;3(5):304-10.
Kavanagh JJ, Kudelka AP. Systemic therapy for gynecologic cancer.
Curr Opin Oncol 1993 Sep;5(5):891-9.
Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M,
Murrer BA, Harrap KR. Preclinical antitumor evaluation of
bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally
active platinum drug. Cancer Res 1993 Jun 1;53(11):2581-6.
Kelland LR, Jones M, Abel G, Valenti M, Gwynne J, Harrap KR.
Human ovarian-carcinoma cell lines and companion xenografts: a
disease-oriented approach to new platinum anticancer drug discovery.
Cancer Chemother Pharmacol 1992;30(1):43-50.
Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA,
Harrap KR. Mechanism-related circumvention of acquired
cis-diamminedichloroplatinum(II) resistance using two pairs of human
ovarian carcinoma cell lines by ammine/amine platinum(IV)
dicarboxylates. Cancer Res 1992 Jul 15;52(14):3857-64.
Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap
KR. Ammine/amine platinum(IV) dicarboxylates: a novel class of
platinum complex exhibiting selective cytotoxicity to intrinsically
cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992
Feb 15;52(4):822-8.
Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler
MF, Bast RC Jr, Iglehart JD, Marks JR. p53 overexpression in
formalin-fixed, paraffin-embedded tissue detected by
immunohistochemistry. J Histochem Cytochem 1992
Jul;40(7):1047-51.
Kido Y, Khokhar AR, Siddik ZH. Differential cytotoxicity, uptake and
DNA binding of tetraplatin and analogous isomers in sensitive and
resistant cancer cell lines. Anticancer Drugs 1993 Apr;4(2):251-8.
Kieback DG, McCamant SK, Press MF, Atkinson EN, Gallager HS,
Edwards CL, Hajek RA, Jones LA. Improved prediction of survival in
advanced adenocarcinoma of the ovary by immunocytochemical
analysis and the composition adjusted receptor level of the estrogen
receptor. Cancer Res 1993 Nov 1;53(21):5188-92.
Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor
DNA ploidy and prognosis of patients with serous cystadenocarcinoma
of the ovary. Cancer 1993 Aug 1;72(3):804-8.
Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S.
High incidence of p53 gene mutation in human ovarian cancer and its
association with nuclear accumulation of p53 protein and tumor DNA
aneuploidy. Jpn J Cancer Res 1992 Sep;83(9):978-84.
Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi
K, Mizuno K, Kawai M, Suganuma N, Tomoda Y. Potentiating effect
of amphotericin B on five platinum anticancer drugs in human
cis-diamminedichloroplatinum (II) sensitive and resistant ovarian
carcinoma cells. Anticancer Res 1993 Jul-Aug;13(4):891-6.
Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T, Nagata I.
Enhancement of antiproliferative effect of
cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in
human ovarian cancer cells. Gynecol Oncol 1993 Jun;49(3):365-72.
Kikuchi Y, Kita T, Miyauchi M, Hirata J, Sasa H, Nagata I, Fukushima
M. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude
mice bearing human ovarian cancer cells. J Cancer Res Clin Oncol
1992;118(6):453-7.
Kimura E, Enns RE, Alcaraz JE, Arboleda J, Slamon DJ, Howell SB.
Correlation of the survival of ovarian cancer patients with mRNA
expression of the 60-kD heat-shock protein HSP-60. J Clin Oncol 1993
May;11(5):891-8.
Kimura E, Enns RE, Thiebaut F, Howell SB. Regulation of HSP60
mRNA expression in a human ovarian carcinoma cell line. Cancer
Chemother Pharmacol 1993;32(4):279-85.
Kimura E, Howell SB. Analysis of the cytotoxic interaction between
cisplatin and hyperthermia in a human ovarian carcinoma cell line.
Cancer Chemother Pharmacol 1993;32(6):419-24.
King BL, Carter D, Foellmer HG, Kacinski BM. Neu proto-oncogene
amplification and expression in ovarian adenocarcinoma cell lines. Am J
Pathol 1992 Jan;140(1):23-31.
Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T.
Increased cell-surface urokinase in advanced ovarian cancer. Jpn J
Cancer Res 1993 Jun;84(6):633-40.
Kobayashi H, Ohi H, Fujii T, Terao T. Characterisation and clinical
usefulness of CA130 antigen recognised by monoclonal antibodies,
130-22 and 145-9, in ovarian cancers. Br J Cancer 1993
Feb;67(2):237-43.
Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T.
Inhibition of in vitro ovarian cancer cell invasion by modulation of
urokinase-type plasminogen activator and cathepsin B. Cancer Res
1992 Jul 1;52(13):3610-4.
Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao T.
Characterization and clinical evaluation of tumor-associated antigen
CA54/61 identified by monoclonal antibodies MA54 and MA61 in
epithelial ovarian cancer. Gynecol Oncol 1992 Dec;47(3):328-36.
Kobayashi H, Ohi H, Sugimura M, Shinohara H, Terao T. Monoclonal
antibodies MA54 and MA61 as potential reagents in the prognosis of
patients with ovarian cancer. Gynecol Oncol 1993 Apr;49(1):80-5.
Kobayashi H, Sakahara H, Saga T, Hosono M, Shirato M, Kanda H,
Ishibashi K, Watanabe T, Endo K, Ishiwata I, et al. A human/mouse
chimeric monoclonal antibody against CA125 for radioimmunoimaging
of ovarian cancer. Cancer Immunol Immunother 1993
Aug;37(3):143-9.
Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an
independent predictor of poor prognosis in patients with epithelial
ovarian cancer. J Clin Oncol 1992 Jan;10(1):95-101.
Kobayashi H, Terao T, Kawashima Y. Sialyl Tn as a prognostic marker
in epithelial ovarian cancer. Br J Cancer 1992;66(5):984-5.
Kobayashi H, Tsuruchi N, Sugihara K, Kaku T, Saito T, Kamura T,
Tsukamoto N, Nakano H, Taniguchi S. Expression of alpha-smooth
muscle actin in benign or malignant ovarian tumors. Gynecol Oncol
71993 Mar;48(3):308-13.
Kohler M, Bauknecht T, Grimm M, Birmelin G, Kommoss F, Wagner
E. Epidermal growth factor receptor and transforming growth factor
alpha expression in human ovarian carcinomas. Eur J Cancer
1992;28A(8-9):1432-7.
Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC Jr, Berchuck
A. Mutation and overexpression of p53 in early-stage epithelial ovarian
cancer. Obstet Gynecol 1993 May;81(5 Pt 1):643-50.
Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM,
Clarke-Pearson DL, Soper JT, Bast RC Jr, Berchuck A. Spectrum of
mutation and frequency of allelic deletion of the p53 gene in ovarian
cancer. J Natl Cancer Inst 1993 Sep 15;85(18):1513-9.
Kohn E. Aging issues in invasion and metastasis. Fertile ground for
investigation. Cancer 1993 Jan 15;71(2 Suppl):552-7.
Kohn EC, Sandeen MA, Liotta LA. In vivo efficacy of a novel inhibitor
of selected signal transduction pathways including calcium,
arachidonate, and inositol phosphates. Cancer Res 1992 Jun
1;52(11):3208-12.
Kommoss F, Bauknecht T, Birmelin G, Kohler M, Tesch H, Pfleiderer
A. Oncogene and growth factor expression in ovarian cancer. Acta
Obstet Gynecol Scand Suppl 1992;155:19-24.
Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer
A. Steroid receptors in ovarian carcinoma: immunohistochemical
determination may lead to new aspects. Gynecol Oncol 1992
Dec;47(3):317-22.
Kotylo PK, Michael H, Fineberg N, Sutton G, Roth LM. Flow
cytometric analysis of DNA content and RAS P21 oncoprotein
expression in ovarian neoplasms. Int J Gynecol Pathol 1992;11(1):30-7.
Krag DN, Haseman MK, Ford P, Smith L, Taylor MH, Schneider P,
Goodnight JE. Gamma probe location of 111indium-labeled B72.3: an
extension of immunoscintigraphy. J Surg Oncol 1992
Dec;51(4):226-30.
Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM,
Bell DA, Yandell DW. p53 gene mutations and protein accumulation in
human ovarian cancer. Proc Natl Acad Sci U S A 1993 Jun
1;90(11):4961-5.
Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the
anti-p53 antibody response in cancer patients. Cancer Res 1993 Aug
1;53(15):3468-71.
Lage JM, Weinberg DS, Huettner PC, Mark SD. Flow cytometric
analysis of nuclear DNA content in ovarian tumors. Association of
ploidy with tumor type, histologic grade, and clinical stage. Cancer
1992 Jun 1;69(11):2668-75.
Lai CH, Hsueh S, Lin CY, Huang MY, You GB, Chang HC, Pao CC.
Human papillomavirus in benign and malignant ovarian and endometrial
tissues. Int J Gynecol Pathol 1992 Jul;11(3):210-5.
Langdon SP, Ritchie A, Young K, Crew AJ, Sweeting V, Bramley T,
Hillier S, Hawkins RA, Tesdale AL, Smyth JF, et al. Contrasting effects
of 17 beta-estradiol on the growth of human ovarian carcinoma cells in
vitro and in vivo. Int J Cancer 1993 Sep 30;55(3):459-64.
Lee CY, Chen KW, Sheu FS, Tsang A, Chao KC, Ng HT. Studies of a
tumor-associated antigen, COX-1, recognized by a monoclonal
antibody. Cancer Immunol Immunother 1992;35(1):19-26.
Lee KS, Kim HK, Moon HS, Hong YS, Kang JH, Kim DJ, Park JG.
Effects of buthionine sulfoximine treatment on cellular glutathione
levels and cytotoxicities of cisplatin, carboplatin and radiation in human
stomach and ovarian cancer cell lines. Korean J Intern Med 1992
Jul;7(2):111-7.
Lee SM, Harris M, Rennison J, McGown A, Bromley M, Elder RH,
Rafferty JA, Crowther D, Margison GP. Expression of
O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's
tumours. Eur J Cancer 1993;29A(9):1306-12.
Leu JG, Jech KS, Wheeler NC, Chen BX, ERlanger BF. Immunoassay
of taxol and taxol-like compounds in plant extracts. Life Sci
1993;53(12):PL183-7.
Leung BS, Stout LE, Shaskan EG, Thompson RM. Differential
induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma
in human gynecologic cancer cells. Cancer Lett 1992 Sep
14;66(1):77-81.
Levin L. Dose intensity in the treatment of ovarian carcinoma. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 251-60.
Lewis AD, Duran GE, Lau DH, Sikic BI. Sensitization of drug resistant
human ovarian cancer cells to cyanomorpholino doxorubicin
(MRA-CN) by modulation of glutathione metabolism. Int J Radiat
Oncol Biol Phys 1992;22(4):821-4.
Li BY, Mohanraj D, Olson MC, Moradi M, Twiggs L, Carson LF,
Ramakrishnan S. Human ovarian epithelial cancer cells cultures in vitro
express both interleukin 1 alpha and beta genes. Cancer Res 1992 Apr
15;52(8):2248-52.
Li S, Han H, Resnik E, Carcangiu ML, Schwartz PE, Yang-Feng TL.
Advanced ovarian carcinoma: molecular evidence of unifocal origin.
Gynecol Oncol 1993 Oct;51(1):21-5.
Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC Jr.
Alkylating agents and immunotoxins exert synergistic cytotoxic activity
against ovarian cancer cells. Mechanism of action. J Clin Invest 1993
Nov;92(5):2440-7.
Lidor YJ, Xu FJ, Martinez-Maza O, Olt GJ, Marks JR, Berchuck A,
Ramakrishnan S, Berek JS, Bast RC Jr. Constitutive production of
macrophage colony-stimulating factor and interleukin-6 by human
ovarian surface epithelial cells. Exp Cell Res 1993 Aug;207(2):332-9.
Locatelli MC, D'Antona A, Labianca R, Vinci M, Tedeschi M,
Carcione R, Corbo A, Venturino P, Luporini G. A phase II study of
combination chemotherapy in advanced ovarian carcinoma with
cisplatin and cyclophosphamide plus reduced glutathione as potential
protective agent against cisplatin toxicity. Tumori 1993 Feb
28;79(1):37-9.
Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR. Reduced drug
accumulation as a major mechanism of acquired resistance to cisplatin
in a human ovarian carcinoma cell line: circumvention studies using
novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer
1992 Dec;66(6):1109-15.
Look KY, Sutton GP, Natsumeda Y, Eble JN, Stehman FB, Ehrlich
CE, Olah E, Prajda N, Bosze P, Eckhardt S, et al. Inhibition by
tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in
extracts of ovarian carcinomas. Gynecol Oncol 1992 Oct;47(1):66-70.
Louie KG, Hamilton TC, Shoemaker RH, Young RC, Ozols RF.
Evaluation of in vitro drug screening leads using experimental models
of human ovarian cancer. Invest New Drugs 1992 Jul;10(2):73-8.
Lucci JA 3d, Manetta A, Cappuccini F, Ininns EK, Dett CA, DiSaia P,
Yamamoto RS, Berman ML, Soopikian J, Granger GA.
Immunotherapy of ovarian cancer. II. In vitro generation and
characterization of lymphokine-activated killer T cells from the
peripheral blood of recurrent ovarian cancer patients. Gynecol Oncol
1992 May;45(2):129-35.
Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch
S, Halsey J, Sikic BI. Clinical trials of modulation of multidrug
resistance: Pharmacokinetic and pharmacodynamic considerations.
Cancer 1993;72(11 Suppl):3502-14.
Luqmani YA, Ryall G, Shousha S, Coombes RC. An
immunohistochemical survey of pS2 expression in human epithelial
cancers. Int J Cancer 1992 Jan 21;50(2):302-4.
MacLean GD, Bowen-Yacyshyn MB, Samuel J, Meikle A, Stuart G,
Nation J, Poppema S, Jerry M, Koganty R, Wong T, et al. Active
immunization of human ovarian cancer patients against a common
carcinoma (Thomsen-Friedenreich) determinant using a synthetic
carbohydrate antigen. J Immunother 1992 May;11(4):292-305.
Maeda O, Terasawa M, Ishikawa T, Oguchi H, Mizuno K, Kawai M,
Kikkawa F, Tumoda Y, Hidaka H. A newly synthesized bifunctional
inhibitor, W-77, enhances adriamycin activity against human ovarian
carcinoma cells. Cancer Res 1993 May 1;53(9):2051-6.
Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M.
Chemosensitizing effect of an antiestrogen, toremifene, on ovarian
cancer. Gynecol Oncol 1992 Sep;46(3):292-7.
Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy
in patients with colorectal, ovarian, and prostate cancer. Results with
site-specific immunoconjugates. Cancer 1993 Dec 1;72(11
Suppl):3453-62.
Maher VE, Drukman SJ, Kinders RJ, Hunter RE, Jennings J, Brigham
C, Stevens S, Griffin TW. Human antibody response to the intravenous
and intraperitoneal administration of the F(ab')2 fragment of the OC125
murine monoclonal antibody. J Immunother 1992 Jan;11(1):56-66.
Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus
40-transformed human ovarian surface epithelial cells escape normal
growth controls but retain morphogenetic responses to extracellular
matrix. Am J Obstet Gynecol 1992 Sep;167(3):729-35.
Malik ST, East N, Boraschi D, Balkwill FR. Effects of intraperitoneal
recombinant interleukin-1 beta in intraperitoneal human ovarian cancer
xenograft models: comparison with the effects of tumour necrosis
factor. Br J Cancer 1992 May;65(5):661-6.
Malmstrom H. Prevention of complications of subcutaneous peritoneal
access devices in intraperitoneal chemotherapy of ovarian carcinoma.
Eur J Gynaecol Oncol 1993;14(4):323-30.
Malmstrom H, Rasmussen S, Simonsen E. Intraperitoneal high-dose
cisplatin and etoposide with systemic thiosulfate protection in
second-line treatment of advanced ovarian cancer. Gynecol Oncol 1993
May;49(2):166-71.
Maneschi F, Geraci P, Barreca PV, Palisi F, Adragna F, Napoli M.
Estradiol, progesterone, 17-hydroxyprogesterone, androstenedione and
CA125 in patients with ovarian carcinoma. Gynecol Endocrinol 1992
Mar;6(1):25-30.
Manetta A, Emma D, Fuchtner C, Gamboa-Vujicic G, Paredes P, Lucci
J, Gatanaga T, Granger G. Effect of recombinant human tumor necrosis
factor alpha and dequalinium chloride on human ovarian cancer cell
lines in vitro. Int J Oncol 1993;3(1):127-33.
Manetta A, Emma D, Gamboa G, Liao S, Berman M, DiSaia P. Failure
to enhance the in vivo killing of human ovarian carcinoma by sequential
treatment with dequalinium chloride and tumor necrosis factor.
Gynecol Oncol 1993 Jul;50(1):38-44.
Mans DR, Schuurhuis GJ, Treskes M, Lafleur MV, Retel J, Pinedo
HM, Lankelma J. Modulation by D,L-buthionine-S,R-sulphoximine of
etoposide cytotoxicity on human non-small cell lung, ovarian and breast
carcinoma cell lines. Eur J Cancer 1992;28A(8-9):1447-52.
Markman M. Current status of intraperitoneal therapy for ovarian
cancer. Curr Opin Obstet Gynecol 1993 Feb;5(1):99-104.
Markman M. Intraperitoneal chemotherapy. In: Markman M, Hoskins
WJ, eds. Cancer of the ovary. New York: Raven Press; 1993. p.
317-25.
Markman M. Intraperitoneal therapy for treatment of malignant disease
principally confined to the peritoneal cavity. Crit Rev Oncol Hematol
1993 Feb;14(1):15-28.
Markman M, Jones W, Lewis JL Jr, Rubin S, Hakes T, Reichman B,
Barakat R, Curtin J, Almadrones L, Hoskins W. Impact of laparotomy
finding of significant intraabdominal adhesions on the surgically defined
complete response rate to subsequent salvage intraperitoneal
chemotherapy. J Cancer Res Clin Oncol 1992;118(2):163-5.
Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S,
Jones W, Lewis JL Jr, Almadrones L, Hoskins W. Salvage
intraperitoneal therapy of small-volume residual ovarian cancer: impact
of pretreatment finding of peritoneal carcinomatosis on the surgical
complete response rate. J Cancer Res Clin Oncol 1992;118(3):235-7.
Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis JL Jr,
Barakat R, Rubin S, Mychalczak B, Saigo P, et al. Intraperitoneal
chemotherapy in the management of ovarian cancer. Cancer 1993 Feb
15;71(4 Suppl):1565-70.
Marth C, Cronauer MV, Doppler W, Ofner D, Ullrich A, Daxenbichler
G. Effects of interferons on the expression of the proto-oncogene
HER-2 in human ovarian carcinoma cells. Int J Cancer 1992 Jan
2;50(1):64-8.
Marth C, Lang T, Cronauer MV, Doppler W, Zeimet AG, Bachmair F,
Ullrich A, Daxenbichler G. Epidermal growth factor reduces HER-2
protein level in human ovarian carcinoma cells. Int J Cancer 1992 Sep
9;52(2):311-6.
Marth C, Muller-Holzner E, Gaugg I, Daxenbichler G, Dapunt O.
Modulation of ovarian carcinoma OV632 antigen by interferons.
Oncology 1992;49(1):53-7.
Marth C, Zeimet AG, Bock G, Daxenbichler G. Modulation of tumour
marker CA-125 expression in cultured ovarian carcinoma cells. Eur J
Cancer 1992;28A(12):2002-6.
Martignone S, Pellegrini R, Villa E, Tandon NN, Mastroianni A,
Tagliabue E, Menard S, Colnaghi MI. Characterization of two
monoclonal antibodies directed against the 67 kDa high affinity laminin
receptor and application for the study of breast carcinoma progression.
Clin Exp Metastasis 1992 Nov;10(6):379-86.
Martin AR, Kotylo PK, Kennedy JC, Fineberg NS, Roth LM. Flow
cytometric DNA analysis of ovarian Brenner tumors and transitional
cell carcinomas. Int J Gynecol Pathol 1992 Jul;11(3):188-96.
Martinez-Maza O, Berek JS. Immunotherapy of ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 301-16.
Massuger LF, Thomas CM, Segers MF, Corstens FH, Verheijen RH,
Kenemans P, Poels LG. Specific and nonspecific immunoassays to
detect HAMA after administration of indium-111-labeled OV-TL 3
F(ab')2 monoclonal antibody to patients with ovarian cancer. J Nucl
Med 1992 Nov;33(11):1958-63.
Mazzoni A, Trave F. Cytoplasmic membrane cholesterol and
doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant
human ovarian cancer cells. Oncol Res 1993;5(2):75-82.
McClay EF, Albright KD, Jones JA, Christen RD, Howell SB.
Tamoxifen modulation of cisplatin cytotoxicity in human malignancies.
Int J Cancer 1993 Dec 2;55(6):1018-22.
McClay EF, Goel R, Andrews P, Gorelick S, Kirmani S, Kim S, Braly
P, Plaxe S, Hoff S, Alcaraz J, et al. A phase I and pharmacokinetic
study of intraperitoneal carboplatin and etoposide. Br J Cancer 1993
Oct;68(4):783-8.
McClay EF, Howell SB. Intraperitoneal therapy in the management of
patients with ovarian cancer. Hematol Oncol Clin North Am 1992
Aug;6(4):915-26.
McGuire WP. Experimental agents (nonbiological) in ovarian cancer.
In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New York:
Raven Press; 1993. p. 287-300.
McGuire WP. Ovarian cancer. Experimental chemotherapy. Hematol
Oncol Clin North Am 1992 Aug;6(4):927-40.
McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS,
Berchuck A, Boyer CM, Bast RC Jr. Serum levels of HER-2 neu
(C-erbB-2) correlate with overexpression of p185neu in human ovarian
cancer. Cancer 1993 Jun 15;71(12):3942-6.
Melioli G, Ferrari I, Casartelli G, Ragni N. Lymphocytes isolated from
the peritoneal fluid of women with advanced ovarian carcinoma differ
significantly from autologous peripheral blood lymphocytes. Gynecol
Oncol 1993 Mar;48(3):301-7.
Micelli G, Lozupone A, Quaranta M, Donadeo A, Coviello M, Lorusso
V. Determination of intraperitoneal mitoxantrone in the serum of
cancer patients using a high performance liquid chromatograph coupled
to an Advanced Automated Sample Processor (AASP). Biomed
Chromatogr 1992 Jul-Aug;6(4):168-71.
Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici C,
Mattei E, Mancuso S, Delpino A. Preliminary evaluation of HER-2/neu
oncogene and epidermal growth factor receptor expression in normal
and neoplastic human ovaries. Int J Biol Markers 1992
Apr-Jun;7(2):114-8.
Mileo AM, Fanuele M, Battaglia F, Scambia G, Benedetti-Panici C,
Mattei E, Mancuso S, Delpino A. Preliminary evaluation of HER-2/neu
oncogene and epidermal growth factor receptor expression in normal
and neoplastic human ovaries. Int J Biol Markers 1992
Jan-Mar;7(1):47-51.
Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly
KF, Parkin DE, Haites NE. p53 mutation is a common genetic event in
ovarian carcinoma. Cancer Res 1993 May 1;53(9):2128-32.
Miotti S, Alberti S, Facheris P, Mantovani L, Fornaro M, Stella M,
Menard S, Canevari S, Colnaghi MI. Membrane association and
shedding of the GPI-anchored Ca-MOv18 antigen in human ovary
carcinoma cells. Int J Cancer 1992 May 28;51(3):499-505.
Mirshahi SS, Vasse M, Soria C, Moreau JF, Taupin JL, Mirshahi M,
Pujade-Lauraine E, Bernadou A, Soria J. Incubation of monocytes with
adriamycin increases secretion of hepatocyte stimulating factor for
fibrinogen biosynthesis. Blood Coagul Fibrinolysis 1993
Feb;4(1):149-52.
Misawa T, Kikkawa F, Oguchi H, Morikawa Y, Kawai M, Maeda O,
Iwata M, Kano T, Furuhashi Y, Tomada Y. Accumulation of
cis-diamminedichloroplatinum (II) and its analogues in sensitive and
resistant human ovarian carcinoma cells. Oncology 1992;49(3):173-9.
Mistry P, Kelland LR, Loh SY, Abel G, Murrer BA, Harrap KR.
Comparison of cellular accumulation and cytotoxicity of cisplatin with
that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)
platinum(IV) (JM221) in human ovarian carcinoma cell lines. Cancer
Res 1992 Nov 15;52(22):6188-93.
Mistry P, Loh SY, Kelland LR, Harrap KR. Effect of buthionine
sulfoximine on PtII and PtIV drug accumulation and the formation of
glutathione conjugates in human ovarian-carcinoma cell lines. Int J
Cancer 1993 Nov 11;55(5):848-56.
Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI.
Contralateral ovary in unilateral ovarian carcinoma: a search for
preneoplastic lesions. Int J Gynecol Pathol 1993 Jan;12(1):59-63.
Mizutani Y, Bonavida B. Overcoming cis-diamminedichloroplatinum
(II) resistance of human ovarian tumor cells by combination treatment
with cis-diamminedichloroplatinum (II) and tumor necrosis
factor-alpha. Cancer 1993 Aug 1;72(3):809-18.
Mobus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, Pollow K,
Knapstein PG, Kreienberg R. Morphological, immunohistochemical
and biochemical characterization of 6 newly established human ovarian
carcinoma cell lines. Int J Cancer 1992 Aug 19;52(1):76-84.
Mochizuki H, Sato I, Nagoya K, Furusako S, Yamauchi T, Masuko H,
Sato H, Morishita H, Yajima M, Sasaki H, et al. An
immunoenzymometric assay for a CA125-like antigen, CA602. J Clin
Lab Anal 1992;6(2):84-90.
Mogensen O, Mogensen B. Measurement of CA 125 by an automated
microparticle enzyme immunoassay; comparison with a manual enzyme
immunoassay. Scand J Clin Lab Invest 1992 Oct;52(6):507-12.
Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC. Unifocal
origin of advanced human epithelial ovarian cancers. Cancer Res 1992
Sep 15;52(18):5119-22.
Molthoff CF, Pinedo HM, Schluper HM, Boven E. Influence of dose
and schedule on the therapeutic efficacy of 131I-labelled monoclonal
antibody 139H2 in a human ovarian cancer xenograft model. Int J
Cancer 1992 Feb 1;50(3):474-80.
Molthoff CF, Pinedo HM, Schluper HM, Nijman HW, Boven E.
Comparison of the pharmacokinetics, biodistribution and dosimetry of
monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and
F(ab')2 fragments in experimental ovarian cancer. Br J Cancer 1992
May;65(5):677-83.
Molthoff CF, Pinedo HM, Schluper HM, Rutgers DH, Boven E.
Comparison of 131I-labelled anti-episialin 139H2 with cisplatin,
cyclophosphamide or external-beam radiation for anti-tumor efficacy in
human ovarian cancer xenografts. Int J Cancer 1992 Apr
22;51(1):108-15.
Monti E, Mimnaugh EG, Sinha BK. Synergistic antiproliferative effects
of interleukin-1 alpha and doxorubicin against the human ovarian
carcinoma cell line (NIH:OVCAR-3). Biochem Pharmacol 1993 May
25;45(10):2099-107.
Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB,
Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1,
interleukin-6, and tumor necrosis factor-alpha in patients with ovarian
epithelial cancer. Cancer 1993 Oct 15;72(8):2433-40.
Morimitsu Y, Yano H, Kojiro M. Morphologic characteristics,
proliferation, and tumor marker expression of two human ovarian
carcinoma cell lines in three-dimensional culture. Gynecol Oncol 1993
Feb;48(2):155-64.
Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow
CP, Curtin J, Schlaerth J. Intraperitoneal therapy for ovarian cancer:
analysis of fluid distribution by computerized tomography. Ann Oncol
1992 Feb;3(2):149-54.
Murphy D, McGown AT, Bromley M, Tsuruo T, Crowther D, Fox
BW. P-glycoprotein expression in ovarian tumour biopsies taken before
or after cytotoxic chemotherapy. J Obstet Gynecol 1992;12(4):269-73.
Murphy D, McGown AT, Hall A, Cattan A, Crowther D, Fox BW.
Glutathione S-transferase activity and isoenzyme distribution in ovarian
tumour biopsies taken before or after cytotoxic chemotherapy. Br J
Cancer 1992 Nov;66(5):937-42.
Mutch DG, Herzog TJ, Chen CA, Collins JL. The effects of
cyclosporin A on the lysis of ovarian cancer cells by cisplatin or
adriamycin. Gynecol Oncol 1992 Oct;47(1):28-33.
Mutch DG, Powell CB, Kao MS, Collins JL. Resistance to cytolysis by
tumor necrosis factor alpha in malignant gynecological cell lines is
associated with the expression of protein(s) that prevent the activation
of phospholipase A2 by tumor necrosis factor alpha. Cancer Res 1992
Feb 15;52(4):866-72.
Naito M, Oh-hara T, Yamazaki A, Danki T, Tsuruo T. Reversal of
multidrug resistance by an immunosuppressive agent FK-506. Cancer
Chemother Pharmacol 1992;29(3):195-200.
Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N, Kanzaki H, Ito Y,
Mori T. Detection of p53 gene mutations in human ovarian and
endometrial cancers by polymerase chain reaction-single strand
conformation polymorphism analysis. Jpn J Cancer Res 1992
Oct;83(10):1030-6.
Nakopoulou L, Janinis J, Panagos G, Comin G, Davaris P. The
immunohistochemical expression of proliferating cell nuclear antigen
(PCNA/cyclin) in malignant and benign epithelial ovarian neoplasms
and correlation with prognosis. Eur J Cancer 1993;29A(11):1599-601.
Nassander UK, Steerenberg PA, Poppe H, Storm G, Poels LG, De
Jong WH, Crommelin DJ. In vivo targeting of OV-TL 3
immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in
athymic nude mice. Cancer Res 1992 Feb 1;52(3):646-53.
Naumann RW, Alvarez RD, Partridge EE, Kilgore LC, Austin JM. The
Groshong catheter as an intraperitoneal access device in the treatment
of ovarian cancer patients. Gynecol Oncol 1993 Sep;50(3):291-3.
Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor
necrosis factor and its receptors in human ovarian cancer. Potential role
in disease progression. J Clin Invest 1993 May;91(5):2194-206.
Neungton N, Moongkarndi P, Laohathai K, Neungton S,
Juntrachotiwit P. Immuno-histological characterization of OVS1 and
OVS2 monoclonal antibodies recognizing human ovarian mucinous
cystadenocarcinoma. Asian Pac J Allergy Immunol 1992
Dec;10(2):129-34.
Neven P, Iles RK, Lee CL, Hudson CN, Shepherd JH, Chard T.
Urinary chorionic gonadotropin subunits and beta-core in nonpregnant
women. A study of benign and malignant gynecologic disorders.
Cancer 1993 Jun 15;71(12):4124-30.
Nguyen HN, Averette HE, Wyble L, Sevin BU, Donato D, Penalver M.
Preliminary experience with a modified Tenckhoff catheter for
intraperitoneal chemotherapy. J Surg Oncol 1993 Apr;52(4):237-40.
Nguyen HN, Sevin BU, Averette HE, Perras J, Ramos R, Donato D,
Ochiai K, Penalver M. Cell cycle perturbations of platinum derivatives
on two ovarian cancer cell lines. Cancer Invest 1993;11(3):264-75.
Nicoletti MI, Lucchini V, Massazza G, Abbott BJ, D'Incalci M,
Giavazzi R. Antitumor activity of taxol (NSC-125973) in human
ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann
Oncol 1993 Feb;4(2):151-5.
Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama
S, Terashima Y, Saijo N. Mechanism of cross-resistance to a
camptothecin analogue (CPT-11) in a human ovarian cancer cell line
selected by cisplatin. Cancer Res 1992 Jan 15;52(2):328-33.
O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L,
George SL, Berchuck A, Soper J, Fowler W, et al. Ha-ras
polymorphisms in epithelial ovarian cancer. Gynecol Oncol 1992
Jun;45(3):299-302.
Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Fibronectin is
an immunosuppressive substance associated with epithelial ovarian
cancer. Cancer 1992 Oct 15;70(8):2137-42.
Orengo G, Noviello E, Cimoli G, Pagnan G, Parodi S, Venturini M,
Conte P, Schenone F, Conzi G, Russo P. Potentiation of topoisomerase
I and II inhibitors cell killing by tumor necrosis factor: relationship to
DNA strand breakage formation. Jpn J Cancer Res 1992
Nov;83(11):1132-6.
Owens OJ, Mutch F. Immunocytochemical staining of ovarian tumours
with Ov632. Cytopathology 1992;3(3):161-6.
Owens OJ, Stewart C, Leake RE, McNicol AM. A comparison of
biochemical and immunohistochemical assessment of EGFR expression
in ovarian cancer. Anticancer Res 1992 Sep-Oct;12(5):1455-8.
Owens OJ, Taggart C, Wilson R, Walker JJ, McKillop JH, Kennedy
JH. Interleukin-2 receptor and ovarian cancer. Br J Cancer 1993
Aug;68(2):364-7.
Ozols RF. Advances in the chemotherapy of gynecologic malignancies.
Hematol Oncol 1992 Jan-Feb;10(1):43-51.
Ozols RF. Chemotherapy for advanced epithelial ovarian cancer.
Hematol Oncol Clin North Am 1992 Aug;6(4):879-94.
Ozols RF. New developments with carboplatin in the treatment of
ovarian cancer. Semin Oncol 1992 Feb;19(1 Suppl 2):85-9.
Ozols RF. Ovarian cancer, Part II: Treatment. Curr Probl Cancer 1992
Mar-Apr;16(2):61-126.
Ozols RF. Role of carboplatin in ovarian cancer. Current results and
thoughts for the future. Acta Obstet Gynecol Scand Suppl
1992;155:75-7.
Ozols RF. Role of chemotherapy in the future treatment of ovarian
cancer. Acta Obstet Gynecol Scand Suppl 1992;155:55-60.
Ozols RF, O'Dwyer PJ, Hamilton TC. Clinical reversal of drug
resistance in ovarian cancer. Gynecol Oncol 1993 Oct;51(1):90-6.
Ozols RF, O'Dwyer PJ, Hamilton TC. Drug resistance in ovarian
cancer. In: Markman M, Hoskins WJ, eds. Cancer of the ovary. New
York: Raven Press; 1993. p. 261-76.
Paganelli G, Belloni C, Magnani P, Zito F, Pasini A, Sassi I, Meroni M,
Mariani M, Vignali M, Siccardi AG, et al. Two-step tumour targetting
in ovarian cancer patients using biotinylated monoclonal antibodies and
radioactive streptavidin. Eur J Nucl Med 1992;19(5):322-9.
Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella
BC. Camptothecin derivatives induce regression of human ovarian
carcinomas grown in nude mice and distinguish between
non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 1993 Mar
12;53(5):863-71.
Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E. Ormaplatin
sensitivity/resistance in human ovarian cancer cells made resistant to
cisplatin. Cancer Res 1993 Jan 15;53(2):242-7.
Pearson JW, Fogler WE, Volker K, Riggs CW, Gruys E, Groves ES,
Wiltrout RH, Longo DL. Restoration of interferon alpha potentiation
of a recombinant ricin A chain immunotoxin following cytoreduction of
xenografts of advanced ovarian tumors. J Natl Cancer Inst 1993 Jun
2;85(11):907-12.
Pedersen N, Schmitt M, Ronne E, Nicoletti MI, Hoyer-Hansen G,
Conese M, Giavazzi R, Dano K, Kuhn W, Janicke F, et al. A
ligand-free, soluble urokinase receptor is present in the ascitic fluid
from patients with ovarian cancer. J Clin Invest 1993
Nov;92(5):2160-7.
Pejovic T, Himmelmann A, Heim S, Mandahl N, Floderus UM, Furgyik
S, Elmfors B, Helm G, Willen H, Mitelman F. Prognostic impact of
chromosome aberrations in ovarian cancer. Br J Cancer 1992
Feb;65(2):282-6.
Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Cell-type
specific interaction of Neu differentiation factor (NDF/heregulin) with
Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J
1993 Mar;12(3):961-71.
Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ. T
cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity
by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993
Nov 15;151(10):5472-80.
Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ.
HLA-A2 presents shared tumor-associated antigens derived from
endogenous proteins in ovarian cancer. J Immunol 1993 Nov
15;151(10):5481-91.
Peoples GE, Schoof DD, Andrews JV, Goedegebuure PS, Eberlein TJ.
T-cell recognition of ovarian cancer. Surgery 1993 Aug;114(2):227-34.
Perez RP, Godwin AK, Handel LM, Hamilton TC. A comparison of
clonogenic, microtetrazolium and sulforhodamine B assays for
determination of cisplatin cytotoxicity in human ovarian carcinoma cell
lines. Eur J Cancer 1993;29A(3):395-9.
Perez RP, Hamaguchi K, Tracey PA, Handel LM, Hamilton TC,
Godwin AK. Transformation of rat ovarian epithelial and Rat-1
fibroblast cell lines by RAST24 does not influence cisplatin sensitivity.
Cancer Res 1993 Aug 15;53(16):3771-5.
Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and
modulation of resistance to chemotherapy in ovarian cancer. Cancer
1993 Feb 15;71(4 Suppl):1571-80.
Perez RP, Handel LM, Hamilton TC. Potentiation of cisplatin
cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a
calmodulin inhibitor. Gynecol Oncol 1992 Jul;46(1):82-7.
Perez RP, Perez KM, Handel LM, Hamilton TC. In vitro interactions
between platinum analogues in human ovarian-carcinoma cell lines.
Cancer Chemother Pharmacol 1992;29(6):430-4.
Perkins AC, Symonds IM, Pimm MV, Price MR, Wastie ML, Symonds
EM. Immunoscintigraphy of ovarian carcinoma using a monoclonal
antibody (111In-NCRC48) defining a polymorphic epithelial mucin
(PEM) epitope. Nucl Med Commun 1993 Jul;14(7):578-86.
Perras JP, Ramos R, Sevin BU. Demonstration of an S phase
population of cells without DNA synthesis generated by cisplatin and
pentoxifylline. Cytometry 1993;14(4):441-8.
Peterson CM, Reed R, Jolles CJ, Jones KP, Straight RC, Poulson AM.
Photodynamic therapy of human ovarian epithelial carcinoma,
OVCAR-3, heterotransplanted in the nude mouse. Am J Obstet
Gynecol 1992 Dec;167(6):1852-5.
Pettersen EO, Larsen RO, Dornish JM, Borretzen B, Juul ME, Aastveit
TE, Nesland JM, Rofstad EK, Oftebro R. Tumour necrotisation in nude
mice xenografts by the reversible protein synthesis inhibitor
zilascorb(2H). Br J Cancer 1993 Apr;67(4):650-6.
Pico JL, Ibrahim A, Castagna L, Bourhis JH, Chazard M, Maraninchi
D, Droz JP. Escalating high-dose carboplatin and autologous bone
marrow transplantation in solid tumors. Oncology 1993 Nov;50 Suppl
2:47-52.
Pirovano C, Balzarini A, Bohm S, Oriana S, Spatti GB, Zunino F.
Peripheral neurotoxicity following high-dose cisplatin with glutathione:
clinical and neurophysiological assessment. Tumori 1992 Aug
31;78(4):253-7.
Pisa P, Halapi E, Pisa EK, Gerdin E, Hising C, Bucht A, Gerdin B,
Kiessling R. Selective expression of interleukin 10, interferon gamma,
and granulocyte-macrophage colony-stimulating factor in ovarian
cancer biopsies. Proc Natl Acad Sci U S A 1992 Aug
15;89(16):7708-12.
Plante M, Wong GY, Nisselbaum JS, Almadrones L, Hoskins WJ,
Rubin SC. Relationship between saliva and serum CA 125 in women
with and without epithelial ovarian cancer. Obstet Gynecol 1993
Jun;81(6):989-92.
Platsoucas CD, Freedman RS. Tumor-infiltrating lymphocytes in gene
therapy. Cancer Bull 1993;45(2):118-24.
Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on
the drug sensitivity of human tumour cell lines resistant to either
cisplatin or doxorubicin. Br J Cancer 1993 Apr;67(4):728-33.
Poirier MC, Shamkhani H, Reed E, Tarone RE, Gupta-Burt S. DNA
adducts induced by platinum drug chemotherapeutic agents in human
tissues. Prog Clin Biol Res 1992;374:197-212.
Poplin E, Smith H, Behrens B, Redman B, Flaherty L, Neidhart J,
Alberts D. SWOG 8825: melphalan GM-CSF: a phase I study. Gynecol
Oncol 1992 Jan;44(1):66-70.
Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53
overexpression in human malignant tumors. An immunohistochemical
study using methacarn-fixed, embedded tissue. Am J Pathol 1992
Jan;140(1):145-53.
Powell CB, Horuchi T, Kao MS, Collins JL. Interferon alfa activates a
lytic mechanism in ovarian and cervical carcinoma cells. Am J Obstet
Gynecol 1993 Sep;169(3):661-7.
Powell CB, Manning K, Collins JL. Interferon-alpha (IFN alpha)
induces a cytolytic mechanism in ovarian carcinoma cells through a
protein kinase C-dependent pathway. Gynecol Oncol 1993
Aug;50(2):208-14.
Powell DE, Puls L, van Nagell J Jr. Current concepts in epithelial
ovarian tumors: does benign to malignant transformation occur? Hum
Pathol 1992 Aug;23(8):846-7. Comment in: Hum Pathol 1992
Aug;23(8):845 and Hum Pathol 1993 May;24(5):562-3.
Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A,
Testa N, Stern P, McDermott R, Potter M, et al. A phase I study of
intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer
1993 Aug;68(2):418-24.
Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE,
Kohorn EI, Stanley ER, Kacinski BM. Colony-stimulating factor-1 in
primary ascites of ovarian cancer is a significant predictor of survival.
Am J Obstet Gynecol 1993 Feb;168(2):520-7.
Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi Ricotti GB,
Bottiroli G. Topoisomerase II alpha and beta in human tumor cells
grown in vitro and in vivo. Anticancer Res 1992
Nov-Dec;12(6B):2093-9.
Provencher DM, Finstad CL, Saigo PE, Rubin SC, Hoskins WJ,
Federici MG, Stockert E, Lloyd KO, Lewis JL Jr. Comparison of
antigen expression on fresh and cultured ascites cells and on solid
tumors of patients with epithelial ovarian cancer. Gynecol Oncol 1993
Jul;50(1):78-83.
Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A,
Kruithof EK, Lijnen HR, Burtin P. The plasminogen-activation system
in ovarian tumors. Int J Cancer 1993 Aug 19;55(1):27-31.
Pupa SM, Bazzini P, Menard S, Colnaghi MI. Network of idiotypic and
anti-idiotypic antibodies related to the ovarian carcinoma-associated
folate binding protein. Anticancer Res 1992 Sep-Oct;12(5):1565-70.
Qian H, Feng J, Cui H, Gao B, Qi G, Fu T, Wei P, Fu Z. Clinical
evaluation of radioimmunoimaging with 131I-C0C183B2 monoclonal
antibody against ovarian carcinoma by intraperitoneal injection.
Gynecol Oncol 1992 Nov;47(2):216-22.
Qian HN, Li WJ. Target therapy of ovarian carcinoma by monoclonal
antibodies bearing chemical drugs entrapped in liposomes. Chin Med J
(Engl) 1993 May;106(5):343-7.
Rader JS. Therapeutic advances in ovarian cancer. Curr Opin Obstet
Gynecol 1992 Feb;4(1):120-7.
Redmond A, Moran E, Clynes M. Multiple drug resistance in the
human ovarian carcinoma cell line OAW42-A. Eur J Cancer
1993;29A(8):1078-81.
Ridderheim M, Mahlck CG, Selstam G, Stendahl U, Backstrom T.
Steroid production in different parts of malignant and benign ovarian
tumors in vitro. Cancer Res 1993 May 15;53(10 Suppl):2309-12.
Risteli L, Risteli J, Puistola U, Tomas C, Zhu GG, Kauppila A.
Aminoterminal propeptide of type III procollagen in ovarian cancer. A
review. Acta Obstet Gynecol Scand Suppl 1992;155:99-103.
Rodriguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC,
Xu F, Bast RC Jr. The effect of antibodies and immunotoxins reactive
with HER-2/neu on growth of ovarian and breast cancer cell lines. Am
J Obstet Gynecol 1993 Jan;168(1 Pt 1):228-32.
Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K,
Hanak H, Vavra N, Salzer H, Leodolter S, et al. First experience with
FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.
Br J Cancer 1993 May;67(5):1122-5.
Rotmensch J, Atcher RW, Schwartz JL, Grdina DJ. Analysis of ascites
from patients with ovarian carcinoma by cell flow cytometry. Gynecol
Oncol 1992 Jan;44(1):10-2.
Rowlands C, Krishnan V, Wang X, Santostefano M, Safe S, Miller
WR, Langdon S. Characterization of the aryl hydrocarbon receptor and
aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines.
Cancer Res 1993 Apr 15;53(8):1802-7.
Rubin SC. Monoclonal antibodies in the management of ovarian cancer.
A clinical perspective. Cancer 1993 Feb 15;71(4 Suppl):1602-12.
Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO.
Prognostic significance of HER-2/neu expression in advanced epithelial
ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 1993
Jan;168(1 Pt 1):162-9.
Rubin SC, Kairemo KJ, Brownell AL, Daghighian F, Federici MG,
Pentlow KS, Finn RD, Lambrecht RM, Hoskins WJ, Lewis JL Jr, et al.
High-resolution positron emission tomography of human ovarian
cancer in nude rats using 124I-labeled monoclonal antibodies. Gynecol
Oncol 1993 Jan;48(1):61-7.
Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd
KO, Larson SM, Hoskins WJ. Biodistribution and intraoperative
evaluation of radiolabeled monoclonal antibody MX35 in patients with
epithelial ovarian cancer. Gynecol Oncol 1993 Oct;51(1):61-6.
Rughetti A, Turchi V, Ghetti CA, Scambia G, Panici PB, Roncucci G,
Mancuso S, Frati L, Nuti M. Human B-cell immune response to the
polymorphic epithelial mucin. Cancer Res 1993 Jun 1;53(11):2457-9.
Russo P, Parodi S, Billi G, Oliva C, Venturini M, Noviello E, Conte P.
Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to
human ovarian cancer cell lines. Jpn J Cancer Res 1992
Jul;83(7):684-7.
Rusthoven JJ, Eisenhauer E, Mazurka J, Hirte H, O'Connell G, Muldal
A, Lu HX, Onetto N, Swenerton K, Jeffrey J. Phase I clinical trial of
recombinant human interleukin-3 combined with carboplatin in the
treatment of patients with recurrent ovarian carcinoma. J Natl Cancer
Inst 1993 May 19;85(10):823-5.
Ryuko K, Iwanari O, Kitao M, Moriwaki S. Immunohistochemical
evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
Gynecol Oncol 1993 May;49(2):215-24.
Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M. Clinical evaluation
of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in
gynecologic cancers. Cancer 1992 May 1;69(9):2368-78.
Safrit JT, Berek JS, Bonavida B. Sensitivity of drug-resistant human
ovarian tumor cell lines to combined effects of tumor necrosis factor
(TNF-alpha) and doxorubicin: failure of the combination to modulate
the MDR phenotype. Gynecol Oncol 1993 Feb;48(2):214-20.
Sasano H, Garrett CT. Oncogenes in gynecological tumors. Curr Top
Pathol 1992;85:357-72.
Sasano H, Nagura H, Silverberg SG. Immunolocalization of c-myc
oncoprotein in mucinous and serous adenocarcinomas of the ovary.
Hum Pathol 1992 May;23(5):491-5.
Sass GL, Mohler JD, Walsh RC, Kalfayan LJ, Searles LL. Structure
and expression of hybrid dysgenesis-induced alleles of the ovarian
tumor (otu) gene in Drosophila melanogaster. Genetics 1993
Feb;133(2):253-63.
Saunders DE, Christensen C, Lawrence WD, Malviya VK, Malone JM,
Williams JR, Deppe G. Receptors for 1,25-dihydroxyvitamin D3 in
gynecologic neoplasms. Gynecol Oncol 1992 Feb;44(2):131-6.
Saunders DE, Christensen C, Wappler NL, Schultz JF, Lawrence WD,
Malviya VK, Malone JM, Deppe G. Inhibition of c-myc in breast and
ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and
dexamethasone. Anticancer Drugs 1993 Apr;4(2):201-8.
Savino L, Baldini B, Susini T, Pulli F, Antignani L, Massi GB. GnRH
analogs in gynecological oncology: a review. J Chemother 1992
Oct;4(5):312-20.
Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, Baiocchi G,
Greggi S, De Vincenzo R, Mancuso S. Significance of epidermal
growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992
Apr;10(4):529-35.
Scambia G, Catozzi L, Panici PB, Ferrandina G, Coronetta F, Barozzi
R, Baiocchi G, Uccelli L, Piffanelli A, Mancuso S. Expression of ras
oncogene p21 protein in normal and neoplastic ovarian tissues:
correlation with histopathologic features and receptors for estrogen,
progesterone, and epidermal growth factor. Am J Obstet Gynecol 1993
Jan;168(1 Pt 1):71-8.
Scambia G, Panici PB, Pierelli L, Baiocchi G, Rumi C, Menichella G,
Foddai ML, Serafini R, Arno E, Bonanno G, et al. Immunological
reconstitution after high-dose chemotherapy and autologous blood
stem cell transplantation for advanced ovarian cancer. Eur J Cancer
1993;29A(11):1518-22.
Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, De Vincenzo
R, Bonanno G, Ferrandina G, Isola G, Mancuso S. Synergistic
antiproliferative activity of tamoxifen and cisplatin on primary ovarian
tumours. Eur J Cancer 1992;28A(11):1885-9.
Scheim DE, Lin JY. Glucose effects in an ovarian cancer protocol of
exceptional activity. Med Hypotheses 1993 Apr;40(4):235-44.
Schilder RJ, Ozols RF. New therapies for ovarian cancer. Cancer Invest
1992;10(4):307-15.
Schisselbauer JC, Hogan WM, Buetow KH, Tew KD. Heterogeneity of
glutathione S-transferase enzyme and gene expression in ovarian
carcinoma. Pharmacogenetics 1992 Apr;2(2):63-72.
Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of
human carcinoma cell lines. Cancer Res 1993 Feb 15;53(4):799-805.
Schneider-Gadicke E, Humm JL, Lau CC, Macklis RM, Bastert G,
Knapp RC. Analysis of cytotoxicity of 131I-labelled OC125 F(ab')2 on
human epithelial ovarian cancer cell lines. Radiother Oncol 1992
Mar;23(3):150-9.
Schwartz PE, Chambers JT. Hormone therapy in ovarian cancer. In:
Markman M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven
Press; 1993. p. 339-48.
See WA, Xia Q. Regional chemotherapy for bladder neoplasms using
continuous intravesical infusion of doxorubicin: impact of concomitant
administration of dimethyl sulfoxide on drug absorption and antitumor
activity. J Natl Cancer Inst 1992 Apr 1;84(7):510-5.
Segna RA, Dottino PR, Jennings TS, Cohen CJ. Feasibility of
intraoperative administration of chemotherapy for gynecologic
malignancies: assessment of acute postoperative morbidity. Gynecol
Oncol 1993 Feb;48(2):227-31.
Sehy DW, Shao LE, Rideout D, Yu J. Sensitivity of committed
hematopoietic progenitor cells in vitro (BFU-E, CFU-E, CFU-GM) and
two human carcinoma cell lines toward rhodamine-123 and
phosphonium salt II-41. Leuk Res 1993 Mar;17(3):247-53.
Seidman JD, Frisman DM, Norris HJ. Expression of the HER-2/neu
proto-oncogene in serous ovarian neoplasms. Cancer 1992 Dec
15;70(12):2857-60.
Sekiya S, Nunoyama T, Shirasawa H, Kimura H, Kawata M, Iijima N,
Sugimoto Y, Tsuruo T, Takamizawa H. Expression of a human
multidrug resistance gene in human ovarian carcinoma cell lines. Arch
Gynecol Obstet 1992;251(2):79-86.
Sevin BU, Perras JP, Averette HE, Donato DM, Penalver M.
Chemosensitivity testing in ovarian cancer. Cancer 1993 Feb 15;71(4
Suppl):1613-20.
Sheid B. Angiogenic effects of macrophages isolated from ascitic fluid
aspirated from women with advanced ovarian cancer. Cancer Lett 1992
Feb 29;62(2):153-8.
Sheldon K, Baumal R, Marks A. Targeting of [111In]biocytin to
cultured ovarian adenocarcinoma cells using covalent monoclonal
antibody-streptavidin conjugates. Int J Rad Appl Instrum [A] 1992
Nov;43(11):1399-402.
Sheridan E, Hancock BW, Goyns MH. High incidence of mutations of
the p53 gene detected in ovarian tumours by the use of chemical
mismatch cleavage. Cancer Lett 1993 Jan 15;68(1):83-9.
Shiozawa T, Tsukahara Y, Ishii K, Ota H, Nakayama J, Katsuyama T.
Histochemical demonstration of gastrointestinal mucins in ovarian
mucinous cystadenoma. Acta Pathol Jpn 1992 Feb;42(2):104-10.
Shiraishi Y, Yamamoto K, Soma H. Characteristic mucinous ovarian
cancer antigen is expressed in malignantly transformed Bloom's
syndrome cells. Cancer Res 1993 Jul 15;53(14):3427-32.
Shpall EJ, Stemmer SM, Bearman SI, Bast RC Jr, Peters WP, Ross M,
Jones RB. High-dose chemotherapy with autologous bone marrow
support for the treatment of epithelial ovarian cancer. In: Markman M,
Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press; 1993.
p. 327-38.
Shpall EJ, Stemmer SM, Bearman SI, Jones RB. Role of
autotransplantation in treatment of other solid tumors. Hematol Oncol
Clin North Am 1993;7(3):663-86.
Sikut R, Veromann S, Piirsoo A, Mikelsaar AV, Saar H, Reintam MA.
Ovarian carcinomas express a sperm acrosomal antigen, defined by
monoclonal antibody 9H8. Tumour Biol 1992;13(4):217-25.
Silvestrini R, Daidone MG, Valentinis B, Ferraris C, Di Re E,
Raspagliesi F, Landoni F, Scarfone G, Bolis G. Potentials of cell
kinetics in the management of patients with ovarian cancers. Eur J
Cancer 1992;28(2-3):386-90. Comment in: Eur J Cancer
1992;29A(1):169-70.
Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of
cisplatin activity by lonidamine in human ovarian cancer cells. Int J
Cancer 1992 Nov 11;52(5):813-7.
Skrincosky DM, Allen HJ, Bernacki RJ. Galaptin-mediated adhesion of
human ovarian carcinoma A121 cells and detection of cellular
galaptin-binding glycoproteins. Cancer Res 1993 Jun
1;53(11):2667-75. Published erratum appears in Cancer Res 1993 Aug
1;53(15):3652.
Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E.
Immunotherapy of minimal residual disease by immunocompetent
lymphocytes and their activation by cytokines. Cancer Invest
1992;10(3):221-7.
Smith LH, Yin A, Glasky MS, Tyler N, Robles M, Foster CA, Bieber
M, Teng NN. Human monoclonal antibody recognizing an antigen
associated with ovarian and other adenocarcinomas. Am J Obstet
Gynecol 1992 Feb;166(2):634-45.
Spitzer G, Velasquez W, Dunphy FR, Spencer V. Autologous bone
marrow transplantation in solid tumors. Curr Opin Oncol 1992
Apr;4(2):272-8.
Strang P, Stendahl U, Tribukait B. Prognostic significance of S-phase
fraction as measured by DNA flow cytometry in gynecologic
malignancies. Ann N Y Acad Sci 1993 Mar 20;677:354-63.
Stromberg K, Collins TJ 4th, Gordon AW, Jackson CL, Johnson GR.
Transforming growth factor-alpha acts as an autocrine growth factor in
ovarian carcinoma cell lines. Cancer Res 1992 Jan 15;52(2):341-7.
Published erratum appears in Cancer Res 1992 Mar 1;52(5):1382.
Stuart GC, Nation JG, Snider DD, Thunberg P. Intraperitoneal
interferon in the management of malignant ascites. Cancer 1993 Mar
15;71(6):2027-30.
Surwit EA, Childers JM, Krag DN, Katterhagen JG, Gallion HH,
Waggoner S, Mann WJ Jr. Clinical assessment of 111In-CYT-103
immunoscintigraphy in ovarian cancer. Gynecol Oncol 1993 Mar;48(3):
285-92. Comment in: Gynecol Oncol 1993 Mar;48(3):283-4.
Tagliabue G, Citti L, Massazza G, Damia G, Giavazzi R, D'Incalci M.
Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity
to BCNU of human xenografts. Anticancer Res 1992
Nov-Dec;12(6B):2123-5.
Taniguchi N, Ishikawa M, Kawaguchi T, Fujii J, Suzuki K, Nakata T.
Expression of Mn-superoxide dismutase in carcinogenesis. Tohoku J
Exp Med 1992 Oct;168(2):105-11.
Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M. c-myc
over-expression in human primary ovarian tumours: its relevance to
tumour progression. Int J Cancer 1992 Mar 12;50(5):828-33.
Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC,
Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian
neoplasms. Cancer Res 1993 Jul 1;53(13):3103-8.
Tenti P, Aguzzi A, Riva C, Usellini L, Zappatore R, Bara J, Samloff
IM, Solcia E. Ovarian mucinous tumors frequently express markers of
gastric, intestinal, and pancreatobiliary epithelial cells. Cancer 1992 Apr
15;69(8):2131-42.
Tepler I, Cannistra SA, Frei E 3d, Gonin R, Anderson KC, Demetri G,
Niloff J, Goodman H, Muntz H, Muto M, et al. Use of peripheral-blood
progenitor cells abrogates the myelotoxicity of repetitive outpatient
high-dose carboplatin and cyclophosphamide chemotherapy. J Clin
Oncol 1993 Aug;11(8):1583-91.
Teyssier JR, Couillin P, Benard J, Ravisse N, Ulrich E, Cornillet P. A
multidrug-resistant ovarian carcinoma cell line with a malignant
suppressed phenotype is a CD44 gene expression defective mutant.
Cancer Genet Cytogenet 1992 May;60(1):14-9.
Thierry AR, Dritschilo A, Rahman A. Effect of liposomes on
P-glycoprotein function in multidrug resistant cells. Biochem Biophys
Res Commun 1992 Sep 16;187(2):1098-105.
Thompson MA, Adelson MD. Aging and development of ovarian
epithelial carcinoma: the relevance of changes in ovarian stromal
androgen production. Adv Exp Med Biol 1993;330:155-65.
Thompson S, Dargan E, Turner GA. Increased fucosylation and other
carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett
1992 Sep 14;66(1):43-8.
Tibben JG, Massuger LF, Claessens RA, Schijf CP, Pak KY, Strijk SP,
Kenemans P, Corstens FH. Tumour detection and localization using
99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer.
Nucl Med Commun 1992 Dec;13(12):885-93.
Treskes M, Boven E, Holwerda U, Pinedo HM, van der Vijgh WJ.
Time dependence of the selective modulation of cisplatin-induced
nephrotoxicity by WR2721 in the mouse. Cancer Res 1992 Apr
15;52(8):2257-60.
Trope C, Makar A, Kaern J. DNA flow cytometry as a new prognostic
factor in ovarian malignancies. A review. Acta Obstet Gynecol Scand
Suppl 1992;155:95-7.
Untch M, Sevin BU, Perras JP, Angioli R, Baibl A, Nguyen HN,
Hightower RD, Averette HE. Chemosensitivity to the new
anthracycline pirarubicin and other chemotherapeutic agents in primary
and recurrent ovarian tumors in vitro. Gynecol Oncol 1992
Nov;47(2):172-8.
Vaage J, Donovan D, Mayhew E, Abra R, Huang A. Therapy of human
ovarian carcinoma xenografts using doxorubicin encapsulated in
sterically stabilized liposomes. Cancer 1993 Dec 15;72(12):3671-5.
Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P,
Russo P. Potentiation of tumour necrosis factor-mediated cell killing by
VP16 on human ovarian cancer cell lines. In vitro results and clinical
implications. Eur J Cancer 1993;29A(8):1157-61.
van den Berg-Bakker CA, Hagemeijer A, Franken-Postma EM, Smit
VT, Kuppen PJ, van Ravenswaay Claasen HH, Cornelisse CJ, Schrier
PI. Establishment and characterization of 7 ovarian carcinoma cell lines
and one granulosa tumor cell line: growth features and cytogenetics. Int
J Cancer 1993 Feb 20;53(4):613-20.
van der Burg MEL, Henzen-Logmans SC, Foekens JA, Berns EMJJ,
Rodenburg CJ, Van Putten WLJ, Klijn JGM. The prognostic value of
epidermal growth factor receptor, determined by both
immunohistochemistry and ligand binding assays, in primary epithelial
ovarian cancer: A pilot study. Eur J Cancer 1993;29A(14):1951-7.
van der Zee AG, van Ommen B, Meijer C, Hollema H, van Bladeren
PJ, de Vries EG. Glutathione S-transferase activity and isoenzyme
composition in benign ovarian tumours, untreated malignant ovarian
tumours, and malignant ovarian tumours after
platinum/cyclophosphamide chemotherapy. Br J Cancer 1992
Nov;66(5):930-6.
Van Niekerk CC, Ramaekers FC, Hanselaar AG, Aldeweireldt J, Poels
LG. Changes in expression of differentiation markers between normal
ovarian cells and derived tumors. Am J Pathol 1993 Jan;142(1):157-77.
van't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC,
Hermens RP, van Oorschot DA, Kievits T, Schrier PI. Activation of the
mas oncogene involves coupling to human alphoid sequences.
Oncogene 1993 Oct;8(10):2673-81.
Vergote IB. Adjuvant treatment of ovarian carcinoma. Acta Obstet
Gynecol Scand 1993;72(8):682-4.
Wagner UA, Oehr PF, Reinsberg J, Schmidt SC, Schlebusch HW,
Schultes B, Werner A, Prietl G, Krebs D. Immunotherapy of advanced
ovarian carcinomas by activation of the idiotypic network. Biotechnol
Ther 1992;3(1-2):81-9.
Wang DP, Konishi I, Koshiyama M, Nanbu Y, Iwai T, Nonogaki H,
Mori T, Fujii S. Immunohistochemical localization of c-erbB-2 protein
and epidermal growth factor receptor in normal surface epithelium,
surface inclusion cysts, and common epithelial tumours of the ovary.
Virchows Arch A Pathol Anat Histopathol 1992;421(5):393-400.
Wasserman L, Aviram R, Levavi H, Ovadia J, Shneyuor Y, Frisch A,
Blau O, Beery E, Novogrodsky A, Nordenberg J. A cell line with
unusual characteristics from an ovarian carcinoma patient: modulation
of sensitivity to antitumour drugs. Eur J Cancer 1992;28(1):22-7.
Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian
cancer cells induced by antisense IL-6 oligonucleotides. Gynecol Oncol
1993 Apr;49(1):8-15.
Whittington R, Faulds D. Interleukin-2: A review of its
pharmacological properties and therapeutic use in patients with cancer.
Drugs 1993;46(3):446-514.
Williams CJ. Implications of an overview of chemotherapy in advanced
ovarian carcinoma. Br J Cancer 1992;66(2):225-6.
Wimalasena J, Dostal R, Meehan D. Gonadotropins, estradiol, and
growth factors regulate epithelial ovarian cancer cell growth. Gynecol
Oncol 1992 Sep;46(3):345-50.
Woynarowska B, Wikiel H, Sharma M, Carpenter N, Fleet GW,
Bernacki RJ. Inhibition of human ovarian carcinoma cell- and
hexosaminidase- mediated degradation of extracellular matrix by sugar
analogs. Anticancer Res 1992 Jan-Feb;12(1):161-6.
Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg
JB, Bast RC Jr. Tumor necrosis factor alpha as an autocrine and
paracrine growth factor for ovarian cancer: monokine induction of
tumor cell proliferation and tumor necrosis factor alpha expression.
Cancer Res 1993 Apr 15;53(8):1939-44.
Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS,
Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC Jr.
Stimulation of ovarian tumor cell proliferation with monocyte products
including interleukin-1, interleukin-6, and tumor necrosis factor-alpha.
Am J Obstet Gynecol 1992 Mar;166(3):997-1007.
Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona
PE, Andrew SM, Zurawski VR Jr, Canevari S, Colnaghi MI, Segal
DM. Bispecific antibodies and retargeted cellular cytotoxicity: novel
approaches to cancer therapy. Int J Clin Lab Res 1992;22(1):17-20.
Xing PX, Prenzoska J, McKenzie IF. Epitope mapping of anti-breast
and anti-ovarian mucin monoclonal antibodies. Mol Immunol 1992
May;29(5):641-50.
Yaginuma Y, Westphal H. Abnormal structure and expression of the
p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992 Aug
1;52(15):4196-9.
Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M, Shimizu T. ras
oncogene product p21 expression and prognosis of human ovarian
tumors. Gynecol Oncol 1992 Jul;46(1):45-50.
Yang FE, Brown RS, Koral KF, Clavo AC, Jackson GA, Wahl RL.
Quantitative autoradiographic evaluation of the influence of protein
dose on monoclonal antibody distribution in human ovarian
adenocarcinoma xenografts. Cancer Immunol Immunother
1992;35(6):365-72.
Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced
c-erbB-2/neu expression in human ovarian cancer cells correlates with
more severe malignancy that can be suppressed by E1A. Cancer Res
1993 Feb 15;53(4):891-8.
Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W,
Kudryk BJ. Tumor cell procoagulant and urokinase expression in
carcinoma of the ovary. J Natl Cancer Inst 1993 Aug
4;85(15):1225-30.
Zhen W, Link CJ Jr, O'Connor PM, Reed E, Parker R, Howell SB,
Bohr VA. Increased gene-specific repair of cisplatin interstrand
cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol
Cell Biol 1992 Sep;12(9):3689-98.
Zheng J, Wan M, Zweizig S, Velicescu M, Yu MC, Dubeau L.
Histologically benign or low-grade malignant tumors adjacent to
high-grade ovarian carcinomas contain molecular characteristics of
high-grade carcinomas. Cancer Res 1993 Sep 15;53(18):4138-42.
Zhou L, Leung BS. Growth regulation of ovarian cancer cells by
epidermal growth factor and transforming growth factors alpha and
beta 1. Biochim Biophys Acta 1992 Dec 10;1180(2):130-6.
Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive
ovarian carcinoma induces synthesis of type I and type III procollagens
in the tumor tissue and peritoneal cavity. Cancer Res 1993 Oct
15;53(20):5028-32.
Zhu GG, Stenback F, Risteli L, Risteli J, Kauppila A. Organization of
type III collagen in benign and malignant ovarian tumors. An
immunohistochemical study. Cancer 1993 Sep 1;72(5):1679-84.
Zinkewich-Peotti K, Andrews PA. Loss of
cis-diamminedichloroplatinum(II) resistance in human ovarian
carcinoma cells selected for rhodamine 123 resistance. Cancer Res
1992 Apr 1;52(7):1902-6.
Zoumpourlis V, Kerr DJ, Spandidos DA. Differential interaction of
cisplatin with the HIV-1 long terminal repeat in a resistant ovarian
carcinoma cell line. Anticancer Drugs 1993 Feb;4(1):77-83.
MONOGRAPHS
Al-Azzawi, F. A. Specific human antibodies against cancer raised by
lymphocyte transformation with Epstein-Barr virus [dissertation].
Glasgow (UK): University of Strathclyde; 1988. 239 p. Available from:
University Microfilms International, Ann Arbor, MI; AADD-97065.
Alvarez, V. Psychosexual adjustment of ovarian cancer patients and
their spouses [dissertation]. Los Angeles: Univ. of California; 1987.
243 p. Available from: University Microfilms International, Ann Arbor,
MI: AAD87-19920.
Barber, Hugh R. K. Ovarian carcinoma: etiology, diagnosis, and
treatment. 3rd ed. New York: Springer-Verlag; 1993. 362 p.
Blackledge, George; Jordan, Joseph A.; Shingleton, Hugh M., eds.
Textbook of gynecologic oncology. London: Saunders; 1991. 504 p.
Burghardt, E., ed. Surgical gynecologic oncology. Stuttgart: G. Thieme
Verlag; 1993. 729 p.
Campbell, V. C. The biologic effects of HER-2/neu proto-oncogene
overexpression [dissertation]. Los Angeles: University of California;
1992. 126 p. Available from: University Microfilms International, Ann
Arbor, MI; AAD92-06689.
Coppleson, Malcolm, ed. Gynecologic oncology: fundamental
principles and clinical practice. 2nd ed. Edinburgh: Churchill
Livingstone; 1992. 2 vol.
Deligdisch, Liane; Altchek, Albert; Cohen, Carmel J. Atlas of ovarian
tumors. New York: Igaku-Shoin; 1994.
DiSaia, Philip J.; Creasman, William T. Clinical gynecologic oncology.
4th ed. St. Louis: Mosby Year Book; 1993. 743 p.
Fleischer, Arthur C., ed. Early detection of ovarian carcinoma with
transvaginal sonography: potentials and limitations. New York: Raven
Press; 1993. 206 p.
Gallup, Donald G.; Talledo, O. Eduardo, eds. Surgical atlas of
gynecologic oncology. Philadelphia : W.B. Saunders; c1994.
Giancotti, F. R. Isolation of an antigen from ascites-derived immune
complexes and the production and characterization of an ovarian
cancer-associated monoclonal antibody [dissertation]. New York:
Columbia Univ.; 1989. 190 p. Available from: University Microfilms
International, Ann Arbor, MI; AAD89-19149.
Greer, Benjamin E.; Berek, Jonathan S., eds. Gynecologic oncology:
treatment rationale and techniques. New York: Elsevier; c1991. 320 p.
Haapasalo, H. K. Prognostic factors in ovarian carcinoma: a
clinicopathologic study with special reference to mitotic counts, nuclear
morphometry and DNA cytometry [dissertation]. Kuopio (Finland):
Kuopion Yliopisto; 1990. 158 p.
Hagen, B. Thio-TEPA: pharmacokinetics and pharmacodynamics in
ovarian cancer patients, and experimental studies of serum protein
binding and metabolism [dissertation]. Trondheim (Norway): Univ. of
Trondheim; 1991. 92 p.
Herbst, Arthur L., et al. Comprehensive gynecology. 2nd ed. St. Louis:
Mosby Year Book; 1992. 1333 p.
Hernandez, Enrique; Rosenshein, Neil B. Manual of gynecologic
oncology. New York: Churchill Livingstone; 1989. 184 p.
Hoffman, A. G. An in vitro model of ovarian epithelial carcinogenesis
[dissertation]. College Station (TX): Texas A & M University; 1992.
165 p. Available from: University Microfilms International, Ann Arbor,
MI: AAD93-15073.
Holcombe, J. K. Social support, perception of illness, and self-esteem
of women with gynecologic cancer [dissertation]. Birmingham (AL):
Univ. of Alabama; 1985. 152 p. Available from: University Microfilms
International, Ann Arbor, MI: AAD86-09028.
Hoskins, William J.; Perez, Carlos A.; Young, Robert C., eds.
Principles and practice of gynecologic oncology. Philadelphia:
Lippincott; 1992. 924 p.
Howell, S. B, ed. Platinum and other metal coordination compounds in
cancer chemotherapy. 6th International Symposium on Platinum and
Other Metal Coordination Compounds in Cancer Chemotherapy; 1991
Jan 23-26; San Diego. New York: Plenum Press; 1991. 545 p.
Knapp, Robert C.; Berkowitz, Ross Stuart, eds. Gynecologic oncology.
2nd ed. New York: McGraw-Hill, Health Professions Division; c1993.
500 p.
Kullander, Stig; Bertelsen, Kamma; Kauppila, Antti, et al., eds. Ovarian
cancer: a prevailing challenge. Proceedings of a Nordic symposium.
1991
May 10-11; Stenungsund, Sweden. Goteborg: Scandinavian
Association of Obstetricians and Gynecologists; Oslo: [distributor]
Scandinavian University Press; 1992. 111 p. (Acta obstetricia et
gynecologica Scandinavica. Supplementum; 155).
Kurjak, Asim, ed. Ultrasound and the ovary. Carnforth (Lancs. UK):
Parthenon Pub. Group; 1994. (Progress in obstetric and gynecological
sonography; 1).
Lambert, Hannah E.; Blake, Peter R. Gynaecological oncology.
Oxford: Oxford University Press; 1992. 230 p.
Lawton, F. An assessment of the clinical role of urinary polyamine
measurement in epithelial ovarian cancer [dissertation]. Manchester
(UK): Victoria Univ. of Manchester; 1987. 224 p. Available from:
University Microfilms International, Ann Arbor, MI: AADD-92362.
Lowe, D. G.; Fox, H., eds. Advances in gynaecological pathology.
Edinburgh: Churchill Livingstone; 1992. 383 p.
Maguire, Robert T.; Van Nostrand, Douglas, eds. Diagnosis of
colorectal and ovarian carcinoma: application of immunoscintigraphic
technology. New York: Marcel Dekker; 1992. 237 p. (Targeted
diagnosis and therapy; 6).
Mancuso, Salvatore, ed. Achievements in gynecology, 1989-90. Basel:
Karger; 1991. 185 p. (Contributions to gynecology and obstetrics; 18).
Markman, Maurie; Hoskins, William J., eds. Cancer of the ovary. New
York: Raven Press; 1993. 442 p.
Milatovich, A. Cytogenic studies of ovarian and endometrial
malignancies [dissertation]. Bloomington (IN): Indiana Univ.; 1990.
237 p. Available from: University Microfilms International, Ann Arbor,
MI: AAD91-07317.
Monaghan, John M. Complications in the surgical management of
gynaecological and obstetrical malignancy. London: Bailliere Tindall;
1989. 170 p.
Morrow, C. Paul; Curtin, John P.; Townsend,
Duane E. Synopsis of gynecologic oncology. 4th ed. New York:
Churchill Livingstone; 1993. 558 p.
Pejovic, T. Cytogenetic analysis of ovarian tumors [dissertation]. Lund
(Sweden): Lunds Univ.; 1991. 141 p.
Phipps, Jeffrey H. Laparoscopic hysterectomy and oophorectomy: a
practical manual and colour atlas. Edinburgh: Churchill Livingstone;
1993. 78 p.
Piver, M. Steven, ed. Manual of gynecologic oncology and gynecology.
Boston: Little, Brown; 1989. 401 p.
Pocinki, Karen McCrory. Cancer of the ovary: research report.
[Bethesda (MD)]: U.S. Dept. of Health and Human Services, Public
Health Service, National Institutes of Health; [1989]. 18 p. (NIH
publication; no. 89-3014).
Powell, Martin C.; Worthington, B. S.; Symonds, E. M. Magnetic
resonance imaging in obstetrics and gynaecology. Oxford:
Butterworth-Heinemann; 1993.
Rothenberg, Mace, ed. Gynecologic oncology: controversies and new
developments. Boston: Kluwer Academic; 1994. (Cancer treatment and
research; CTAR 70).
Rubin, Stephen C.; Sutton, Gregory P., eds. Ovarian cancer. New
York: McGraw-Hill, Health Professions Division; 1993. 498 p.
Sasano, Nobuaki, ed. Gynecological tumors: recent progress in
diagnostic pathology. Berlin: Springer-Verlag; c1992. 378 p. (Current
topics in pathology; 85).
Scully, Robert E., et al. Histological typing of female genital tract
tumours. 2nd ed. Berlin: Springer-Verlag; 1994.
Sharp, F.; Mason, W. Peter; Creasman, William T., eds. Ovarian cancer
2: biology, diagnosis and management. The result of the 3rd Helene
Harris Memorial Trust Biennial International Forum on Ovarian
Cancer; 1991 Apr 16-20; Charleston, SC. New York: Chapman & Hall
Medical; 1992. 453 p.
Sharp, F.; Mason, W. Peter; Leake, R. E., eds. Ovarian cancer:
biological and therapeutic challenges. Based on the proceedings of the
2nd Helene Harris Memorial Trust Biennial International Forum on
Ovarian Cancer; [1989]; Graz (Austria). London: Chapman and Hall
Medical; c1990. 480 p.
Sheldon, K. M. Immunoscintigraphy of ovarian carcinoma using
indium-111-labelled monoclonal antibodies [dissertation]. Toronto:
Univ. of Toronto; 1991. 139 p. Available from: University Microfilms
International, Ann Arbor, MI: AADNN-69169.
Shepherd, John H.; Monaghan, John M., eds. Clinical gynaecological
oncology. 2nd ed. Oxford: Blackwell Scientific Publications; 1990. 479
p.
Teoh, Eng-Soon; Ratnam, S. S.; Macnaughton, Malcolm C., eds.
Gynaecological cancer. Proceedings of the 13th World Congress of
Gynaecology and Obstetrics; 1991 Sep; Singapore. Carnforth (Lanc.,
UK): Parthenon Pub. Group; 1993. 235 p. (Current status of
gynaecology and obstetrics series; 3).
Tholander, B. Tumor markers for ovarian carcinoma: diagnostic and
prognostic studies with emphasis on the CA-125 antigen [dissertation].
Uppsalla (Sweden): Uppsalla Universitet; 1992. 55 p.
Thorvinger, B. Diagnostic and interventional radiology in gynecologic
neoplasms [dissertation]. Lund (Sweden): Lunds University; 1990. 46
p.
Tourigny, S. C. Remission or death: the social-psychology of stress and
coping in epithelial ovarian carcinoma patients [dissertation]. Storrs
(CT): Univ. of Connecticut; 1988. 738 p. Available from University
Microfilms International, Ann Arbor, MI: AAD89-16139.
Uyttenbroeck, Frans. Function and sense of radical surgery in
gynaecological and mammary cancerology in a period of biological
evolution: controversies and pitfalls. Leuven (Belgium): Peeters; 1990.
660 p.
Zeller, Kathleen R. Screening for gynecologic malignancy: what every
internist should know. [Dallas]: University of Texas Southwestern
Medical Center at Dallas; [1992]. 35 p.
AUDIOVISUALS
Advances in surgery for gynecologic cancer [videorecording].
University of Texas Medical School at Houston. [Houston (TX):
UT/TV]; c1991. 1 videocassette: 60 min., sound, color, 1/2 in.
(OB/GYN grand rounds). Credits: Mitchell Morris, presenter.
Cancers that threaten women [videorecording]. Princeton (NJ): Films
for the Humanities; c1992. 1 videocassette:
19 min., sound, color, 1/2 in. Credits: Herbert Hyman.
Current concepts in ovarian cancer [videorecording]. [Houston (TX):
UT/TV]; c1990. 1 videocassette:
53 min., sound, color, 1/2 in. Credits: Charles Levenback, presenter.
Gynecologic tumors [slide]. New York: Gower Medical Pub.; c1991.
80 slides : color. with black & white. Accompanied by: 1 guide, 38 p.
(Slide atlas of diagnostic oncology; 5). Credits: Karen J. Krag.
Is there life after menopause [videorecording]. University of California,
San Diego School of Medicine Office of Learning
Resources-Television. [Berkeley (CA)]: UC Regents; c1990. 1
videocassette: 32 min., sound, color with black & white, 1/2 in.
(Ob/gyn ultrasound; tape 17). Credits: Barbara B. Gosink.
Ovarian cancer 1991 [videorecording]. Marshfield Clinic; St. Joseph's
Hospital; Marshfield Medical Research Foundation. Marshfield (WI):
Marshfield Regional Video Network; [1991]. 1 videocassette: 35 min.:
sound, color, 1/2 in. Credits: Dale M. Larson.
Radiation therapy in carcinoma of the ovary: indications, technical
considerations, and results [sound recording]. American Society for
Therapeutic Radiology and Oncology. Chicago: Teach'em; [1989]. 2
sound cassettes: analog. Recorded at ASTRO's 31st annual meeting.
Screening for epithelial ovarian cancer [videorecording]. Bast, Robert
C., Jr. Secaucus (NJ): Network for Continuing Medical Education;
1992. 1 videocassette: 12 min., sound, color, 1/2 in. (NCME
telecourse; no. 624). Issued with: Neurological emergencies in head
trauma; Anesthetic infusion assisted by the programmable calculator.
Screening for ovarian cancer [videorecording]. [Houston (TX)]:
UT-TV; c1991. 1 videocassette: 60 min., sound, color with black &
white, 1/2 in. (OB/GYN grand rounds). Credits: Rajat Goswamy,
presenter.
Surgery for staging and treatment of early ovarian carcinoma
[videorecording]. Buschbaum, Herbert J.; Davis & Geck, Inc ., Medical
Device Division. [Wayne (NJ)]: American Cyanamid; c1990.
1 videocassette: 22 min., sound, color, 1/2 in. Credits: James H.
Nelson, co-author and narrator.
Transvaginal color Doppler scanning techniques [videorecording].
Nashville (TN): Vanderbilt University Medical Center; c1990. 1
videocassette: sound, color with black & white, 1/2 in. (Advances in
color Doppler sonography). Credits: Patricia C. Freeman. From a
course given by the Dept. of Radiological Sciences, Vanderbilt
University, School of Medicine, Nashville, TN, Nov. 1-3, 1990.
Transvaginal color Doppler sonography: current and potential clinical
applications [videorecording]. Health Video Dynamics, Inc. Nashville
(TN): Vanderbilt University Medical Center; c1990.
1 videocassette: sound, color with black & white, 1/2 in. (Advances in
color Doppler sonography). Credits: Arthur C. Fleischer. From a
course given by the Dept. of Radiology and Radiological Sciences,
Vanderbilt University, School of Medicine, Nashville, Tenn., Nov. 1-3,
1990.
Transvaginal ultrasonography for ovarian and e[n]dometrial cancer
[videorecording]. [Houston (TX)]: UT/TV-Houston; c1992. 1
videocassette: 61 min., sound, color, 1/2 in. (OB/GYN grand rounds /
University of Texas Medical School at Houston). Credits: Arthur
Fleisher, presenter.
Last updated: 31 December 1996
First published: 31 December 1996
Metadata | Permanence level: Permanent: Stable Content
| 
